Engineered cd25 polypeptides and uses thereof

ABSTRACT

Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International Application No. PCT/US2019/061567, filed Nov. 14, 2019, which claims the priority benefit of U.S. Provisional Application No. 62/902,334, filed Sep. 18, 2019; and U.S. Provisional Application No. 62/767,431, filed Nov. 14, 2018, the entire contents of which are hereby incorporated by reference in their entirety for all purposes.

DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: RBYC_024_01US_SeqList_ST25.txt, date recorded: Aug. 2, 2021, file size ˜393 kilobytes).

BACKGROUND

The CD25 protein is the alpha chain of the interleukin-2 (IL-2) receptor and is a transmembrane protein present on regulatory T cells, and activated T cells. In a normal state, regulatory T cells constitutively express CD25 and act to suppress the expansion of effector T cells. Regulatory T cells maintain the healthy state and inhibit effector T cells from reacting against self antigens or over-reacting to foreign antigens. In a normal, protective immune response, effector T cells multiply after contact with foreign antigen and overcome inhibition by regulatory T cells. In case of proliferative diseases, however, cancer cells may disable the healthy immune response by increasing the amount of regulatory T cells and thereby limiting the generation of effector T cells against them. Thus, there is interest in therapeutics for to alter the proliferation of CD25-expressing regulatory T cells, for example to dampen the immune system for use in cancer therapies. These therapeutics may include CD25-targeting antibodies.

CD25-targeting antibodies can be produced by immunization of animals using CD25 immunogens, however, current methods of developing CD25 immunogens often lead to unpredictable, undesirable characteristics, such as antibody promiscuity or low cross-reactivity across species.

Thus, what is needed in the art are new engineered polypeptides having structural and/or dynamic similarity to CD25 or portions thereof, for example engineered polypeptides designed to mimic epitopes outside the IL-2 binding site.

SUMMARY

In one aspect, the disclosure provides an engineered polypeptide, wherein the engineered polypeptide shares at least 46% structural and/or dynamic identity to a CD25 reference target, wherein the CD25 reference target is a portion of a CD25 selected from CD25 residues 55-63, 13-20:127-132, 5-17, 5-11:156-163, 77-89, 147-157, 11-14, or 44-56.

In embodiments, the engineered polypeptide shares at least 60% structural and/or dynamic identity to the CD25 reference target. In embodiments, the engineered polypeptide shares at least 80% structural and/or dynamic identity to the CD25 reference target. In embodiments, the engineered polypeptide shares at least 80% sequence identity to an amino-acid sequence selected from SEQ ID NOS: 1-16. In embodiments, the engineered polypeptide shares at least 46% structural and/or dynamic identity to a CD25 reference target, wherein the CD25 reference target is a portion of CD25 selected from CD25 residues 55-63, 13-20:127-132, 5-17, 5-11:156-163, 77-89, 147-157, 11-14, or 44-56. In embodiments, the engineered polypeptide shares at least 80% structural and/or dynamic identity to the CD25 reference target. In embodiments, the structural and/or dynamic identity to the CD25 reference target is determined using the structure of CD25 deposited at PDB ID NO: 2ERJ, chain A. In embodiments, the engineered polypeptide comprises an N-terminal modification or a C-terminal modification, optionally an N-terminal Biotin-PEG2- or a C-terminal -GSGSGK-Biotin (SEQ ID NO: 846).

In embodiments, between 10% to 98% of the amino acids of the engineered polypeptide meet one or more CD25 reference target-derived constraints. In embodiments, the amino acids that meet the one or more CD25 reference target-derived constraints have less than 8.0 Abackbone root-mean-square deviation (RSMD) structural homology with the CD25 reference target. In embodiments, the amino acids that meet the one or more CD25 reference target-derived constraints have a van der Waals surface area overlap with the reference of between 30 Å² to 3000 Å². In embodiments, the CD25 reference target-derived constraints are independently selected from the group consisting of: atomic distances; atomic fluctuations; atomic energies; chemical descriptors; solvent exposures; amino acid sequence similarity; bioinformatic descriptors; non-covalent bonding propensity; phi angles; psi angles; van der Waals radii; secondary structure propensity; amino acid adjacency; and amino acid contact. In embodiments, the engineered polypeptide shares 46%-96% RMSIP or more structural similarity to the reference target across the amino acids of the polypeptide that meet the one or more reference target-derived constraints.

In another aspect, the disclosure provides a CD25-specific antibody comprising an antigen-binding domain that specifically binds a CD25 epitope selected from CD25 residues 55-63, 13-20:127-132, 5-17, 5-11:156-163, 77-89, 147-157, 11-14, or 44-56. In embodiments, the antibody competes for binding of CD25 with an epitope-specific reference binding agent, wherein the epitope-specific binding agent is IL-2, daclizumab, basioliximab, and/or 7G7B6. In embodiments, the antibody does not compete with an off-target reference binding agent, wherein the off0target binding agent is IL-2, daclizumab, basioliximab, and/or 7G7B6. In embodiments, the antibody has a k_(off) of less than 10⁻²/s, less than 10⁻³/s, or less than 10⁻⁴/s, wherein the k_(off) is measured using biolayer interferometry with soluble human CD25. In embodiments, the antibody has a k_(off) of between 10⁻²/s 10⁻⁵/s, wherein the k_(off) is measured using biolayer interferometry with soluble human CD25. In embodiments, the antibody has a K_(D) less than 100 nM, less than 25 nM, or less than 5 nM, wherein the K_(D) is measured using biolayer interferometry with soluble human CD25. In embodiments, the antibody has a K_(D) between 100 nM and 1 nM, wherein the K_(D) is measured using biolayer interferometry with soluble human CD25.

In embodiments, the antibody specifically binds cells expressing CD25. In embodiments, the antibody binds cells expressing CD25 with a mean fluorescence intensity (MFI) of at least 10⁴ or at least 10⁵. In embodiments, the antibody binds cells expressing CD25 with a mean fluorescence intensity (MFI) of between 10⁴ and 106. In embodiments, the antibody does not bind CD25(−) cells. In embodiments, the antibody binds CD25(−) cells with a mean fluorescence intensity (MFI) of less than 10′. In embodiments, the antibody comprises the six CDRs of any one of Combinations 1-126 of Table 7D.

In embodiments, the antibody comprising six complementarity determining regions (CDRs) for any one of YU390-B12, YU397-F01, YU397-D01, YU398-A11, YU404-H01, YU400-B07, YU400-D09, YU401-B01, YU401-G07, YU404-C02, YU403-G07, YU403-G05, YU391-B12, YU400-A03, YU400-D02, YU392-A09, YU392-B11, YU392-B12, YU392-E05, YU392-E06, YU392-G08, YU389-A03, YU392-G09, YU392-G12, YU392-H02, YU392-H04, YU402-F01, YU389-B111, YU394-D08, or YU390-A11, as provided in Table 3A and Table 3B.

In embodiments, the antibody comprises a heavy chain variable region and a light chain variable region that each share at least 90%, 95%, 99%, or 100% sequence identity with the heavy chain variable region and the light chain variable region of YU390-B12, YU397-F01, YU397-D01, YU398-A11, YU404-H01, YU400-B07, YU400-D09, YU401-B01, YU401-G07, YU404-C02, YU403-G07, YU403-G05, YU391-B12, YU400-A03, YU400-D02, YU392-A09, YU392-B11, YU392-B12, YU392-E05, YU392-E06, YU392-G08, YU389-A03, YU392-G09, YU392-G12, YU392-H02, YU392-H04, YU402-F01, YU389-B11, YU394-D08, or YU390-All, as provided in Table 5. In embodiments, the antibody is a full-length immunoglobulin G monoclonal antibody. In embodiments, the antibody comprises single chain variable fragment (scFv) that share at least 90%, 95%, 99%, or 100% sequence identity with the scFv sequence of YU390-B12, YU397-F01, YU397-D01, YU398-A11, YU404-H01, YU400-B07, YU400-D09, YU401-B01, YU401-G07, YU404-C02, YU403-G07, YU403-G05, YU391-B12, YU400-A03, YU400-D02, YU392-A09, YU392-B11, YU392-B12, YU392-E05, YU392-E06, YU392-G08, YU389-A03, YU392-G09, YU392-G12, YU392-H02, YU392-H04, YU402-F01, YU389-B11, YU394-D08, or YU390-A11, as provided in Table 5.

In embodiments, the antibody is a human antibody. In embodiments, the antibody is a humanized antibody. In embodiments, the antibody is a chimeric antibody. In embodiments, the antibody comprises a mouse variable domain and a human constant domain. In embodiments, the antibody also binds cynomologous monkey CD25.

In another aspect, the disclosure provides a pharmaceutical composition comprising any antibody of disclosure and optionally a pharmaceutically acceptable excipient. In another aspect, the disclosure provides a method of treating a subject in need of treatment comprising administering to the subject a therapeutically effective amount of any antibody or pharmaceutical composition of the disclosure. In embodiments, the subject suffers from a cancer. In embodiments, the subject suffers from an autoimmune disease or disorder. In another aspect, the disclosure provides a method of depleting the number of regulatory T cells in a subject comprising administering to the subject a therapeutically effective amount of any antibody or pharmaceutical composition of the disclosure. In embodiments, the subject suffers from a cancer. In embodiments, the subject suffers from an autoimmune disease or disorder.

In another aspect, the disclosure provides a kit comprising the antibodies of any antibody or pharmaceutical composition of the disclosure.

In some aspects, provided herein is an engineered immunogen having at least 60% sequence similarity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11. In some embodiments, the engineered immunogen has at least 80% similarity to the sequence. In other embodiments, the engineered immunogen has at least 90% similarity to the sequence. In certain embodiments, the engineered immunogen shares at least one characteristic with CD25. In still further embodiments, the engineered immunogen binds to an antibody of CD25. In some embodiments, the engineered immunogen has higher binding affinity to an antibody of CD25 at pH below 7.0, compared to binding affinity at pH between about 7.3 and about 7.5. In some embodiments, the engineered immunogen has higher binding affinity to an antibody of CD25 at pH between about 6.4 and about 6.6, compared to binding affinity at pH between about 7.3 and about 7.5.

In yet other embodiments, provided herein is a method of producing an antibody, comprising immunizing an animal with an engineered immunogen having at least 60% sequence similarity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11; and producing an antibody. In some embodiments of the method, the antibody is an antibody to CD25. In certain embodiments, the antibody exhibits higher binding affinity for CD25 at pH below 7.0, compared to binding affinity at pH between about 7.3 and about 7.5. In still further embodiments, the antibody exhibits higher binding affinity for CD25 at pH between about 6.4 and about 6.6, compared to binding affinity at pH between about 7.3 and about 7.5. In some embodiments, the antibody does not block binding of CD25 to IL-2. In other embodiments, the antibody does block binding of CD25 to IL-2. The method of any one of claims 8 to 11, wherein the antibody does not block binding of CD25 to IL-2. In some embodiments, the antibody prevents heterotrimerization of IL-2R-alpha, IL-2R-beta, and IL-2R-gamma. In certain embodiments, the antibody is capable of binding to both the cis orientation and the trans orientation of CD25.

DESCRIPTION OF THE FIGURES

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. The present application can be understood by reference to the following description taking in conjunction with the accompanying figures.

FIG. 1 provides a schematic demonstrating construction of an exemplary combination of three spatially-associated topological constraints, for use in selecting an engineered polypeptide as described herein.

FIG. 2 provides a schematic of the steps involved in some exemplary methods of determining the reference-derived spatially-associated topological constraints and their use in selecting an engineered polypeptide. The engineered polypeptides are herein referred to as meso-scale molecules, MEMs, or meso-scale peptides.

FIGS. 3A-3C provide schematics demonstrating the selection of a group of engineered polypeptides using the methods described herein. FIG. 3A shows the extraction of spatially-associated topological information about an interface of interest in a reference, and use thereof in defining a topological constraint for use in selecting an engineered polypeptide. FIG. 3B provides a schematic detailing the in silico screen step, demonstrating how mismatched candidates are discarded while candidates that match the topology are retained. FIG. 3C presents the top 12 selected engineered polypeptide candidates identified.

FIGS. 4A-4B provide a second set of schematics demonstrating the selection of a different group of engineered polypeptides based on a different set of reference parameters, using the methods described herein. FIG. 4A shows extraction of spatially-associated topological information and construction of a topology matrix. FIG. 4B provides a list of top 8 engineered polypeptide candidates selected by in silico comparing candidates to the topological constraints.

FIG. 5 is a schematic providing an overview of the design of an exemplary programmable in vitro selection using engineered polypeptides as described herein, and also using native proteins as positive (T) or negative (X) selection molecules.

FIG. 6 shows a diagram of eight epitopes on CD25 outside the IL-2 interface targeted for generation of the engineered polypeptides of the disclosure.

FIG. 7 shows 16 engineered polypeptides designed to mimic eight epitopes outside the IL-2 interface on CD25. In each diagram the CD25 target epitope residues are shown in gold. Scaffold residues designed to support these epitope residues are shown in gray.

FIG. 8 shows diagrams of computationally determined deviation of the engineered polypeptide from target epitope. The engineered polypeptides show similarity in structure and dynamics to the target epitope (46% to 96% RMSIP).

FIG. 9 show ELISA analysis for 384 anti-CD25 scFv clones per in vitro selection strategy. Eight CD25 epitopes were targeted with 32 programmed selection strategies. The figures show the ELISA analysis of individual scFv's from each selection strategy. Each scFv was tested by ELISA against full-length CD25. Selection strategies S1-S32 are ordered by epitope number 1-8, corresponding to the epitope shown in FIG. 6 .

FIG. 10 shows that MEM-programmed selection schemes enrich distinct high affinity clonal subsets. Histograms for two different selection strategies (Scheme A and Scheme B) for each of three MEM polypeptides are shown. The schemes in the right panel resulted in higher numbers of high-affinity clones. Panning with full-length CD25 results in comparatively few high-affinity clones.

FIG. 11 shows data from biolayer interferometry for 1433 anti-CD25 scFv's identified by phage display panning. The y-axis plots k_(off)(1/s) for each clone. Median observed k_(on) was 1.35×10⁵ (1/Ms). K_(D) estimates assume k_(on) of 4.5×10⁴ (1/Ms). 1433 out of 1475 tested screening hits (97%) are confirm to bind CD25. The plot depicts the off-rate distribution for the 1433 confirmed hits.

FIG. 12 shows data from biolayer interferometry for anti-CD25 scFv's identified by phage display panning. Hits are identified by panning strategy used. Data is shown for only those hits with k_(off) of less than 10⁻³/s.

FIG. 13 shows data from flow cytometry for anti-CD25 scFv's identified by phage display panning. The CD25 specificity the different scFv antibodies were evaluated on flow cytometer using cells that express CD25 [CD25(+)] or do not express CD25 [CD25(−)].

FIG. 14A-14B show data from flow cytometry for anti-CD25 scFv's identified by phage display panning. Hits are identified by panning strategy used. FIG. 14A shows bind to CD25(+) cells. FIG. 14B shows binding to control CD25(−) cells.

FIG. 15 show amino acid residue enrichment at each CDR H3 position in a representative enrichment strategy (S12).

FIG. 16 shows a graph of sequence diversity during each round of MEM- or CD25-steered in vitro selection.

FIG. 17 shows a graph of CDR length during each round of MEM- or CD25-steered in vitro selection.

FIG. 18 shows ribbon diagrams of CD25 indicated the approximate binding sites for IL-2 and three antibodies (daclizumab, Tusk 7G7B6, and basiliximab) used in epitope resolution with a four-target competitive binding assay.

FIG. 19 shows that full-length CD25 panning clones are dominated by IL-2 interface epitope. Most clones are blocked by IL-2, daclizumab, and basioliximab, but not 7G7B6.

FIG. 20 shows that 147-157 epitope MEM-steered clones primarily bind at the intended epitope. Most clones are blocked by daclizumab but not by IL-2, basioliximab, or 7G7B6.

FIG. 21 shows that 6-17 epitope MEM-steered clones primarily bind at the intended epitope. Most clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab.

FIG. 22 shows that 13-20:127-132 epitope MEM-steered clones primarily bind at the intended epitope. Most clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab.

FIG. 23 shows that 44-56 epitope MEM-steered clones primarily bind at the intended epitope. The clones divided into two profiles. In profile 1, clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab. In profile 2, clones are blocked by IL-2, daclizumab, and basioliximab, but not 7G7B6. These blocking profiles indicate binding to the intended epitope from different approach angles.

FIG. 24 shows that 55-63 epitope MEM-steered clones primarily bind at the intended epitope. The clones divided into three profiles. In profile 1, clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab. In profile 2, clones are blocked by IL-2, daclizumab, and basioliximab, but not 7G7B6. These blocking profiles indicate binding to the intended epitope from different approach angles. In profile 3, clones are blocked by IL-2 and 7G7B6, but not daclizumab or basioliximab. These blocking profiles indicate binding to the intended epitope from different approach angles.

FIG. 25 shows alanine mutations designed to confirm or reject that MEM-steered clones bin the intended epitopes. The eight epitopes are indicated in color. Sites of residues mutated to alanine are shown by red sticks.

FIG. 26 shows alanine mutations in the 147-157 CD25 epitope do not impact global or local stability. For each mutant and wild-type: RMSD from 3 independent 100 ns MD simulations in explicit solvent for each of 8 different starting apo-CD25 configurations using the crystal structure as the reference.

FIG. 27 shows reliability of Ala-mutant epitope mapping demonstrated with basiliximab control antibody. Ala mutant binding responses corroborate crystal structure of the basiliximab epitope. The basiliximab-CD25 epitope known from X-ray crystal structures is shown in orange.

FIG. 28 shows reliability of Ala-mutant epitope mapping demonstrated with daclizumab control antibody. Ala mutant binding responses corroborate crystal structure of the daclizumab epitope. The daclizumab-CD25 epitope known from X-ray crystal structures is shown in orange. Inset at bottom left shows an epitope zoom, showing T175A impact on daclizumab binding.

FIG. 29 shows reliability of Ala-mutant epitope mapping demonstrated with 7G7B6 control antibody. Ala mutant binding responses corroborate peptide mapping of the 7G7B6 epitope.

FIG. 30 shows epitope mapping of MEM-programmed selection hits for the 147-157 epitope. Most hits show ala mutation sensitivity in the intended epitope.

FIG. 31 shows sensitivity to alanine substitution of various MEM-steered antibodies hits. Functional epitope diversity is observed. MEM-steered hits have distinct in-epitope alanine substitution position sensitivity.

FIG. 32 presents a model of CD25 (ribbon) binding with IL-2 ligand (space-filling), IL-2R-gamma, and IL-2R-beta. The left and right arrows indicate selected sections of CD25 that were used to develop engineered immunogens that mimic CD25.

FIG. 33A is an exemplary graph of molecule stability vs. root mean square deviation (RMSD) evaluation at physiological pH for an engineered immunogen developed using as an initial input the section of CD25 indicated with the left arrow in FIG. 32 .

FIG. 33B is an exemplary graph of molecule stability vs. root mean square deviation (RMSD) evaluation at physiological pH for an engineered immunogen developed using as an initial input the section of CD25 indicated with the right arrow in FIG. 32 .

FIG. 33C is an exemplary graph of molecule stability vs. root mean square deviation (RMSD) evaluation at tumor microenvironment pH (lower pH) for the engineered immunogen in FIG. 2B (developed using as an initial input the section of CD25 indicated with the right arrow in FIG. 32 ).

FIG. 34A is a model of IL-2 binding with the IL-2R complex, showing the CD25 section (ribbon), IL-2 (1), IL-2R-gamma (2), and IL-2R-beta (3).

FIG. 34B is another view of IL-2 binding with the IL-2R complex, listing areas of CD25 that were used as inputs to develop different selected exemplary engineered immunogens.

FIG. 34C is another view of IL-2 binding with the IL-2R complex listing areas of CD25 that were used as inputs to develop different selected exemplary engineered immunogens.

DETAILED DESCRIPTION

Provided herein are engineered polypeptides that share structural and/or dynamic identity with a portion of reference CD25 target. Epitopes of interest include but are not limited to the eight epitopes shown in FIG. 6 . In some embodiments, the selected epitope is non-overlapping with the binding site (epitope) for IL-2, daclizumab, and/or basiliximab. In some embodiments, the epitope overlaps the epitope for 7G7B6. In some embodiments, the selected epitope is selected from 55-63, 12-20:127-132 (a discontinuous epitope), 5-17, 5-11:156-163 (a discontinuous epitope), 77-89, 147-157, 11-14, or 44-56. In some embodiments, the engineered polypeptides are conformationally stable and represent CD25 epitopes that are involved in interactions with antibodies that bind specifically to CD25. In some embodiments, the engineered polypeptides represent a surface portion of CD25 that is not known to interact with antibodies that bind specifically to CD25. Such engineered polypeptides may be used, for example, to select and/or produce antibodies that bind specifically to CD25.

I. Engineered Polypeptides.

In some embodiments, the engineered polypeptide provided herein shares at least 4600 structural and/or dynamic identity to a CD25 reference target, wherein the CD25 reference target is a portion of CD25 selected from those listed in the table below. As generally provided herein, the % structural/dynamic identity is the root mean square inner product (RMI5P) identity (as provided herein above)×10000. In some embodiments, the structural identity refers to sequence identity.

Reference Target No. CD25 Residues Sequence 1 55-63 SWDNQCQCT (SEQ ID NO: 22) 2 13-20:127-132 ATFKAMA (SEQ ID NO: 23):MVYYQC (SEQ ID NO: 24) 3  5-17 DDPPEIPHATFKA (SEQ ID NO: 25) 4 5-11:156-163 DDPPEIP (SEQ ID NO: 26):RWTQPQLI (SEQ ID NO: 27) 5 77-89 QPEEQKERKTTEM (SEQ ID NO: 28) 6 147-157 VCKMTHGKTRW (SEQ ID NO: 29) 7 11-14 IPHA (SEQ ID NO: 30) 8 44-56 YMLCTGSSSHSSW (SEQ ID NO: 31)

In some embodiments, the engineered polypeptide provided herein 8000 sequence identity to an amino-acid sequence selected from:

(SEQ ID NO: 1) C D C Q A QWT PGMRAPGYDPYCLNC (SEQ ID NO: 2) MVY C Q PDC T A K C M HGCDRDTMKECCDRLK (SEQ ID NO: 3) DD C PE V PHATFK GPGQKWEGPGGGDCSK (SEQ ID NO: 4) DD CI E V P GPAECAERACRAQEE R QR QPQ C I (SEQ ID NO: 5) AE EE KI K IE QKERKTT IKLAKEAK (SEQ ID NO: 6) CHLQI MTHGK IIYVPC (SEQ ID NO: 7) DDGDRCAKEH EIPHAT GEECQKRDKS (SEQ ID NO: 8) CKQLVIYF TGNSS HSSVFYIYYDC (SEQ ID NO: 9) GSGDEDCKKFQSD D NW E NYTSTR H L TF CDEKRS (SEQ ID NO: 10) GSGNEEIEKKIKDC TGNSSHSSW EEALECALKK (SEQ ID NO: 11) GSGDERIERLIKEC TGNSSHSSW EEALECALRR (SEQ ID NO: 12) GSGSHPCAYWRWVI KMTHGKTRW VLELVFCYRD (SEQ ID NO: 13) GSGKCEEEAKKIAS KMTHGKTR EEEAEEYLKKC (SEQ ID NO: 14) GSGDDESEKRTTERDTRKCTKAKAN DNQCQ P T E (SEQ ID NO: 15) GSGSSEWDKWVEEWYKKMCTEAKKN DNQCQ P T K (SEQ ID NO: 16) GSGQCTVWVFRNGDKILYIYEDCDN DNQ H Q Q T L

In some embodiments, the polypeptide shares at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% structural and/or dynamic identity to the CD25 reference target. In some embodiments, polypeptide shares at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to the CD25 reference target.

In some embodiments, the engineered polypeptide is designed to mimic a selected CD25 epitope. For example, in some embodiments, the polypeptide comprises a meso-scale engineered molecule, e.g. a meso-scale engineered polypeptide. Provided herein are methods of selecting meso-scale engineered polypeptides, and compositions comprising and methods of using said engineered polypeptides. For example, provided herein are methods of using engineered polypeptides in in vitro selection of antibodies.

The engineered polypeptides of the present disclosure are between 1 kDa and 10 kDa, referred to herein as “meso-scale”. Engineered polypeptides of this size may, in some embodiments, have certain advantages, such as protein-like functionality, a large theoretical space from which to select candidates, cell permeability, and/or structural and dynamical variability. The terms meso-scale peptides and meso-scale polypeptides are used interchangeably herein, and the term meso-scale molecules (MEM) is intended to cover these.

The methods provided herein comprise identifying a plurality of spatially-associated topological constraints, some of which may be derived from a CD25 reference target, constructing a combination of said constraints, comparing candidate peptides with said combination, and selecting a candidate that has constraints which overlap with the combination. By using spatially-associated topological constraints, different aspects of an engineered polypeptide can be included in the combination depending on the intended use, or desired function, or another desired characteristic. Further, not all constraints must, in some embodiments, be derived from a CD25 reference target. Through such methods, in some embodiments the selected engineered polypeptides are not simply variations of a CD25 reference target (such as might be obtained through peptide mutagenesis or progressive modification of a single reference), but rather may have a different overall structure than the reference peptide, while still retaining desired functional characteristics and/or key substructures.

Further provided herein are methods of using said engineered polypeptides, which include methods of programmable in vitro selection using one or more engineered polypeptides. Such selection may be used, for example, in the identification of antibodies.

These methods and engineered polypeptides are described in greater detail below.

II. Methods of Selecting Engineered Polypeptides

In some aspects, provided herein are methods of selecting an engineered polypeptide, comprising:

identifying one or more topological characteristics of a CD25 reference target;

designing spatially-associated constraints for each topological characteristic to produce a combination of CD25 reference target-derived constraints;

comparing spatially-associated topological characteristics of candidate peptides with the combination derived from the CD25 reference target; and

selecting a candidate peptide with spatially-associated topological characteristics that overlap with the combination of constraints derived from the CD25 reference target.

In some embodiments, one or more additional spatially-associated topological constraints that are not derived from the CD25 reference target are included in the combination.

a. Spatially-Associated Topological Constraints

The engineered polypeptides described herein are selected based on how closely they match a combination of spatially-associated topological constraints. This combination may also be described using the mathematical concept of a “tensor”. In such a combination (or tensor), each constraint is independently described in three dimensional space (e.g., spatially-associated), and the combination of these constraints in three dimensional space provides, for example, a representational “map” of different desired characteristics and their desired level (if applicable) relative to location. This map is not, in some embodiments, based on a linear or otherwise pre-determined amino acid backbone, and therefore can allow for flexibility in the structures that could fulfill the desired combination, as described. For example, in some embodiments, the “map” includes a spatial area wherein the prescribed constraint limitations could be adequately met by two adjacent amino acids—in some embodiments, these amino acids could be directly bonded (e.g., two contiguous amino acids) while in other embodiments, the amino acids are not directly bonded to each other but could be brought together in space by the folding of the peptide (e.g., are not contiguous amino acids). The separate constraints themselves are also not necessarily based on structure, but could include, for example, chemical descriptors and/or functional descriptors. In some embodiments, constraints include structural descriptors, such as a desired secondary structure or amino acid residue. In certain embodiments, each constraint is independently selected.

For example, FIG. 1 is a schematic demonstrating the construction of a representative combination of spatially-associated topological constraints. The three constraints in FIG. 1 are sequence, nearest neighbor distance, and atomic motion, with nearest neighbor distance and atomic motion combined into one graphic. As shown, some constraints are mapped independent of the location of the backbone (e.g., atomic motion of certain side chains), therefore allowing for a much greater variety of structural configurations to be tried, compared to just varying one or more positions on a reference scaffold. The three different constraints and their spatial descriptions are combined into a matrix (e.g., tensor), and then a series of candidate peptides can be compared with this combination to identify new engineered polypeptides which meet the desired criteria. In some embodiments, one or more additional non-reference derived constraints is also included in the combination. Comparison of candidate peptides with a defined combination may be done, for example, using in silico methods to evaluate the constraints of each candidate peptide against the desired combination, and rate how well candidates match. Said candidates which have the desired level of overlap with the prescribed combination may then be synthesized using standard peptide synthetic methods known to one of skill in the art, and evaluated.

In some embodiments, the combination of constraints comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, between 3 to 12, between 3 to 10, between 3 to 8, between 3 to 6, or 3, or 4, or 5, or 6 independently selected spatially-associated topological constraints. One or more of the constraints is derived from a CD25 reference target. In some embodiments, each of the constraints is derived from the CD25 reference target. In other embodiments, at least one constraint is derived from the CD25 reference target, and the remaining constraints are not derived from the reference target. For example, in some embodiments, between 1 and 9 constraints, between 1 and 7 constraints, between 1 and 5 constraints, or between 1 and 3 constraints are derived from the CD25 reference target, and between 1 and 9 constraints, between 1 and 7 constraints, between 1 and 5 constraints, or between 1 and 3 constraints are not derived from the CD25 reference target.

Once the combination of constraints has been constructed, a series of candidate peptides is compared to said combination to identify one or more new engineered polypeptides which meet the desired criteria. In some embodiments, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 125, at least 150, at least 175, at least 200, or at least 250 or more candidate peptides are compared to the combination to identify one or more new engineered polypeptides which meet the desired criteria. In some embodiments, more than 250 candidate peptides, more than 300 candidate peptides, more than 400 candidate peptides, more than 500 candidate peptides, more than 600 candidate peptides, or more than 750 candidate peptides are compared, for example. In some embodiments, topological characteristic simulations are used to evaluate the topological characteristic overlap, if any, of a candidate peptide compared to the combination of constraints. In some embodiments, one or more candidate peptides are also compared to the CD25 reference target, and overlap, if any, of candidate peptide topological characteristics with CD25 reference target topological characteristics is evaluated. In some embodiments, the engineered polypeptide is identified from a computational sample of more than 5, more than 10, more than 20, more than 30, more than 40, more than 50, more than 60, more than 70, more than 80, more than 90, or more than 100 distinct peptide and topological characteristic simulations and an engineered polypeptide is selected, wherein the selected engineered polypeptide has the highest topological characteristic overlap compared the CD25 reference target, out of the total sampled population.

The spatially-associated topological constraints used to construct the desired combination (e.g., the desired tensor) may each be independently selected from a wide group of possible characteristics. These may include, for example, constraints describing structural, dynamical, chemical, or functional characteristics, or any combinations thereof.

Structural constraints may include, for example, atomic distance, amino acid sequence similarity, solvent exposure, phi angle, psi angle, secondary structure, or amino acid contact, or any combinations thereof.

Dynamical constraints may include, for example, atomic fluctuation, atomic energy, van der Waals radii, amino acid adjacency, or non-covalent bonding propensity. Atomic energy may include, for example, pairwise attractive energy between two atoms, pairwise repulsive energy between two atoms, atom-level solvation energy, pairwise charged attraction energy between two atoms, pairwise hydrogen bonding attraction energy between two atoms, or non-covalent bonding energy, or any combinations thereof.

Chemical characteristics may include, for example, chemical descriptors. Such chemical descriptors may include, for example, hydrophobicity, polarity, atomic volume, atomic radius, net charge, log P, HPLC retention, van der Waals radii, charge patterns, or H-bonding patterns, or any combinations thereof.

Functional characteristics may include, for example, bioinformatic descriptors, biological responses, or biological functions. Bioinformatic descriptors may include, for example, BLOSUM similarity, pKa, zScale, Cruciani Properties, Kidera Factors, VHSE-scale, ProtFP, MS-WHIM scores, T-scale, ST-scale, Transmembrane tendency, protein buried area, helix propensity, sheet propensity, coil propensity, turn propensity, immunogenic propensity, antibody epitope occurrence, and/or protein interface occurrence, or any combinations thereof.

In some embodiments, designing the constraints incorporates information about per-residue energy, per-residue interaction, per-residue fluctuation, per-residue atomic distance, per-residue chemical descriptor, per-residue solvent exposure, per-residue amino acid sequence similarity, per-residue bioinformatic descriptor, per-residue non-covalent bonding propensity, per-residue phi/psi angles, per-residue van der Waals radii, per-residue secondary structure propensity, per-residue amino acid adjacency, or per-residue amino acid contact. In some embodiments, these characteristics are used for a subset of the total residues in the CD25 reference target, or a subset of the total residues of the total combination of constraints, or a combination thereof. In some embodiments, one or more different characteristics are used for one or more different residues. That is, in some embodiments, one or more characteristics are used for a subset of residues, and at least one different characteristic is used for a different subset of residues. In some embodiments, one or more of said characteristics used to design one or more constraints is determined by computer simulation. Suitable computer simulation methods may include, for example, molecular dynamics simulations, Monte Carlo simulations, coarse-grained simulations, Gaussian network models, machine learning, or any combinations thereof.

In some embodiments multiple constraints are selected from one category. For example, in some embodiments, the combination comprises two or more constraints that are independently a type of biological response. In some embodiments, two or more constraints are independently a type of secondary structure. In certain embodiments, two or more constraints are independently a type of chemical descriptor. In other embodiments, the combination comprises no overlapping categories of constraints.

In some embodiments, one or more constraints is independently associated with a biological response or biological function. In some embodiments, said constraint is a spatially defined atom(s)-level constraint, or spatially defined shape/area/volume-level constraint (such as a characteristic shape/area/volume that can be satisfied by several different atomic compositions), or a spatially defined dynamic-level constraint (such as a characteristic dynamic or set of dynamics that can be satisfied by several different atomic compositions).

In some embodiments, one or more constraints is derived from a protein structure or peptide structure associated with a biological function or biological response. For example, in some embodiments, one or more constraints is derived from an extracellular domain, such as a G protein-coupled receptor (GPCR) extracellular domain, or an ion channel extracellular domain. In some embodiments, one or more constraints is derived from a protein-protein interface junction. In some embodiments, one or more constraints is derived from a protein-peptide interface junction, such as MHC-peptide or GPCR-peptide interfaces. In certain embodiments, the atoms or amino acids constrained to such a protein or peptide structure are atoms or amino acids associated with a biological function or biological response. In some embodiments, the atoms or amino acids in the engineered polypeptide constrained to such a protein or peptide structure are atoms or amino acids derived from a CD25 reference target. In some embodiments, one or more constraints is derived from a polymorphic region of a CD25 reference target (e.g., a region subject to allelic variation between individuals).

In some embodiments, the one or more atoms associated with a biological function or biological response are selected from the group consisting of carbon, oxygen, nitrogen, hydrogen, sulfur, phosphorus, sodium, potassium, zinc, manganese, magnesium, copper, iron, molybdenum, and nickel. In certain embodiments, the atoms are selected from the group consisting of oxygen, nitrogen, sulfur, and hydrogen.

In some embodiments, wherein one of the constraints is one or more amino acids associated with a biological function or biological response, and/or the engineered polypeptide comprises one or more amino acids associated with a biological function or biological response, the one or more amino acids are independently selected from the group consisting of the 20 proteinogenic naturally occurring amino acids, non-proteinogenic naturally occurring amino acids, and non-natural amino acids. In some embodiments, the non-natural amino acids are chemically synthesized. In certain embodiments, the one or more amino acids are selected from the 20 proteinogenic naturally occurring amino acids. In other embodiments, the one or more amino acids are selected from the non-proteinogenic naturally occurring amino acids. In still further embodiments, the one or more amino acids are selected from non-natural amino acids. In still further embodiments, the one or more amino acids are selected from a combination of 20 proteinogenic naturally occurring amino acids, non-proteinogenic naturally occurring amino acids, and non-natural amino acids.

While the combination of constraints used to select an engineered polypeptide as described herein comprises at least one constraint derived from a CD25 reference target, in some embodiments one or more constraints of the combination are not derived from a CD25 reference target. Thus, in certain embodiments, the selected engineered polypeptide comprises one or more characteristics that are not shared with the CD25 reference target.

In some embodiments, one or more constraints derived from the CD25 reference target and used in the combination describes the inverse of the characteristic as observed in the CD25 reference target. Thus, for example, a CD25 reference target may have a certain pattern of positive charge, a constraint related to charge is derived from said CD25 reference target, and the derived constraint describes a similar pattern but of neutral charge, or of negative charge. Thus, in some embodiments one or more inverse constraints are derived from the CD25 reference target and included in the combination. Such inverse constraints may be useful, for example, in selecting engineered polypeptides as control molecules for certain assays or panning methods, or as negative selection molecules in the programmable in vitro selection methods described herein.

In some embodiments, the combination of spatially-defined topological constraints comprises one or more non-reference derived topological constraints. In some embodiments, the one or more non-reference derived topological constraints enforces or stabilizes one or more secondary structural elements, enforces atomic fluctuations, alters peptide total hydrophobicity, alters peptide solubility, alters peptide total charge, enables detection in a labeled or label-free assay, enables detection in an in vitro assay, enables detection in an in vivo assay, enables capture from a complex mixture, enables enzymatic processing, enables cell membrane permeability, enables binding to a secondary target, or alters immunogenicity. In certain embodiments, the one or more non-reference derived topological constraints constrains one or more atoms or amino acids in the combination of constraints (or subsequently selected peptide) that were derived from the CD25 reference target. For example, in some embodiments, the combination of constraints includes a secondary structure that was derived from the CD25 reference target, and the combination of constraints also comprises a constraint that stabilizes the secondary structural element (e.g., through additional hydrogen bonding, or hydrophobic interactions, or side chain stacking, or a salt bridge, or a disulfide bond), wherein the stabilizing constraint is not present in the CD25 reference target. In another example, in some embodiments the combination of constraints (or subsequently selected peptide) comprises one or more atoms or amino acids that was derived from the CD25 reference target, and the combination of constraints also includes a constraint that enforces atomic fluctuations in at least a portion of the atoms or amino acids derived from the target reference, wherein the constraint is not present in the target reference. In some embodiments, one or more non-reference derived constraints is an inverse constraint. For example, in some embodiments, two combinations of constraints are constructed to select engineered polypeptides with inverse characteristics. In some such embodiments, a first combination of constraints will comprise one or more constraints derived from the CD25 reference target, and one or more constraints not derived from the CD25 reference target; and a second combination of constraints will comprise the same one or more constraints derived from the CD25 reference target, and the inverse of one or more of non-CD25 reference target constraints of the first combination.

b. CD25 Reference Target

Any suitable CD25 reference target may be used to derive one or more spatially-associated topological constraints for use in the methods provided herein. In some embodiments, the CD25 reference target is a full-length native protein. In other embodiments, the CD25 reference target is a portion of a full-length native protein. In still further embodiments, the CD25 reference target is a non-native protein, or portion thereof.

In some embodiments, a CD25 reference target is selected from:

Reference Target No. CD25 Residues Sequence 1 55-63 SWDNQCQCT (SEQ ID NO: 22) 2 13-20:127-132 ATFKAMA (SEQ ID NO: 23):MVYYQC (SEQ ID NO: 24) 3  5-17 DDPPEIPHATFKA (SEQ ID NO: 25) 4 5-11:156-163 DDPPEIP (SEQ ID NO: 26):RWTQPQLI (SEQ ID NO: 27) 5 77-89 QPEEQKERKTTEM (SEQ ID NO: 28) 6 147-157 VCKMTHGKTRW (SEQ ID NO: 29) 7 11-14 IPHA (SEQ ID NO: 30) 8 44-56 YMLCTGSSSHSSW (SEQ ID NO: 31)

For example, in some embodiments, the CD25 reference target is a portion of CD25, such as an epitope or a predicted epitope. In some embodiments, the methods provided herein may be used to select one or more engineered polypeptides that are immunogens, and which may be used to raise one or more antibodies that specifically bind to the protein from which the target reference is derived. In still further embodiments, the methods provided herein may be used to select one or more engineered polypeptides which in turn may be used to select one or more binding partners of a protein of interest, such as an antibody, a Fab-displaying phage, or an scFv-displaying phage.

c. Comparison of Constraints

In some embodiments, the one or more constraints (e.g., reference-derived or non-reference derived) are determined by molecular simulation (e.g. molecular dynamics), or laboratory measurement (e.g. NMR), or a combination thereof. Once the constraints have been derived and combined, engineered polypeptide candidates are, in some embodiments, generated using a computational protein design (e.g., Rosetta). In some embodiments, other methods of sampling peptide space are used. Dynamics simulations may then be carried out on the candidate engineered polypeptides to obtain the parameters of constraints that have been selected. A covariance matrix of atomic fluctuations is generated for the CD25 reference target, covariance matrices are generated for the residues in each of the candidate engineered polypeptides, and these covariance matrices are compared to determine overlap. Principal component analysis is performed to compute the eigenvectors and eigenvalues for each covariance matrix—one covariance matrix for the CD25 reference target and one covariance for each of the candidate engineered polypeptides—and those eigenvectors with the largest eigenvalues are retained.

The eigenvectors describe the most, second-most, third-most, N-most dominant motion observed in a set of simulated molecular structures. Without wishing to be bound by any theory, if a candidate engineered polypeptide moves like the CD25 reference target, its eigenvectors will be similar to the eigenvectors of the CD25 reference target. The similarity of eigenvectors corresponds to their components (a 3D vector centered on each CA atom) being aligned, pointing in the same direction.

In some embodiments, this similarity between candidate engineered polypeptide and CD25 reference target eigenvectors is computed using the inner product of two eigenvectors. The inner product value is 0 if two eigenvectors are 90 degrees to each other or 1 if the two eigenvectors point precisely in the same direction. Without wishing to be bound by theory, since the ordering of eigenvectors is based on their eigenvalues, and eigenvalues may not necessarily be the same between two different molecules due to the stochastic nature by which molecular dynamics (MD) simulations sample the underlying energy landscape of those different molecules, the inner product between multiple, differentially ranked eigenvectors is, in some embodiments, needed (e.g. eigenvector 1 of the engineered polypeptide by eigenvector 2, 3, 4, etc. of the CD25 reference target). In addition, molecular motions are complex and may involve more than one (or more than a few) dominant/principal modes of motion. Thus, in some embodiments, the inner product between all pairs of eigenvectors in a candidate engineered polypeptide and the CD25 reference target are computed. This results in a matrix of inner products the dimensions of which are determined by the number of eigenvectors analyzed. For example, for 10 eigenvectors, the matrix of inner products is 10 by 10. This matrix of inner products can be distilled into a single value by computing the root mean-square value of the 100 (if 10 by 10) inner products. This is the root mean square inner product (RMSIP). From this comparison, one or more candidate engineered polypeptides that have similarity with the defined combination of constraints are selected.

d. Additional Steps

In some embodiments, selection of one or more engineered polypeptides comprises one or more additional steps. For example, in some embodiments an engineered polypeptide candidate is selected based on similarity to the defined combination of spatially-associated topological constraints, as described herein, and then undergoes one or more analyses to determine one or more additional characteristics, and one or more structural adjustments to impart or enforce said desired characteristics. For example, in some embodiments, the selected candidate is analyzed, such as through molecule dynamics simulations, to determine overall stability of the molecule and/or propensity for a particular folded structure. In some embodiments, one or more modifications are made to the engineered polypeptide to impart or reinforce a desired level of stability, or a desired propensity for a desired folded structure. Such modifications may include, for example, the installation of one or more cross-links (such as a disulfide bond), salt bridges, hydrogen bonding interactions, or hydrophobic interactions, or any combinations thereof.

The methods provided herein may further comprise assaying one or more selected engineered polypeptides for one or more desired characteristics, such as desired binding interactions or activity. Any suitable assay may be used, as appropriate to measure the desired characteristic.

In other aspects, provided herein are engineered polypeptides, such as engineered polypeptides selected through the methods described herein. In some embodiments, the engineered polypeptide has a molecular mass between 1 kDa and 10 kDa, and comprises up to 50 amino acids. In certain embodiments, the engineered polypeptide has a molecular mass between 2 kDa and 10 kDa, between 2 kDa and 10 kDa, between 3 kDa and 10 kDa, between 4 kDa and 10 kDa, between 5 kDa and 10 kDa, between 6 kDa and 10 kDa, between 7 kDa and 10 kDa, between 8 kDa and 10 kDa, between 9 kDa and 10 kDa, between 1 kDa and 9 kDa, between 1 kDa and 8 kDa, between 1 kDa and 7 kDa, between 1 kDa and 6 kDa, between 1 kDa and 5 kDa, between 1 kDa and 4 kDa, between 1 kDa and 3 kDa, or between 1 kDa and 2 kDa. In certain embodiments, the engineered polypeptide comprises up to 45 amino acids, up to 40 amino acids, up to 35 amino acids, up to 30 amino acids, up to 25 amino acids, up to 20 amino acids, at least 5 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, at least 25 amino acids, at least 30 amino acids, at least 35 amino acids, or at least 40 amino acids.

In certain embodiments, the engineered polypeptide comprises a combination of spatially-associated topological constraints, wherein one or more of the constraints is a CD25 reference target-derived constraint. Any constraints described herein may be used in the combination, in some embodiments. In still further embodiments, between 10% to 98% of the amino acids of the engineered polypeptide meet the one or more CD25 reference target-derived constraints (e.g., if the engineered polypeptide comprises 50 amino acids, between 5 to 49 amino acids meet the one or more CD25 reference target-derived constraints). In some embodiments, between 20% to 98%, between 30% to 98%, between 40% to 98%, between 50% to 98%, between 60% to 98%, between 70% to 98%, between 80% to 98%, between 90% to 98%, between 10% to 90%, between 10% to 80%, between 10% to 70%, between 10% to 60%, between 10% to 50%, between 10% to 40%, between 10% to 30%, or between 10% to 20% of the amino acids of the engineered polypeptide meet the one or more CD25 reference target-derived constraints. In still further embodiments, the one or more amino acids that meet the one or more CD25 reference target-derived constraints have less than 8.0 Å, less than 7.5 Å, less than 7.0 Å, less than 6.5 Å, less than 6.0 Å, less than 5.5 Å, or less than 5.0 Å backbone root-mean-square deviation (RSMD) structural homology with the CD25 reference target. In some embodiments, the engineered polypeptide has a molecular mass of between 1 kDa and 10 kDa; comprises up to 50 amino acids; a combination of spatially-associated topological constraints, wherein one or more of the constraints is a CD25 reference target-derived constraint; between 10% to 98% of the amino acids of the engineered polypeptide meet the one or more CD25 reference target-derived constraints; and the amino acids that meet the one or more CD25 reference target-derived constraints have less than 8.0 Å backbone root-mean-square deviation (RSMD) structural homology with the CD25 reference target.

In some embodiments, the amino acids of the engineered polypeptide that meet the one or more CD25 reference target-derived constraints have between 10% and 90% sequence homology, between 20% and 90% sequence homology, between 30% and 90% sequence homology, between 40% and 90% sequence homology, between 50% and 90% sequence homology, between 60% and 90% sequence homology, between 70% and 90% sequence homology, or between 80% and 90% sequence homology with the CD25 reference target. In some embodiments, the amino acids that meet the one or more CD25 reference target-derived constraints have a van der Waals surface area overlap with the reference of between 30 Å² to 3000 Å², or between 100 Å² to 3000 Å², or between 250 Å² to 3000 Å², or between 500 Å² to 3000 Å², or between 750 Å² to 3000 Å², or between 1000 Å² to 3000 Å², or between 1250 Å² to 3000 Å², or between 1500 Å² to 3000 Å², or between 1750 Å² to 3000 Å², or between 2000 Å² to 3000 Å², or between 2250 Å² to 3000 Å², or between 2500 Å² to 3000 Å², or between 2750 Å² to 3000 Å².

The combination of constraints that the engineered polypeptide meets may comprise two or more, three or more, four or more, five or more, six or more, or seven or more CD25 reference target-derived constraints. The combination may comprise one or more constraints not derived from the CD25 reference target, as described elsewhere in the present disclosure. These reference-derived constraints, and non-reference derived constraints if present, may independently be any of the constraints described herein, such as any of the structural, dynamical, chemical, or functional characteristics described herein, or any combinations thereof.

In some embodiments, the engineered polypeptide comprises at least one structural difference when compared to the CD25 reference target. Such structural differences may include, for example, a difference in the sequence, number of amino acid residues, total number of atoms, total hydrophilicity, total hydrophobicity, total positive charge, total negative charge, one or more secondary structures, shape factor, Zernike descriptors, van der Waals surface, structure graph nodes and edges, volumetric surface, electrostatic potential surface, hydrophobic potential surface, local diameter, local surface features, skeleton model, charge density, hydrophilic density, surface to volume ratio, amphiphilicity density, or surface roughness, or any combinations thereof. In some embodiments, the difference in one or more characteristics (such as one or more characteristics described herein) is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, or greater than 100% when compared to the characteristic in the CD25 reference target, as applicable to the type of characteristic. For example, in some embodiments the difference is the total number of atoms, and the engineered polypeptide has at least 10%, at least 20%, or at least 30% more atoms than the CD25 reference target, or at least 10%, at least 20%, or at least 30% fewer atoms than the CD25 reference target. In some embodiments, the difference is in total positive charge, and the total positive charge of the engineered polypeptide is at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% larger (e.g., more positive) than the CD25 reference target, while in other embodiments the total positive charge of the engineered polypeptide is at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% smaller (e.g., less positive) than the CD25 reference target.

In some embodiments, the combination of spatially-defined topological constraints includes one or more secondary structural elements not present in the CD25 reference target. Thus, in some embodiments, the engineered polypeptide comprises one or more secondary structural elements that are not present in the CD25 reference target. In some embodiments, the combination and/or engineered polypeptide comprises one secondary structural element, two secondary structural elements, three secondary structural elements, four secondary structural elements, or more than four secondary structural elements not found in the CD25 reference target. In some embodiments, each secondary structural element is independently selected form the group consisting of helices, sheets, loops, turns, and coils. In some embodiments, each secondary structural element not present in the CD25 reference target is independently an α-helix, β-bridge, β-strand, 3₁₀ helix, π-helix, turn, loop, or coil.

In certain embodiments, the CD25 reference target comprises one or more atoms associated with a biological response or a biological function (such as one described herein); the engineered polypeptide comprises one or more atoms associated with a biological response or a biological function (such as one described herein); and the atomic fluctuations of said atoms in the engineered polypeptide overlap with the atomic fluctuations of said atoms in the CD25 reference target. Thus, for example, in some embodiments the atoms themselves are different atoms, but their atomic fluctuations overlap. In other embodiments, the atoms are the same atoms, and their atomic fluctuations overlap. In still further embodiments, the atoms are independently the same or different. In some embodiments, the overlap is a root mean square inner product (RMSIP) greater than 0.25. In some embodiments, the overlap is a RMSIP greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, greater than 0.5, greater than 0.55, greater than 0.6, greater than 0.65, greater than 0.7, greater than 0.75, greater than 0.8, greater than 0.85, greater than 0.9, or greater than 0.95. In certain embodiments, the RMSIP is calculated by:

${{RMSIP} = \left( {\frac{1}{10}{\sum\limits_{i = 1}^{10}\;{\sum\limits_{j = 1}^{10}\;\left( {\eta_{i} \cdot v_{j}} \right)^{2}}}} \right)^{1\text{/}2}},$

where n is the eigenvector of the engineered polypeptide topological constraints, and v is the eigenvector of the CD25 reference target topological constraints.

In some embodiments, the engineered polypeptide comprises atoms or amino acids (or combination thereof) associated with a biological response or biological function, and at least a portion of said atoms or amino acids or combination is derived from a CD25 reference target, and certain constraints of the set of atoms or amino acids in the engineered polypeptide and the set in the CD25 reference target can be described by a matrix. In some embodiments, the matrix is an L×L matrix. In other embodiments, the matrix is an S×S×M matrix. In still further embodiments, the matrix is an L×2 phi/psi angle matrix

For example in some embodiments, the atomic fluctuations of the atoms or amino acids in the engineered polypeptide that are associated with a biological response or biological function are described by an L×L matrix; a portion of said atoms or amino acids are derived from the CD25 reference target; and the atomic fluctuations in the CD25 reference target of said portion are described by an L×L matrix. In some embodiments, the adjacency of each set (related to amino acid location) is described by corresponding L×L matrices. In certain embodiments, the mean percentage error (MPE) across all matrix elements (i, j) of the engineered polypeptide L×L atomic fluctuation or adjacency matrix is less than or equal to 75% relative to the corresponding (i, j) elements in the CD25 reference target atomic fluctuation or adjacency matrix, for the fraction of the engineered polypeptide derived from the CD25 reference target. In some embodiments, the MPE is less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, or less than 40% relative to the corresponding elements in the CD25 reference target matrix, for the fraction of the engineered polypeptide derived from the CD25 reference target. In some embodiments, wherein the matrices represent atomic fluctuations, L is the number of amino acid positions and the (i, j) value in the atomic fluctuation matrix element is the sum of intra-molecular atomic fluctuations for the i^(th) and j^(th) amino acid respectively if the (i, j) atomic distance is less than or equal to 7 Å, or zero if the (i, j) atomic distance is greater than 7 Å or if (i, j) is on the diagonal. Alternatively, in some embodiments the atomic distance can serve as a weighting factor for the atomic fluctuation matrix element (i, j) instead of a 0 or 1 multiplier. In certain embodiments, the i^(th) and j^(th) atomic fluctuations and distances can be determined by molecular simulation (e.g. molecular dynamics) and/or laboratory measurement (e.g. NMR). In other embodiments, wherein the matrices represent adjacency, L is the number of amino acid positions and the value in adjacency matrix element (i, j) is the intra-molecular atomic distance between the i^(th) and j^(th) amino acid respectively if the atomic distance is less than or equal to 7 Å, or zero if the atomic distance is greater than 7 Å or if (i, j) is on the diagonal. Alternatively, in some embodiments the atomic distance can serve as a weighting factor for the adjacency matrix element (i, j) instead of a 0 or 1 multiplier. In certain embodiments, the i^(th) and j^(th) atomic distances could be determined by molecular simulation (e.g. molecular dynamics) and/or laboratory measurement (e.g. NMR).

In certain embodiments, the atoms or amino acids associated with a response or function in the engineered polypeptide have a topological constraint chemical descriptor vector and a mean percentage error (MPE) less than 75% relative to the reference described by the same chemical descriptor, for the fraction of the engineered polypeptide derived from the CD25 reference target, wherein each i^(th) element in the chemical descriptor vector corresponds to an amino acid position index. In some embodiments, the MPE is less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, or less than 40% relative to the reference described by the same chemical descriptor, for the fraction of the engineered polypeptide derived from the CD25 reference target.

In still further embodiments, the matrix is an L×2 phi/psi angel matrix, and the atoms or amino acids associated with a response or function in the engineered polypeptide have an MPE less than 75% with respect to the reference phi/psi angles matrix in the fraction of the engineered polypeptide derived from the reference target, wherein L is the number of amino acid positions and phi, psi values are in dimensions (L,1) and (L,2) respectively. In some embodiments, the MPE is less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, or less than 40% with respect to the reference phi/psi angles matrix in the fraction of the engineered polypeptide derived from the reference target. In some embodiments, the phi/psi values are determined by molecular simulation (e.g. molecular dynamics), knowledge-based structure prediction, or laboratory measurement (e.g. NMR).

In some embodiments, the matrix is an S×S×M secondary structural element interaction matrix, and the atoms or amino acids associated with a response or function in the engineered polypeptide have less than 75% mean percentage error (MPE) relative to the reference secondary structural element relationship matrix, in the fraction of the engineered polypeptide derived from the reference target, where S is the number of secondary structural elements and M is the number of interaction descriptors. In some embodiments, the MPE is less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, or less than 40% relative to the reference secondary structural element relationship matrix, in the fraction of the engineered polypeptide derived from the reference target. Interaction descriptors may include, for example, hydrogen bonding, hydrophobic packing, van der Waals interaction, ionic interaction, covalent bridge, chirality, orientation, or distance, or any combinations thereof. In the secondary structural element interaction matrix index, (i, j, m)=m^(th) interaction descriptor value between the i‘ and j’ secondary structural elements.

Mean Percentage Error (MPE) for different matrices as described herein may be calculated by:

${{{Mean}\mspace{14mu}{Percentage}\mspace{14mu}{Error}\mspace{14mu}({MPE})} = {\frac{100\%}{n}{\sum\limits_{n}^{1}\frac{{{ref}_{n} - {eng}_{n}}}{{ref}_{n}}}}},$

where n is the topological constraint vector or matrix position index for the engineered polypeptide (eng_(n)) and the corresponding reference (ref_(n)), summed up to vector or matrix position n.

In some embodiments, the engineered polypeptide has an MPE of less than 75% compared to the CD25 reference target. In certain embodiments, the engineered polypeptide has an MPE of less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, or less than 40% compared to the CD25 reference target. In some embodiments, the MPE is determined by Total Topological Constraint Distance (TCD), topological clustering coefficient (TCC), Euclidean distance, power distance, Soergel distance, Canberra distance, Sorensen distance, Jaccard distance, Mahalanobis distance, Hamming distance, Quantitative Estimate of Likeness (QEL), or Chain Topology Parameter (CTP).

e. Secondary Structural Element

In some embodiments, at least a portion of the engineered polypeptide is topologically constrained to one or more secondary structural elements. In some embodiments, the atoms or amino acids associated with a biological response or biological function in the engineered polypeptide are topologically constrained to one or more secondary structural elements. In some embodiments, the secondary structural element is independently a sheet, helix, turn, loop, or coil. In some embodiments, the secondary structural element is independently an α-helix, β-bridge, β-strand, 3₁₀ helix, π-helix, turn, loop, or coil. In certain embodiments, one or more of the secondary structural elements to which at least a portion of the engineered polypeptide is topologically constrained is present in the CD25 reference target. In some embodiments, at least a portion of the engineered polypeptide is topologically constrained to a combination of secondary structural elements, wherein each element is independently selected from the group consisting of sheet, helix, turn, loop, and coil. In still further embodiments, each element is independently selected from the group consisting of an α-helix, β-bridge, β-strand, 3₁₀ helix, π-helix, turn, loop, and coil.

In some embodiments, the secondary structural element is a parallel or anti-parallel sheet. In some embodiments, a sheet secondary structure comprises greater than or equal to 2 residues. In some embodiments, a sheet secondary structure comprises less than or equal to 50 residues. In still further embodiments, a sheet secondary structure comprises between 2 and 50 residues. Sheets can be parallel or anti-parallel. In some embodiments, a parallel sheet secondary structure may be described as having two strands i, j in a parallel (N-termini of i and j strands opposing orientation), and a pattern of hydrogen bonding of residues i:j. In some embodiments, an anti-parallel sheet secondary structure may also be described as having two strands i, j in an anti-parallel (N-termini of i and j strands same orientation), and a pattern of hydrogen bonding of residues i:j−1, i:j+1. In certain embodiments, the orientation and hydrogen bonding of strands can be determined by knowledge-based or molecular dynamics simulation and/or laboratory measurement.

In some embodiments, the secondary structural element is a helix. Helices may be right or left handed. In some embodiments, the helix has a residue per turn (residues/turn) value of between 2.5 and 6.0, and a pitch between 3.0 Å and 9.0 Å. In some embodiments, the residues/turn and pitch are determined by knowledge-based or molecular dynamics simulation and/or laboratory measurement.

In some embodiments, the secondary structural element is a turn. In some embodiments, a turn comprises between 2 to 7 residues, and 1 or more inter-residue hydrogen bonds. In some embodiments, the turn comprises 2, 3, or 4 inter-residue hydrogen bonds. In certain embodiments, the turn is determined by knowledge-based or molecular dynamics simulation and/or laboratory measurement.

In still further embodiments, the secondary structural element is a coil. In certain embodiments, the coil comprises between 2 to 20 residues and zero predicted inter-residue hydrogen bonds. In some embodiments, these coil parameters are determined by knowledge-based or molecular dynamics simulation and/or laboratory measurement.

In still further embodiments, the engineered polypeptide comprises one or more atoms or amino acids derived from the CD25 reference target, wherein said atoms or amino acids have a secondary structure. In some embodiments, these atoms or amino acids are associated with a biological response or biological function. In some embodiments, the secondary structure motif vector of the atoms or amino acids in the engineered polypeptide has a cosine similarity greater than 0.25 relative to the CD25 reference target secondary structure motif vector for the fraction of the engineered polypeptide derived from the CD25 reference target, wherein the length of the vector is the number of secondary structure motifs and the value at the i^(th) vector position defines the identity of the secondary structure motif (e.g. helix, sheet) derived from a lookup table. In some embodiments, each motif comprises two or more amino acids. In certain embodiments, motifs include, for example, α-helix, β-bridge, β-strand, 3₁₀ helix, π-helix, turn, and loop. In some embodiments, the cosine similarity is greater than 0.3, greater than 0.35, greater than 0.4, greater than 0.45, or greater than 0.5 relative to the CD25 reference target secondary structure motif vector for the fraction of the engineered polypeptide derived from the CD25 reference target. Cosine similarity may be calculated by:

${{Cosine}\mspace{14mu}{Similarity}} = \frac{\sum\limits_{i = 1}^{n}\;{A_{i}B_{i}}}{\sqrt{\sum\limits_{i = 1}^{n}\; A_{i}^{2}}\sqrt{\sum\limits_{i = 1}^{n}\; B_{i}^{2}}}$

wherein A is the peptide vector of secondary structure motif identifiers, B is the reference vector of secondary structure motif identifiers, n is the length of the secondary structure motif vector, and i is the i^(th) secondary structure motif.

In some embodiments, one or more atoms or amino acids of the engineered polypeptide which are derived from the CD25 reference target can be compared to the corresponding CD25 reference target atoms or amino acids using a total topological constraint distance (TCD). In some embodiments, the total TCD of said engineered polypeptide atoms or amino acids derived from the CD25 reference target is +/−75% relative to the TCD distance of the corresponding atoms in the CD25 reference target, wherein two intra-molecule topological constraints are interacting if their pairwise distance is less than or equal to 7 Å. In some embodiments, the atoms or amino acids in the engineered polypeptide being compared are associated with a biological function or biological response. The i^(th), j^(th) pairwise distance of two atoms or amino acids can, in some embodiments, be determined by molecular simulation (e.g. molecular dynamics) and/or laboratory measurement (e.g. NMR). An exemplary equation for calculating total topological constraint distance (TCD) is:

${\frac{1}{L^{2}}{\sum\limits_{i < j}^{i = {1\text{:}L}}{{S_{ij}}\Delta_{ij}}}},$

where i, j are the intra-molecular position indices for amino acids (i, j), S_(ij) is the difference between constraints S(i) and S(j), A(i,j)=1 if amino acids (i, j) are within the 7 Å interaction threshold, and L is the number of amino acid positions in the peptide or the corresponding CD25 reference target. Alternatively, in some embodiments, A(i,j) can serve as a weighting factor for the S_(ij) difference instead of a 0 or 1 multiplier.

In some embodiments, one or more atoms or amino acids of the engineered polypeptide which are derived from the CD25 reference target can be compared to the corresponding CD25 reference target atoms or amino acids using a chain topology parameter (CTP). In some embodiments, the CTP of said engineered polypeptide atoms or amino acids is +/−50% relative to the CTP of the corresponding atoms or amino acids in the CD25 reference target, wherein intra-chain topological interaction is a pairwise distance less than or equal to 7 Å. In some embodiments, the atoms or amino acids in the engineered polypeptide being compared are associated with a biological function or biological response. In some embodiments, i^(th), j^(th) pairwise distance can be determined by molecular simulation (e.g. molecular dynamics) and/or laboratory measurement (e.g. NMR). An exemplary equation for evaluating CTP is:

${{{Chain}\mspace{14mu}{Topology}\mspace{14mu}{Parameter}\mspace{14mu}({CTP})} = {\frac{1}{L \cdot N}{\sum\limits_{i < j}^{i = {1\text{:}L}}{S_{ij}^{2}\Delta_{ij}}}}},$

where i, j are the position indices for amino acids (i, j), S_(ij) is the difference between topological constraints S(i) and S(j), A(i,j)=1 if amino acids (i, j) are within the 7 Å chain topological interaction threshold, L is the number of amino acid positions in the peptide or the corresponding CD25 reference target, and N is the total number of intra-chain contacts that meet the 7 Å topological interaction threshold in the engineered polypeptide or CD25 reference target. Alternatively, in some embodiments A(i,j) can serve as a weighting factor for the S_(ij) difference instead of a 0 or 1 multiplier.

In some embodiments, one or more atoms or amino acids of the engineered polypeptide which are derived from the CD25 reference target can be compared to the corresponding CD25 reference target atoms or amino acids using a quantitative estimate of likeness (QEL). In some embodiments, the QEL of said engineered polypeptide atoms or amino acids is +/−50% relative to the QEL of the corresponding atoms or amino acids in the CD25 reference target. In some embodiments, the atoms or amino acids in the engineered polypeptide being compared are associated with a biological function or biological response. An exemplary equation for determining QEL is:

${{{Quantitative}\mspace{14mu}{Estimate}\mspace{14mu}{of}\mspace{14mu}{Likeness}\mspace{14mu}({QEL})} = {\exp\left( {\frac{1}{n}{\sum\limits_{i = 1}^{n}\;{\ln\mspace{14mu}{di}}}} \right)}},$

wherein di is a topological constraint for the i^(th) amino acid or atom position, or a composition function (e.g. linear regression function) that combines multiple topological constraints for the i^(th) amino acid or atom position, and n is the number of amino acid or atom positions in the peptide or the CD25 reference target.

In some embodiments, one or more atoms or amino acids of the engineered polypeptide which are derived from the CD25 reference target can be compared to the corresponding CD25 reference target atoms or amino acids using a topological clustering coefficient (TCC) vector and a mean percentage error (MPE). In some embodiments, the TCC vector and MPE is less than 75% relative to the TCC of the corresponding atoms or amino acids in the CD25 reference target, wherein each element (i) of the vector is a topological clustering coefficient for the i^(th) amino acid position, intra-molecule clusters are defined by an interacting edge distance less than or equal to 7 Å, and two edges: i−j, j−1 from the i^(th) amino acid position. In some embodiments, the atoms or amino acids in the engineered polypeptide being compared are associated with a biological function or biological response. In some embodiments, the i^(th), j^(th) and 1^(th) edge distance can be determined by molecular simulation (e.g. molecular dynamics) and/or laboratory measurement (e.g. NMR). An exemplary equation for evaluating the topological clustering coefficient for the i^(th) position is:

${{{Topological}\mspace{14mu}{Clustering}\mspace{14mu}{Coefficient}\mspace{14mu}{for}\mspace{14mu}{the}\mspace{14mu} i^{th}\mspace{14mu}{position}\mspace{14mu}\left( {TCC}_{i} \right)} = \frac{{{}_{}^{i = {1\text{:}L}}{}_{}^{}}\Delta_{ij}\Delta_{il}\Delta_{jl}}{{N_{c}\left( {N_{c} - 1} \right)}\text{/}2}},$

wherein Δ(i,j)=1, Δ(i,1)=1, Δ(j,1)=1 if intra-molecular amino acid positions: (i, j), (i, 1), (j, 1) are within the 7 Å interacting edge threshold respectively, Sip is the combination (e.g. sum) of topological constraints for the i^(th), j^(th) and 1^(th) amino acid, L is the number of amino acid positions in the peptide vector or corresponding CD25 reference target vector, No is the number of intra-molecular interacting amino acid positions for the i^(th) amino acid, meeting the 7 Å edge threshold and two edges: i−j, j−1 from the i^(th) amino acid. Alternatively, in some embodiments, Δ(i,j), Δ(i,1) and Δ(j,1) can serve as weighting factors for the clustering coefficient vector element (i) instead of a 0 or 1 multiplier.

In still further embodiments, one or more atoms or amino acids of the engineered polypeptide which are derived from the CD25 reference target can be compared to the corresponding CD25 reference target atoms or amino acids using an L×M topological constraint matrix and mean percentage error (MPE) of: Euclidean distance, power distance, Soergel distance, Canberra distance, Sorensen distance, Jaccard distance, Mahalanobis distance, or Hamming distance across all M-dimensions. The L×M matrix element (1, m) contains the m^(th) constraint value for the l^(th) amino acid position, wherein L is the number of amino acid positions and M is the number of distinct topological constraints. In some embodiments, the MPE of the engineered polypeptide L×M matrix is less than 75% relative to the matrix of the corresponding CD25 reference target atoms or amino acids. In some embodiments, the MPE is less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, or less than 45%. In some embodiments, the atoms or amino acids in the engineered polypeptide being compared are associated with a biological function or biological response.

III. Programmable In Vitro Selection

In other aspects, further provided herein are methods of using the engineered polypeptides described herein in selecting binding partners using a series of programmed selection steps, wherein at least one selection step includes evaluating the interactions of a pool of potential binding partners with an engineered polypeptide.

In some embodiments, provided herein are methods of steering the selection of a binding molecule using two or more selection molecules. In some embodiments, the methods include subjecting a pool of candidate binding molecules to at least one round of selection, wherein each round comprises at least one negative selection step wherein at least a portion of the pool is screened against a negative selection molecule, and at least one positive selection step wherein at least a portion of the pool is screened against a positive selection molecule. In some embodiments the method comprises at least two rounds, at least three rounds, at least four rounds, at least five rounds, at least six rounds, at least seven rounds, at least eight rounds, at least nine rounds, at least ten rounds, or more, wherein each round independently comprises at least one negative selection step and at least one positive selection step. In some embodiments, each round independently comprises more than one negative selection step, or more than one positive selection step, or a combination thereof. FIG. 5 provides an exemplary schematic detailing three rounds of selection, wherein the first and third round comprise more than one negative selection step, and the first round further comprises more than one positive selection round. As shown in the scheme, two negative selection molecules (“baits”) are used in the first round, and three negative selection molecules are used in the third round. In addition, two positive selection molecules are used in the first round.

In some embodiments wherein the method comprises more than one round, each negative and positive selection molecule is independently chosen. In other embodiments, the same negative selection molecule, or the same positive selection molecule, or a combination thereof, may be used in more than one round. For example, in FIG. 5 , the same negative selection molecules used in round 1 are used again in round 3, with an additional third negative selection molecule also included in round 3. The order of negative and positive selection steps may be, in certain embodiments, independently chosen within each round of selection. Thus, for example, in some embodiments, the method comprises one or more rounds of selection, wherein each round comprises first a negative selection step, and then a positive selection step. In other embodiments, the method comprises one or more rounds of selection, wherein each round comprises first a positive selection step, and then a negative selection step. In still further embodiments, the method comprises one or more rounds of selection, wherein each round independently comprise a negative selection step and a positive selection step, wherein in each round the negative selection step is independently before the positive selection step or after the positive selection step.

Such methods of selection use positive (+) and negative (−) steps to steer the library of candidate binding molecules towards and away from certain desired characteristics, such as binding specificity or binding affinity. By using multiple steps with both positive and negative selection molecules, the pool of candidates can be directed in a stepwise manner to select for characteristics that are desirable and against characteristics that are undesirable. Further, in some embodiments the order of each step within each round, and the order of the rounds relative to each other can direct the selection in different directions. Thus, for example, in some embodiments a method comprising one round with (+) selection followed by (−) selection will result in a different final pool of candidates than if (−) selection is first, followed by (+) selection. Extrapolating this out to methods comprising multiple rounds, the order of selection steps may result in a different final pool of selected candidates even if the same positive and negative selection molecules are used overall.

In some embodiments a selection molecule is used that has in inverse characteristic of another selection molecule. This may be useful, for example, to ensure that the candidate binding partners identified using the positive selection molecule (or excluded because of a negative selection molecule) were identified (or excluded) because of a desired trait (or undesired trait), not because of a separate, unrelated binding interaction. To remove binding partners that are binding through unrelated interactions, an inverse selection molecule can be used that has similar or the same structure and characteristics as the selection molecule, except for the residues/structures conveying the desired trait (or undesired trait). For example, if interaction with a particular charge pattern in a positive selection molecule is desired, an inverse negative selection molecule may be used that has replaced the residues providing that charge pattern with uncharged residues, and/or residues of the opposite charge. Thus, for certain selection molecules, multiple different corresponding inverse selection molecules may be possible.

In the selection methods provided herein, at least one of the selection molecules is an engineered polypeptide as described herein. In some embodiments, more than one engineered polypeptide is used. In some embodiments, each engineered polypeptide is independently a positive or negative selection molecule. In certain embodiments, each selection molecule used in the one or more rounds of selection is independently an engineered polypeptide. In other embodiments, at least one molecule that is not an engineered polypeptide is used as a selection molecule. Such selection molecules that are not engineered polypeptides may comprise, for example, a naturally-occurring polypeptide, or a portion thereof. In other embodiments, one or more selection molecules that are not engineered polypeptides may comprise, for example, a non-naturally occurring polypeptide or portion thereof. For example, in some embodiments one or more selection molecules (e.g., positive selection molecule or negative selection molecule) is an immunogen, an antibody, cell-surface receptor, or a transmembrane protein, or a signaling protein, or a multiprotein complex, or a peptide-protein complex, or any portions thereof, or any combinations thereof. In some embodiments, one or more selection molecules is CD25 or a portion of any of CD25.

The positive and negative characteristics being selected for or against in each step may be selected from a variety of traits, and may be tailored depending on the desired features of the final one or more binding molecules obtained. Such desired features may depend, for example, on the intended use of the one or more binding molecules. For example, in some embodiments the methods provided herein are used to screen antibody candidates for one or more positive characteristics such as high specificity, and against one or more negative characteristics such as cross-reactivity. It should be understood that what is considered a positive characteristic in one context might be a negative characteristic in another context, and vice versa. Thus, a positive selection molecule in one series of selection rounds may, in some embodiments, be a negative selection molecule in a different series of selection rounds, or in selecting a different type of binding molecule, or in selecting the same type of binding molecule but for a different purpose.

In some embodiments, each selection characteristic is independently selected from the group consisting of amino acid sequence, polypeptide secondary structure, molecular dynamics, chemical features, biological function, immunogenicity, CD25 reference target(s) multi-specificity, cross-species CD25 reference target reactivity, selectivity of desired CD25 reference target(s) over undesired reference target(s), selectivity of reference target(s) within a sequence and/or structurally homologous family, selectivity of reference target(s) with similar protein function, selectivity of distinct desired reference target(s) from a larger family of undesired targets with high sequence and/or structurally homology, selectivity for distinct reference target alleles or mutations, selectivity for distinct reference target residue level chemical modifications, selectivity for cell type, selectivity for tissue type, selectivity for tissue environment, tolerance to reference target(s) structural diversity, tolerance to reference target(s) sequence diversity, and tolerance to reference target(s) dynamics diversity. In some embodiments, each selection characteristic is a different type of selection characteristic. In other embodiments, two or more selection characteristics are different characteristics but of the same type. For example, in some embodiments, two or more selection characteristics are polypeptide secondary structure, wherein one is a positive selection for a desired polypeptide secondary structure and one is a negative selection for an undesired polypeptide secondary structure. In some embodiments, two or more selection characteristics are selectivity for cell type, wherein a positive selection characteristic is selectivity for a specific desired cell type, and a negative selection characteristic is selectivity for a specific undesired cell type. In some embodiments, two or more, three or more, four or more, five or more, or six or more selection characteristics are of the same type.

In some embodiments, the selection characteristic is binding to an engineered polypeptide of the disclosure. For example, the engineered polypeptides shown in FIG. 7 , Table 1, Table 8, and Table 9 may be used to select for antibodies (or other binding agents) that specifically bind to the epitopes shown in FIG. 6 and Table 7. Illustrative selection strategies are provided in Table 10.

In yet another aspect, provided herein is a composition comprising two or more selection steering polypeptides, wherein each polypeptide is independently a positive selection molecule comprising one or more positive steering characteristics, or a negative selection molecule comprising one or more negative steering characteristics. Such characteristics may, in some embodiments, be selected from the group consisting of amino acid sequence, polypeptide secondary structure, molecular dynamics, chemical features, biological function, immunogenicity, reference target(s) multi-specificity, cross-species reference target reactivity, selectivity of desired reference target(s) over undesired reference target(s), selectivity of reference target(s) within a sequence and/or structurally homologous family, selectivity of reference target(s) with similar protein function, selectivity of distinct desired reference target(s) from a larger family of undesired targets with high sequence and/or structurally homology, selectivity for distinct reference target alleles or mutations, selectivity for distinct reference target residue level chemical modifications, selectivity for cell type, selectivity for tissue type, selectivity for tissue environment, tolerance to reference target(s) structural diversity, tolerance to reference target(s) sequence diversity, and tolerance to reference target(s) dynamics diversity.

Thus, in further aspects, provided herein is a method of screening a library of binding molecules with a selection steering composition as described herein, wherein each round of selection comprises: a negative selection step of screening at least a portion of the pool against a negative selection molecule; and a positive selection step of screening at least a portion of the pool for a positive selection molecule; wherein the order of selection steps within each round, and the order of rounds, result in the selection of a different subset of the pool than an alternative order.

In some embodiments, the binding partners being evaluated using the composition of selection steering polypeptides as described herein, or the methods of screening as described herein, are a phage library, for example a Fab-containing phage library; or a cell library, for example a B-cell library or a T-cell library.

In some embodiments of the methods of screening provided herein, the methods comprise two or more, three or more, four or more, five or more, six or more, or seven or more rounds of selection. In some embodiments, wherein there is more than one round, each round comprises a different set of selection molecules. In other embodiments, wherein there is more than one round, at least two rounds comprise the same negative selection molecule, the same positive selection molecule, or both.

In some embodiments of the screening methods, the method comprises analyzing the subset of the pool prior to proceeding to the next round of selection. In certain embodiments, each subset pool analysis is independently selected from the group consisting of peptide/protein biosensor binding, peptide/protein ELISA, peptide library binding, cell extract binding, cell surface binding, cell activity assay, cell proliferation assay, cell death assay, enzyme activity assay, gene expression profile, protein modification assay, Western blot, and immunohistochemistry. In some embodiments, gene expression profile comprises full sequence repertoire analysis of the subset pool, such as next-generation sequencing. In some embodiments, statistical and/or informatic scoring, or machine learning training is used to evaluate one or more subsets of the pool in one or more selection rounds.

In some embodiments, the identity and/or order of positive and/or negative selection molecules for a subsequent round is determined by analyzing a subset pool from one selection round. In some embodiments, statistical and/or informatic scoring, or machine learning training, is used to evaluate one or more subsets of the pool in one or more selection rounds to determine the identity and/or order of the positive and/or negative selection molecules for a subsequent round (such as the next round, or a round further along in the program).

In still further embodiments, the methods of selection include modifying a subset pool obtained from a selection round before proceeding to the next selection round. Such modifications may include, for example, genetic mutation of the subset pool, genetic depletion of the subset pool (e.g., selecting a subset of the subset pool to move forward in selection), genetic enrichment of the subset pool (e.g., increasing the size of the pool), chemical modification of at least a portion of the subset pool, or enzymatic modification of at least a portion of the subset pool, or any combinations thereof. In some embodiments, statistical and/or informatic scoring, or machine learning training is used to evaluate a subset pool and determine the one or more modifications to make prior to moving the modified subset pool forward in selection. In certain embodiments, such statistical and/or informatic scoring, or machine learning training, is also used to determine the identity and/or order of positive and/or negative selection molecules for a subsequent round of selection.

Any suitable assay may be used to evaluate the binding of a pool of binding partners with the selection molecules in each step. In some embodiments, binding is directly evaluated, for example by directly detecting a label on the binding partner. Such labels may include, for example, fluorescent labels, such as a fluorophore or a fluorescent protein. In other embodiments, binding is indirectly evaluated, for example using a sandwich assay. In a sandwich assay, a binding partner binds to the selection molecule, and then a secondary labeled reagent is added to label the bound binding partner. This secondary labeled reagent is then detected. Examples of sandwich assay components include His-tagged-binding partner detected with an anti-His-tag antibody or His-tag-specific fluorescent probe; a biotin-labeled binding partner detected with labeled streptavidin or labeled avidin; or an unlabeled binding partner detected with an anti-binding-partner antibody.

In some embodiments, the binding partners being selected in each step are identified based on the binding signal, or dose-response, using any number of available detection methods. These detection methods may include, for example, imaging, fluorescence-activated cell sorting (FACS), mass spectrometry, or biosensors. In some embodiments, a hit threshold is defined (for example the median signal), and any with signal above that signal is flagged as a putative hit motif.

IV. Use of Engineered polypeptides to Produce Antibodies

The engineered polypeptides provided herein, and identified by the methods provided herein, may be used, for example, to produce one or more antibodies. In some embodiments, the antibody is a monoclonal or polyclonal antibody. Thus, in some embodiments, provided herein is an antibody produced by immunizing an animal with an immunogen, wherein the immunogen is an engineered polypeptide as provided herein. In some embodiments, the animal is a human, a rabbit, a mouse, a hamster, a monkey, etc. In certain embodiments, the monkey is a cynomolgus monkey, a macaque monkey, or a rhesus macaque monkey. Immunizing the animal with an engineered polypeptide can comprise, for example, administering at least one dose of a composition comprising the peptide and optionally an adjuvant to the animal. In some embodiments, generating the antibody from an animal comprises isolating a B cell which expresses the antibody. Some embodiments further comprise fusing the B cell with a myeloma cell to create a hybridoma which expresses the antibody. In some embodiments, the antibody generated using the engineered polypeptide can cross react with a human and a monkey, for example a cynomolgus monkey.

a. Characteristics of the Engineered Polypeptide

The engineered polypeptides provided herein have one or more characteristics in common with CD25. In some embodiments, they exhibit at least one characteristic of the surface of CD25, for example the functional interface surface that binds with a binding partner of CD25. In some embodiments, the binding partner is an antibody that binds specifically to CD25. In some embodiments, the engineered polypeptide exhibits at least one characteristic of a portion of the surface of CD25 that is not known to interact to an antibody to CD25.

In some embodiments of certain types of characteristics, the engineered polypeptide presents a mimic of a functional interface of CD25 (such as a binding surface), but the characteristic shared by the engineered polypeptide may be best described as being shared with CD25 as a whole. For example, one characteristic that is shared may be binding between a binding partner of CD25 and CD25, wherein the binding occurs with a functional binding interface of CD25, but the structure and orientation of the functional binding interface is supported by the rest of the CD25 protein.

Such shared characteristics may include, for example, structural metrics, or functional metrics, or combinations thereof. The at least one shared characteristic may include, for example, one or more structural similarities, similarity of conformational entropy, one or more chemical descriptor similarities, one or more functional binding similarities, or one or more phenotypic similarities, or any combinations thereof. In certain embodiments, the engineered polypeptide shares one or more of these characteristics with at least a portion of the surface of CD25, such as a functional interface, for example a binding surface.

In some embodiments, the engineered polypeptide has structural similarity to CD25 (or a portion of the surface of CD25, such as a binding surface), and this structural similarity is evaluated by backbone root-mean-square deviation (RMSD) or side-chain RMSD. RMSD evaluates the average distance between atoms, and can be applied to three-dimensional structures to compare how similar two separate structures are in three-dimensional space. In some embodiments, the RMSD of the backbone, or amino acid side chains, or both, between the engineered polypeptide and CD25 (or a functional interface of CD25) is lower than the RMSD between CD25 (or a functional interface of CD25) and a different molecule. In some embodiments, it is a portion of CD25 (or a portion of a functional interface of CD25) that is compared with the engineered polypeptide. The RMSD may be evaluated, for example, using the experimentally measured structure or the simulated structure of the engineered polypeptide; and the experimentally measured structure or the simulated structure of CD25 (or a functional interface thereof). In some embodiments, a engineered polypeptide is considered structurally similar to CD25 if the backbone of the engineered polypeptide has an average RMSD less than or equal to 6.0 Å relative to the backbone of an x-ray structure of CD25.

In some embodiments, the engineered polypeptide has similar conformational entropy to CD25 (or a portion of the surface of CD25, such as a binding surface), and this conformational entropy is evaluated, for example, using the experimentally measured structure or the simulated structure of the engineered polypeptide, and the experimentally measured structure or the molecular dynamics simulated motion of CD25 (or portion thereof). In such simulations, in some embodiments the experimentally measured structure or the molecular dynamics simulated motion of CD25 (or portion thereof, such as a portion of the binding surface) is used. In certain embodiments, the conformational entropy of the engineered polypeptide is considered similar to that of CD25 (or portion thereof) if an engineered polypeptide molecular dynamics ensemble run under standard physiological conditions has all states with all non-hydrogen atomic position RMSDs ≤6.0 Å relative to a known x-ray crystal structure of CD25 (or portion thereof).

In still other embodiments, the engineered polypeptide has one or more chemical descriptors similar to CD25 (or a portion thereof, such as the binding surface). In other embodiments, the engineered polypeptide has one or more chemical descriptors complementary to a binding partner of CD25 (e.g., an antibody to CD25). Such chemical descriptors (which may be similar or complementary) may include, for example, hydrophobicity patterns, H-bonding patterns, atomic volume/radii, charge patterns, or atomic occupancy patterns, or any combinations thereof. These chemical descriptors may, in some embodiments, be evaluated using the experimentally measured structure or the simulated structure of the engineered polypeptide, and the experimentally measured structure or the simulated structure of CD25 (or a portion thereof, such as the binding surface).

In still other embodiments, the engineered polypeptide has similar functional binding as CD25. For example, in some embodiments the engineered polypeptide has binding to a CD25 binding partner, or fragment thereof. In some embodiments, the binding partner is a fragment of the native binding partner, or is a modified native binding partner. Such modifications may include, for example, a fusion protein comprising at least a fragment of the native binding partner; labeling with a chromophore; labeling with a fluorophore; labeling with biotin; or labeling with a His-tag. In some embodiments, the engineered polypeptide has binding with a binding partner of CD25 that is within about two orders of magnitude, or within about one order of magnitude, of the binding of CD25 with a binding partner. In some embodiments, the similarity of binding is evaluated by comparing the binding constant (K_(d)), or the inhibitory constant (Ki), or the binding on-rate, or the binding off-rate, or the binding affinity of the binding pairs, or the Gibbs free energy of binding (AG). In some embodiments, the binding partner is an antibody to CD25.

In some embodiments, the binding constant (K_(d)) of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the K_(d) of CD25 with the binding partner. In other embodiments, the inhibitory constant (Ki) of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the Ki of CD25 and the binding partner. In still further embodiments, the binding on-rate of the engineered polypeptide with a CD25 binding partner is similar to the binding on-rate of CD25 and the binding partner. In some embodiments, the binding on-rate of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the on-rate of CD25 and the binding partner. In other embodiments, the binding off-rate of the engineered polypeptide with a CD25 binding partner is similar to the binding off-rate of CD25 and the binding partner. In some embodiments, the binding off-rate of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the off-rate of CD25 and the binding partner. In still further embodiments, the binding affinity of the engineered polypeptide with a CD25 binding partner is similar to the binding affinity of CD25 and the binding partner. In some embodiments, the binding affinity of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the binding affinity of CD25 and the binding partner. In some embodiments, the Gibbs free energy of binding of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the Gibbs free energy of binding of CD25 and the binding partner. In some embodiments, the CD25 binding partner is an antibody of CD25.

In yet other embodiments, the engineered polypeptide shares sequence similarity with CD25, or a portion thereof (such as a binding surface of CD25). The similarity may be compared to the continuous amino acid sequence of CD25 (or portion thereof), or to a discontinuous sequence of CD25 (or portion thereof). For example, in certain embodiments, a binding surface of CD25 is formed by discontinuous amino acid sequences, and the engineered polypeptide has sequence similarity with at least a portion of the discontinuous sequences that form the surface. In other embodiments, the engineered polypeptide has sequence similarity with at least a portion of a continuous amino acid sequence that forms a binding surface of CD25. In some embodiments, the binding surface of CD25 comprises an epitope that binds to an antibody to CD25.

In some embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to a portion of the continuous sequence of CD25, for example a continuous sequence that forms a binding surface of CD25. In certain embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to a portion of the discontinuous sequence of CD25, for example the discontinuous sequence that forms a binding surface of CD25. In certain embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to a contiguous portion of a binding surface of CD25. In still further embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to two or more discontiguous portions of a binding surface of CD25. In some embodiments, the engineered polypeptide has a sequence at least partly identical (as described herein) with a binding surface of CD25, wherein the binding surface comprises an epitope that binds to one or more antibodies to CD25.

In certain embodiments, sequence similarity of the engineered polypeptide and CD25 (or portion thereof) is evaluated using the peptide portion(s) of the engineered polypeptide, not including a linker, if present. In certain embodiments, one or more linking moieties are considered as well, for example if the engineered polypeptide comprises one or more linkers that comprise an amino acid.

b. Engineered Polypeptide

In some embodiments, the engineered polypeptide comprises more than one peptide, for example at least two peptides, or at least three peptides, or greater. In some embodiments, the engineered polypeptide comprises between 1 and 10 peptides, between 1 and 8 peptides, between 1 and 6 peptides, between 1 and 4 peptides, between 2 and 10 peptides, between 2 and 8 peptides, between 2 and 6 peptides, or between 2 and 4 peptides.

In some embodiments, the engineered polypeptide comprises between 2 to 100 amino acids, for example, between 2 to 80 amino acids, between 2 to 70 amino acids, between 2 to 60 amino acids, between 2 to 50 amino acids, between 2 to 40 amino acids, between 2 to 30 amino acids, between 2 to 25 amino acids, between 2 to 20 amino acids, between 2 to 15 amino acids, between 5 to 30 amino acids, between 5 to 25 amino acids, between 5 to 20 amino acids, between 5 to 15 amino acids, or between 9 and 15 amino acids.

In certain embodiments, the engineered polypeptide comprises greater than one peptide, for example at least two peptides, or at least three peptides, or at least four peptides, or greater, and each peptide independently comprises between 1 to 100 amino acids, or between 2 to 100 amino acids, for example, between 2 to 80 amino acids, between 2 to 70 amino acids, between 2 to 60 amino acids, between 2 to 50 amino acids, between 2 to 40 amino acids, between 2 to 30 amino acids, between 2 to 25 amino acids, between 2 to 20 amino acids, between 2 to 15 amino acids, between 5 to 30 amino acids, between 5 to 25 amino acids, between 5 to 20 amino acids, between 5 to 15 amino acids, or between 9 and 15 amino acids.

In some embodiments, the engineered polypeptide comprises only naturally occurring amino acids. In other embodiments, the engineered polypeptide comprises non-natural amino acids, for example a combination of naturally occurring and non-natural amino acids.

In some embodiments, wherein the engineered polypeptide comprises two or greater peptides, each peptide independently exhibits at least one characteristic of CD25, or a portion thereof (such as a binding surface). In some embodiments, each peptide independently exhibits 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1, to 6, 1 to 5, 1 to 4, 1 to 3, or 1, or 2 characteristics of CD25, or a portion thereof. In some embodiments, the characteristics are shared with a portion of CD25 that interacts with an antibody of CD25.

In some embodiments, the engineered polypeptide has at least one characteristic that is complementary to a binding partner of CD25, for example an antibody of CD25.

In some embodiments, a peptide of the engineered polypeptide shares one or more structural similarities with CD25, or a portion thereof. The structural similarity may be, in some embodiments, evaluated by backbone RMSD or side-chain RMSD. For example, in certain embodiments, the RMSD of the backbone, or amino acid side chains, or both, between a peptide of the engineered polypeptide and CD25 (or a portion thereof) is lower than the RMSD between CD25 (or portion thereof) and a different molecule (such as a different peptide). In some embodiments, a portion of CD25 is compared with the peptide, for example a portion of the surface of CD25, such as a surface that interacts with an antibody to CD25. RMSD of structural similarity may be evaluated, for example, using the experimentally measured structure or the simulated structure of the peptide and the experimentally measured structure or the simulated structure of CD25 or portion thereof. In some embodiments, a peptide of the engineered polypeptide is considered structurally similar to CD25 (or portion thereof) if the backbone of the peptide has an average RMSD less than or equal to 6.0 Å relative to the backbone of a known x-ray structure of CD25, or the portion thereof.

In some embodiments, the engineered polypeptide has similar conformational entropy to CD25 or a portion thereof. In some embodiments, the experimentally measured structure or the molecular dynamics simulated motion of the peptide is used to compare the conformation entropy with the experimentally measured structure or the simulated structure of CD25, or a portion thereof. The conformational entropy is considered similar, in some embodiments, if a peptide molecular dynamics ensemble run under standard physiological conditions has all states with all non-hydrogen atomic portions RMSDs ≤6.0 Å relative to a known x-ray crystal structure of CD25, or portion thereof. In some embodiments, a portion of CD25 is compared with the peptide, for example a surface portion of CD25 that interacts with an antibody of CD25.

In further embodiments, the similarity between a peptide of the engineered polypeptide and CD25 (or portion thereof) may be one or more chemical descriptors. In some embodiments, the peptide has one or more chemical descriptors in common with CD25 (or a portion thereof), or one or more chemical descriptors that is complementary to a binding partner of CD25 (for example, an antibody to CD25). Chemical descriptors may include, for example, hydrophobicity patterns, H-bonding patterns, atomic volume/radii, charge patterns, or atomic occupancy patterns, or any combinations thereof. In some embodiments, a peptide of the engineered polypeptide has one or more hydrophobicity patterns, H-bonding patterns, atomic volume/radii, charge patterns, or atomic occupancy patterns, or any combinations thereof, similar those in CD25 or a portion thereof, or which is complementary to a binding partner of CD25 (such as an antibody to CD25). In some embodiments, the similarity is having the same chemical descriptor in common, such as one or more of the same hydrophobicity patterns, H-bonding patterns, atomic volume/radii, charge patterns, or atomic occupancy patterns. Complementary chemical descriptors includes, for example, a peptide with a positive charge pattern that complements the negative charge pattern of a binding partner of CD25, such as an antibody to CD25. These chemical descriptors may, in some embodiments, be evaluated using an experimentally measured structure or a simulated structure of the peptide, and an experimentally measured structure or a simulated structure of CD25, or the CD25 binding partner (e.g., for complementary evaluation).

For example, in some embodiments, the engineered polypeptide binds binding partner of CD25 that is similar to the binding of CD25 with the binding partner (for example, IL-2). In some embodiments, the binding partner is the native binding partner, a fragment of a native binding partner, or a modified native binding partner or fragment thereof, or an antibody that binds specifically to CD25. In some embodiments, the binding partner binds under certain circumstances but not others. In some embodiments, the binding partner binds under pathological conditions, or binds under non-pathological conditions. The binding partner may be, for example, constitutively expressed, or the product of a facultative gene, or comprise a protein or a fragment thereof. In certain embodiments, the binding partner is a fragment of a native binding partner, or is a modified native binding partner. Modifications may include, in some embodiments, a fusion protein comprising at least a fragment of the native binding partner; labeling with a chromophore; labeling with a fluorophore; labeling with biotin; or labeling with a His-tag.

In some embodiments, the engineered polypeptide has binding with a binding partner of CD25 that is within about two orders of magnitude, or within about one order of magnitude, of the binding of CD25 with the binding partner. In some embodiments, the similarity of binding is evaluated by comparing the binding constant (K_(d)), or the inhibitory constant (Ki), or the binding on-rate, or the binding off-rate, or the binding affinity of the binding pairs, or the Gibbs free energy of binding (AG). In some embodiments, the binding partner is an antibody to CD25.

In some embodiments, the binding constant (K_(d)) of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the K_(d) of CD25 with the binding partner. In other embodiments, the inhibitory constant (Ki) of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the Ki of CD25 and the binding partner. In still further embodiments, the binding on-rate of the engineered polypeptide with a CD25 binding partner is similar to the binding on-rate of CD25 and the binding partner. In some embodiments, the binding on-rate of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the on-rate of CD25 and the binding partner. In other embodiments, the binding off-rate of the engineered polypeptide with a CD25 binding partner is similar to the binding off-rate of CD25 and the binding partner. In some embodiments, the binding off-rate of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the off-rate of CD25 and the binding partner. In still further embodiments, the binding affinity of the engineered polypeptide with a CD25 binding partner is similar to the binding affinity of CD25 and the binding partner. In some embodiments, the binding affinity of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the binding affinity of CD25 and the binding partner. In some embodiments, the Gibbs free energy of binding of the engineered polypeptide with a CD25 binding partner is within 1000-fold, within 800-fold, within 600-fold, within 400-fold, within 200-fold, within 100-fold, within 90-fold, within 80-fold, within 70-fold, within 60-fold, within 50-fold, within 40-fold, within 30-fold, within 20-fold, within 10-fold, within 8-fold, within 6-fold, within 4-fold, within 2-fold, within 1.5-fold, within 1.2-fold, or about the same as the Gibbs free energy of binding of CD25 and the binding partner. In some embodiments, the CD25 binding partner is an antibody of CD25.

In some embodiments, the engineered polypeptide has sequence similarity with CD25, or a portion thereof. In some embodiments, the engineered polypeptide has sequence similarity with a portion of the surface of CD25 that binds to an antibody of CD25. In certain embodiments, the sequence similarity is compared to the continuous amino acid sequence of CD25. In other embodiments, the sequence similarity is compared to a discontinuous sequence of CD25. For example, in certain embodiments, a binding surface of folded CD25 is formed by discontinuous amino acid sequences, and the engineered polypeptide has sequence similarity with at least a portion of the discontinuous sequences that form the surface. In some embodiments, the engineered polypeptide has sequence similarity with at least a portion of a continuous amino acid sequence that forms a binding surface of CD25. In some embodiments, the engineered polypeptide has a sequence that is at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or at least 99% identical to at least a portion of a continuous sequence of CD25, such as a continuous sequence that forms a binding surface. In certain embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to at least a portion of the discontinuous sequence of CD25, for example the discontinuous sequence that forms a binding surface. In certain embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to a contiguous portion of CD25. In still further embodiments, the engineered polypeptide has a sequence that is at least 40% identical, at least 45% identical, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, or at least 90% identical, to two or more discontiguous portions of CD25. In some embodiments, for engineered polypeptides that comprise at least two peptides, two or more peptides of the engineered immunogen independently share sequence similarity with CD25, such as with a binding surface of CD25. In some embodiments, the portion of CD25 that shares sequence similarity with the engineered polypeptide is a surface that binds to an antibody to CD25.

c. Linking Moiety

The engineered polypeptides provided herein optionally comprise a linking moiety. When present, the linking moiety may be, for example, independently a cross-link or a linker.

In some embodiments, the engineered polypeptide comprises N number of peptides, and N−1 number of linking moieties; or N number of peptides, and N−1 number of linking moieties; or N number of peptides, and N number of linking moieties; or N number of peptides, and N+1 number of linking moieties; or N number of peptides, and N+2 number of linking moieties; or N number of peptides, and N−2 number of linking moieties, wherein N is 3 or larger.

In some embodiments, the engineered polypeptide comprises at least one linking moiety, at least two linking moieties, at least three linking moieties, at least four linking moieties, at least five linking moieties, at least six linking moieties, between one to six linking moieties, between one to five linking moieties, between one to four linking moieties, between one to three linking moieties, one linking moiety, or two linking moieties. In some embodiments, each linking moiety is independently a cross-link or a linker. In certain embodiments, each linking moiety is a cross-link. In other embodiments, each linking moiety is a linker. In still further embodiments, at least one linking moiety is a cross-link, and the remaining linking moieties are independently cross-links or a linkers. In other embodiments, at least one linking moiety is a linker, and the remaining linking moieties are independently cross-links or a linkers.

A cross-link includes, for example, a covalent bond between the side chain of one amino acid and a moiety of another amino acid. The amino acids may be independently natural or non-natural amino acids. In some embodiments, cross-links include a covalent bond between the side chains of two amino acids, or between the side chain of one amino acid and the amine or carboxyl group of another amino acid. A cross-link may form within one peptide or between two separate peptides. In some embodiments, the engineered polypeptides provided herein comprise mixture of both intra-peptide and inter-peptide cross-links. In some embodiments, the cross-link is a disulfide bond between two thiol groups of amino acid side chains, such as a disulfide bond between two cysteines. In some embodiments, the cross-link is an amide bond between an amine group and a carboxylic acid group of two amino acids, wherein at least one of the amine and the carboxylic acid group is located on a side chain of an amino acid (e.g., the amide bond is not a backbone amide bond). In some embodiments, the cross-link is an amide bond formed between diaminopimelic acid and aspartic acid. In some embodiments, an amide cross-link is a lactam. In some embodiments, the cross-link is an oxime. In some embodiments, the cross-link is a hydrazone. In some embodiments, a cross-link comprises a covalent bond between a side chain of an amino acid and a moiety of another amino acid, wherein one or both of the side chain and the moiety are modified to form the covalent bond. Such modifications may include, for example, oxidation, reduction, reaction with a catalyst to form an intermediate, or other modifications known to one of skill in the art.

A linker includes, for example, a molecule that is covalently bonded to at least two sites of a peptide, or between at least two peptides. A linker may bond to two sites within one peptide or between two separate peptides, or a combination of both. For example, a linker that comprises at more than two peptide-attachment sites may form both intra-peptide and inter-peptide bonds. In engineered polypeptides comprising at least two peptides and at least one linker, the peptides and linker may be connected in a variety of different configurations. For example, an engineered polypeptide may have peptide-linker-peptide-etc. pattern, ending with a peptide. In some embodiments, an engineered polypeptide comprises a linker that forms a branching point, for example a linker that is independently attached to three peptides. In some embodiments, an engineered polypeptide comprises a linker with three peptide-attachment sites, wherein the linker is only attached to two peptides.

In some embodiments, a linker comprises one or more amino acids. Amino acids that form part of a linker may, in some embodiments, be identified separately from the the engineered polypeptide. In certain embodiments, the linker is a region that separates and presents peptides of the engineered polypeptide in a structural, chemical, and/or dynamical manner that reflects the structure and/or function of a functional interface of the interface protein. In still further embodiments, the linker does not have a function on its own when not connected to the peptides of engineered polypeptide, for example does not exhibit binding to a binding partner of CD25. In some embodiments, each linker independently comprises at least one, at least two, at least three, at least four, at least five, at least six, or more amino acids. In some embodiments, each linker independently comprises one amino acid, two amino acids, three amino acids, four amino acids, five amino acids, or six amino acids. Amino acids that form part of a linker may be, in some embodiments, naturally occurring amino acids or non-naturally occurring amino acids. Each linker may, in some embodiments, independently comprise one or more alpha-amino acids, one or more beta-amino acids, or one or more gamma-amino acids, or any combinations thereof. In certain embodiments, a linker independently comprises a cyclic beta residue. Cyclic beta residues may include, for example, APC or ACPC. In still further embodiments, a linker may comprise one or more glycine residues, one or more serine residues, or one or more proline residues. In some embodiments, a linker has an amino acid sequence selected from the group consisting of AP, GP, GSG (SEQ ID NO: 32), (GGGGS)n (SEQ ID NO: 33), (GSG)n (SEQ ID NO: 34), GGGSGGGGS (SEQ ID NO: 35), GGGGSGGGS (SEQ ID NO: 36), (PGSG)n (SEQ ID NO: 37), and PGSGSG (SEQ ID NO: 38), wherein n is an integer between 1 and 10. In some embodiments, the engineered polypeptide comprises at least one linker, wherein each linker does not comprise amino acids, or wherein each linker does not comprise natural amino acids, or wherein each linker comprises at least one non-natural amino acid.

In some embodiments, a linker comprises a polymer. In some embodiments, the polymer is polyethylene glycol (PEG). A linker comprising PEG may comprise, for example, at least 3 PEG monomer units, at least 4 PEG monomer units, at least 5 PEG monomer units, at least 6 PEG monomer units, at least 7 PEG monomer units, at least 8 PEG monomer units, at least 9 PEG monomer units, at least 10 PEG monomer units, at least 11 PEG monomer units, at least 12 PEG monomer units, or greater than 12 PEG monomer units. In some embodiments of a linker comprising PEG, the PEG comprises between 3 to 12 monomer units, between 3 to 6 monomer units, between 6 to 12 monomer units, or between 4 to 8 monomer units. In some embodiments, the engineered polypeptide comprises at least one linker comprising PEG3 (comprising 3 monomer units), PEG6, or PEG12. In some embodiments, at least one linker is independently PEG3, PEG6, or PEG12. In further embodiments, the linker comprises a multi-arm PEG. For example, in certain embodiments, at least one linker independently comprises a 4-arm PEG, or an 8-arm PEG. In certain embodiments, each arm independently comprises between 3 to 12 monomer units, or between 3 to 6 monomer units, or between 6 to 12 monomer units, or between 4 to 8 monomer units. In certain embodiments, each arm of the multi-arm PEG comprises the same number of monomer units, for example a 4- or 8-arm PEG wherein each arm comprises 3 monomer units, 6 monomer units, or 12 monomer units.

In other embodiments, a linker comprises a dendrimer. Dendrimers include, for example, molecules with a tree-like branching architecture, comprising a symmetric core from which molecular moieties radially extend, with branch points forming new layers in the molecule. Each new branch point introduces a new, larger layer, and these radial extensions often terminate in functional groups at the exterior terminal surface of the dendrimer. Thus, increasing the number of branch points in turn amplifies the possible number of terminal functional groups at the surface.

In some embodiments, at least one linker comprises a small molecule that is not an amino acid or polymer. In some embodiments, at least one linker comprises a benzodiazepine. In some embodiments, the linker comprises a moiety that is the product of a sulfhydryl-maleimide reaction, which may be a pyrrolidine dione moiety (for example a pyrrolidine-2,5-dione moiety). In some embodiments, the linker comprises an amidine moiety. In some embodiments, the linker comprises a thioether moiety.

In some embodiments, at least one linker comprises trans-pyrrolidine-3,4-dicarboxamide.

In some embodiments, wherein the engineered polypeptide comprises at least two linkers (e.g., in embodiments wherein the engineered polypeptide comprises at least two linking moieties wherein each linking moiety is independently a linker or a cross-link, or wherein each linking moiety is independently a linker), each linker is independently any of the linkers described herein. For example, in some embodiments, each linker is independently a linker comprising one or more amino acids, a linker comprising a polymer, a linker comprising a dendrimer, or a linker comprising a small molecule that is not an amino acid or polymer.

The one or more linking moieties of the engineered polypeptide may impart a particular structural or functional characteristic of interest, or a combination thereof. For example, in some embodiments a linking moiety is present in the engineered polypeptide to impart a structural characteristic, or a functional characteristic, or a combination thereof. Such structural characteristics may include, for example, increased structural flexibility, decreased structural flexibility, a directional feature, increased length, or decreased length. Directional features that may be of interest may include, for example, a structural turn, or maintaining a linear structure. Functional characteristics may include, for example, enhanced solubility, one or more protonation sites, one or more proteolytic sites, one or more enzymatic modification sites, one or more oxidation sites, a label, or a capture handle. In some embodiments, a linker comprises one or more functional characteristics, or one or more structural characteristics, or a combinations thereof.

In some embodiments, one or more linkers independently introduce a structural “turn” into the engineered polypeptide. Examples of such linker include Gly-Pro, Ala-Pro, and trans-pyrrolidine-3,4-dicarboxamide. In some embodiments, one or more linkers present in the engineered polypeptide increases structural flexibility of the engineered polypeptide, compared to the linker not being present, or the selection of a different linker. For example, a linker that is longer and/or less sterically hindered than another linker may, in some embodiments, result in the molecule having greater structural flexibility than if the linker were not present, or if another linker were used instead. In other embodiments, one or more linking moieties independently decreases structural flexibility in the engineered polypeptide, such as including a linker that is shorter and/or more sterically hindered than another linker, or a cross-link at a location or of a type that reduces flexibility of one or more peptides. The presence of a cross-link at a particular location between certain peptides, or between certain amino acid side chains, may result in the molecule having less structural flexibility than if the cross-link was at a different location or between different side chains (e.g., a disulfide or an amide cross-link), or if the cross-link were not present.

d. Additional Components

In some embodiments, the engineered polypeptides provided herein comprise one or more additional components. For example, in some embodiments, the engineered polypeptide comprises one or more moieties that attach the engineered polypeptide to a solid surface, such as a bead or flat surface. In some embodiments, the attachment moieties comprise a polymer (such as PEG), or biotin, or a combination thereof. In some embodiments, attaching the engineered polypeptide to a solid surface may, for example, enable assessment of one or more characteristics of the engineered polypeptide, such as assessment of binding with a binding partner of CD25 (for example, an antibody to CD25).

e. Sequence Similarity

In some embodiments, the engineered polypeptide provided herein has one of the sequences listed in Table 1:

TABLE 1 SEQ ID NO Sequence SEQ ID NO: 1 CDCQAQWTPGMRAPGYDPYCLNC SEQ ID NO: 2 MVYCQPDCTAKCMHGCDRDTMKECCDRLK SEQ ID NO: 3 DDCPEVPHATFKGPGQKWEGPGGGDCSK SEQ ID NO: 4 DDCIEVPGPAECAERACRAQEERQRQPQCI SEQ ID NO: 5 AEEEKIKIEQKERKTTIKLAKEAK SEQ ID NO: 6 CHLQIMTHGKIIYVPC SEQ ID NO: 7 DDGDRCAKEHEIPHATGEECQKRDKS SEQ ID NO: 8 CKQLVIYFTGNSSHSSVFYIYYDC SEQ ID NO: 9 GSGDEDCKKFQSDDNWENYTSTRHLTFCDEKRS SEQ ID NO: 10 GSGNEEIEKKIKDCTGNSSHSSWEEALECALKK SEQ ID NO: 11 GSGDERIERLIKECTGNSSHSSWEEALECALRR SEQ ID NO: 12 GSGSHPCAYWRWVIKMTHGKTRWVLELVFCYRD SEQ ID NO: 13 GSGKCEEEAKKIASKMTHGKTREEEAEEYLKKC SEQ ID NO: 14 GSGDDESEKRTTERDTRKCTKAKANDNQCQPTE SEQ ID NO: 15 GSGSSEWDKWVEEWYKKMCTEAKKNDNQCQPTK SEQ ID NO: 16 GSGQCRVWVFRNGDKILYIYEDCDNDNQHQQTL

In some embodiments, the engineered polypeptide has at least 6000 sequence similarity with any one of SEQ ID NOS: 1-21. In some embodiments, the engineered polypeptide has at least 7000 sequence similarity with any one of SEQ ID NOS: 1-21. In some embodiments, the engineered polypeptide has at least 8000 sequence similarity with any one of SEQ ID NOS: 1-21. In some embodiments, the engineered polypeptide has at least 90% sequence similarity with any one of SEQ TD NOS: 1-21. In some embodiments, the engineered polypeptide has at least 9500 sequence similarity with any one of SEQ ID NOS: 1-21. In some embodiments, the engineered polypeptide comprises any one of SEQ TD NOS: 1-21. In certain embodiments, the engineered polypeptide has any one of SEQ ID NOS: 1-21.

In some embodiments, the engineered polypeptide comprises any one of SEQ ID NOS: 1-21; and is modified at the N terminus, or the C terminus, or both. For example, in some embodiments the C terminus or the N terminus is covalently bonded to another molecule. In still further embodiments, the engineered polypeptide comprises any one of SEQ ID NOS: 1-21; and one or more amino acids at the N terminus or the C terminus, or both.

In some embodiments, the N-terminal molecule is a biotin-PEG2:

In some embodiments, the C-terminal molecule is a linker followed by biotin (e.g. a -GSGSGK-Biotin (SEQ ID NO: 846)). Other linkers suitable for attaching biotin to the C-terminus of the engineered polypeptide include GSG (SEQ ID NO: 32), GSS (SEQ ID NO: 39), GGS (SEQ ID NO: 40), GGSGGS (SEQ ID NO: 41), GSSGSS (SEQ ID NO: 42), GSGK (SEQ ID NO: 43), GSSK (SEQ ID NO: 44), GGSK (SEQ ID NO: 45), GGSGGSK (SEQ ID NO: 46), GSSGSSK (SEQ ID NO: 47), and the like.

V. Methods of Selecting an Engineered polypeptide

Further provided herein are methods of selecting an engineered polypeptide as described herein. Such methods may include, for example, using an iterative optimization of engineered polypeptide structural characteristics.

In some embodiments, one or more sections of CD25 are identified as the target interface. In some embodiments, at least a portion of the identified section(s) binds to an antibody of CD25. Thus, for example, in some embodiments a portion of CD25 that is an epitope for one or more antibodies is identified as the target interface. In other embodiments, a section of CD25 is identified as the target interface that does not bind to an antibody, or for which it is unknown if antibody binding occurs. In certain embodiments, the crystal structure for at least a portion of CD25 is unknown, and the initial selection of a target interface includes molecular dynamics simulations of CD25 and CD25 binding. In some embodiments, one or more initial input sequences are obtained from the identified section or sections, wherein each sequence is independently continuous or discontinuous. In developing an engineered polypeptide candidate, at least some of the interface residues of each sequence are retained, and one or more linking moieties are incorporated into the sequence to provide desired structural and dynamic characteristics. In some embodiments, one or more non-interface residues are added to the sequence, or one or more residues in the input sequence are replaced with one or more non-interface residues, to achieve desired structural and dynamic characteristics relative to the cognate target structure and dynamics. In some embodiments, these non-interface residues are not from the target interface of CD25, or do not share one or more characteristics with the target interface of CD25, or share fewer characteristics and/or share characteristics less strongly with the target interface of CD25 than the retained interface residues. These intermediate, non-interface residues may, in some embodiments, form part or all of an amino acid linker.

Next, in some embodiments the initial design (or multiple designs) is produced and the molecular dynamics simulated to determine flexibility and overall stability of the design. If this initial design does not meet RMSD requirements, it may undergo iterative optimization of one or more linking moieties (such as one or more cross-links, or intermediate linker residues) using computational mutagenesis, in some embodiments. During this optimization, in some embodiments the interface residues are fixed while one or more of the linking moieties is changed, or removed, or added. The iterative optimization may be repeated until the engineered polypeptide RMSD interface residue positions relative to the target interface and structural order metric meet certain requirements (for example, ≤6.0 Å and ≥0.25, respectively, wherein structural order is on a 0-1 normalized scale, where 1=perfect structural stability).

In some embodiments, the intermediate structural stability residue regions can range from 1-50 amino acids in length. In certain embodiments, these intermediate structural stability residue regions are linkers, for example amino acid linkers. In some embodiments, the relatively small size of an engineered polypeptide produced by certain embodiments of the methods provided herein (compared, for example, to approaches that graft an interface onto a large structurally stabilizing scaffold) may enable chemical synthesis of the molecule, in contrast to a larger molecule that may require an in vitro expression system. Furthermore, in some embodiments the methods provided herein enable the incorporation of non-natural amino acids into intermediate positions or the interface positions, which may allow for fine control of interface engineering with novel moieties and properties such as post-translational modifications, solubility, cell-permeability, enzyme reactivity, pH sensitivity, oxidation sensitivity, etc. In still further embodiments, an engineered polypeptide may be selected with a higher likelihood of species cross-reactivity or disease-related mutation reactivity in selected antibodies when the engineered polypeptide is used as an immunogen or epitope-bait.

In some embodiments, the optimized molecule is the engineered polypeptide provided herein. In other embodiments, the optimized molecule is a candidate engineered polypeptide that may undergo further evaluation, further adjustment, or be used to generate a peptide library or a candidate engineered polypeptide library, or any combinations thereof. In certain embodiments, the method further includes using the engineered polypeptide candidate to generate a peptide library, or an engineered polypeptide candidate library, and then contacting the library with a binding partner of CD25 (such as an antibody to CD25). The peptide library may include, for example, peptides which are smaller than and share at least some sequence similarity with the engineered polypeptide candidate, and in which certain residues are optionally replaced with other residues. An engineered polypeptide candidate library may include, for example, variations of the engineered polypeptide candidate.

In some embodiments, the peptides of the peptide library comprise between 2 to 15 amino acids, between 5 to 15 amino acids, between 10 to 15 amino acids, between 2 to 10 amino acids, or between 5 to 10 amino acids. In some embodiments, the total number of amino acids in each peptide of the library includes both the interface amino acids and structural amino acids, which may include, for example, linker amino acids. The engineered polypeptide candidate library may be prepared by, for example, varying one or more amino acids or linking moieties in the candidates to make new library members. The engineered polypeptide candidates in the engineered polypeptide candidate library, in some embodiments, independently comprise between 5 to 40 amino acids, between 10 to 35 amino acids, between 15 to 35 amino acids, or between 20 to 30 amino acids. In some embodiments, the total number of amino acids in each engineered polypeptide candidate of the candidate library can, in some embodiments, include both the interface amino acids and structural amino acids, which may include, for example, linker amino acids. The peptide library and the engineered polypeptide candidate library can, in some embodiments, independently comprise between 5,000 and 100,000 members, between 5,000 and 80,000 members, between 5,000 and 60,000 members, between 5,000 and 40,000 members, between 5,000 and 30,000 members, between 10,000 and 25,000 members, between 15,000 and 20,000 members, or about 17,000 members (e.g., distinct peptides or distinct engineered polypeptide candidates). In some embodiments, multiple separate libraries are produced and evaluated. In certain embodiments, the library members do not comprise certain cross-links. For example, in some embodiments, a library is evaluated wherein the library members do not have disulfide cross-links.

In some embodiments, to produce candidates for a candidate library, one or more linking moieties is added or removed, or location changed, in the design of the original engineered polypeptide candidate. For example, in some embodiments, a disulfide cross-link is removed, or is added, or the location of which is moved. In other embodiments, a lactam cross-link is removed, or is added, or the location of which is moved. In some embodiments, one or more amino acid residues is replaced. The binding of a CD25 binding partner to the peptide library, or engineered polypeptide candidate library, or both (if present), can provide additional information that may be used to further refine the design of the engineered polypeptide, or to select an engineered polypeptide. Additional information from screening these libraries may, for example, be used to make changes to the engineered polypeptide, for example to increase binding affinity with a binding partner of CD25. The engineered polypeptide candidate library can, in some embodiments, provide additional information regarding the effect of certain linker moieties on binding interactions (including presence or location of such moieties), such as cross-links including disulfide bonds and lactams. The peptide or engineered polypeptide candidate libraries, or both, may in some embodiments be used to identify common motifs (e.g., amino acid patterns or linking moieties, or combinations thereof) that may increase binding affinity or binding specificity for a binding partner of CD25, or provide other desired characteristics. Evaluating the binding of the cognate binding partner with the members of the peptide or the engineered polypeptide candidate libraries, or both, can provide additional structural and functional information, which may be used to further refine the engineered polypeptide design or to select an engineered polypeptide candidate.

a. Selection by Binding under Variable pH

In some embodiments, an engineered polypeptide is selected based, at least in part, on structural flexibility at physiological pH compared to structural flexibility at a lower pH. For example, CD25 may be overexpressed on tumor cells, and therefore binding of an antibody to CD25 with greater affinity in a tumor microenvironment may be desired in some embodiments. Therefore, in some embodiments, it may be desirable to select an engineered polypeptide that is more rigid at lower pH, or in which one or more amino acids have a particular orientation at lower pH, or has greater binding affinity or binding selectivity at lower pH, compared to the same engineered polypeptide at physiological pH. In many cancerous tumors, the growth rate of cancerous cells can outpace the oxygen supply available in portions of the tumor, resulting in a hypoxic microenvironment within the tumor. The level of oxygen in tissues can affect the pH of the tissue environment, and hypoxic levels can lead to decreased pH (including, for example, by the buildup of acidic metabolites from anaerobic glycolysis). Thus, in some embodiments, selecting an engineered polypeptide that has greater binding at low pH (e.g., has desirable structural characteristics that lead to binding interactions), but has reduced binding at physiological pH (e.g., has decreased, fewer, or no desirable structural characteristics that lead to binding interactions), can, in some embodiments, result in an engineered polypeptide that can produce an antibody with greater binding to the desired target in a tumor, compared to binding not in a tumor. Physiological pH is typically between about 7.35 and about 7.45, for example about 7.4. The pH of a tumor microenvironment may be, for example, less than about 7.45, less than about 7.45, between about 7.45 and about 6.0, between about 7.0 and about 6.0, between about 6.8 and about 6.2, between about 6.7 and about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9 or about 7.0. In some embodiments, an engineered polypeptide can be evaluated at different pHs using computational methods, for example molecular dynamics simulations. In other embodiments, an engineered polypeptide is selected based on differential pH characteristics using an in vitro method. Suitable in vitro methods may include, for example, phage panning at different pHs. For example, an antibody phage display library can be used to pan one or more engineered polypeptides at physiological pH, and phage that bind at that pH can be discarded. Then, a second round of panning can be carried out at a lower pH, and phage that bind to the one or more engineered polypeptides at the lower pH can be selected. In some embodiments, engineered polypeptides which bind to no phage at a lower pH, or which bind to phage with similar affinity at both low and physiological pH, may be less desirable for use in generating an antibody that targets tumor cells.

b. Inverse Peptide Evaluation

In still further embodiments, selecting an engineered polypeptide may include comparing the binding of the engineered polypeptide to binding of an inverse engineered polypeptide. An inverse engineered polypeptide may be based on the engineered polypeptide, but replacing one or more of the interface-interacting amino acid residues (e.g., based on the surface of CD25) with an amino acid that exhibits an inverse characteristic. For example, an amino acid with a large, sterically bulky, hydrophobic side chain may be replaced with an amino acid that has a smaller side chain, or hydrophilic side chain, or a side chain that is both smaller and hydrophilic. In some embodiments, an amino acid with a hydrogen bond-donating side chain may be replaced with an amino acid that has a hydrogen bond-accepting side chain, or with a an amino acid that has a side chain that does not hydrogen bond. Binding characteristics that may be compared using the engineered polypeptide and the inverse engineered polypeptide may include, in some embodiments, specificity and/or affinity. Comparing the binding characteristics of a engineered polypeptide with the binding characteristics of an inverse engineered polypeptide may, in some embodiments, help select engineered polypeptides in which the interface-interacting amino acids drive the binding interactions, rather than characteristics of a linking moiety such as a linker. Engineered polypeptides in which binding is driven by a linking moiety such as a linker may be less desirable in some embodiments as they may exhibit off-target binding, or other undesirable binding characteristics.

In further embodiments, the method further comprises modifying the selected engineered polypeptides.

c. Binding Evaluation

As described herein, in some embodiments, the method of selecting an engineered polypeptide provided herein comprises evaluating the binding of an engineered polypeptide candidate to a protein or fragment thereof, for example a binding partner of CD25 (such as an antibody to CD25). For example, in some embodiments, an engineered polypeptide candidate library or peptide library is screened for binding to a binding partner of CD25.

Binding of a protein or fragment thereof (e.g., a binding partner of CD25) with one or more peptides or engineered polypeptide candidates (such as a member of a library) may be evaluated in various ways. In some embodiments, binding is directly evaluated, for example by directly detecting a label on the protein or fragment thereof. Such labels may include, for example, fluorescent labels, such as a fluorophore or a fluorescent protein. In other embodiments, binding is indirectly evaluated, for example using a sandwich assay. In a sandwich assay, a peptide or engineered polypeptide candidate (such as a member of a library) binds to a binding partner, and then a secondary labeled reagent is added to label the bound binding partner. This secondary labeled reagent is then detected. Examples of sandwich assay components include His-tagged-binding partner detected with an anti-His-tag antibody or His-tag-specific fluorescent probe; a biotin-labeled binding partner detected with labeled streptavidin or labeled avidin; or an unlabeled binding partner detected with an anti-binding-partner antibody.

In some embodiments, peptides or engineered polypeptide candidates of interest are identified based on the binding signal, or dose-response, using any number of available detection methods. These detection methods may include, for example, imaging, fluorescence-activated cell sorting (FACS), mass spectrometry, or biosensors. In some embodiments, a hit threshold is defined (for example the median signal), and any with signal above that signal is flagged as a putative hit motif.

For the development of the combinatorial library, peptides identified from the peptide library based on binding with the protein or fragment thereof may, in some embodiments, be further clustered into distinct groups using sequence or structural information, or a combinations thereof. This grouping may be done, for example, using generally available sequence alignment, chemical descriptors, structural prediction, and entropy prediction informatics tools (e.g. MUSCLE, CLUSTALW, PSIPRED, AMBER, Hydropathy Calculator, and Isoelectric Point Calculator) and clustering algorithms (e.g., K-Means, Gibbs, and Hierarchical). Clusters of motifs (e.g., structural or functional motifs) present in peptide hits can be identified from this analysis. Individual peptide motif hits can also be identified. Using these motif clusters and individual motifs, in some embodiments, design rules can be formulated that define one or more of sequence, structure, and chemical characteristics of the motifs that appear to drive the protein interactions at the target interface. In some embodiments, the structure of the target interface is not necessary for identification of these interface motif design rules. Rather, the design rules can, in some embodiments, be derived from analysis of peptides identified from screening the peptide library.

In some embodiments, the binding assay has a sensitivity dynamic range of about 10⁵. Thus, in some embodiments, an engineered polypeptide candidate is identified as of interest if it has a binding event with a CD25 binding partner that is within a 10⁵ signal bracket of the native CD25:binding partner signal. The type of signal may be different depending on what type of assay is being used, or how it is being evaluated. For example, in some embodiments, the signal is response units in a sensorgram, fluorescence signal in an image-based readout, or enzymatic readout in an enzyme-based assay. The signal for binding events may be measured relative to CD25:binding partner signal.

In some embodiments, the engineered polypeptide candidate is modified prior to evaluating binding. For example, in some embodiments, biotin, PEG, or another attachment moiety, or combination thereof, is bonded to the C terminus or the N terminus of the peptide to enable it to be used with a binding evaluation system. For example, in some embodiments biotin-PEG12- is covalently attached to the N-terminus of the engineered polypeptide. In other embodiments, the engineered polypeptide candidate is modified at the C terminus with -GSGSGK-PEG4-biotin (SEQ ID NO: 48). In certain embodiments, such a biotin-modified engineered polypeptide candidate is then bound to a streptavidin bead through the biotin moiety, and the bead-supported immunogen is evaluated for binding to a binding partner of CD25.

VI. Use of Engineered Polypeptides and CD25 Antibodies

The engineered polypeptides provided herein, and identified by the methods provided herein, may be used, for example, to produce one or more antibodies that bind specifically to CD25. In some embodiments, the antibody is a monoclonal or polyclonal antibody.

The term “antibody,” as used herein, refers to a protein, or polypeptide sequences derived from an immunoglobulin molecule, which specifically binds to an antigen. Antibodies can be intact immunoglobulins of polyclonal or monoclonal origin, or fragments thereof and can be derived from natural or from recombinant sources.

The terms “antibody fragment” or “antibody binding domain” refer to at least one portion of an antibody, or recombinant variants thereof, that contains the antigen binding domain, i.e., an antigenic determining variable region of an intact antibody, that is sufficient to confer recognition and specific binding of the antibody fragment to a target, such as an antigen and its defined epitope. Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab′)2, and Fv fragments, single-chain (sc)Fv (“scFv”) antibody fragments, linear antibodies, single domain antibodies (abbreviated “sdAb”) (either VL or VH), camelid VHH domains, and multi-specific antibodies formed from antibody fragments.

The term “scFv” refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a short flexible polypeptide linker, and capable of being expressed as a single polypeptide chain, and wherein the scFv retains the specificity of the intact antibody from which it is derived.

“Heavy chain variable region” or “VH” (or, in the case of single domain antibodies, e.g., nanobodies, “VHH”) with regard to an antibody refers to the fragment of the heavy chain that contains three CDRs interposed between flanking stretches known as framework regions, these framework regions are generally more highly conserved than the CDRs and form a scaffold to support the CDRs.

Unless specified, as used herein a scFv may have the VL and VH variable regions in either order, e.g., with respect to the N-terminal and C-terminal ends of the polypeptide, the scFv may comprise VL-linker-VH or may comprise VH-linker-VL.

The term “antibody light chain,” refers to the smaller of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations. Kappa (“K”).

Thus, in some embodiments, provided herein is an antibody produced by immunizing an animal with an immunogen, wherein the immunogen is an engineered polypeptide as provided herein. In some embodiments, the animal is a human, a rabbit, a mouse, a hamster, a monkey, etc. In certain embodiments, the monkey is a cynomolgus monkey, a macaque monkey, or a rhesus macaque monkey. Immunizing the animal with an engineered polypeptide can comprise, for example, administering at least one dose of a composition comprising the immunogen and optionally an adjuvant to the animal. In some embodiments, generating the antibody from an animal comprises isolating a B cell which expresses the antibody. Some embodiments further comprise fusing the B cell with a myeloma cell to create a hybridoma which expresses the antibody. In some embodiments, the antibody generated using the engineered polypeptide can cross react with a human and a monkey, for example a cynomolgus monkey.

In certain embodiments, the method of generating an antibody further comprises determining one or more epitopes for the antibody. In some embodiments, the method comprises screening the antibody for binding to two or more epitopes, for example by contacting an epitope library with the antibody, and evaluating binding of the antibody to epitopes of the library. In certain embodiments, an antibody that binds to two or more epitopes is discarded. In some embodiments, the engineered polypeptide mimics one epitope of CD25. In other embodiments, the engineered polypeptide mimics two or more epitopes of CD25. In certain embodiments, screening an antibody for binding to two or more epitopes, wherein the engineered polypeptide mimics two or more epitopes of the CD25, comprises contacting an epitope library with the antibody, and evaluating binding of the antibody to epitopes of the library, and discarding one or more antibodies that binds to two or more epitopes, wherein the epitopes are not those mimicked by the engineered polypeptide.

In some embodiments, the antibody produced using an engineered polypeptide as provided herein binds specifically to CD25. In certain embodiments, the antibody does not block binding of IL-2 with CD25 when the antibody is bound to CD25.

In some embodiments, the antibody is a non IL-2-blocking antibody (a non IL-2 blocker)—that is, the binding of the antibody to CD25 does not disrupt or prevent binding of the IL-2 ligand to CD25 (the IL-2 alpha chain), and does not affect IL-2 mediated signal transduction, e.g. signaling through the IL-2/JAK3/STAT-5 signaling pathway. In some embodiments, the antibody does not disrupt the binding of IL-2 ligand to CD25 (IL-2 alpha chain), and binds to a different epitope than where the 7G7B6 antibody binds. In some embodiments, the antibody does not disrupt the binding of the IL-2 ligand to CD25 (IL-2 alpha chain), but does disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor.

In some embodiments, the antibody is an IL-2 blocking antibody, e.g., the antibody disrupts or prevents binding of the IL-2 ligand to the alpha, beta, and/or gamma chains of the receptor, and decreases or inhibits IL-2 mediated signal transduction. In certain embodiments, the antibody disrupts or prevents binding of the IL-2 ligand to CD25. In some embodiments, the antibody disrupts or prevents the binding of the IL-2 ligand to CD25, and binds to a different epitope than to which either daclizumab or baciliximab bind.

In some embodiments, the CD25 antibody is a partially blocking antibody, and partially, but not completely, disrupts binding of the IL-2 ligand to the alpha, beta, and/or gamma chains of the IL-2 receptor (CD25), and/or partially, but not completely decreases IL-2 mediated signal transduction.

In some embodiments, the antibody disrupts or prevents heterotrimerization of the alpha, beta, and gamma IL-2 chains. In some embodiments, the antibody does not block binding of the IL-2 ligand with CD25, but does disrupt or prevent heterotrimerization of the alpha, beta, and gamma IL-2R chains. In certain embodiments, the antibody selectively binds to Treg cells. In other embodiments, the antibody selectively binds to Teff cells.

In still further embodiments, whether an antibody produced using an engineered polypeptide as provided herein blocks binding of CD25 with IL-2 is evaluated. In some embodiments, an antibody that does not block CD25 binding with IL-2 is selected. In other embodiments, an antibody that does block binding of CD25 with IL-2 is selected. Such blocking or non-blocking may be evaluated, for example, by coupling CD25 to a biosensor tip, and evaluating binding by the antibody in the presence and absence IL-2. In some embodiments, the an antibody is expressed with a 6×His tag that can be used with Ni-NTA in flow cytometry to evaluate binding of the antibody, and blocking or non-blocking of IL-2 binding to CD25. In certain embodiments, the binding of the antibody is evaluated at physiological pH (e.g., between about pH 7.3 and about pH 7.5, or about pH 7.4), and also at the pH of a tumor microenvironment (e.g., between about pH 6.4 and about pH 6.6, or about pH 6.5). In certain embodiments, the blocking/non-blocking activity is compared to the binding of an IL-2 blocker antibody (for example, daclizumab or bacliliximab). In certain embodiments, the blocking/non-blocking activity is compared to the binding of an IL-2 non-blocker antibody (for example, antibody 7G7B6). In certain embodiments, the blocking/non-blocking activity is compared to both an IL-2 blocking antibody and an IL-2 non-blocking antibody.

In some embodiments, the antibody is an agonist antibody to CD25. In other embodiments, the antibody is an antagonist antibody to CD25.

In some embodiments, the antibody binds to CD25 in the trans orientation. In other embodiments the antibody binds to CD25 in the cis orientation. In still further embodiments, the antibody is capable of binding to CD25 in either the cis or the trans configuration.

The antibody clone of origin can be identified by the ID shown, e.g. the Clone ID in Table 2. For example, the antibody may comprise the heavy chain complementary determining regions of antibody clone “YU389-A01” as presented in row 1 of Table 2.

In some embodiments, the antibody has a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, each independently selected from those disclosed in Table 2.

TABLE 2 Light Light Light Heavy Chain Heavy Chain Heavy Chain Chain Chain Chain Clone ID CDR 1 CDR 2 CDR 3 CDR 1 CDR 2 CDR 3 YU389-A01 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU389-A02 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU389-A03 GGSISSGGY IYYSGST ARGNLWSGYYF SSNIGNNF DST GSWDTN Y (SEQ ID (SEQ ID NO: (SEQ ID NO: 111) (SEQ ID (SEQ LSGYV NO: 283) 384) NO: 650) ID NO: (SEQ ID 191) NO: 289) YU389-A05 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU389-A07 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU389-B11 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU389-D07 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISNY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 563) ID NO: ID NO: 49) 534) YU390-A11 GFTFSSYG ISYDGSNK AKELLEGAFDI NIETKS DDD QVWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 64) (SEQ ID (SEQ SGHREV 275) 362) NO: 455) ID NO: (SEQ ID 158) NO: 613) YU390-A12 GYTFTSYY INPSGGST ARDRVTMVRGALA KLGDKY KDN QAWDSS (SEQ ID NO: (SEQ ID NO: Y (SEQ ID NO: 97) (SEQ ID (SEQ TYV (SEQ 313) 339) NO: 404) ID NO: ID NO: 386) 473) YU390-B12 GFTFSSYG ISYDGSNK AKELLEGAFDI NIETKS DDD QVWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 64) (SEQ ID (SEQ SGHREV 275) 362) NO: 455) ID NO: (SEQ ID 158) NO: 613) YU390-C03 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ ID PT (SEQ 286) 326) NO: 567) NO: 49) ID NO: 534) YU390-C11 GYTFTSYG ISAYNGNT ARERSYYGMDV QSVSNY GAS QQYNHW (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 105) (SEQ ID (SEQ PPL (SEQ 312) 346) NO: 574) ID NO: ID NO: 260) 544) YU390-D01 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU390-D03 GGTFSSYA IMPIFDTA ASWSERIGYQYGL QTISQW KAS QQYSGD (SEQ ID NO: (SEQ ID NO: DV (SEQ ID NO: (SEQ ID (SEQ SMYT 286) 332) 145) NO: 582) ID NO: (SEQ ID 385) NO: 553) YU390-D05 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU390-D11 GYTFTSYG ISAYNGNT ARERSYYGMDV QSVSNY GAS QQYNHW (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 105) (SEQ ID (SEQ PPL (SEQ 312) 346) NO: 574) ID NO: ID NO: 260) 544) YU390-G03 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU390-H11 GYTFTSYG ISAYNGNT ARERSYYGMDV QSVSNY GAS QQYNHW (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 105) (SEQ ID (SEQ PPL (SEQ 312) 346) NO: 574) ID NO: ID NO: 260) 544) YU392-A05 GYTFTSYY INPSGGST ARDILGLDY (SEQ SSNIGSNY RNN AAWDDS (SEQ ID NO: (SEQ ID NO: ID NO: 81) (SEQ ID (SEQ LSGVV 313) 339) NO: 655) ID NO: (SEQ ID 635) NO: 56) YU392-A07 GYTFTDYY VDPEDGET ATEDTAMGGIDY SSNIGSNY SNN AAWDDS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 146) (SEQ ID (SEQ LNGVV 306) 693) NO: 655) ID NO: (SEQ ID 644) NO: 53) YU392-A09 GYTFTDYY VDPEDGET ATEGRYGMDV NFNIGNNL AND ATWDDS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 147) (SEQ ID (SEQ LSGVV 306) 693) NO: 453) ID NO: (SEQ ID 69) NO: 151) YU392-B11 GYTFTDYY VDPEDGET AVEGGRAPGTYYY SSNIGSNY SNN ATWDDS (SEQ ID NO: (SEQ ID NO: DSSGLAY (SEQ ID (SEQ ID (SEQ LSGVV 306) 693) NO: 153) NO: 655) ID NO: (SEQ ID 644) NO: 151) YU393-A01 GGSISSGGY IYHSGST ARAGYYYGMDV RNIWSY GAS QQSHSTP S (SEQ ID (SEQ ID NO: (SEQ ID NO: 71) (SEQ ID (SEQ IT (SEQ NO: 282) 365) NO: 634) ID NO: ID NO: 260) 526) YU393-A02 GGTFSSYA IIPIFGTA ARDLGTMVRGVIE QSISSW DAF QQYNSY (SEQ ID NO: (SEQ ID NO: PYYFDY (SEQ ID (SEQ ID (SEQ SRT (SEQ 286) 326) NO: 85) NO: 566) ID NO: ID NO: 156) 551) YU393-A03 GGSISSSN IYHSGST ARGVRGTGFDP QSVSSR GAS QQYTNW W (SEQ ID (SEQ ID NO: (SEQ ID NO: 118) (SEQ ID (SEQ PQT (SEQ NO: 284) 365) NO: 576) ID NO: ID NO: 260) 554) YU393-A04 GYTFTSYG ISAYNGNT ARDRNGYFQH QTISGL GAS LQYDRY (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 94) (SEQ ID (SEQ SGA (SEQ 312) 346) NO: 581) ID NO: ID NO: 260) 426) YU393-A08 GFTFSSYG ISYDGSNK AKDLLGELSFFDY DIESEM DDS QVWHTT (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 61) (SEQ ID (SEQ NDHVL 275) 362) NO: 163) ID NO: (SEQ ID 159) NO: 615) YU393-A09 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU393-A11 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU393-B02 GGTFSSYA IIPIFGTA ARDRSYYGMDV QSIGNY AAT QQSKQIP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 96) (SEQ ID (SEQ YT (SEQ 286) 326) NO: 558) ID NO: ID NO: 50) 528) YU393-B03 GGTFSSYA IIPIFGTA ARDKGYYGMDV QGISSW AVS QQSYSLP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 83) (SEQ ID (SEQ LT (SEQ 286) 326) NO: 489) ID NO: ID NO: 154) 531) YU393-B04 GGTFSSYA IIPIFGTA ARDRSYYGMDV QSIGNY AAT QQSKQIP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 96) (SEQ ID (SEQ YT (SEQ 286) 326) NO: 558) ID NO: ID NO: 50) 528) YU393-B05 GFTFSNYG ISHDGHVK AKEISPRSSVGWPL QSVS STY GAS QQFDISG (SEQ ID NO: (SEQ ID NO: DY (SEQ ID NO: 63) (SEQ ID (SEQ GLI (SEQ 271) 349) NO: 577) ID NO: ID NO: 260) 518) YU393-B06 GFTFSSSA ISYDGSNK ARDFWSGYNELGG QDISNY DAS QQYDNL (SEQ ID NO: (SEQ ID NO: MDV (SEQ ID NO: (SEQ ID (SEQ PLT (SEQ 272) 362) 76) NO: 485) ID NO: ID NO: 157) 542) YU393-B07 GFTFSSYW IKQDGSEK ARTWFGEFFDY NIESES DDS QVWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 134) (SEQ ID (SEQ SDHTVA 277) 328) NO: 454) ID NO: (SEQ ID 159) NO: 609) YU393-B08 GYTFTSYG ISAYNGNT ARVIGGWFDP (SEQ SSDVGAY GVS SSYTTTD (SEQ ID NO: (SEQ ID NO: ID NO: 136) NY (SEQ (SEQ TFV (SEQ 312) 346) ID NO: 647) ID NO: ID NO: 295) 665) YU393-C02 GFIFSRHA ISYDGSNK ARGRLAYGDIEGF QDINNY DAS QQYDNL (SEQ ID NO: (SEQ ID NO: DY (SEQ ID NO: (SEQ ID (SEQ PYT (SEQ 264) 362) 112) NO: 482) ID NO: ID NO: 157) 543) YU393-C03 GYTFNNYG ISVYNGDI ARDILRGESSILDH QGISNS AAS QQYYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 82) (SEQ ID (SEQ PH (SEQ 302) 359) NO: 488) ID NO: ID NO: 49) 556) YU393-C05 GGTFSSYA IIPIFGTA ARDRYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 98) (SEQ ID (SEQ LT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 532) YU393-C07 GFTFSSYA ISYDGSNK ARDLLGSGYDIIDY NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 86) (SEQ ID (SEQ SDHVV 273) 362) NO: 456) ID NO: (SEQ ID 159) NO: 610) YU393-C08 GYTFTSYG ISAYNGNT ARVWGKNGDFDY SSNIGNNY DNN GTWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 142) (SEQ ID (SEQ LSAYV 312) 346) NO: 651) ID NO: (SEQ ID 190) NO: 294) YU393-D03 GYTFTTYA INTNTGDP ARDRFHYGMDV EGIRTS GAS QQTHTW (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 90) (SEQ ID (SEQ PWT (SEQ 314) 344) NO: 218) ID NO: ID NO: 260) 538) YU393-D04 GYTFTSYG ISAYNGNT ARDRGDY (SEQ ID QGTSSW AAS QQANSFP (SEQ ID NO: (SEQ ID NO: NO: 92) (SEQ ID (SEQ LT (SEQ 312) 346) NO: 491) ID NO: ID NO: 49) 514) YU393-D05 GFTFNNAW IKSKTDGG TTEGVELLSFGGAP QSISSY AAS QQSYSTP (SEQ ID NO: TT (SEQ ID FDY (SEQ ID NO: (SEQ ID (SEQ YT (SEQ 267) NO: 330) 683) NO: 567) ID NO: ID NO: 49) 536) YU393-D07 GFTFSSYE ISSSGSTI ARRRGGGFDY SSDVGGY DVS SSYTSSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 132) NY (SEQ (SEQ TYV (SEQ 274) 351) ID NO: 649) ID NO: ID NO: 201) 664) YU393-E04 GFTFSSYW IKQDGSEK AREKGSWFDP QSVSNNY GAS QRYGSSP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 102) (SEQ ID (SEQ R (SEQ ID 277) 328) NO: 573) ID NO: NO: 557) 260) YU393-E05 GGTFSSYA IIPIFGTA ARDKGYYGMDV QGINSY AAS QQVHSFP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 83) (SEQ ID (SEQ FT (SEQ 286) 326) NO: 487) ID NO: ID NO: 49) 541) YU393-E07 GFTFSSYG ISSRGSTI ARDRGDRVGGLVF NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: DY (SEQ ID NO: 91) (SEQ ID (SEQ SDHVV 275) 350) NO: 456) ID NO: (SEQ ID 159) NO: 610) YU393-F03 GYSFTTYW IYPGDSDT ARQVAGGLDY QAVRID GAS LQHNTFP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 131) (SEQ ID (SEQ YT (SEQ 300) 377) NO: 472) ID NO: ID NO: 260) 423) YU393-F04 GYTFTSYG ISAYNGNT ARDRGYYGMDV QSISRY AAS QQSHSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 93) (SEQ ID (SEQ LT (SEQ 312) 346) NO: 564) ID NO: ID NO: 49) 527) YU393-F06 GYSFTSYW IYPGDSDT FRFGEGFDY (SEQ QSIGYW RAS QQYNSY (SEQ ID NO: (SEQ ID NO: ID NO: 259) (SEQ ID (SEQ PFT (SEQ 299) 377) NO: 559) ID NO: ID NO: 619) 548) YU393-F07 GYSFTTYW IYPGDSDT ARQVAGGLDY SSNVGSN RNN AAWDDS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 131) Y (SEQ ID (SEQ LSGVV 300) 377) NO: 656) ID NO: (SEQ ID 635) NO: 56) YU393-G01 GYSFNTYW IYPSDSDT ARDGGYYFDD QSVSSTY GTS QQYNSSP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 79) (SEQ ID (SEQ LMYT 297) 383) NO: 577) ID NO: (SEQ ID 291) NO: 547) YU393-G03 GGTFSSYA IIPIFGTA ARDKGYYGMDV QSIKNY AAS QQTYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 83) (SEQ ID (SEQ LT (SEQ 286) 326) NO: 561) ID NO: ID NO: 49) 540) YU393-G04 GYTFTSYG ISAYNGNT ARDFRMDV (SEQ QDIKRR DAS QQANTFP (SEQ ID NO: (SEQ ID NO: ID NO: 75) (SEQ ID (SEQ QT (SEQ 312) 346) NO: 480) ID NO: ID NO: 157) 516) YU393-G07 GFTFRRYW IKQDGSEK ARDAYAYGLDV SGSIASSY EDN QSYDGSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 73) (SEQ ID (SEQ VV (SEQ 268) 328) NO: 640) ID NO: ID NO: 216) 579) YU393-G08 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU393-G11 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU393-G12 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU393-H03 GGSISSSN IYHSGST ARDLMNYGMDV QSISSY AAS QQSYSTP W (SEQ ID (SEQ ID NO: (SEQ ID NO: 87) (SEQ ID (SEQ PT (SEQ NO: 284) 365) NO: 567) ID NO: ID NO: 49) 534) YU393-H07 GFTFSSYA ISYDGSNK ARDLLGSGYDIIDY NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 86) (SEQ ID (SEQ SDHVV 273) 362) NO: 456) ID NO: (SEQ ID 159) NO: 610) YU393-H09 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-A01 GFTFSSYW IKQDGSEK AREYDYGDYVFDY NSNVGNN DND GSWEAR (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 107) Y (SEQ ID (SEQ ESVFV 277) 328) NO: 465) ID NO: (SEQ ID 188) NO: 290) YU394-A02 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-A07 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-A09 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU394-C01 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-E02 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-H01 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-H03 GYSFTSYW IYPGDSDT ARLENNWNYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 128) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-H04 GYSFTSYW IYPGDSDT ARLENNWDYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 127) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-H05 GYSFTSYW IYPGDSDT ARLENNWNYGGW NIGSKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: FDP (SEQ ID NO: (SEQ ID (SEQ SDHWV 299) 377) 128) NO: 456) ID NO: (SEQ ID 159) NO: 611) YU394-H07 GGTFSSYA IIPIFGTA ARDYYYYGMDV QSISRY GAS QQTYND (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 101) (SEQ ID (SEQ PPT (SEQ 286) 326) NO: 564) ID NO: ID NO: 260) 539) YU395-A02 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU395-B12 GYTFTSYG ISAYNGNT ARDIGYYYGMDV SLRSYY GKN NSRDSSG (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 80) (SEQ ID (SEQ NHVV 312) 346) NO: 643) ID NO: (SEQ ID 287) NO: 466) YU395-C06 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISNY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 563) ID NO: ID NO: 49) 534) YU395-C08 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU395-D05 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISNY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 563) ID NO: ID NO: 49) 534) YU396-B12 GYSFSTYW IYPGDSDT ARVGDGYSLDY KLGERF QYI QTWDGSI (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 135) (SEQ ID (SEQ VV (SEQ 298) 377) NO: 405) ID NO: ID NO: 616) 583) YU396-C03 GFTFSSYG ISYDGSNK AKAITSIEPY (SEQ SGSVSTSY NTD VLYMGS (SEQ ID NO: (SEQ ID NO: ID NO: 60) Y (SEQ ID (SEQ GIWV 275) 362) NO: 641) ID NO: (SEQ ID 467) NO: 694) YU396-C12 GYSFSTYW IYPGDSDT ARVGDGYSLDY SSNIGRNY RNH ATWDDA (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 135) (SEQ ID (SEQ LSGWV 298) 377) NO: 652) ID NO: (SEQ ID 633) NO: 149) YU396-G10 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 567) ID NO: ID NO: 49) 534) YU396-H12 GFAFSSYG ISYDGSNK AKGQGDGMDV SSDVGGY GVS SSYTSSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 66) NY (SEQ (SEQ ID TLVV 262) 362) ID NO: 649) NO: (SEQ ID 295) NO: 660) YU397-A01 GYKFANY IYPGDSDT ARLGWGMDV (SEQ QSISSY AAS QQSYSTP W (SEQ ID (SEQ ID NO: ID NO: 129) (SEQ ID (SEQ WT (SEQ NO: 296) 377) NO: 567) ID NO: ID NO: 49) 535) YU397-A02 GYTFKNFG ISGRKGNT ARVWGDTTLGYG QDISNY DAS QQYDNL (SEQ ID NO: (SEQ ID NO: MDV (SEQ ID NO: (SEQ ID (SEQ PLT (SEQ 301) 347) 141) NO: 485) ID NO: ID NO: 157) 542) YU397-A03 GFTFSSYE ISSSGSTI ARRRGGGFDY SSDVGGY DVS SSYTSSS (SEQ ID NO: (SEQ ID NO: SEQ ID NO: 132) NY (SEQ (SEQ TWV 274) 351) ID NO: 649) ID NO: (SEQ ID 201) NO: 663) YU397-B01 GYSFTSYW IYPGDSDT AIPWDAELGNYGM QSISSY AAS LQDYNY (SEQ ID NO: (SEQ ID NO: DV (SEQ ID NO: 59) (SEQ ID (SEQ PPA (SEQ 299) 377) NO: 567) ID NO: ID NO: 49) 422) YU397-B02 GGTFSSYA IIPIFGTA ARGRWSGLGDY EDIRMY EGS QQYYDD (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 113) (SEQ ID (SEQ PQ (SEQ 286) 326) NO: 215) ID NO: ID NO: 219) 555) YU397-D01 GGSISSSN IYHSGST ARARGGRYFDY QGISTY AAS QQLNGY W (SEQ ID (SEQ ID NO: (SEQ ID NO: 72) (SEQ ID (SEQ PTT (SEQ NO: 284) 365) NO: 490) ID NO: ID NO: 49) 525) YU398-A11 GFTFSSYG ISYDGSNK AKGQGDGMDV SSNVGSRT SNN AAWDDS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 66) (SEQ ID (SEQ LIGHV 275) 362) NO: 657) ID NO: (SEQ ID 644) NO: 51) YU398-E10 GFTFSSYS ISSSSSYI ARDQLAARRGYYY NIGTKS DDS QVWDSS (SEQ ID NO: (SEQ ID NO: GMDV (SEQ ID NO: (SEQ ID (SEQ SDHVV 276) 352) 89) NO: 459) ID NO: (SEQ ID 159) NO: 610) YU400-A05 GFTFSSYG ISYDGSNK AKGDVNYGMDV NIGSKT DGR QVWDTS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 65) (SEQ ID (SEQ GDLHWA 275) 362) NO: 457) ID NO: (SEQ ID 162) NO: 614) YU400-A12 GGSISSSN IYHSGST ARDFYYGSGSYPN QSINSY TAS QQSYTTP W (SEQ ID (SEQ ID NO: GYYYGMDV (SEQ (SEQ ID (SEQ LT (SEQ NO: 284) 365) ID NO: 77) NO: 562) ID NO: ID NO: 667) 537) YU400-B07 GFTFSSYG ISYDGSNK AKGDVNYGMDV NIGSKS DDT QVWDSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 65) (SEQ ID (SEQ SDLLWV 275) 362) NO: 456) ID NO: (SEQ ID 160) NO: 612) YU400-D09 GGTFSSYA IIPIFGTA ARDFNPFSITIFEMD SSNIGNNY DNN GTWDSS (SEQ ID NO: (SEQ ID NO: V (SEQ ID NO: 74) (SEQ ID (SEQ LSALV 286) 326) NO: 651) ID NO: (SEQ ID 190) NO: 292) YU400-F07 GFTFSSYG ISYDGSNK AKGDVNYGMDV NIGSKT DGR QVWDTS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 65) (SEQ ID (SEQ GDLHWA 275) 362) NO: 457) ID NO: (SEQ ID 162) NO: 614) YU400-H08 GFTFSSYG ISYDGSNK AKGDVNYGMDV NIGSKT DGR QVWDTS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 65) (SEQ ID (SEQ GDLHWA 275) 362) NO: 457) ID NO: (SEQ ID 162) NO: 614) YU401-A11 GFTFSSYG ISYDGSNK ANLAMGQYFDY SSNIGSNT SNN AAWDDS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 70) (SEQ ID (SEQ LNGPV 275) 362) NO: 654) ID NO: (SEQ ID 644) NO: 52) YU401-B01 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSIITY AAS QQSYSTP (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 103) (SEQ ID (SEQ PT (SEQ 286) 326) NO: 560) ID NO: ID NO: 49) 534) YU401-D11 GFTFSSYG ISYDGSNK ANLAMGQYFDY SSNIGSNT SNN AAWDDS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 70) (SEQ ID (SEQ LNGPV 275) 362) NO: 654) ID NO: (SEQ ID 644) NO: 52) YU401-E11 GFTFSSYA ISYDGSNK ARDLGEAKSSSPHE QSLLHSD EVS MQTKQL (SEQ ID NO: (SEQ ID NO: PDY (SEQ ID NO: GKTY (SEQ PLT (SEQ 273) 362) 84) (SEQ ID ID NO: ID NO: NO: 570) 237) 443) YU401-F11 GFTFSSYA ISYDGSNK ARDLGEAKSSSPHE QSLLHSD EVS MQTKQL (SEQ ID NO: (SEQ ID NO: PDY (SEQ ID NO: GKTY (SEQ PLT (SEQ 273) 362) 84) (SEQ ID ID NO: ID NO: NO: 570) 237) 443) YU401-G07 GFTFSSYG ISYDGSNK AKGDVNYGMDV NIGSKT DGR QVWDTS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 65) (SEQ ID (SEQ GDLHWA 275) 362) NO: 457) ID NO: (SEQ ID 162) NO: 614) YU402-A02 GDSISSSSY INHSGST ARDQEMYYFDY QGISSW AAS QQANSFP Y (SEQ ID (SEQ ID NO: (SEQ ID NO: 88) (SEQ ID (SEQ PT (SEQ NO: 261) 333) NO: 489) ID NO: ID NO: 49) 515) YU402-A11 GGSISRSN IYHTGST ARGKGSYAFDI GGNIARN EDD QSYDGN W (SEQ ID (SEQ ID NO: (SEQ ID NO: 110) Y (SEQ ID (SEQ NHMV NO: 281) 366) NO: 279) ID NO: (SEQ ID 214) NO: 578) YU402-D10 GFTFSSYG ISYDGNNK AKGYSSSPGDY SSDVGAY DVS SSYTSSS (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 67) NY (SEQ (SEQ TLWV 275) 360) ID NO: 647) ID NO: (SEQ ID 201) NO: 661) YU403-G05 GGSISRSN IYHTGST ARGKGSYAFDI GGNIARN EDD QSYDGN W (SEQ ID (SEQ ID NO: (SEQ ID NO: 110) Y (SEQ ID (SEQ NHMV NO: 281) 366) NO: 279) ID NO: (SEQ ID 214) NO: 578)

In some embodiments, the CDR-H1 is selected from: GGTFSSYA (SEQ ID NO: 286), GGSISSGGYY (SEQ ID NO: 283), GFTFSSYG (SEQ ID NO: 275), GYTFTSYY (SEQ ID NO: 313), GYTFTSYG (SEQ ID NO: 312), GYTFTDYY (SEQ ID NO: 306), GGSISSGGYS (SEQ ID NO: 282), GGSISSSNW (SEQ ID NO: 284), GYSFTSYW (SEQ ID NO: 299), GFTFSNYG (SEQ ID NO: 271), GFTFSSSA (SEQ ID NO: 272), GFTFSSYW (SEQ ID NO: 277), GFIFSRHA (SEQ ID NO: 264), GYTFNNYG (SEQ ID NO: 302), GFTFSSYA (SEQ ID NO: 273), GYTFTTYA (SEQ ID NO: 314), GFTFNNAW (SEQ ID NO: 267), GFTFSSYE (SEQ ID NO: 274), GYSFTTYW (SEQ ID NO: 300), GYSFNTYW (SEQ ID NO: 297), GFTFRRYW (SEQ ID NO: 268), GYSFSTYW (SEQ ID NO: 298), GFAFSSYG (SEQ ID NO: 262), GYKFANYW (SEQ ID NO: 296), GYTFKNFG (SEQ ID NO: 301), GFTFSSYS (SEQ ID NO: 276), GDSISSSSYY (SEQ ID NO: 261), and GGSISRSNW (SEQ ID NO: 281);

In some embodiments, the CDR-H2 is selected from: IIPIFGTA (SEQ ID NO: 326), IIPIFGTA (SEQ ID NO: 326), IYYSGST (SEQ ID NO: 384), ISYDGSNK (SEQ ID NO: 362), INPSGGST (SEQ ID NO: 339), ISAYNGNT (SEQ ID NO: 346), IMPIFDTA (SEQ ID NO: 332), VDPEDGET (SEQ ID NO: 693), IYHSGST (SEQ ID NO: 365), IYPGDSDT (SEQ ID NO: 377), ISHDGHVK (SEQ ID NO: 349), IKQDGSEK (SEQ ID NO: 328), ISVYNGDI (SEQ ID NO: 359), INTNTGDP (SEQ ID NO: 344), IKSKTDGGTT (SEQ ID NO: 330), ISSSGSTI (SEQ ID NO: 351), ISSRGSTI (SEQ ID NO: 350), IYPSDSDT (SEQ ID NO: 383), ISGRKGNT (SEQ ID NO: 347), ISSSSSYI (SEQ ID NO: 352), INHSGST (SEQ ID NO: 333), IYHTGST (SEQ ID NO: 366), and ISYDGNNK (SEQ ID NO: 360);

In some embodiments, the CDR-H3 is selected from: AREMYYYYGMDV (SEQ ID NO: 103), AREMYYYYGMDV (SEQ ID NO: 103), ARGNLWSGYYF (SEQ ID NO: 111), AKELLEGAFDI (SEQ ID NO: 64), ARDRVTMVRGALAY (SEQ ID NO: 97), ARERSYYGMDV (SEQ ID NO: 105), ASWSERIGYQYGLDV (SEQ ID NO: 145), ARDILGLDY (SEQ ID NO: 81), ATEDTAMGGIDY (SEQ ID NO: 146), ATEGRYGMDV (SEQ ID NO: 147), AVEGGRAPGTYYYDSSGLAY (SEQ ID NO: 153), ARAGYYYGMDV (SEQ ID NO: 71), ARDLGTMVRGVIEPYYFDY (SEQ ID NO: 85), ARGVRGTGFDP (SEQ ID NO: 118), ARDRNGYFQH (SEQ ID NO: 94), AKDLLGELSFFDY (SEQ ID NO: 61), ARLENNWDYGGWFDP (SEQ ID NO: 127), ARDRSYYGMDV (SEQ ID NO: 96), ARDKGYYGMDV (SEQ ID NO: 83), AKEISPRSSVGWPLDY (SEQ ID NO: 63), ARDFWSGYNELGGMDV (SEQ ID NO: 76), ARTWFGEFFDY (SEQ ID NO: 134), ARVIGGWFDP (SEQ ID NO: 136), ARGRLAYGDTEGFDY (SEQ ID NO: 112), ARDILRGESSILDH (SEQ ID NO: 82), ARDRYYYGMDV (SEQ ID NO: 98), ARDLLGSGYDIIDY (SEQ ID NO: 86), ARVWGKNGDFDY (SEQ ID NO: 142), ARDRFHYGMDV (SEQ ID NO: 90), ARDRGDY (SEQ ID NO: 92), TTEGVELLSFGGAPFDY (SEQ ID NO: 683), ARRRGGGFDY (SEQ ID NO: 132), AREKGSWFDP (SEQ ID NO: 102), ARDRGDRVGGLVFDY (SEQ ID NO: 91), ARQVAGGLDY (SEQ ID NO: 131), ARDRGYYGMDV (SEQ ID NO: 93), FRFGEGFDY (SEQ ID NO: 259), ARDGGYYFDD (SEQ ID NO: 79), ARDFRMDV (SEQ ID NO: 75), ARDAYAYGLDV (SEQ ID NO: 73), ARDLMNYGMDV (SEQ ID NO: 87), AREYDYGDYVFDY (SEQ ID NO: 107), ARLENNWNYGGWFDP (SEQ ID NO: 128), ARDYYYYGMDV (SEQ ID NO: 101), ARDIGYYYGMDV (SEQ ID NO: 80), ARVGDGYSLDY (SEQ ID NO: 135), AKAITSIEPY (SEQ ID NO: 60), AKGQGDGMDV (SEQ ID NO: 66), ARLGWGMDV (SEQ ID NO: 129), ARVWGDTTLGYGMDV (SEQ ID NO: 141), AIPWDAELGNYGMDV (SEQ ID NO: 59), ARGRWSGLGDY (SEQ ID NO: 113), ARARGGRYFDY (SEQ ID NO: 72), ARDQLAARRGYYYGMDV (SEQ ID NO: 89), AKGDVNYGMDV (SEQ ID NO: 65), ARDFYYGSGSYPNGYYYGMDV (SEQ ID NO: 77), ARDFNPFSITIFEMDV (SEQ ID NO: 74), ANLAMGQYFDY (SEQ ID NO: 70), ARDLGEAKSSSPHEPDY (SEQ ID NO: 84), ARDQEMYYFDY (SEQ ID NO: 88), ARGKGSYAFDI (SEQ ID NO: 110), and AKGYSSSPGDY (SEQ ID NO: 67);

In some embodiments, the CDR-L1 is selected from: QSISSY (SEQ ID NO: 567), QSISSY (SEQ ID NO: 567), SSNIGNNF (SEQ ID NO: 650), QSISNY (SEQ ID NO: 563), NIETKS (SEQ ID NO: 455), KLGDKY (SEQ ID NO: 404), QSVSNY (SEQ ID NO: 574), QTISQW (SEQ ID NO: 582), SSNIGSNY (SEQ ID NO: 655), NFNIGNNL (SEQ ID NO: 453), RNIWSY (SEQ ID NO: 634), QSISSW (SEQ ID NO: 566), QSVSSR (SEQ ID NO: 576), QTISGL (SEQ ID NO: 581), DIESEM (SEQ ID NO: 163), NIGSKS (SEQ ID NO: 456), QSIGNY (SEQ ID NO: 558), QGISSW (SEQ ID NO: 489), QSVSSTY (SEQ ID NO: 577), QDISNY (SEQ ID NO: 485), NIESES (SEQ ID NO: 454), SSDVGAYNY (SEQ ID NO: 647), QDINNY (SEQ ID NO: 482), QGISNS (SEQ ID NO: 488), SSNIGNNY (SEQ ID NO: 651), EGIRTS (SEQ ID NO: 218), QGTSSW (SEQ ID NO: 491), SSDVGGYNY (SEQ ID NO: 649), QSVSNNY (SEQ ID NO: 573), QGINSY (SEQ ID NO: 487), QAVRID (SEQ ID NO: 472), QSISRY (SEQ ID NO: 564), QSIGYW (SEQ ID NO: 559), SSNVGSNY (SEQ ID NO: 656), QSIKNY (SEQ ID NO: 561), QDIKRR (SEQ ID NO: 480), SGSIASSY (SEQ ID NO: 640), NSNVGNNY (SEQ ID NO: 465), SLRSYY (SEQ ID NO: 643), KLGERF (SEQ ID NO: 405), SGSVSTSYY (SEQ ID NO: 641), SSNIGRNY (SEQ ID NO: 652), EDIRMY (SEQ ID NO: 215), QGISTY (SEQ ID NO: 490), SSNVGSRT (SEQ ID NO: 657), NIGTKS (SEQ ID NO: 459), NIGSKT (SEQ ID NO: 457), QSINSY (SEQ ID NO: 562), SSNIGSNT (SEQ ID NO: 654), QSIITY (SEQ ID NO: 560), QSLLHSDGKTY (SEQ ID NO: 570), and GGNIARNY (SEQ ID NO: 279).

In some embodiments, the CDR-L2 is selected from: AAS (SEQ ID NO: 49), AAS (SEQ ID NO: 49), DST (SEQ ID NO: 191), DDD (SEQ ID NO: 158), KDN (SEQ ID NO: 386), GAS (SEQ ID NO: 260), KAS (SEQ ID NO: 385), RNN (SEQ ID NO: 635), SNN (SEQ ID NO: 644), AND (SEQ ID NO: 69), DAF (SEQ ID NO: 156), DDS (SEQ ID NO: 159), AAT (SEQ ID NO: 50), AVS (SEQ ID NO: 154), DAS (SEQ ID NO: 157), GVS (SEQ ID NO: 295), DNN (SEQ ID NO: 190), DVS (SEQ ID NO: 201), RAS (SEQ ID NO: 619), GTS (SEQ ID NO: 291), EDN (SEQ ID NO: 216), DND (SEQ ID NO: 188), GKN (SEQ ID NO: 287), QYI (SEQ ID NO: 616), NTD (SEQ ID NO: 467), RNH (SEQ ID NO: 633), EGS (SEQ ID NO: 219), DGR (SEQ ID NO: 162), TAS (SEQ ID NO: 667), DDT (SEQ ID NO: 160), EVS (SEQ ID NO: 237), and EDD (SEQ ID NO: 214).

In some embodiments, the CDR-L3 is selected from: QQSYSTPPT (SEQ ID NO: 534), QQSYSTPPT (SEQ ID NO: 534), GSWDTNLSGYV (SEQ ID NO: 289), QVWDSSSGHREV (SEQ ID NO: 613), QAWDSSTYV (SEQ ID NO: 473), QQYNHWPPL (SEQ ID NO: 544), QQYSGDSMYT (SEQ ID NO: 553), AAWDDSLSGVV (SEQ ID NO: 56), AAWDDSLNGVV (SEQ ID NO: 53), ATWDDSLSGVV (SEQ ID NO: 151), QQSHSTPIT (SEQ ID NO: 526), QQYNSYSRT (SEQ ID NO: 551), QQYTNWPQT (SEQ ID NO: 554), LQYDRYSGA (SEQ ID NO: 426), QVWHTTNDHVL (SEQ ID NO: 615), QVWDSSSDHWV (SEQ ID NO: 611), QQSKQIPYT (SEQ ID NO: 528), QQSYSLPLT (SEQ ID NO: 531), QQFDISGGLI (SEQ ID NO: 518), QQYDNLPLT (SEQ ID NO: 542), QVWDSSSDHTVA (SEQ ID NO: 609), SSYTTTDTFV (SEQ ID NO: 665), QQYDNLPYT (SEQ ID NO: 543), QQYYSTPPH (SEQ ID NO: 556), QQSYSTPLT (SEQ ID NO: 532), QVWDSSSDHVV (SEQ ID NO: 610), GTWDSSLSAYV (SEQ ID NO: 294), QQTHTWPWT (SEQ ID NO: 538), QQANSFPLT (SEQ ID NO: 514), QQSYSTPYT (SEQ ID NO: 536), SSYTSSSTYV (SEQ ID NO: 664), QRYGSSPR (SEQ ID NO: 557), QQVHSFPFT (SEQ ID NO: 541), LQHNTFPYT (SEQ ID NO: 423), QQSHSTPLT (SEQ ID NO: 527), QQYNSYPFT (SEQ ID NO: 548), QQYNSSPLMYT (SEQ ID NO: 547), QQTYSTPLT (SEQ ID NO: 540), QQANTFPQT (SEQ ID NO: 516), QSYDGSSVV (SEQ ID NO: 579), GSWEARESVFV (SEQ ID NO: 290), QQTYNDPPT (SEQ ID NO: 539), NSRDSSGNHVV (SEQ ID NO: 466), QTWDGSIVV (SEQ ID NO: 583), VLYMGSGIWV (SEQ ID NO: 694), ATWDDALSGWV (SEQ ID NO: 149), SSYTSSSTLVV (SEQ ID NO: 660), QQSYSTPWT (SEQ ID NO: 535), SSYTSSSTWV (SEQ ID NO: 663), LQDYNYPPA (SEQ ID NO: 422), QQYYDDPQ (SEQ ID NO: 555), QQLNGYPTT (SEQ ID NO: 525), AAWDDSLIGHV (SEQ ID NO: 51), QVWDTSGDLHWA (SEQ ID NO: 614), QQSYTTPLT (SEQ ID NO: 537), QVWDSSSDLLWV (SEQ ID NO: 612), GTWDSSLSALV (SEQ ID NO: 292), AAWDDSLNGPV (SEQ ID NO: 52), MQTKQLPLT (SEQ ID NO: 443), QQANSFPPT (SEQ ID NO: 515), QSYDGNNHMV (SEQ ID NO: 578), and SSYTSSSTLWV (SEQ ID NO: 661).

In some embodiments, the antibody has a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, each independently selected from those disclosed in Table 3 Å and Table 3B. It is possible to combine the CDRs from different antibodies in any combination to generate new antibodies. Gene synthesis and high-throughput screening technologies enable the skilled person to test all combinations of six CDRs without undue experimentation.

TABLE 3A VH_CDR1 VH_CDR2 VH_CDR3 GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGSISSGGYY IYYSGST (SEQ ARGNLWSGYYF (SEQ ID NO: 111) (SEQ ID NO: 283) ID NO: 384) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GFTFSSYG (SEQ ISYDGSNK (SEQ AKELLEGAFDI (SEQ ID NO: 64) ID NO: 275) ID NO: 362) GYTFTSYY INPSGGST (SEQ ARDRVTMVRGALAY (SEQ ID NO: 97) (SEQ ID NO: 313) ID NO: 339) GFTFSSYG (SEQ ISYDGSNK (SEQ AKELLEGAFDI (SEQ ID NO: 64) ID NO: 275) ID NO: 362) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GYTFTSYG ISAYNGNT (SEQ ARERSYYGMDV (SEQ ID NO: 105) (SEQ ID NO: 312) ID NO: 346) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IMPIFDTA (SEQ ASWSERIGYQYGLDV (SEQ ID NO: 145) ID NO: 286) ID NO: 332) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GYTFTSYG ISAYNGNT (SEQ ARERSYYGMDV (SEQ ID NO: 105) (SEQ ID NO: 312) ID NO: 346) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GYTFTSYG ISAYNGNT (SEQ ARERSYYGMDV (SEQ ID NO: 105) (SEQ ID NO: 312) ID NO: 346) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GYTFTSYY INPSGGST (SEQ ARDILGLDY (SEQ ID NO: 81) (SEQ ID NO: 313) ID NO: 339) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYTFTDYY VDPEDGET ATEDTAMGGIDY (SEQ ID NO: 146) (SEQ ID NO: 306) (SEQ ID NO: 693) GYTFTDYY VDPEDGET ATEGRYGMDV (SEQ ID NO: 147) (SEQ ID NO: 306) (SEQ ID NO: 693) GYTFTDYY VDPEDGET AVEGGRAPGTYYYDSSGLAY (SEQ ID NO: (SEQ ID NO: 306) (SEQ ID NO: 693) 153) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGSISSSNW IYHSGST (SEQ ARGVIAAAGTYFDY (SEQ ID NO: 116) (SEQ ID NO: 284) ID NO: 365) GGSISSSNW IYHSGST (SEQ ARERTHYYYGMDI (SEQ ID NO: 106) (SEQ ID NO: 284) ID NO: 365) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDGAGNYDILTGDRSEDYYYYYGMDV ID NO: 286) ID NO: 326) (SEQ ID NO: 78) GGSISSGGYS IYHSGST (SEQ ARAGYYYGMDV (SEQ ID NO: 71) (SEQ ID NO: 282) ID NO: 365) GGSISSGGYY IYYSGST (SEQ ARDSSSGPYGMDV (SEQ ID NO: 100) (SEQ ID NO: 283) ID NO: 384) GGSISSSNW IYHSGST (SEQ ARVNYGDYDWYFDL (SEQ ID NO: 137) (SEQ ID NO: 284) ID NO: 365) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDLGTMVRGVIEPYYFDY (SEQ ID NO: 85) ID NO: 286) ID NO: 326) GGSISSSNW IYHSGST (SEQ ARGVRGTGFDP (SEQ ID NO: 118) (SEQ ID NO: 284) ID NO: 365) GYTFTSYG ISAYNGNT (SEQ ARDRNGYFQH (SEQ ID NO: 94) (SEQ ID NO: 312) ID NO: 346) GFTFSSYG (SEQ ISYDGSNK (SEQ AKDLLGELSFFDY (SEQ ID NO: 61) ID NO: 275) ID NO: 362) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDRSYYGMDV (SEQ ID NO: 96) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDKGYYGMDV (SEQ ID NO: 83) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDRSYYGMDV (SEQ ID NO: 96) ID NO: 286) ID NO: 326) GFTFSNYG (SEQ ISHDGHVK AKEISPRSSVGWPLDY (SEQ ID NO: 63) ID NO: 271) (SEQ ID NO: 349) GFTFSSSA (SEQ ISYDGSNK (SEQ ARDFWSGYNELGGMDV (SEQ ID NO: 76) ID NO: 272) ID NO: 362) GFTFSSYW IKQDGSEK (SEQ ARTWFGEFFDY (SEQ ID NO: 134) (SEQ ID NO: 277) ID NO: 328) GYTFTSYG ISAYNGNT (SEQ ARVIGGWFDP (SEQ ID NO: 136) (SEQ ID NO: 312) ID NO: 346) GFIFSRHA (SEQ ISYDGSNK (SEQ ARGRLAYGDTEGFDY (SEQ ID NO: 112) ID NO: 264) ID NO: 362) GYTFNNYG ISVYNGDI (SEQ ARDILRGESSILDH (SEQ ID NO: 82) (SEQ ID NO: 302) ID NO: 359) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDRYYYGMDV (SEQ ID NO: 98) ID NO: 286) ID NO: 326) GFTFSSYA (SEQ ISYDGSNK (SEQ ARDLLGSGYDIIDY (SEQ ID NO: 86) ID NO: 273) ID NO: 362) GYTFTSYG ISAYNGNT (SEQ ARVWGKNGDFDY (SEQ ID NO: 142) (SEQ ID NO: 312) ID NO: 346) GYTFTTYA INTNTGDP (SEQ ARDRFHYGMDV (SEQ ID NO: 90) (SEQ ID NO: 314) ID NO: 344) GYTFTSYG ISAYNGNT (SEQ ARDRGDY (SEQ ID NO: 92) (SEQ ID NO: 312) ID NO: 346) GFTFNNAW IKSKTDGGTT TTEGVELLSFGGAPFDY (SEQ ID NO: 683) (SEQ ID NO: 267) (SEQ ID NO: 330) GFTFSSYE (SEQ ISSSGSTI (SEQ ARRRGGGFDY (SEQ ID NO: 132) ID NO: 274) ID NO: 351) GFTFSSYW IKQDGSEK (SEQ AREKGSWFDP (SEQ ID NO: 102) (SEQ ID NO: 277) ID NO: 328) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDKGYYGMDV (SEQ ID NO: 83) ID NO: 286) ID NO: 326) GFTFSSYG (SEQ ISSRGSTI (SEQ ARDRGDRVGGLVFDY (SEQ ID NO: 91) ID NO: 275) ID NO: 350) GYSFTTYW IYPGDSDT (SEQ ARQVAGGLDY (SEQ ID NO: 131) (SEQ ID NO: 300) ID NO: 377) GYTFTSYG ISAYNGNT (SEQ ARDRGYYGMDV (SEQ ID NO: 93) (SEQ ID NO: 312) ID NO: 346) GYSFTSYW IYPGDSDT (SEQ FRFGEGFDY (SEQ ID NO: 259) (SEQ ID NO: 299) ID NO: 377) GYSFTTYW IYPGDSDT (SEQ ARQVAGGLDY (SEQ ID NO: 131) (SEQ ID NO: 300) ID NO: 377) GYSFNTYW IYPSDSDT (SEQ ARDGGYYFDD (SEQ ID NO: 79) (SEQ ID NO: 297) ID NO: 383) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDKGYYGMDV (SEQ ID NO: 83) ID NO: 286) ID NO: 326) GYTFTSYG ISAYNGNT (SEQ ARDFRMDV (SEQ ID NO: 75) (SEQ ID NO: 312) ID NO: 346) GFTFRRYW IKQDGSEK (SEQ ARDAYAYGLDV (SEQ ID NO: 73) (SEQ ID NO: 268) ID NO: 328) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GGSISSSNW IYHSGST (SEQ ARDLMNYGMDV (SEQ ID NO: 87) (SEQ ID NO: 284) ID NO: 365) GFTFSSYA (SEQ ISYDGSNK (SEQ ARDLLGSGYDIIDY (SEQ ID NO: 86) ID NO: 273) ID NO: 362) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GFTFSSYW IKQDGSEK (SEQ AREYDYGDYVFDY (SEQ ID NO: 107) (SEQ ID NO: 277) ID NO: 328) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYTFTGYY INPNSGDT (SEQ AILEYSSSGAEYFQH (SEQ ID NO: 58) (SEQ ID NO: 307) ID NO: 336) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYTFTTYA ISAYNGNT (SEQ ARGGLGGDDAFDI (SEQ ID NO: 108) (SEQ ID NO: 314) ID NO: 346) GGTFSSYA (SEQ ISAYNGNT (SEQ AREPLRYYYYYGMDV (SEQ ID NO: 104) ID NO: 286) ID NO: 346) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWNYGGWFDP (SEQ ID NO: 128) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWDYGGWFDP (SEQ ID NO: 127) (SEQ ID NO: 299) ID NO: 377) GYSFTSYW IYPGDSDT (SEQ ARLENNWNYGGWFDP (SEQ ID NO: 128) (SEQ ID NO: 299) ID NO: 377) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDYYYYGMDV (SEQ ID NO: 101) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGSISSSSYY IYYSGST (SEQ ARLSRYYYYGMDV (SEQ ID NO: 130) (SEQ ID NO: 285) ID NO: 384) GYTFTSYG ISAYNGNT (SEQ ARDIGYYYGMDV (SEQ ID NO: 80) (SEQ ID NO: 312) ID NO: 346) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GFTFSNAW IKSKNDGGTT TTAPSLMDV (SEQ ID NO: 682) (SEQ ID NO: 270) (SEQ ID NO: 329) GYSFSTYW IYPGDSDT (SEQ ARVGDGYSLDY (SEQ ID NO: 135) (SEQ ID NO: 298) ID NO: 377) GFTFSSYG (SEQ ISYDGSNK (SEQ AKAITSIEPY (SEQ ID NO: 60) ID NO: 275) ID NO: 362) GYSFSTYW IYPGDSDT (SEQ ARVGDGYSLDY (SEQ ID NO: 135) (SEQ ID NO: 298) ID NO: 377) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GFTFSSYA (SEQ ISGSGGST (SEQ AKNPYSNYVYWFDP (SEQ ID NO: 68) ID NO: 273) ID NO: 348) GFAFSSYG (SEQ ISYDGSNK (SEQ AKGQGDGMDV (SEQ ID NO: 66) ID NO: 262) ID NO: 362) GYKFANYW IYPGDSDT (SEQ ARLGWGMDV (SEQ ID NO: 129) (SEQ ID NO: 296) ID NO: 377) GYTFKNFG ISGRKGNT (SEQ ARVWGDTTLGYGMDV (SEQ ID NO: 141) (SEQ ID NO: 301) ID NO: 347) GFTFSSYE (SEQ ISSSGSTI (SEQ ARRRGGGFDY (SEQ ID NO: 132) ID NO: 274) ID NO: 351) GYSFTSYW IYPGDSDT (SEQ AIPWDAELGNYGMDV (SEQ ID NO: 59) (SEQ ID NO: 299) ID NO: 377) GGTFSSYA (SEQ IIPIFGTA (SEQ ARGRWSGLGDY (SEQ ID NO: 113) ID NO: 286) ID NO: 326) GGSISSSNW IYHSGST (SEQ ARARGGRYFDY (SEQ ID NO: 72) (SEQ ID NO: 284) ID NO: 365) GFTFSSYG (SEQ ISYDGSNK (SEQ AKGQGDGMDV (SEQ ID NO: 66) ID NO: 275) ID NO: 362) GFTFSSYS (SEQ ISSSSSYI (SEQ ARDQLAARRGYYYGMDV (SEQ ID NO: 89) ID NO: 276) ID NO: 352) GFDFNWYG IWYDGSNE ARDRRGSGWYEYFDY (SEQ ID NO: 95) (SEQ ID NO: 263) (SEQ ID NO: 363) GFTFSSYG (SEQ ISYDGSNK (SEQ AKGDVNYGMDV (SEQ ID NO: 65) ID NO: 275) ID NO: 362) GFTFSSYG (SEQ ISYDGSDK (SEQ AKDLSGLPIIDY (SEQ ID NO: 62) ID NO: 275) ID NO: 361) GGSISSSNW IYHSGST (SEQ ARDFYYGSGSYPNGYYYGMDV (SEQ ID NO: (SEQ ID NO: 284) ID NO: 365) 77) GFTFSSYG (SEQ ISYDGSNK (SEQ AKGDVNYGMDV (SEQ ID NO: 65) ID NO: 275) ID NO: 362) GGTFSSYA (SEQ IIPIFGTA (SEQ ARDFNPFSITIFEMDV (SEQ ID NO: 74) ID NO: 286) ID NO: 326) GFTFSSYG (SEQ ISYDGSNK (SEQ AKGDVNYGMDV (SEQ ID NO: 65) ID NO: 275) ID NO: 362) GFTFSSYG (SEQ ISYDGSNK (SEQ AKGDVNYGMDV (SEQ ID NO: 65) ID NO: 275) ID NO: 362) GFTFSSYG (SEQ ISYDGSNK (SEQ ANLAMGQYFDY (SEQ ID NO: 70) ID NO: 275) ID NO: 362) GGTFSSYA (SEQ IIPIFGTA (SEQ AREMYYYYGMDV (SEQ ID NO: 103) ID NO: 286) ID NO: 326) GFTFGDYA INTDGSIT (SEQ ARDSHTVYYGSGSQDY (SEQ ID NO: 99) (SEQ ID NO: 266) ID NO: 343) GFTFSSYG (SEQ ISYDGSNK (SEQ ANLAMGQYFDY (SEQ ID NO: 70) ID NO: 275) ID NO: 362) GFTFSSYA (SEQ ISYDGSNK (SEQ ARDLGEAKSSSPHEPDY (SEQ ID NO: 84) ID NO: 273) ID NO: 362) GFTFSSYA (SEQ ISYDGSNK (SEQ ARDLGEAKSSSPHEPDY (SEQ ID NO: 84) ID NO: 273) ID NO: 362) GFTFSSYG (SEQ ISYDGSNK (SEQ AKGDVNYGMDV (SEQ ID NO: 65) ID NO: 275) ID NO: 362) GDSISSSSYY INHSGST (SEQ ARDQEMYYFDY (SEQ ID NO: 88) (SEQ ID NO: 261) ID NO: 333) GGSISRSNW IYHTGST (SEQ ARGKGSYAFDI (SEQ ID NO: 110) (SEQ ID NO: 281) ID NO: 366) GFTFSSYG (SEQ ISYDGSDK (SEQ AKDLSGLPIIDY (SEQ ID NO: 62) ID NO: 275) ID NO: 361) GFTFSSYG (SEQ ISYDGNNK AKGYSSSPGDY (SEQ ID NO: 67) ID NO: 275) (SEQ ID NO: 360) GGSISRSNW IYHTGST (SEQ ARGKGSYAFDI (SEQ ID NO: 110) (SEQ ID NO: 281) ID NO: 366)

TABLE 3B VL_CDR1 VL_CDR2 VL_CDR3 QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) SSNIGNNF (SEQ ID NO: 650) DST (SEQ ID NO: 191) GSWDTNLSGYV (SEQ ID NO: 289) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISNY (SEQ ID NO: 563) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) NIETKS (SEQ ID NO: 455) DDD (SEQ ID NO: 158) QVWDSSSGHREV(SEQ ID NO: 613) KLGDKY (SEQ ID NO: 404) KDN (SEQ ID NO: 386) QAWDSSTYV (SEQ ID NO: 473) NIETKS (SEQ ID NO: 455) DDD (SEQ ID NO: 158) QVWDSSSGHREV (SEQ ID NO: 613) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSVSNY (SEQ ID NO: 574) GAS (SEQ ID NO: 260) QQYNHWPPL (SEQ ID NO: 544) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QTISQW (SEQ ID NO: 582) KAS (SEQ ID NO: 385) QQYSGDSMYT (SEQ ID NO: 553) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSVSNY (SEQ ID NO: 574) GAS (SEQ ID NO: 260) QQYNHWPPL (SEQ ID NO: 544) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSVSNY (SEQ ID NO: 574) GAS (SEQ ID NO: 260) QQYNHWPPL (SEQ ID NO: 544) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPA (SEQ ID NO: 533) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPA (SEQ ID NO: 533) SSNIGSNY (SEQ ID NO: 655) RNN (SEQ ID NO: 635) AAWDDSLSGVV (SEQ ID NO: 56) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) SSNIGSNY (SEQ ID NO: 655) SNN (SEQ ID NO: 644) AAWDDSLNGVV (SEQ ID NO: 53) NFNIGNNL (SEQ ID NO: 453) AND (SEQ ID NO: 69) ATWDDSLSGVV (SEQ ID NO: 151) SSNIGSNY (SEQ ID NO: 655) SNN (SEQ ID NO: 644) ATWDDSLSGVV (SEQ ID NO: 151) QSISNY (SEQ ID NO: 563) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) RPNVASNS (SEQ ID NO: 636) SDN (SEQ ID NO: 638) ETWDDSLRGVV (SEQ ID NO: 227) SSNIGSNT (SEQ ID NO: 654) SNN (SEQ ID NO: 644) AAWDDSLNGYV (SEQ ID NO: 54) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) YSNIGSNT (SEQ ID NO: 726) SDN (SEQ ID NO: 638) ATWDDSLNGPV (SEQ ID NO: 150) RNIWSY (SEQ ID NO: 634) GAS (SEQ ID NO: 260) QQSHSTPIT (SEQ ID NO: 526) NIGSQS (SEQ ID NO: 458) DDY (SEQ ID NO: 161) QIWDSSSAHVV (SEQ ID NO: 510) SSNIGSNF (SEQ ID NO: 653) SNN (SEQ ID NO: 644) AAWDDSLRSYV (SEQ ID NO: 55) QSISSW (SEQ ID NO: 566) DAF (SEQ ID NO: 156) QQYNSYSRT (SEQ ID NO: 551) QSVSSR (SEQ ID NO: 576) GAS (SEQ ID NO: 260) QQYTNWPQT (SEQ ID NO: 554) QTISGL (SEQ ID NO: 581) GAS (SEQ ID NO: 260) LQYDRYSGA (SEQ ID NO: 426) DIESEM (SEQ ID NO: 163) DDS (SEQ ID NO: 159) QVWHTTNDHVL (SEQ ID NO: 615) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) QSIGNY (SEQ ID NO: 558) AAT (SEQ ID NO: 50) QQSKQIPYT (SEQ ID NO: 528) QGISSW (SEQ ID NO: 489) AVS (SEQ ID NO: 154) QQSYSLPLT (SEQ ID NO: 531) QSIGNY (SEQ ID NO: 558) AAT (SEQ ID NO: 50) QQSKQIPYT (SEQ ID NO: 528) QSVSSTY (SEQ ID NO: 577) GAS (SEQ ID NO: 260) QQFDISGGLI (SEQ ID NO: 518) QDISNY (SEQ ID NO: 485) DAS (SEQ ID NO: 157) QQYDNLPLT (SEQ ID NO: 542) NIESES (SEQ ID NO: 454) DDS (SEQ ID NO: 159) QVWDSSSDHTVA (SEQ ID NO: 609) SSDVGAYNY (SEQ ID NO: 647) GVS (SEQ ID NO: 295) SSYTTTDTFV (SEQ ID NO: 665) QDINNY (SEQ ID NO: 482) DAS (SEQ ID NO: 157) QQYDNLPYT (SEQ ID NO: 543) QGISNS (SEQ ID NO: 488) AAS (SEQ ID NO: 49) QQYYSTPPH (SEQ ID NO: 556) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPLT (SEQ ID NO: 532) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHVV (SEQ ID NO: 610) SSNIGNNY (SEQ ID NO: 651) DNN (SEQ ID NO: 190) GTWDSSLSAYV (SEQ ID NO: 294) EGIRTS (SEQ ID NO: 218) GAS (SEQ ID NO: 260) QQTHTWPWT (SEQ ID NO: 538) QGTSSW (SEQ ID NO: 491) AAS (SEQ ID NO: 49) QQANSFPLT (SEQ ID NO: 514) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPYT (SEQ ID NO: 536) SSDVGGYNY (SEQ ID NO: 649) DVS (SEQ ID NO: 201) SSYTSSSTYV (SEQ ID NO: 664) QSVSNNY (SEQ ID NO: 573) GAS (SEQ ID NO: 260) QRYGSSPR (SEQ ID NO: 557) QGINSY (SEQ ID NO: 487) AAS (SEQ ID NO: 49) QQVHSFPFT (SEQ ID NO: 541) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHVV (SEQ ID NO: 610) QAVRID (SEQ ID NO: 472) GAS (SEQ ID NO: 260) LQHNTFPYT (SEQ ID NO: 423) QSISRY (SEQ ID NO: 564) AAS (SEQ ID NO: 49) QQSHSTPLT (SEQ ID NO: 527) QSIGYW (SEQ ID NO: 559) RAS (SEQ ID NO: 619) QQYNSYPFT (SEQ ID NO: 548) SSNVGSNY (SEQ ID NO: 656) RNN (SEQ ID NO: 635) AAWDDSLSGVV (SEQ ID NO: 56) QSVSSTY (SEQ ID NO: 577) GTS (SEQ ID NO: 291) QQYNSSPLMYT (SEQ ID NO: 547) QSIKNY (SEQ ID NO: 561) AAS (SEQ ID NO: 49) QQTYSTPLT (SEQ ID NO: 540) QDIKRR (SEQ ID NO: 480) DAS (SEQ ID NO: 157) QQANTFPQT (SEQ ID NO: 516) SGSIASSY (SEQ ID NO: 640) EDN (SEQ ID NO: 216) QSYDGSSVV (SEQ ID NO: 579) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHVV (SEQ ID NO: 610) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NSNVGNNY (SEQ ID NO: 465) DND (SEQ ID NO: 188) GSWEARESVFV (SEQ ID NO: 290) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) QSVSSN (SEQ ID NO: 575) AAS (SEQ ID NO: 49) QQYNNWWT (SEQ ID NO: 545) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) QSISSH (SEQ ID NO: 565) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPWT (SEQ ID NO: 535) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHWV (SEQ ID NO: 611) QSISRY (SEQ ID NO: 564) GAS (SEQ ID NO: 260) QQTYNDPPT (SEQ ID NO: 539) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) SSNIGNNY (SEQ ID NO: 651) DNN (SEQ ID NO: 190) GTWDSSLSAWV (SEQ ID NO: 293) SLRSYY (SEQ ID NO: 643) GKN (SEQ ID NO: 287) NSRDSSGNHVV (SEQ ID NO: 466) QSISNY (SEQ ID NO: 563) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) QSISNY (SEQ ID NO: 563) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) NIGSKS (SEQ ID NO: 456) DDS (SEQ ID NO: 159) QVWDSSSDHPVV (SEQ ID NO: 608) KLGERF (SEQ ID NO: 405) QYI (SEQ ID NO: 616) QTWDGSIVV (SEQ ID NO: 583) SGSVSTSYY (SEQ ID NO: 641) NTD (SEQ ID NO: 467) VLYMGSGIWV (SEQ ID NO: 694) SSNIGRNY (SEQ ID NO: 652) RNH (SEQ ID NO: 633) ATWDDALSGWV (SEQ ID NO: 149) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPPT (SEQ ID NO: 534) SGRIASNY (SEQ ID NO: 639) QDD (SEQ ID NO: 479) QSYDSTTLV (SEQ ID NO: 580) SSDVGGYNY (SEQ ID NO: 649) GVS (SEQ ID NO: 295) SSYTSSSTLVV (SEQ ID NO: 660) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) QQSYSTPWT (SEQ ID NO: 535) QDISNY (SEQ ID NO: 485) DAS (SEQ ID NO: 157) QQYDNLPLT (SEQ ID NO: 542) SSDVGGYNY (SEQ ID NO: 649) DVS (SEQ ID NO: 201) SSYTSSSTWV (SEQ ID NO: 663) QSISSY (SEQ ID NO: 567) AAS (SEQ ID NO: 49) LQDYNYPPA (SEQ ID NO: 422) EDIRMY (SEQ ID NO: 215) EGS (SEQ ID NO: 219) QQYYDDPQ (SEQ ID NO: 555) QGISTY (SEQ ID NO: 490) AAS (SEQ ID NO: 49) QQLNGYPTT (SEQ ID NO: 525) SSNVGSRT (SEQ ID NO: 657) SNN (SEQ ID NO: 644) AAWDDSLIGHV (SEQ ID NO: 51) NIGTKS (SEQ ID NO: 459) DDS (SEQ ID NO: 159) QVWDSSSDHVV (SEQ ID NO: 610) SSDVGGYNY (SEQ ID NO: 649) EVS (SEQ ID NO: 237) SSYTSSSTPV (SEQ ID NO: 662) NIGSKT (SEQ ID NO: 457) DGR (SEQ ID NO: 162) QVWDTSGDLHWA (SEQ ID NO: 614) SSDVGGYNY (SEQ ID NO: 649) EVS (SEQ ID NO: 237) SSYTSSSTLV (SEQ ID NO: 659) QSINSY (SEQ ID NO: 562) TAS (SEQ ID NO: 667) QQSYTTPLT (SEQ ID NO: 537) NIGSKS (SEQ ID NO: 456) DDT (SEQ ID NO: 160) QVWDSSSDLLWV (SEQ ID NO: 612) SSNIGNNY (SEQ ID NO: 651) DNN (SEQ ID NO: 190) GTWDSSLSALV (SEQ ID NO: 292) NIGSKT (SEQ ID NO: 457) DGR (SEQ ID NO: 162) QVWDTSGDLHWA (SEQ ID NO: 614) NIGSKT (SEQ ID NO: 457) DGR (SEQ ID NO: 162) QVWDTSGDLHWA (SEQ ID NO: 614) SSNIGSNT (SEQ ID NO: 654) SNN (SEQ ID NO: 644) AAWDDSLNGPV (SEQ ID NO: 52) QSIITY (SEQ ID NO: 560) AAS (SEQ ID NO: 49)  QQSYSTPPT (SEQ ID NO: 534) SSDVGGYNY (SEQ ID NO: 649) EVS (SEQ ID NO: 237) SSYTSSSTLV (SEQ ID NO: 659) SSNIGSNT (SEQ ID NO: 654) SNN (SEQ ID NO: 644) AAWDDSLNGPV (SEQ ID NO: 52) QSLLHSDGKTY (SEQ ID NO: 570) EVS (SEQ ID NO: 237) MQTKQLPLT (SEQ ID NO: 443) QSLLHSDGKTY (SEQ ID NO: 570) EVS (SEQ ID NO: 237) MQTKQLPLT (SEQ ID NO: 443) NIGSKT (SEQ ID NO: 457) DGR (SEQ ID NO: 162) QVWDTSGDLHWA (SEQ ID NO: 614) QGISSW (SEQ ID NO: 489) AAS (SEQ ID NO: 49) QQANSFPPT (SEQ ID NO: 515) GGNIARNY (SEQ ID NO: 279) EDD (SEQ ID NO: 214) QSYDGNNHMV (SEQ ID NO: 578) SSDVGGYNF (SEQ ID NO: 648) EVS (SEQ ID NO: 237) SSYTKNNSVV (SEQ ID NO: 658) SSDVGAYNY (SEQ ID NO: 647) DVS (SEQ ID NO: 201) SSYTSSSTLWV (SEQ ID NO: 661) GGNIARNY (SEQ ID NO: 279) EDD (SEQ ID NO: 214) QSYDGNNHMV (SEQ ID NO: 578)

In some embodiments, the antibody has the six CDRs of any one of the combinations provided in Table 4.

TABLE 4 Combi- nation # VH_CDR1 VH_CDR2 VH_CDR3 VL_CDR1 VL_CDR2 VL_CDR3   1. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)   2. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)   3. GGSISSGGY IYYSGST ARGNLWS SSNIGNNF DST (SEQ GSWDTNLS Y (SEQ ID (SEQ ID GYYF (SEQ (SEQ ID ID NO: 191) GYV (SEQ NO: 283) NO: 384) ID NO: 111) NO: 650) ID NO: 289)   4. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)   5. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)   6. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)   7. GGTFSSYA IIPIFGTA AREMYYY QSISNY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 563) NO: 534) NO: 103)   8. GFTFSSYG ISYDGSNK AKELLEGA NIETKS DDD (SEQ QVWDSSS (SEQ ID NO: (SEQ ID FDI (SEQ ID (SEQ ID ID NO: 158) GHREV 275) NO: 362) NO: 64) NO: 455) (SEQ ID NO: 613)   9. GYTFTSYY INPSGGST ARDRVTM KLGDKY KDN (SEQ QAWDSST (SEQ ID NO: (SEQ ID VRGALAY (SEQ ID ID NO: 386) YV (SEQ ID 313) NO: 339) (SEQ ID NO: 404) NO: 473) NO: 97)  10. GFTFSSYG ISYDGSNK AKELLEGA NIETKS DDD (SEQ QVWDSSS (SEQ ID NO: (SEQ ID FDI (SEQ ID (SEQ ID ID NO: 158) GHREV 275) NO: 362) NO: 64) NO: 455) (SEQ ID NO: 613)  11. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  12. GYTFTSYG ISAYNGNT ARERSYYG QSVSNY GAS (SEQ QQYNHWP (SEQ ID NO: (SEQ ID MDV (SEQ (SEQ ID ID NO: 260) PL (SEQ ID 312) NO: 346) ID NO: 105) NO: 574) NO: 544)  13. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  14. GGTFSSYA IMPIFDTA ASWSERIG QTISQW KAS (SEQ QQYSGDS (SEQ ID NO: (SEQ ID YQYGLDV (SEQ ID ID NO: 385) MYT (SEQ 286) NO: 332) (SEQ ID NO: 582) ID NO: 553) NO: 145)  15. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  16. GYTFTSYG ISAYNGNT ARERSYYG QSVSNY GAS (SEQ QQYNHWP (SEQ ID NO: (SEQ ID MDV (SEQ (SEQ ID ID NO: 260) PL (SEQ ID 312) NO: 346) ID NO: 105) NO: 574) NO: 544)  17. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  18. GYTFTSYG ISAYNGNT ARERSYYG QSVSNY GAS (SEQ QQYNHWP (SEQ ID NO: (SEQ ID MDV (SEQ (SEQ ID ID NO: 260) PL (SEQ ID 312) NO: 346) ID NO: 105) NO: 574) NO: 544)  19. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) A (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 533) NO: 103)  20. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) A (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 533) NO: 103)  21. GYTFTSYY INPSGGST ARDILGLD SSNIGSNY RNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID Y (SEQ ID (SEQ ID ID NO: 635) SGVV (SEQ 313) NO: 339) NO: 81) NO: 655) ID NO: 56)  22. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  23. GYTFTDYY VDPEDGET ATEDTAM SSNIGSNY SNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID GGIDY (SEQ ID ID NO: 644) NGVV (SEQ 306) NO: 693) (SEQ ID NO: 655) ID NO: 53) NO: 146)  24. GYTFTDYY VDPEDGET ATEGRYG NFNIGNNL AND (SEQ ATWDDSLS (SEQ ID NO: (SEQ ID MDV (SEQ (SEQ ID ID NO: 69) GVV (SEQ 306) NO: 693) ID NO: 147) NO: 453) ID NO: 151)  25. GYTFTDYY VDPEDGET AVEGGRAP SSNIGSNY SNN (SEQ ATWDDSLS (SEQ ID NO: (SEQ ID GTYYYDSS (SEQ ID ID NO: 644) GVV (SEQ 306) NO: 693) GLAY (SEQ NO: 655) ID NO: 151) ID NO: 153)  26. GGTFSSYA IIPIFGTA AREMYYY QSISNY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 563) NO: 534) NO: 103)  27. GGSISSSNW IYHSGST ARGVIAAA RPNVASNS SDN (SEQ ETWDDSLR (SEQ ID NO: (SEQ ID GTYFDY (SEQ ID ID NO: 638) GVV (SEQ 284) NO: 365) (SEQ ID NO: 636) ID NO: 227) NO: 116)  28. GGSISSSNW IYHSGST ARERTHYY SSNIGSNT SNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID YGMDI (SEQ ID ID NO: 644) NGYV (SEQ 284) NO: 365) (SEQ ID NO: 654) ID NO: 54) NO: 106)  29. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  30. GGTFSSYA IIPIFGTA ARDGAGN YSNIGSNT SDN (SEQ ATWDDSL (SEQ ID NO: (SEQ ID YDILTGDR (SEQ ID ID NO: 638) NGPV (SEQ 286) NO: 326) SEDYYYY NO: 726) ID NO: 150) YGMDV (SEQ ID NO: 78)  31. GGSISSGGY IYHSGST ARAGYYY RNIWSY GAS (SEQ QQSHSTPIT S (SEQ ID (SEQ ID GMDV (SEQ ID ID NO: 260) (SEQ ID NO: 282) NO: 365) (SEQ ID NO: 634) NO: 526) NO: 71)  32. GGSISSGGY IYYSGST ARDSSSGP NIGSQS DDY (SEQ QIWDSSSA Y (SEQ ID (SEQ ID YGMDV (SEQ ID ID NO: 161) HVV (SEQ NO: 283) NO: 384) (SEQ ID NO: 458) ID NO: 510) NO: 100)  33. GGSISSSNW IYHSGST ARVNYGD SSNIGSNF SNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID YDWYFDL (SEQ ID ID NO: 644) RSYV (SEQ 284) NO: 365) (SEQ ID NO: 653) ID NO: 55) NO: 137)  34. GGTFSSYA IIPIFGTA ARDLGTM QSISSW DAF (SEQ QQYNSYSR (SEQ ID NO: (SEQ ID VRGVIEPY (SEQ ID ID NO: 156) T (SEQ ID 286) NO: 326) YFDY (SEQ NO: 566) NO: 551) ID NO: 85)  35. GGSISSSNW IYHSGST ARGVRGT QSVSSR GAS (SEQ QQYTNWP (SEQ ID NO: (SEQ ID GFDP (SEQ (SEQ ID ID NO: 260) QT (SEQ ID 284) NO: 365) ID NO: 118) NO: 576) NO: 554)  36. GYTFTSYG ISAYNGNT ARDRNGY QTISGL GAS (SEQ LQYDRYSG (SEQ ID NO: (SEQ ID FQH (SEQ (SEQ ID ID NO: 260) A (SEQ ID 312) NO: 346) ID NO: 94) NO: 581) NO: 426)  37. GFTFSSYG ISYDGSNK AKDLLGEL DIESEM DDS (SEQ QVWHTTN (SEQ ID NO: (SEQ ID SFFDY (SEQ ID ID NO: 159) DHVL (SEQ 275) NO: 362) (SEQ ID NO: 163) ID NO: 615) NO: 61)  38. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  39. GGTFSSYA IIPIFGTA ARDRSYY QSIGNY AAT (SEQ QQSKQIPY (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 50) T (SEQ ID 286) NO: 326) (SEQ ID NO: 558) NO: 528) NO: 96)  40. GGTFSSYA IIPIFGTA ARDKGYY QGISSW AVS (SEQ QQSYSLPL (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 154) T (SEQ ID 286) NO: 326) (SEQ ID NO: 489) NO: 531) NO: 83)  41. GGTFSSYA IIPIFGTA ARDRSYY QSIGNY AAT (SEQ QQSKQIPY (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 50) T (SEQ ID 286) NO: 326) (SEQ ID NO: 558) NO: 528) NO: 96)  42. GFTFSNYG ISHDGHVK AKEISPRSS QSVSSTY GAS (SEQ QQFDISGG (SEQ ID NO: (SEQ ID VGWPLDY (SEQ ID ID NO: 260) LI (SEQ ID 271) NO: 349) (SEQ ID NO: 577) NO: 518) NO: 63)  43. GFTFSSSA ISYDGSNK ARDFWSG QDISNY DAS (SEQ QQYDNLPL (SEQ ID NO: (SEQ ID YNELGGM (SEQ ID ID NO: 157) T (SEQ ID 272) NO: 362) DV (SEQ ID NO: 485) NO: 542) NO: 76)  44. GFTFSSYW IKQDGSEK ARTWFGEF NIESES DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID FDY (SEQ (SEQ ID ID NO: 159) DHTVA 277) NO: 328) ID NO: 134) NO: 454) (SEQ ID NO: 609)  45. GYTFTSYG ISAYNGNT ARVIGGWF SSDVGAY GVS (SEQ SSYTTTDT (SEQ ID NO: (SEQ ID DP (SEQ ID NY (SEQ ID ID NO: 295) FV (SEQ ID 312) NO: 346) NO: 136) NO: 647) NO: 665)  46. GFIFSRHA ISYDGSNK ARGRLAY QDINNY DAS (SEQ QQYDNLP (SEQ ID NO: (SEQ ID GDTEGFDY (SEQ ID ID NO: 157) YT (SEQ ID 264) NO: 362) (SEQ ID NO: 482) NO: 543) NO: 112)  47. GYTFNNYG ISVYNGDI ARDILRGE QGISNS AAS (SEQ QQYYSTPP (SEQ ID NO: (SEQ ID SSILDH (SEQ ID ID NO: 49) H (SEQ ID 302) NO: 359) (SEQ ID NO: 488) NO: 556) NO: 82)  48. GGTFSSYA IIPIFGTA ARDRYYY QSISSY AAS (SEQ QQSYSTPL (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 532) NO: 98)  49. GFTFSSYA ISYDGSNK ARDLLGSG NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID YDIIDY (SEQ ID ID NO: 159) DHVV (SEQ 273) NO: 362) (SEQ ID NO: 456) ID NO: 610) NO: 86)  50. GYTFTSYG ISAYNGNT ARVWGKN SSNIGNNY DNN (SEQ GTWDSSLS (SEQ ID NO: (SEQ ID GDFDY (SEQ ID ID NO: 190) AYV (SEQ 312) NO: 346) (SEQ ID NO: 651) ID NO: 294) NO: 142)  51. GYTFTTYA INTNTGDP ARDRFHY EGIRTS GAS (SEQ QQTHTWP (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 260) WT (SEQ ID 314) NO: 344) (SEQ ID NO: 218) NO: 538) NO: 90)  52. GYTFTSYG ISAYNGNT ARDRGDY QGTSSW AAS (SEQ QQANSFPL (SEQ ID NO: (SEQ ID (SEQ ID (SEQ ID ID NO: 49) T (SEQ ID 312) NO: 346) NO: 92) NO: 491) NO: 514)  53. GFTFNNAW IKSKTDGG TTEGVELL QSISSY AAS (SEQ QQSYSTPY (SEQ ID NO: TT (SEQ ID SFGGAPFD (SEQ ID ID NO: 49) T (SEQ ID 267) NO: 330) Y (SEQ ID NO: 567) NO: 536) NO: 683)  54. GFTFSSYE ISSSGSTI ARRRGGGF SSDVGGY DVS (SEQ SSYTSSSTY (SEQ ID NO: (SEQ ID DY (SEQ ID NY (SEQ ID ID NO: 201) V (SEQ ID 274) NO: 351) NO: 132) NO: 649) NO: 664)  55. GFTFSSYW IKQDGSEK AREKGSW QSVSNNY GAS (SEQ QRYGSSPR (SEQ ID NO: (SEQ ID FDP (SEQ (SEQ ID ID NO: 260) (SEQ ID 277) NO: 328) ID NO: 102) NO: 573) NO: 557)  56. GGTFSSYA IIPIFGTA ARDKGYY QGINSY AAS (SEQ QQVHSFPF (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 487) NO: 541) NO: 83)  57. GFTFSSYG ISSRGSTI ARDRGDR NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID VGGLVFD (SEQ ID ID NO: 159) DHVV (SEQ 275) NO: 350) Y (SEQ ID NO: 456) ID NO: 610) NO: 91)  58. GYSFTTYW IYPGDSDT ARQVAGG QAVRID GAS (SEQ LQHNTFPY (SEQ ID NO: (SEQ ID LDY (SEQ (SEQ ID ID NO: 260) T (SEQ ID 300) NO: 377) ID NO: 131) NO: 472) NO: 423)  59. GYTFTSYG ISAYNGNT ARDRGYY QSISRY AAS (SEQ QQSHSTPL (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 49) T (SEQ ID 312) NO: 346) (SEQ ID NO: 564) NO: 527) NO: 93)  60. GYSFTSYW IYPGDSDT FRFGEGFD QSIGYW RAS (SEQ QQYNSYPF (SEQ ID NO: (SEQ ID Y (SEQ ID (SEQ ID ID NO: 619) T (SEQ ID 299) NO: 377) NO: 259) NO: 559) NO: 548)  61. GYSFTTYW IYPGDSDT ARQVAGG SSNVGSNY RNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID LDY (SEQ (SEQ ID ID NO: 635) SGVV (SEQ 300) NO: 377) ID NO: 131) NO: 656) ID NO: 56)  62. GYSFNTYW IYPSDSDT ARDGGYY QSVSSTY GTS (SEQ QQYNSSPL (SEQ ID NO: (SEQ ID FDD (SEQ (SEQ ID ID NO: 291) MYT (SEQ 297) NO: 383) ID NO: 79) NO: 577) ID NO: 547)  63. GGTFSSYA IIPIFGTA ARDKGYY QSIKNY AAS (SEQ QQTYSTPL (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 561) NO: 540) NO: 83)  64. GYTFTSYG ISAYNGNT ARDFRMD QDIKRR DAS (SEQ QQANTFPQ (SEQ ID NO: (SEQ ID V (SEQ ID (SEQ ID ID NO: 157) T (SEQ ID 312) NO: 346) NO: 75) NO: 480) NO: 516)  65. GFTFRRYW IKQDGSEK ARDAYAY SGSIASSY EDN (SEQ QSYDGSSV (SEQ ID NO: (SEQ ID GLDV (SEQ (SEQ ID ID NO: 216) V (SEQ ID 268) NO: 328) ID NO: 73) NO: 640) NO: 579)  66. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  67. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  68. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  69. GGSISSSNW IYHSGST ARDLMNY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 49) T (SEQ ID 284) NO: 365) (SEQ ID NO: 567) NO: 534) NO: 87)  70. GFTFSSYA ISYDGSNK ARDLLGSG NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID YDIIDY (SEQ ID ID NO: 159) DHVV (SEQ 273) NO: 362) (SEQ ID NO: 456) ID NO: 610) NO: 86)  71. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  72. GFTFSSYW IKQDGSEK AREYDYG NSNVGNN DND (SEQ GSWEARES (SEQ ID NO: (SEQ ID DYVFDY Y (SEQ ID ID NO: 188) VFV (SEQ 277) NO: 328) (SEQ ID NO: 465) ID NO: 290) NO: 107)  73. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  74. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  75. GYTFTGYY INPNSGDT AILEYSSSG QSVSSN AAS (SEQ QQYNNW (SEQ ID NO: (SEQ ID AEYFQH (SEQ ID ID NO: 49) WT (SEQ ID 307) NO: 336) (SEQ ID NO: 575) NO: 545) NO: 58)  76. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  77. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  78. GYTFTTYA ISAYNGNT ARGGLGG QSISSH AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID DDAFDI (SEQ ID ID NO: 49) T (SEQ ID 314) NO: 346) (SEQ ID NO: 565) NO: 534) NO: 108)  79. GGTFSSYA ISAYNGNT AREPLRYY QSISSY AAS (SEQ QQSYSTPW (SEQ ID NO: (SEQ ID YYYGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 346) (SEQ ID NO: 567) NO: 535) NO: 104)  80. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  81. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  82. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID NYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 128) NO: 611)  83. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID DYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 127) NO: 611)  84. GYSFTSYW IYPGDSDT ARLENNW NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID NYGGWFD (SEQ ID ID NO: 159) DHWV 299) NO: 377) P (SEQ ID NO: 456) (SEQ ID NO: 128) NO: 611)  85. GGTFSSYA IIPIFGTA ARDYYYY QSISRY GAS (SEQ QQTYNDPP (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 260) T (SEQ ID 286) NO: 326) (SEQ ID NO: 564) NO: 539) NO: 101)  86. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  87. GGSISSSSYY IYYSGST ARLSRYYY SSNIGNNY DNN (SEQ GTWDSSLS (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 190) AWV (SEQ 285) NO: 384) (SEQ ID NO: 651) ID NO: 293) NO: 130)  88. GYTFTSYG ISAYNGNT ARDIGYYY SLRSYY GKN (SEQ NSRDSSGN (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 287) HVV (SEQ 312) NO: 346) (SEQ ID NO: 643) ID NO: 466) NO: 80)  89. GGTFSSYA IIPIFGTA AREMYYY QSISNY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 563) NO: 534) NO: 103)  90. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  91. GGTFSSYA IIPIFGTA AREMYYY QSISNY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 563) NO: 534) NO: 103)  92. GFTFSNAW IKSKNDGG TTAPSLMD NIGSKS DDS (SEQ QVWDSSS (SEQ ID NO: TT (SEQ ID V (SEQ ID (SEQ ID ID NO: 159) DHPVV 270) NO: 329) NO: 682) NO: 456) (SEQ ID NO: 608)  93. GYSFSTYW IYPGDSDT ARVGDGY KLGERF QYI (SEQ QTWDGSIV (SEQ ID NO: (SEQ ID SLDY (SEQ (SEQ ID ID NO: 616) V (SEQ ID 298) NO: 377) ID NO: 135) NO: 405) NO: 583)  94. GFTFSSYG ISYDGSNK AKAITSIEP SGSVSTSY NTD (SEQ VLYMGSGI (SEQ ID NO: (SEQ ID Y (SEQ ID Y (SEQ ID ID NO: 467) WV (SEQ ID 275) NO: 362) NO: 60) NO: 641) NO: 694)  95. GYSFSTYW IYPGDSDT ARVGDGY SSNIGRNY RNH (SEQ ATWDDAL (SEQ ID NO: (SEQ ID SLDY (SEQ (SEQ ID ID NO: 633) SGWV (SEQ 298) NO: 377) ID NO: 135) NO: 652) ID NO: 149)  96. GGTFSSYA IIPIFGTA AREMYYY QSISSY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 567) NO: 534) NO: 103)  97. GFTFSSYA ISGSGGST AKNPYSNY SGRIASNY QDD (SEQ QSYDSTTL (SEQ ID NO: (SEQ ID VYWFDP (SEQ ID ID NO: 479) V (SEQ ID 273) NO: 348) (SEQ ID NO: 639) NO: 580) NO: 68)  98. GFAFSSYG ISYDGSNK AKGQGDG SSDVGGY GVS (SEQ SSYTSSSTL (SEQ ID NO: (SEQ ID MDV (SEQ NY (SEQ ID ID NO: 295) VV (SEQ ID 262) NO: 362) ID NO: 66) NO: 649) NO: 660)  99. GYKFANYW IYPGDSDT ARLGWGM QSISSY AAS (SEQ QQSYSTPW (SEQ ID NO: (SEQ ID DV (SEQ ID (SEQ ID NO: 129) T (SEQ ID 296) NO: 377) ID NO: 49) NO: 567) NO: 535) 100. GYTFKNFG ISGRKGNT ARVWGDT QDISNY DAS (SEQ QQYDNLPL (SEQ ID NO: (SEQ ID TLGYGMD (SEQ ID ID NO: 157) T (SEQ ID 301) NO: 347) V (SEQ ID NO: 485) NO: 542) NO: 141) 101. GFTFSSYE ISSSGSTI ARRRGGGF SSDVGGY DVS (SEQ SSYTSSST (SEQ ID NO: (SEQ ID DY (SEQ ID NY (SEQ ID ID NO: 201) WV (SEQ ID 274) NO: 351) NO: 132) NO: 649) NO: 663) 102. GYSFTSYW IYPGDSDT AIPWDAEL QSISSY AAS (SEQ LQDYNYPP (SEQ ID NO: (SEQ ID GNYGMDV (SEQ ID ID NO: 49) A (SEQ ID 299) NO: 377) (SEQ ID NO: 567) NO: 422) NO: 59) 103. GGTFSSYA IIPIFGTA ARGRWSG EDIRMY EGS (SEQ QQYYDDP (SEQ ID NO: (SEQ ID LGDY (SEQ (SEQ ID ID NO: 219) Q (SEQ ID 286) NO: 326) ID NO: 113) NO: 215) NO: 555) 104. GGSISSSNW IYHSGST ARARGGR QGISTY AAS (SEQ QQLNGYPT (SEQ ID NO: (SEQ ID YFDY (SEQ (SEQ ID ID NO: 49) T (SEQ ID 284) NO: 365) ID NO: 72) NO: 490) NO: 525) 105. GFTFSSYG ISYDGSNK AKGQGDG SSNVGSRT SNN (SEQ AAWDDSLI (SEQ ID NO: (SEQ ID MDV (SEQ (SEQ ID ID NO: 644) GHV (SEQ 275) NO: 362) ID NO: 66) NO: 657) ID NO: 51) 106. GFTFSSYS ISSSSSYI ARDQLAA NIGTKS DDS (SEQ QVWDSSS (SEQ ID NO: (SEQ ID RRGYYYG (SEQ ID ID NO: 159) DHVV (SEQ 276) NO: 352) MDV (SEQ NO: 459) ID NO: 610) ID NO: 89) 107. GFDFNWYG IWYDGSNE ARDRRGSG SSDVGGY EVS (SEQ SSYTSSSTP (SEQ ID NO: (SEQ ID WYEYFDY NY (SEQ ID ID NO: 237) V (SEQ ID 263) NO: 363) (SEQ ID NO: 649) NO: 662) NO: 95) 108. GFTFSSYG ISYDGSNK AKGDVNY NIGSKT DGR (SEQ QVWDTSG (SEQ ID NO: (SEQ ID GMDV SEQ ID ID NO: 162) DLHWA 275) NO: 362) (SEQ ID NO: 457) (SEQ ID NO: 65) NO: 614) 109. GFTFSSYG ISYDGSDK AKDLSGLP SSDVGGY EVS (SEQ SSYTSSSTL (SEQ ID NO: (SEQ ID IIDY (SEQ NY (SEQ ID ID NO: 237) V (SEQ ID 275) NO: 361) ID NO: 62) NO: 649) NO: 659) 110. GGSISSSNW IYHSGST ARDFYYGS QSINSY TAS (SEQ QQSYTTPL (SEQ ID NO: (SEQ ID GSYPNGYY (SEQ ID ID NO: 667) T (SEQ ID 284) NO: 365) YGMDV NO: 562) NO: 537) (SEQ ID NO: 77) 111. GFTFSSYG ISYDGSNK AKGDVNY NIGSKS DDT (SEQ QVWDSSS (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 160) DLLWV 275) NO: 362) (SEQ ID NO: 456) (SEQ ID NO: 65) NO: 612) 112. GGTFSSYA IIPIFGTA ARDFNPFSI SSNIGNNY DNN (SEQ GTWDSSLS (SEQ ID NO: (SEQ ID TIFEMDV (SEQ ID ID NO: 190) ALV (SEQ 286) NO: 326) (SEQ ID NO: 651) ID NO: 292) NO: 74) 113. GFTFSSYG ISYDGSNK AKGDVNY NIGSKT DGR (SEQ QVWDTSG (SEQ ID NO: (SEQ ID GMDV SEQ ID ID NO: 162) DLHWA 275) NO: 362) (SEQ ID NO: 457) (SEQ ID NO: 65) NO: 614) 114. GFTFSSYG ISYDGSNK AKGDVNY NIGSKT DGR (SEQ QVWDTSG (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 162) DLHWA 275) NO: 362) (SEQ ID NO: 457) (SEQ ID NO: 65) NO: 614) 115. GFTFSSYG ISYDGSNK ANLAMGQ SSNIGSNT SNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID YFDY (SEQ (SEQ ID ID NO: 644) NGPV (SEQ 275) NO: 362) ID NO: 70) NO: 654) ID NO: 52) 116. GGTFSSYA IIPIFGTA AREMYYY QSIITY AAS (SEQ QQSYSTPP (SEQ ID NO: (SEQ ID YGMDV (SEQ ID ID NO: 49) T (SEQ ID 286) NO: 326) (SEQ ID NO: 560) NO: 534) NO: 103) 117. GFTFGDYA INTDGSIT ARDSHTVY SSDVGGY EVS (SEQ SSYTSSSTL (SEQ ID NO: (SEQ ID YGSGSQDY NY (SEQ ID ID NO: 237) V (SEQ ID 266) NO: 343) (SEQ ID NO: 649) NO: 659) NO: 99) 118. GFTFSSYG ISYDGSNK ANLAMGQ SSNIGSNT SNN (SEQ AAWDDSL (SEQ ID NO: (SEQ ID YFDY (SEQ (SEQ ID ID NO: 644) NGPV (SEQ 275) NO: 362) ID NO: 70) NO: 654) ID NO: 52) 119. GFTFSSYA ISYDGSNK ARDLGEA QSLLHSDG EVS (SEQ MQTKQLPL (SEQ ID NO: (SEQ ID KSSSPHEP KTY (SEQ ID NO: 237) T (SEQ ID 273) NO: 362) DY (SEQ ID ID NO: 570) NO: 443) NO: 84) 120. GFTFSSYA ISYDGSNK ARDLGEA QSLLHSDG EVS (SEQ MQTKQLPL (SEQ ID NO: (SEQ ID KSSSPHEP KTY (SEQ ID NO: 237) T (SEQ ID 273) NO: 362) DY (SEQ ID ID NO: 570) NO: 443) NO: 84) 121. GFTFSSYG ISYDGSNK AKGDVNY NIGSKT DGR (SEQ QVWDTSG (SEQ ID NO: (SEQ ID GMDV (SEQ ID ID NO: 162) DLHWA 275) NO: 362) (SEQ ID NO: 457) (SEQ ID NO: 65) NO: 614) 122. GDSISSSSYY INHSGST ARDQEMY QGISSW AAS (SEQ QQANSFPP (SEQ ID NO: (SEQ ID YFDY (SEQ (SEQ ID ID NO: 49) T (SEQ ID 261) NO: 333) ID NO: 88) NO: 489) NO: 515) 123. GGSISRSNW IYHTGST ARGKGSY GGNIARNY EDD (SEQ QSYDGNN (SEQ ID NO: (SEQ ID AFDI (SEQ (SEQ ID ID NO: 214) HMV (SEQ 281) NO: 366) ID NO: 110) NO: 279) ID NO: 578) 124. GFTFSSYG ISYDGSDK AKDLSGLP SSDVGGY EVS (SEQ SSYTKNNS (SEQ ID NO: (SEQ ID IIDY (SEQ NF (SEQ ID ID NO: 237) VV (SEQ ID 275) NO: 361) ID NO: 62) NO: 648) NO: 658) 125. GFTFSSYG ISYDGNNK AKGYSSSP SSDVGAY DVS (SEQ SSYTSSSTL (SEQ ID NO: (SEQ ID GDY (SEQ NY (SEQ ID ID NO: 201) WV (SEQ ID 275) NO: 360) ID NO: 67) NO: 647) NO: 661) 126. GGSISRSNW IYHTGST ARGKGSY GGNIARNY EDD (SEQ QSYDGNN (SEQ ID NO: (SEQ ID AFDI (SEQ (SEQ ID ID NO: 214) HMV (SEQ 281) NO: 366) ID NO: 110) NO: 279) ID NO: 578)

In some embodiments, the antibody is an scFv selected from Table 5, or any antibody having an antigen-binding domain derived from the scFv's in Table 5. In embodiments, the full length heavy chain and light chain variable regions are extracted from the scFv sequences in Table 5 and used to generate soluble Fab fragments, monoclonal antibodies, bispecific antibodies, or any other type of antibody known in the art. Where an scFv in Table 5 is a VH:VL scFv, it is possible to reverse the order of the heavy and light chains to generate a VL:VH scFv. Where an scFv in Table 5 is a VL: VH scFv, it is possible to reverse the order of the heavy and light chains to generate a VH: VL scFv.

TABLE 5 Clone ID scFv sequence YU389-A01 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIKCQQSYSTPPTF (SEQ ID NO: 728) YU389-A02 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWEIVMTQSPSSLSASVGDRVTITCR ASQSISSYLNWYQQKPGKAPKLLTYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGPGTKVDIKCQQSYSTPPTF (SEQ ID NO: 729) YU389-A03 PSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYN PSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGNLWSGYYFWG QGTLVTVSSCARGNLWSGYYFWQSVLTQPPSVSAAPGQKVTISCSGSSS NIGNNFVSWYQQVPGTAPKLLTYDSTKRPAGIPDRFSGSKSGTSATLEIA GLQTGDEADYYCGSWDTNLSGYVFGTGTKVTVLCGSWDTNLSGYVF (SEQ ID NO: 730) YU389-A04 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIKCQQSYSTPPTF (SEQ ID NO: 731) YU389-A05 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVETNCQQSYSTPPTF (SEQ ID NO: 732) YU389-A07 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVETKCQQSYSTPPTF (SEQ ID NO: 733) YU389-B11 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWEIVMTQSPSSLSASVGDRVTITCR ASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCQQSYSTPPTFGQGTKLEIKCQQSYSTPPTF (SEQ ID NO: 734) YU389-D07 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSYSTPPTFGQGTKLEIKCQQSYSTPPTF (SEQ ID NO: 735) YU390-A11 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKELLEGAFDIW GQGTMVTVSSCAKELLEGAFDIWSYVLTQPPSLSVAPGQTARITCGGD NIETKSVHWYQQRPGQAPVLVVYDDDDRPSGIPERFSGSNSGNTATLTI SRVEAGDEADYYCQVWDSSSGHREVFGGRTKPALLCQVWDSSSGHRE VF (SEQ ID NO: 736) YU390-A12 PGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSY AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDRVTMVRGA LAYWGQGTLVTVSSCARDRVTMVRGALAYWSYELTQPPSVSVSPGHT ATITCSGEKLGDKYVYWYQQKPGQSPLLVMYKDNKRPSATPERFSGSN SGDTATLTIRGTQAMDEADYYCQAWDSSTYVFGSGTKVTVLCQAWDS STYVF (SEQ ID NO: 737) YU390-B12 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKELLEGAFDIW GQGTMVTVSSCAKELLEGAFDIWSYVLTQPPSLSVAPGQTARITCGGD NIETKSVHWYQQRPGQAPVLVVYDDDDRPSGIPERFSGSNSGNTATLTI SRVEAGDEADYYCQVWDSSSGHREVFGGGTKLTVLCQVWDSSSGHRE VF (SEQ ID NO: 738) YU390-C03 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGPKVEIKCQQSYSTPPTF (SEQ ID NO: 739) YU390-C11 PGASAKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARERSYYGMDV WGQGTTVTVSSCARERSYYGMDVWTQSPATLSVSPGESATLSCRASQS VSNYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSL QSEDFAVYYCQQYNHWPPLFGGGTKVETKCQQYNHWPPLF (SEQ ID NO: 740) YU390-D01 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGPKVELKCQQSYSTPPTF (SEQ ID NO: 741) YU390-D03 PGSSVKVSCKVSGGTFSSYAISWVRQAPGQGLEWMGGIMPIFDTAEYA QKFQGRVTITADESTSTAYMELSTLRSEDTAVYYCASWSERIGYQYGL DVWGQGTTVTVSSCASWSERIGYQYGLDVWDIRMTQSPSTLSASVGD RVSITCRASQTISQWLAWFHQKPGKAPKWYKASRLESGVSSRFSGSGS GTEFTLTITSLQPDDIGTYYCQQYSGDSMYTFGQGTRLEIRCQQYSGDS MYTF (SEQ ID NO: 742) YU390-D05 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVETCQQSYSTPPTF (SEQ ID NO: 743) YU390-D11 PGASAKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARERSYYGMDV WGQGTTVTVSSCARERSYYGMDVWTQSPATLSVSPGESATLSCRASQS VSNYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSL QSEDFAVYYCQQYNHWPPLFGGGTKVEIKCQQYNHWPPLF (SEQ ID NO: 744) YU390-G03 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVELKCQQSYSTPPTF (SEQ ID NO: 745) YU390-H11 PGASAKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARERSYYGMDV WGQGTTVTVSSCARERSYYGMDVWTQSPATLSVSPGESATLSCRASQS VSNYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSL QSEDFAVYYCQQYNHWPPLFGGGNGGEIKCQQYNHWPPLF (SEQ ID NO: 746) YU392-A05 PGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSY AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDILGLDYWG QGTLVTVSSCARDILGLDYWQPGLTQPPSASETPGQRVTISCSGSSSNIG SNYVYWYQQLPGTAPKLLIYRNNQRPSGVPGRFSGSKSGTSASLAISGL RSEDEADYYCAAWDDSLSGVVFGGGTKLTVCAAWDDSLSGVVF (SEQ ID NO: 747) YU392-A07 PGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIY AEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATEDTAMGGIDY WGQGTLVTVSSCATEDTAMGGIDYWQPVLTQSPSASGTPGQRVTISCS GSSSNIGSNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSA SLAISGLQSEDEADYYCAAWDDSLNGVVFGGGTKLTVLCAAWDDSLN GVVF (SEQ ID NO: 748) YU392-A09 PGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIY AEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATEGRYGMDVW GQGTTVTVSSCATEGRYGMDVWQAVLTQPPSVSGTPGQRVTISCSGNN FNIGNNLVYWYQQLPGTAPKLLIYANDERPSGVPDRFSGSKSGTSASLA ISGLRSEDDADYYCATWDDSLSGVVFGGGTKLTALCATWDDSLSGVV F (SEQ ID NO: 749) YU392-B11 PGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIY AEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCAVEGGRAPGTYY YDSSGLAYWGQGTLVTVSSCAVEGGRAPGTYYYDSSGLAYWQAGLT QPPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYSNNQR PSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDSLSGVVFGGG TKLTVLCATWDDSLSGVVF (SEQ ID NO: 750) YU393-A01 PSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSGSTYYNP SLKSRVTISVDRSKNQFSLKLSSVTAADTAVYYCARAGYYYGMDVWG QGTTVTVSSCARAGYYYGMDVWDIVMTQTPSSLSASVGDRVAITCQA SRNIWSYVNWYQQKPGEAPRLLIYGASTLQRGVPSRFSGSGSGTGFTLT INSLQPEDFATYFCQQSHSTPITFGGGTRVDIKCQQSHSTPITF (SEQ ID NO: 751) YU393-A02 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADKSTSTAYMELSSLRSDDTAVYYCARDLGTMVRGVIEP YYFDYWGQGTLVTVSSCARDLGTMVRGVIEPYYFDYWDIQMTQSPST LSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDAFSLESGVP SRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIKCQ QYNSYSRTF (SEQ ID NO: 752) YU393-A03 PSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNP SLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARGVRGTGFDPWGQ GTLVTVSSCARGVRGTGFDPWTQSPGTLSVSPGERATLSCRASQSVSSR LAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSED FAVYFCQQYTNWPQTFGQGTKVEIKCQQYTNWPQTF (SEQ ID NO: 753) YU393-A04 PGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDRNGYFQH WGQGTLVTVSSCARDRNGYFQHWDIVMTQTPSTLSASVGDRVTITCRA SQTISGLLAWYQQKPGKAPNLLIYGASNSQSGVPSRFTGSGSGTEFTLTI TNLQPDDFATYYCLQYDRYSGAFGQGTKLEIKCLQYDRYSGAF (SEQ ID NO: 754) YU393-A08 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLLGELSFFD YWGQGTLVTVSSCAKDLLGELSFFDYWSVLTQPPSVSVAPGQTARIPC GGDDIESEMVHWYQQKPGQAPVLVVYDDSVRPSGIPERFSGSNSGNTA TLIISGVEAGDEAAYYCQVWHTTNDHVLFGGGTNLTVLCQVWHTTND HVLF (SEQ ID NO: 755) YU393-A09 PGDLWKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 756) YU393-A11 PGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGWF DPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQT ARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNS GNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 757) YU393-B02 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDRSYYGMDVWG QGTTVTVSSCARDRSYYGMDVWDIRLTQSPSSLSASVGDRVTITCRASQ SIGNYLNWYQQRLGEAPKVLIYAATRLQRGVPSRFSASASGTDFTLTISS LQPEDFTTYYCQQSKQIPYTFGQGTKLQIKCQQSKQIPYTF (SEQ ID NO: 758) YU393-B03 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDKGYYGMDVWG QGTTVTVSSCARDKGYYGMDVWDIQMTQSPSSVSASVGDRVTITCRAS QGISSWLAWYQQKPGKAPKLLIYAVSSLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQSYSLPLTFGGGTEVLIKCQQSYSLPLTF (SEQ ID NO: 759) YU393-B04 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDRSYYGMDVWG QGTTVTVSSCARDRSYYGMDVWDIQMTQSPSSLSASVGDRVTITCRAS QSIGNYLNWYQQRLGEAPKVLIYAATRLQRGVPSRFSAGASGTDFTLTI SSLQPEDFTTYYCQQSKQIPYTFGQGTKLQIKCQQSKQIPYTF (SEQ ID NO: 760) YU393-B05 PGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVISHDGHVKW HGDSVKGRFTISRDNSKNTLYLQLDSLRTEDTAVYYCAKEISPRSSVGW PLDYWGQGTLVTVSSCAKEISPRSSVGWPLDYWTQSPGTLSLSPGERAT LSCRADQSVSSTYLAWYQQRPGQAPRLLIYGASNRATGIPDRFSGSGSG SDFTLTISRLEPEDFAVYYCQQFDISGGLIFGPGTKVDIKCQQFDISGGLIF (SEQ ID NO: 761) YU393-B06 PGRSLRLSCAASGFTFSSSAMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDKAKNSLYLQMNSLRAEDTAVYYCARDFWSGYNEL GGMDVWGQGTTVTVSSCARDFWSGYNELGGMDVWEIVMTQSPSSLS ASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSR FSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGGGTKVEIKCQQY DNLPLTF (SEQ ID NO: 762) YU393-B07 PGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYY VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTWFGEFFDY WGQGTLVTVSSCARTWFGEFFDYWSVLTQPPSVSVAPGQTARVTCGG NNIESESVHWYQQKPGQAPVLVVYDDSARPSGIPERFSGSNSGNTATLT ISRVEAGDEADYYCQVWDSSSDHTVAFGGGTKLAVLCQVWDSSSDHT VAF (SEQ ID NO: 763) YU393-B08 PGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVIGGWFDPW GQGTLVTVSSCARVIGGWFDPWQSALTQPASVSGSPGQSITISCTGTSSD VGAYNYVSWYQQQPGKAPELMIYGVSHRPSRVSNRFSGSKSGNTASLT ISGLQTEDEADYYCSSYTTTDTFVLGSGTKVTVLCSSYTTTDTFVL (SEQ ID NO: 764) YU393-C02 PGRSLRLSCAASGFIFSRHAMHWVRQAPDKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNPKNTLYLQMNSLRAEDTAVYYCARGRLAYGDTE GFDYWGQGTLVTVSSCARGRLAYGDTEGFDYWDIVMTQSPSSLSASV GDRVTITCQASQDINNYLSWFQHKPGKAPKLLIYDASDLETGVPSRFSG SGSGPEFSFTITNLQPEDVATYYCQQYDNLPYTFGQGTKVEIRCQQYDN LPYTF (SEQ ID NO: 765) YU393-C03 PGASVKVSCKASGYTFNNYGLAWVRQAPGQGLEWMGWISVYNGDIN YAQKFQGRVTMTTDRATRTAYMELRSLISDDTAVYYCARDILRGESSIL DHWGQGTLVTVSCARDILRGESSILDHWDIVMTQSPSSLSASVGDRVTI TCRASQGISNSLAWYQQKPGKAPKLLLYAASRLESGVPSRFSGSGSGTD YTLTISSLQPEDFATYYCQQYYSTPPHFGGGTKVEIKCQQYYSTPPHF (SEQ ID NO: 766) YU393-C05 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARDRYYYGMDVWG QGTTVTVSSCARDRYYYGMDVWAIRMTQSPSSLSASVGDRVTITCRAS QSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYCQQSYSTPLTFGGGTKVEIKCQQSYSTPLTF (SEQ ID NO: 767) YU393-C07 PGRSLRLSCAASGFTFSSYAMEIWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLGSGYDII DYWGQGTLVTVSSCARDLLGSGYDIIDYWSYVLTQPPSVSVAPGQTAR ITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGN TATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLCQVWDSS SDHVVF (SEQ ID NO: 768) YU393-C08 PGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVWGKNGDF DYWGQGTLVTVSSCARVWGKNGDFDYWQSVLTQPPSVSAAPGQKVTI SCSGSSSNIGNNYVSWYQQLPGTAPKWYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCGTWDSSLSAYVFGTGTKVTVLCGTWDSSL SAYVF (SEQ ID NO: 769) YU393-D03 PGASVKVSCKASGYTFTTYAMNWVRQAPGQGLEWMGGINTNTGDPT YAQGSTGRFVFSSDTSVSTAYLQISSLKPEDTAVYYCARDRFHYGMDV WGQGTTVTVSSCARDRFHYGMDVWTQSPDTLSVSPGDGATLSCRASE GIRTSVAWYQQRPGQAPRLLIYGASTRAAGVPARFSGSGSGTEFTLTISS LQSDDFAVYYCQQTHTWPWTFGQGTKAEIKCQQTHTWPWTF (SEQ ID NO: 770) YU393-D04 PGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDRGDYWGQ GTLVTVSSCARDRGDYWDIQMTQSPSSVSASVGDRVTITCRASQGTSS WLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQANSFPLTFGGGTKVEIKCQQANSFPLTF (SEQ ID NO: 771) YU393-D05 PGGSLRLSCAASGFTFNNAWMSWVRQAPGKGLEWVGRIKSKTDGGTT DYGAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTEGVELLSF GGAPFDYWGQGTLVTVSSCTTEGVELLSFGGAPFDYWDIQMTQSPSSL SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKLEIKCQQ SYSTPYTF (SEQ ID NO: 772) YU393-D07 PGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYAD SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRRGGGFDYWGQ GTLVTVSSCARRRGGGFDYWQSALTQPASVSGSPGQSITISCTGTSSDV GGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTI SGLQAEDEADYYCSSYTSSSTYVFGTGTKVTVLCSSYTSSSTYVF (SEQ ID NO: 773) YU393-E04 PGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYY VDSVGGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREKGSWFDPW GQGTLVTVSSCAREKGSWFDPWTQSPGTLSLSPGERATLSCRASQSVSN NYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGNGSGTDFTLTISRLEP EDFAVYYCQRYGSSPRFGGGTKVEIKCQRYGSSPRF (SEQ ID NO: 774) YU393-E05 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDKGYYGMDVWG QGTTVTVS SCARDKGYYGMDVWMTQSPSFLSASVGDRVTITCRASQGI NSYLVWYKQKPGKAPDLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQ PEDFATYYCQQVHSFPFTFGPGTKVEIKCQQVHSFPFTF (SEQ ID NO: 775) YU393-E07 PGGSLRLSCAASGFTFSSYGINWVRQAPGKGLEWVSYISSRGSTILYADS VKGRFTISRDNARNSVHLQMNSLRDEDTAVYYCARDRGDRVGGLVFD YWGQGSLVTVSSCARDRGDRVGGLVFDYWVLTQPPSVSVAPGQTARI TCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGN TATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLCQVWDSS SDHVVF (SEQ ID NO: 776) YU393-F03 PGESLKISCKGSGYSFTTYWIAWVRQMPGKGLEWMGIIYPGDSDTTYSP SFQGQVTISADKSITTTYLQWSSLKASDTAMYYCARQVAGGLDYWGQ GTLVTVSSCARQVAGGLDYWDIVLTQSPSSLSASVGDRVTITCRASQAV RIDLSWYQQKPGKAPERLIFGASGLQRGVPSRFSGSGSGTEFTLTISSLQP EDFATYYCLQHNTFPYTFGQGTKLEIKCLQHNTFPYTF (SEQ ID NO: 777) YU393-F04 PGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDRGYYGMD VWGQGTTVTVSSCARDRGYYGMDVWDIQMTQSPSSLSASVGDRVTIT CRASQSISRYLNWYQQKPGKDPKLLIYAASSLQSGVPSRFSGSGSGTDF TLTISSLQPEDFATYYCQQSHSTPLTFGGGTKVEIKCQQSHSTPLTF (SEQ ID NO: 778) YU393-F06 PGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMYYCFRFGEGFDYWGQGT LVTVSSCFRFGEGFDYWMTQSPSTLSASVGDRVTITCRASQSIGYWLA WYQQRPGRAPKLLMYRASNLKSGVPSRFSGSGSGTEFTLTISSLQPDDF ATYYCQQYNSYPFTFGPGTKVDIKCQQYNSYPFTF (SEQ ID NO: 779) YU393-F07 PGESLKISCKGSGYSFTTYWIAWVRQMPGKGLEWMGIIYPGDSDTTYSP SFQGQVTISADKSITTTYLQWSSLKASDTAMYYCARQVAGGLDYWGQ GTLVTVSSCARQVAGGLDYWQSVLTQPPSASGTPGQRVTISCSGSSSNV GSNYVSWYQQLPGTAPKLLIQRNNRRPSGVPDRFSGSKSGTSASLAISG LRSEDEADYYCAAWDDSLSGVVFGGGTKLTVLCAAWDDSLSGVVF (SEQ ID NO: 780) YU393-G01 PGESLKISCKSSGYSFNTYWIGWVRQMPGKGLEWMGIIYPSDSDTRYSP SFQGQVTISADKSINTAYLQWSSLKASDSAMYYCARDGGYYFDDWGQ GTLVTVSSCARDGGYYFDDWTQSPGTLSLSPGERATLSCRASQSVSSTY LAWYQQKPGQAPRLLIYGTSRRATGIPDRFSGSGSGTDFTLTISRLEPED FAVYYCQQYNSSPLMYTFGQGTRLEIKCQQYNSSPLMYTF (SEQ ID NO: 781) YU393-G03 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDKGYYGMDVWG QGTTVTVSPCARDKGYYGMDVWDIVMTQSPSSLSASIGDRVTITCRAS QSIKNYLNWYQQKPGKAPKLLIYAASSLQNGVPSRFSGSGSGTDFTVTI SSLQPEDFAIYYCQQTYSTPLTFGGGTNVEIKCQQTYSTPLTF (SEQ ID NO: 782) YU393-G04 PGSSVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRGLRSDDTAVYYCARDFRMDVWG QGTTVTVSSCARDFRMDVWDIRLTQSPSSVASSVGDSVTVTCRASQDIK RRLAWYLQKPGQAPKLLIFDASRLHTGVPSRFSGSGSGTDFTLIINSLQP EDFGTYYCQQANTFPQTFGQGTKVEIKCQQANTFPQTF (SEQ ID NO: 783) YU393-G07 PGGSLRLSCAASGFTFRRYWMTWVRQAPGKGLEWVANIKQDGSEKYY VDSVKGRFAVSRDNANNSLYLRMNSLRAEDTAVYYCARDAYAYGLD VWGQGTAVTVSSCARDAYAYGLDVWVLTQPHSVSESPGKTVTISCTGS SGSIASSYVHWYQQRPGRVPTPVIYEDNQRPSGVPDRFSGSIDSSSNSAS LTISGLKTEDEADYYCQSYDGSSVVFGGGTKLTVLCQSYDGSSVVF (SEQ ID NO: 784) YU393-G08 PGDLRKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 785) YU393-G11 PGNLWKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 786) YU393-G12 PGNLLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 787) YU393-H03 PSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNP SLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARDLMNYGMDVWG QGTTVTVSSCARDLMNYGMDVWMTQSPSSLSASVGDRVTITCRASQSI SSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQ PEDFATYYCQQSYSTPPTFGQGTKVEIKCQQSYSTPPTF (SEQ ID NO: 788) YU393-H07 PGRSLRLSCAASGFTFSSYAMEIWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDSSKNTLYLQMNSLRAEDTAVYYCARDLLGSGYDIID YWGQGTLVTVSSCARDLLGSGYDIIDYWVLTQSPSVSVAPGKTARITC GGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTA TLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLCQVWDSSSD HVVF (SEQ ID NO: 789) YU393-H09 PGDL*KISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGWF DPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQT ARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNS GNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 790) YU394-A01 PGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANIKQDGSEKYY VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREYDYGDYVF DYWGQGTLVTVSSCAREYDYGDYVFDYWYELTQPPSMSATPGQKVTI TCSGSNSNVGNNYVSWYQQVPGTAPKWYDNDRRPSGIPDRFSGAKS GTSATLGITGLQTGDEADYYCGSWEARESVFVFGGGTKLTVCGSWEAR ESVFVF (SEQ ID NO: 791) YU394-A02 PGDLLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGHYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 792) YU394-A07 RGDLLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 793) YU394-A09 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIVMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIKCQQSYSTPPTF (SEQ ID NO: 794) YU394-C01 PGDPLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 795) YU394-E02 PGDFLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 796) YU394-H01 PGEFRKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGWF DPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQT ARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNS GNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 797) YU394-H03 RGDLLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWNYGGW FDPWGQGTLVTVSSCARLENNWNYGGWFDPWVLTQPPSVSVAPGQTA RITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSG NTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVWDS SSDHWVF (SEQ ID NO: 798) YU394-H04 RGNLLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWDYGGW FDPWGQGTLVTVSSCARLENNWDYGGWFDPWSYVLTQPPSVSVAPGQ TARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSN SGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVW DSSSDHWVF (SEQ ID NO: 799) YU394-H05 PGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLENNWNYGGWF DPWGQGTLVTVSSCARLENNWNYGGWFDPWVLTQPPSVSVAPGQTA RITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSG NTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVLCQVWDS SSDHWVF (SEQ ID NO: 800) YU394-H07 PGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDYYYYGMDVWG QGTTVTVSSCARDYYYYGMDVWDIRMTQSPSSLSASVGDRVTITCRAS QSISRYVNWYQQKPGKAPNLLIYGASNLESGVPSRFSGSGSGTDFTLTN SSLQPEDFASYYCQQTYNDPPTFGGGTRMEIKCQQTYNDPPTF (SEQ ID NO: 801) YU395-A02 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIVMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGPKVEIKCQQSYSTPPTF (SEQ ID NO: 802) YU395-B12 PGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDIGYYYGMD VWGQGTTVTVSSCARDIGYYYGMDVWSSELTQDPAVSVALGQTVRIT CQGDSLRSYYASWYQQEPGQAPVLVIYGKNNRPSGISDRFSGSSSGNTA SLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTRLTVLCNSRDSSGNH VVF (SEQ ID NO: 803) YU395-C06 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSYSTPPTFGQGTKLETKCQQSYSTPPTF (SEQ ID NO: 804) YU395-C08 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIVMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVELKCQQSYSTPPTF (SEQ ID NO: 805) YU395-D05 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIQMTQSPSSLSASVGDRVTITC RASQSISNYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQSYSTPPTFGQGPKLEIKCQQSYSTPPTF (SEQ ID NO: 806) YU396-B12 SGESLKISCKGSGYSFSTYWIGWVRQMPGKGLEWMGLIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVGDGYSLDYWG QGTLVTVSSCARVGDGYSLDYWSVLTQPPSVSVSPGQTASITCSGHKLG ERFAYWYQQKPGQSPVLVINQYIRRPSGIPERFSGSNSGSTATLTISGTQ AMDEADYYCQTWDGSIVVFGGGTKLTVLCQTWDGSIVVF (SEQ ID NO: 807) YU396-C03 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAITSIEPYWG QGTLVTVSSCAKAITSIEPYWQTVVTQEPSFSVSPGGTVTLTCGLSSGSV STSYYPSWYQQTPGQAPRTLIYNTDTRSSRVPDRFSGSIVGNKAALTITG AQADDESDYYCVLYMGSGIWVFGGGTKLTVLCVLYMGSGIWVF (SEQ ID NO: 808) YU396-C12 SGESLKISCKGSGYSFSTYWIGWVRQMPGKGLEWMGLIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVGDGYSLDYWG QGTLVTVSSCARVGDGYSLDYWQPVLTQPPSASGTPGQRVTISCSGGSS NIGRNYVYWYQQLPGTAPNLLISRNHQRPSGVPDRFSGSRSDTSASLAIS GLRSEDEADYYCATWDDALSGWVFGGGTKLTVLCATWDDALSGWVF (SEQ ID NO: 809) YU396-G10 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIVMTQSPSSLSASVGDRVTITC RASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKVETKCQQSYSTPPTF (SEQ ID NO: 810) YU396-H12 PGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGQGDGMDV WGQGTTVTVSSCAKGQGDGMDVWQSALTQPPSASGSPGQSVTISCTGT SSDVGGYNYVSWYQQHPGKAPKLMLYGVSNRPSGISSRFSGSKSGNTA SLTISGLQAEDEADYYCSSYTSSSTLVVFGGGTKLTVLCSSYTSSSTLVV F (SEQ ID NO: 811) YU397-A01 PGESLQISCKGSGYKFANYWIGWVRQMPGKGLEWMGIIYPGDSDTRYS PSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARLGWGMDVWGQ GTTVTVSSCARLGWGMDVWDIVMTQSPSSLSASVGDRVTITCRASQSIS SYLNWYQQKPGKAPNLIYAASSLRSGVPSRFSGSGSGTDFTLTISSLQPE DFATYYCQQSYSTPWTFGQGTKVEIKCQQSYSTPWTF (SEQ ID NO: 812) YU397-A02 PGASVKVSCKASGYTFKNFGISWVRRAPGQGPEWMGWISGRKGNTIY AQKFQGRVTMTTDTSTTTAYMELRSLRSDDTAVYYCARVWGDTTLGY GMDVWGQGTTVTVSSCARVWGDTTLGYGMDVWDIQMTQSPSSLSAS VGDRVTITCQASQDISNYLNWYQQKPGKAPKWYDASNLETGVPSRFS GSGSGTDFTFTISSLQPEDIATYYCQQYDNLPLTFGGGTKVEIKCQQYD NLPLTF (SEQ ID NO: 813) YU397-A03 PGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSYISSSGSTIYYAD SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRRGGGFDYWGQ GTLVTVSSCARRRGGGFDYWQSALTQPASVSGSPGQSITISCTGTSSDV GGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTI SGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVLCSSYTSSSTWVF (SEQ ID NO: 814) YU397-B01 PGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSP SFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAIPWDAELGNYGMD VWGQGTTVTVSSCAIPWDAELGNYGMDVWDIQMTQSPSSLSASVGDR VTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCLQDYNYPPAFGQGTKVEIKCLQDYNYPPA F (SEQ ID NO: 815) YU397-B02 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRWSGLGDYWG QGTLVTVSSCARGRWSGLGDYWMTQSPSSLSASVGDRVTITCQASEDI RMYLGWYQQKAGRAPKLLIFEGSSLEPGVPSRFSGSGSGTHFTFTISSLQ PDDFATYYCQQYYDDPQFGGGTKVVLKCQQYYDDPQF (SEQ ID NO: 816) YU397-D01 PSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNP SLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARARGGRYFDYWGQ GTLVTVSSCARARGGRYFDYWDIVLTQSPSFLSASVGDRVTITCRASQG ISTYLAWYQQKPGTAPKVLMYAASTLHSGVPSRFSGSGSGTEFTLTISSL QPEDFAIYYCQQLNGYPTTFGGGTRVEIKCQQLNGYPTTF (SEQ ID NO: 817) YU398-A11 PGRSLRLSCAASGFTFSSYGMEIWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGQGDGMDV WGQGTTVTVSSCAKGQGDGMDVWYELTQPPSASGTPGQRVTISCSGSS SNVGSRTVSWFQQLPGTAPKLLIYSNNLRPSGVPDRFSGSKSGTSASLAI SGLQSEDEADYYCAAWDDSLIGHVFGTGTKVTVVCAAWDDSLIGHVF (SEQ ID NO: 818) YU398-E10 PGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYAD SVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDQLAARRGYYY GMDVWGQGTTVTVSSCARDQLAARRGYYYGMDVWVLTQPPSVSVAP GQTATIACGGNNIGTKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFS GSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLCQ VWDSSSDHVVF (SEQ ID NO: 819) YU400-A05 PGRSLRLSCAASGFTFSSYGMEIWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDVNYGMDV WGQGTTVTVSSCAKGDVNYGMDVWSYVLTQPPSVSVAPGQTARISCG GSNIGSKTVNWYRKKAGQAPVLVVYDGRDRPSGIPERFSGSNSGNAAT LIISRVEVGDEADYYCQVWDTSGDLHWAFGGGTKLTVLCQVWDTSGD LHWAF (SEQ ID NO: 820) YU400-A12 PSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNP SLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARDFYYGSGSYPNG YYYGMDVWGQGTTVTVSSCARDFYYGSGSYPNGYYYGMDVWDIVM TQSPSSLSASLGDRVTITCRASQSINSYLNWYQQKPGKAPRLLIYTASTL QSGVPSRFSGSGAGTDFTLTISSLQPEDVATYYCQQSYTTPLTFGGGTK MEIKCQQSYTTPLTF (SEQ ID NO: 821) YU400-B07 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDVNYGMDV WGQGTTVTVSSCAKGDVNYGMDVWSYVLTQPPSVSVAPGKTARITCG GNNIGSKSVHWYQQKPGQAPVLVVYDDTDRPSGIPERFSGSNSGNTAT LTISRVEAGDEADYYCQVWDSSSDLLWVFGGGTKLAVLCQVWDSSSD LLWVF (SEQ ID NO: 822) YU400-D09 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDFNPFSITIFEMDV WGQGTTVTVSSCARDFNPFSITIFEMDVWQSVLTQPPSVSAAPGQKVTI SCSGSSSNIGNNYVSWYQQLPGTAPKWYDNNKRPSGIPDRFSGSKSGT SATLGITGLQTGDEADYYCGTWDSSLSALVFGGGTKLTVLCGTWDSSL SALVF (SEQ ID NO: 823) YU400-F07 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDVNYGMDV WGQGTTVTVSSCAKGDVNYGMDVWSYVLTQPPSVSVAPGQTARISCG GSNIGSKTVNWYRKKAGQAPVLVVYDGRDRPSGIPERFSGSNSGNAAT LIISRVEVGDEADYYCQVWDTSGDLHWAFGGRTKLTRCQVWDTSGDL HWAF (SEQ ID NO: 824) YU400-H08 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDVNYGMDV WGQGTTVTVSSCAKGDVNYGMDVWSYVLTQPPSVSVAPGQTARISCG GSNIGSKTVNWYRKKAGQAPVLVVYDGRDRPSGIPERFSGSNSGNAAT LIISRVEVGEGGQY*LQVWDTSGDLHWAFGGGTKLTVLLQVWDTSGD LHWAF (SEQ ID NO: 825) YU401-A11 PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANLAMGQYFDY WGQGTLVTVSSCANLAMGQYFDYWQAVLTQPPSASGTPGQRVTISCS GSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSA SLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVLCAAWDDSLN GPVF (SEQ ID NO: 826) YU401-B01 PGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQ KFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREMYYYYGMDVW GQGTTVTVSSCAREMYYYYGMDVWDIVMTQSPSSLSASVGDRVTITC RASQSIITYLNWYQQKPGKVPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQSYSTPPTFGQGTKLEIKCQQSYSTPPTF (SEQ ID NO: 827) YU401-D11 PGGSLRFSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANLAMGQYFDY WGQGTLVTVSSCANLAMGQYFDYWQAVLTQPPSASGTPGQRVTISCS GSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSA SLAISGLQSEDEADYYCAAWDDSLNGPVFGGGTKLTVLCAAWDDSLN GPVF (SEQ ID NO: 828) YU401-E11 PGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGEAKSSSP HEPDYWGQGTLVTVSSCARDLGEAKSSSPHEPDYWLTQSPLSLSVTPG QPASISCKSSQSLLHSDGKTYLDWYLQKPGQPPQLLIYEVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGIYYCMQTKQLPLTFGGGPKLEICMQ TKQLPLTF (SEQ ID NO: 829) YU401-F11 PGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYY ADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLGEAKSSSP HEPDYWGQGTLVTVSSCARDLGEAKSSSPHEPDYWLTQSPLSLSVTPG QPASISCKSSQSLLHSDGKTYLDWYLQKPGQPPQLLIYEVSNRFSGVPD RFSGSGSGTDFTLKISRVEAEDVGIYYCMQTKQLPLTFGGGTKLEICMQ TKQLPLTF (SEQ ID NO: 830) YU401-G07 LGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYY ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDVNYGMDV WGQGTTVTVSSCAKGDVNYGMDVWSYVLTQPPSVSVAPGQTARISCG GSNIGSKTVNWYRKKAGQAPVLVVYDGRDRPSGIPERFSGSNSGNAAT LIISRVEVGDEADYYCQVWDTSGDLHWAFGGGTKLTVLCQVWDTSGD LHWAF (SEQ ID NO: 831) YU402-A02 PSETLSLTCTVSGDSISSSSYYWSWIRQPPGKGLEWIGEINHSGSTNYNPS LKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDQEMYYFDYWGQ GTLVTVSSCARDQEMYYFDYWDIQMTQSPSSVSASVGDRVTITCRASQ GISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISS LQPEDFATYYCQQANSFPPTFGPGTKVDIKCQQANSFPPTF (SEQ ID NO: 832) YU402-A11 PSGTLSLTCDVSGGSISRSNWWIWVRQPPGKGLEWIGEIYHTGSTNYNP SLKRRVTISVDKSKNQFSLNLSSVTAADTAVYYCARGKGSYAFDIWGL GTMVTVSSCARGKGSYAFDIWVLTQPHSVSESPGKTVTISCTGSGGNIA RNYVQWYQHRPGRAPSTVIYEDDRRPSGVPDRFSGSTDISSNSASLTISG LKTEDEADYYCQSYDGNNHMVFGGGTRVTVLCQSYDGNNHMVF (SEQ ID NO: 833) YU402-D10 PGRSLRLSCAASGFTFSSYGMEIWVRQAPGKGLEWVAVISYDGNNKYY TDSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKGYSSSPGDY WGQGTLVTVSSCAKGYSSSPGDYWQSALTQPASVSGSPGQSITISCTGT SSDVGAYNYVSWYQQYPGKAPKLMIYDVSNRPSGVSDRFSGSKSGNT ASLTISGLQAEDEADYYCSSYTSSSTLWVFGGGTKLTALCSSYTSSSTL WVF (SEQ ID NO: 834) YU403-G05 PSGDLSLTCDVSGGSISRSNWWIWVRQPPGKGLEWIGEIYHTGSTNYNP SLKRRVTISVDKSKNQFSLNLSSVTAADTAVYYCARGKGSYAFDIWGL GTMVTVSSCARGKGSYAFDIWVLTQPHSVSESPGKTVTISCTGSGGNIA RNYVQWYQHRPGRAPSTVIYEDDRRPSGVPDRFSGSTDISSNSASLTISG LKTEDEADYYCQSYDGNNHMVFGGGTRVTVLCQSYDGNNHMVF (SEQ ID NO: 835) YU391-B12 QMQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEW MGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC AREMYYYYGMDVWGQGTTVTVSSDIQMTQSPSSLSASVGDRVTITCR ASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCQQSYSTPPAFGQGTKLEIK (SEQ ID NO: 836) YU392-E05 QVQLQESGPGLVKPSGTLSLTCTVSGGSISSSNWWSWVRQPPGKGLEW IGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCAR GVIAAAGTYFDYWGQGTLVTVSSQAVLTQPPSASGTPGQRVTISCSGSR PNVASNSVNWYQQFPGTAPRLLIYSDNQRPSGVPDRFSGSKSGTSASLA ISGLQFEDEADYYCETWDDSLRGVVFGGGTKVTVL (SEQ ID NO: 837) YU392-E06 QLQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEW IGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCAR ERTHYYYGMDIWGQGTTVTVSSQSVLTQPPSTSGTPGQRVTISCSGSSS NIGSNTVNWYHQLPGTAPRLLIYSNNQRPSGVPDRFSGSKSGTSASLAL SGLQSEDEGDYYCAAWDDSLNGYVFGTGTKVTVL (SEQ ID NO: 838) YU392-G08 EVRLGQSGPELKNPGDFRKISCKGSGYSFTSYWIGWVRQMPGKGLEW MGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYC ARLENNWDYGGWFDPWGQGTLVTVSSSYVLTQPPSVSVAPGQTARIT CGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNT ATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL (SEQ ID NO: 839) YU392-G09 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEW MGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYC ARDGAGNYDILTGDRSEDYYYYYGMDVWGQGTTVTVSSSYELTQPPS ASGAPGQRVSISCSGGYSNIGSNTVNWYQQLPGAAPKFLIYSDNQRPSG VPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGPVFGGGTK LTVL (SEQ ID NO: 840) YU392-G12 QVQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEW IGYIYHSGSTYYNPSLKSRVTISVDRSKNQFSLKLSSVTAADTAVYYCA RAGYYYGMDVWGQGTTVTVSSDIVMTQTPSSLSASVGDRVAITCQAS RNIWSYVNWYQQKPGEAPRLLIYGASTLQRGVPSRFSGSGSGTGFTLTI NSLQPEDFATYFCQQSHSTPITFGGGTRVDIK (SEQ ID NO: 841) YU392-H02 QLQLQESGPGLVNLSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLE WIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYC ARDSSSGPYGMDVWGQGTTVTVSSQSVLTQPPSVSVAPGQTARVTCG GSNIGSQSVHWYQQKPGQAPVLVVYDDYDRPSGIPERFSGSNSGNTAT LTITRVDAGDEADYYCQIWDSSSAHVVFGGGTKLTVL (SEQ ID NO: 842) YU392-H04 QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEW IGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCAR VNYGDYDWYFDLWGRGTLVTVSSQPVLTQPPSASGTPGQRVTISCSGS SSNIGSNFVTWYQQLPGTAPKWYSNNQRPSGVSDRFSASKSGTSASLA ISRLQSQDEAEYYCAAWDDSLRSYVFGSGTKVTVV (SEQ ID NO: 843) YU394-D08 QVQLGESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEW MGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVY YCAREPLRYYYYYGMDVWGQGTTVTVSSDIQMTQSPSSLSASVGDRV TITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGT DFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK (SEQ ID NO: 844)

In some embodiments, the antibody has a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, each independently selected from those disclosed in Table 14 Å and Table 14B. In some embodiments, the antibody has a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, each independently selected from any one clone listed in Table 14 Å and Table 14B. In some embodiments, the antibody has a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, each independently selected from those disclosed, in groups, in Table 15 Å and Table 15B. The disclosure provides antibodies having CDRs from individual clones or from matching any one CDR with any other five CDRs. The antibodies identified in Table 14 Å and Table 14B are derived from mouse phage-display library. Known methods may be used to convert these CDRs into humanized or chimeric antibodies.

VII. Use of CD25 Antibodies

In some embodiments, the CD25 antibodies provided herein are useful for therapeutics, e.g. for use in proliferative diseases or disorders such as cancer or for use in autoimmune diseases.

Accordingly provided herein are methods of treating a cancer comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic CD25 antibody. In some embodiments, the cancer is a primary cancer. In some embodiments, the cancer is a metastatic cancer. In some embodiments, the cancer involves a solid tumor; in other embodiments, the cancer involves a liquid tumor, e.g. a blood based cancer. In exemplary embodiments, the CD25 antibody is a non-IL-2 blocking antibody.

Accordingly provided herein are methods of treating an autoimmune-related disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic CD25 antibody. In exemplary embodiments, the CD25 antibody is an non IL-2 blocking antibody.

As used herein, a subject refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sport, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, and the like. Subjects may be male or female.

The administration of any of the therapeutic CD25 antibodies provided herein may be administered in combination with other known drugs/treatments (e.g. small molecule drugs, or biologics. The administration may be sequential or concurrent.

In vivo administration of the therapeutic CD25 antibodies described herein may be carried out intravenously, intratumorally, intracranially, intralesionally (e.g. intralesional injection, direct contact diffusion), intracavitary (intraperitoneal, intralpleural, intrauterine, intrarectal), intraperitoneally, intramuscularly, subcutaneously, topically, orally, transdermally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In an exemplary embodiment, the route of administration is by intravenous injection.

A therapeutically effective amount of the therapeutic antibody generally will be administered. The appropriate dosage of the therapeutic antibody may be determined based on the severity of the disease, the clinical condition of the subject, the subject's clinical history and response to the treatment, and the discretion of the attending physician.

VIII. Diagnostic Uses

The CD25 antibodies provided herein may be used for diagnostic and detection purposes. Depending on the application, the CD25 antibody may be detected and quantified in vivo or in vitro.

The CD25 antibodies provided herein are amendable for use in a variety of immunoassays. These immunoassays include, but are not limited to enzyme-linked immunosorbent assay (ELISA), Western blot, radioimmunoassay (RIA), flow cytometry, a radioimmunoassay, an immunofluorescence assay, spectrophotometry, radiography, electrophoresis, high performance liquid chromatography (HPLC), or thin layer chromatography (TLC).

The CD25 antibodies provided herein may be comprise a detectable label, for example detectable by spectroscopic, photochemical, biochemical, immunochemical, fluorescent, electrical, optical or chemical methods. Useful labels in the present invention include, but are not limited to fluorescent dyes, radiolabels, enzymes, colorimetric lables, avidin or biotin.

In some embodiments, the CD25 antibody is radiolabeled with an isotope, useful for imaging by nuclear medicine equipment (SPECT, PET, or scintigraphy).

VIII. Pharmaceutical Compositions

The disclosure provides compositions comprising therapeutic CD25 antibodies, In some embodiments the composition is sterile. The pharmaceutical compositions generally comprise an effective amount of the therapeutic antibody in a pharmaceutically acceptable excipient.

IX. Kits and Articles of Manufacture

The disclosure also provides for kits comprising any of the CD25 antibodies described herein, e.g. for either therapeutic or diagnostic uses. In some embodiments, the kits further contain a component selected from any of secondary antibodies, reagents for immunohistochemistry analysis, pharmaceutically acceptable excipient and instruction manual and any combination thereof. In some embodiments, the kit comprises any one or more of the therapeutic compositions described herein, with one or more pharmaceutically acceptable excipients.

The present application also provides articles of manufacture comprising any one of the therapeutic or diagnostic compositions or kits described herein. Examples of an article of manufacture include vials (e.g. sealed vials).

The description provided herein sets forth numerous exemplary configurations, methods, parameters, and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure, but is instead provided as a description of exemplary embodiments.

EXAMPLES

The following Examples are merely illustrative and are not meant to limit any aspects of the present disclosure in any way.

Example 1: Development of Engineered Immunogens Sharing Characteristics of CD25

A crystal structure of CD25 was obtained. A number of the crystal structures available for CD25 are missing a mobile loop section of the protein. Molecular dynamics simulations were performed to gain a greater understanding of this mobile loop, and binding interactions of CD25 with IL-2.

Different sections of CD25 were selected as inputs for developing an engineered immunogen. Some of these areas are shown in FIG. 34B and FIG. 34C. These inputs were used with the ROSETTA program to improve to the overall desirable structural and dynamic properties of the interfacial residues. This process made changes to the structural (non-interface) parts of the segment to stabilize and recapitulate the structure, conformation, dynamics and other properties of the interface residues in-context of the native CD25 from which they were derived. The stability and flexibility of the segment under development was also analyzed, and the sequence adjusted if needed to change these parameters. For example, the N or the C terminus can be extended by the addition of one or more amino acids to add desired properties. The effect of cross-linking on the engineered immunogen candidates was also evaluated, using disulfide bonds bonds forming between the side chains of different amino acid residues. At each stage of design engineering—amino acid addition, crosslinking, and structural residue optimization—the native scoring and energy functions of the ROSETTA program were used to quantitatively evaluate each of the many design candidates. Those candidates possessing the best ROSETTA energies are carried forward to subsequent stages of design, and ultimately forward to evaluation and validation by molecular dynamics simulation. In addition to evaluating these parameters at physiological pH (e.g., around pH 7.4), parameters were also evaluated in some instances at tumor microenvironment pH (e.g., around pH 6.5).

Quantitative metrics for ranking the different designs using molecular dynamics (MD) simulation included similarity to CD25, evaluated through RMSD; and structural flexibility of the candidates. FIG. 33A and FIG. 33B show exemplary comparisons of stability vs. RMSD at physiological pH for exemplary engineered immunogens developed using the input sections indicated in FIG. 32 (left arrow for FIG. 33A, right arrow for FIG. 33B). FIG. 33C is an exemplary comparison of stability vs. RMSD at tumor microenvironment pH for the exemplary immunogen of FIG. 33B. A representative scoring algorithm is presented below.

${{Score}_{{similarity} + {flexibility}} = \frac{\Sigma\left( {\alpha_{i}f_{i}} \right)}{f_{0}}},{\alpha_{i} = \left\{ {{\begin{matrix} {0,{{rmsd}_{i} > {k_{\max}(Å)}}} \\ {1,{{rmsd}_{i} \leq {k_{\max}(Å)}}} \end{matrix}f_{i}} = {{{Fraction}\mspace{14mu}{of}\mspace{14mu}{ensemble}k_{\max}} = {{Similarity}\mspace{14mu}{cutoff}}}} \right.}$

Structural similarity was calculated using root mean square deviation (RMSD) between the atomic coordinates of each peptide conformation in the MD ensemble and the reference structure after RMS alignment to the reference structure. The RMSD was computed using the computationally designed engineered immunogen candidate structure as the reference structure or by using the experimentally characterized (e.g., X-ray crystal structure) structure as the reference. In these simulations, the functional interface residues of the candidate (in some simulations) and all residues including the structural residues of the candidate (in other simulations) were compared to the reference.

The ensemble of conformations sampled by MD were clustered into groups (clusters) structurally similar to each other based on RMSD. Disorder was evaluated as the fraction of the conformations in the MD ensemble that could not be grouped into a cluster of similar conformations due to structural dissimilarity (e.g., high RMSD) to all other conformations in the ensemble. Thus, an engineered immunogen candidate with more disorder than an alternative candidate was more flexible. Order was evaluated as the fraction of the conformations in the MD ensemble that were grouped into a cluster of similar conformations (low RMSD). An engineered immunogen candidate with more order than an alternate candidate was less flexible when a higher fraction of its ensemble of conformations fell into fewer clusters than the alternate candidate.

The clusters populated by an engineered immunogen candidate were compared with a reference structure using RMSD. If the RMSD of a cluster was below a threshold value of 4 Angstroms, the cluster was considered ordered (e.g., low flexibility) and similar to the reference (structural similarity). An engineered immunogen candidate with a high fraction of its ensemble meeting this criterion of low flexibility and high structural similarity is predicted to be more active than an alternate candidate with a low fraction of its ensemble meeting this criterion of low flexibility and high structural similarity.

This quantitative analysis was combined with qualitative analysis of the MD trajectories regarding biophysical, biological and physical-chemical interactions, and used to select given immunogen candidates to evaluate in vitro. Table 6 below lists eleven engineered immunogens prepared as described above.

TABLE 6 Engineered Immunogens Label Sequence Cross-Link SEQ ID 13_131_CYN TVYPQPDATAKCVHGCDPREYTKAVEDAK C12-C16 17 11_14_CYN DWGDDCKKKHEITHATGDYCEKLDKS C6-C20 18 6_163_CYN DDCIKVTGPAECAERACRAQEERQRQPQCI C3-C17 19 57_63 CDCQAQWTPGMRAPGYDPYCLNCGS C1-C23, C3-C20 20 13_131 MVYCQPDCTAKCMHGCDRDTMKECCDRLK C12-C16, 2 C8-C25, C4-C24 6_130 DDCPEVPHATFKGPGQKWEGPGGGDCSK C3-C26 3 6_163 DDCIEVPGPAECAERACRAQEERQRQPQCI C3-C17, 4 C12-C29 77_89 AEEEKIKIEQKERKTTIKLAKEAK none 5 147_156 CHLQIMTHGKIIYVPCGS C1-C23 21 11_14 DDGDRCAKEHEIPHATGEECQKRDKS C6-C23 7 44_56 CKQLVIYFTGNSSHSSVFYIYYDC C1-C24 8

Example 2: Evaluation of Engineered Immunogens In Vitro

The binding of the engineered immunogens prepared in Example 1 are evaluated using an antibody to CD25. The engineered immunogens are modified on the C-terminus with a -GSGSGK-biotin group (SEQ ID NO: 846), and then bound separately to a streptavidin-coated biosensor tip. Buffer containing the CD25 antibody is flowed over the tip during an association phase of 300 seconds, and then the flowed solution is switched to buffer without the CD25 antibody and the dissociation from the biosensor tip will be measured. A control is also run where the tip does not have any engineered immunogen or protein initially bound, to evaluate any background binding of the CD25 antibody to the tip. A second control is performed where full length CD25 is biotinylated and bound to the biosensor tip, to demonstrate the binding level of the CD25 antibody to full length CD25. The data obtained from these biosensor experiments is used to qualitatively rank binding of the engineered immunogens.

Example 3: Evaluation of Engineered Immunogens with Phage Panning

Engineered immunogens provided herein are evaluated using phage panning techniques.

Mouse HuCD25 immunized phage libraries are transformed by electroporation in TG1 and phage propagated with the addition of CM13 using standard Phage Display protocols. TG1 cultures secreting phage are PEG precipitated with PEG/NaCl after incubation on ice for one hour. Exemplary libraries that may be used include 7807, 7808, 7809, and 7810.

Tumor microenvironment (TME) pH subtractive selections: Phage panning is carried out physiological pH and TME pH. To deplete antibodies that bind with high affinity to full-length CD25 at physiological pH, subtractive panning is first carried out by counter-selection of 3×10{circumflex over ( )}11 pfu phage (1000-fold representation of a 3×10{circumflex over ( )}8) at pH 7.4 by absorption for 1 hour on ELISA plates coated with 10 ug/ml full-length CD25 (400 nM) in PBST pH 7.4. Resulting phage supernatant is collected and pH is adjusted to pH 6.5 with PBST. Subsequent phage panning selections are carried out at pH 6.5.

Panning selections are pre-cleared with 25 microliters streptavidin Dynabeads with no antigen after a one hour incubation. Phage are then added to new pre-blocked Eppendorf LoBind tube. Biotinylated engineered immunogens (such as those described in Example 1) are added at 100 nM concentration (in some cases, additional 500 mMNaCl was added to reduce non-specific binding of immunogen to phage) for 40 min to one hour. Samples are then incubated with 25 microliters streptavidin beads or streptavidin coated plates at RT for one hour. Samples are pelleted and washed using magnet/magnetic beads or with plates, washed 7-10 times with PBST. Tubes are changed twice to remove residual phage.

To elute phage, 50-800 μL glycine pH 2.2 is added to the beads and plates, respectively, and incubated for no more than ten minutes, then neutralized with high pH Tris 9.0. Eluted phage is added to 1-5 ml TG1 freshly grown (OD600˜0.5), and incubated for 20-30 minutes.

Fractional log dilution series are plated, and the remainder transferred to 25 ml 2×YT. 1 ml glycerol stock is saved for a subsequent panning round, and helper phage/IPTG added at OD600˜0.5.

The selection against the engineered immunogen at pH 6.5 with counter-selection at pH 7.4 is carried out once more. The periplasmic extracts are subsequently evaluated using phage ELISA and octet screening.

To ensure that fab phage also bind full-length CD25 in addition to the engineered immunogen, a final selection with full-length CD25 can optionally be carried out, with full-length CD25 in place of the engineered immunogen (2 rounds selection against engineered immunogen, then 1 round selection against full length CD25).

To carry out selection with full-length CD25, after preclearing the panning selections with 25 microliters streptavidin Dynabeads, and adding phage to new pre-blocked Eppendorf LoBind tubes, biotinylated full-length CD25 is added at 100 nm concentration for one hour. The samples are then incubated with 25 microliters streptavidin beads at RT for one hour. Pelleting, washing, and elution steps are followed as described above.

Example 4: Phage ELISA Protocol and Biosensor/Octet Screening

ELISA Extract Preparation: Phage ELISA and periplasmic extract preparation for Fab Octet screening are conducted.

The CD25 antigen is diluted, added to the ELISA plate wells, and incubated. Following the incubation, wells are washed twice with PBS, then blocked by adding BSA followed by incubation for 2 hours at 25° C. Phage are diluted two-fold in 1×PBST 1.0% BSA, pH 6.5, 50 microliters are added per and incubated for 5 minutes at room temperature. The blocking solution is shaken out of the wells, and 50 μL of the dilute phage preparation is added to each well, and incubated for 1 hour at room temperature. The ELISA plate wells are washed 3-5 times with 200 microliters PBST pH 6.5. HRP-conjugated anti-M13 antibodies are diluted (Abcam, ab50370) 1:5000 with 1×PBST 1.0% BSA pH 6.5. 50 microliters of diluted secondary antibody conjugate is added to each well, and incubated for 1 hour at room temperature. ELISA plate wells are washed 3-5 times with 200 microliters PBST pH 6.5. The ECL Lumo substrate is prepared (e.g. Supersignal ELISA Pico Chemiluminescent Substrate) as described, into a 1:1 mixture. 50 microliters substrate solution is added to each well, incubated at room temperature for 5 to 60 minutes before reading.

Colonies are inoculated in 0.03-4 ml 2×YT 0.2% Glucose with 0.1 ml overnight culture (1 ml cultures in 96-well plate or 4 ml cultures in 14-ml falcon tubes). They are incubated at 250-700 rpm at 37° C. until the OD600˜0.5-1.0. Cultures are induced with 50-400 μL 0.025-0.1M IPTG. In some cases, the temperature is reduced to 30° C. with shaking at 250 rpm. They are then incubated overnight. 1-4 ml cultures are harvested by pelleting 3400 rcf for 10-15 minutes. The supernatant is discarded. Cultures are resuspended with 50-75 μL PPB buffer (30 mM Tris-HCl, pH 8.0, 1 mM EDTA, 20% Sucrose) with 1× Halt Protease Inhibitor and incubated on a rocking platform for 15 minutes at room temperature or 4° C. for 10 min. Then, cultures are resuspended with 150-225 μL of cold ddH20 with 1× Halt Protease Inhibitor and incubated on a rocking platform for one hour at room temperature or 4° C. for 1-2 hours. The lysate suspension was spun at 15000 rcf for 10-15 min at 4° C. Supernatant is collected and diluted.

Fab Expression and Purification Protocol: Cell cultures are inoculated, grown up overnight, and then induced with 50 μL of 25 mM-1M IPTG. The temperature was reduced to 30° C. and rpm to 150. Incubation was done overnight. 50 ml cultures or plates were harvested by pelleting 3400 rcf for 15 minutes. The supernatant was discarded. Cell pellets from 50 mL cultures were placed in a −80° C. freezer for 1 hour, while cultures grown in plates had 75 μL of PPB added with 1× Halt protease inhibitor, EDTA-free (Thermo Fisher Scientific) and vortexed. Plates are shaken at 4° C. for 10 minutes at 1000 rpm. The volume of 225 uL of cold water with 1× Halt protease inhibitor, EDTA-free (Thermo Fisher Scientific) is added to each well. Samples were mixed and shaken at 4° C. for 1-2 hours at max speed i.e. 1000 rpm. Plates are spun at 3500 rpm for 10 mins at 4° C. The supernatant (PPE) is transferred to fresh plates and stored at −20° C. Cell pellets from the 50 mL cultures are removed from the freezer and 5 ml PBS, 10 mM Imidazole is added with 2.5 mg/ml lysozyme and 1× Halt protease inhibitor, EDTA-free (Thermo Fisher Scientific). After pellets are thawed at room temperature for 30 minutes and lysates were centrifuged for 15 minutes at 3400 rcf The supernatant is removed and pellet discarded. 500 μL Ni-NTA resin was added (pre-washed and pelleted) or a Ni-NTA spin column was used for Fab purification. Incubate with cleared lysate for 30 min-1 hr. This was spun at 1500 rcf. These were washed 5 times with 1 ml PBS, 10 mM Imidazole. Buffer was discarded after each spin. 1 ml PBS, 200 mM Imidazole were added and mixed, incubated for 30 minutes and spun at 1500 rcf for 15 minutes. The eluted protein was stored at 4° C. or 20° C. after determining protein concentration. Zeba columns were used for desalting/buffer exchange.

OctetBiosensor Screening: For Octet Koff rate screening in raw supernatants, 50 μL of lysate is used in 384-well Pall ForteBio Octet plates. Data is collected on an Octet RED 384 (MD ForteBio). Briefly, Human CD25 is coupled to AR2G tips (1 ug/ml). For data collection, baseline is assessed in PBST 1% BSA buffer for 60 seconds. Tips are then moved to 50 μL lysate and association measured for 300 seconds. Finally, tips are moved to PBST 1% BSA buffer. Tips are then regenerated with 200 mM Tris-Glycine, pH 2.5 and neutralized with PBST, 1% BSA. For data analysis, double referencing (no CD25 on tip as well as blank reference well) is performed on Octet HT 11.0 software for reference subtraction.

Example 5: Evaluation of Antibodies Generated from Immunogens

Antibodies are produced by immunizing mice with the engineered immunogens described herein. These antibodies are evaluated for cross-reactivity, cross-blocking, affinity, and off-rate estimation.

Protocol for cross-reactivity determination by Biosensor (Octet Red 384, Pall Forte Bio): This protocol is used to determine the ability of individual test clones (anti-human CD25 mouse monoclonals) to bind the target (antigen) from human, cynomologous monkey, and mouse species. The target proteins are either covalently coupled via primary amines to dextran coated sensor tips or by affinity capturing the 6×-His tagged target proteins on anti-6×-His monoclonal antibody coated sensor tip. The monoclonal supernatants, in solution, are made to bind to the antigen on the biosensor tip. The net binding signal is the binding signal with the subtraction of corresponding signal with blank media or buffer binding to blank or antigen coated tips. A signal >3× background binding is considered as real binding event.

Protocol for cross-blocking by Biosensor: This method is to determine if the individual test clones (anti-human CD25 mouse monoclonals) are able to cross-block control antibodies. Cross-blocking may indicate that the test clones recognize an epitope that overlaps with the corresponding epitopes of the control antibodies. Additionally, this might imply that the test antibodies could have similar functional properties as the control antibodies. For this protocol, the control antibodies are covalently coupled via primary amines to dextran coated sensor tips. The target antigens, in solution, are made to bind to the control antibodies. Following this step, the test antibody, in solution, is made to bind to the antigen in a sandwich format. If the test antibody can bind to the antigen, it indicates that it does not cross-block the control antibody, while a non-binding may be interpreted as an ability to cross-block the control antibody.

Protocol for affinity determination by Biosensor: This method is used to determine the affinities of the individual test clones with antigens, when the concentration of the test antibodies is known. A capture molecule, such as Protein G or anti-mouse IgG-monoclonal or anti-human IgG-monoclonal is coated on the biosensor tip. Test clones are captured on the capture molecule coated surface. To these test clones, antigens in solution are made to associate and dissociate for time periods ranging from 60 to 600 seconds for association phase and 60 to 1800 seconds for dissociation phase. The result data (or ‘sensograms’) are then fit using either a 1:1 Langmuir model or 2:1 heterogeneous model. The former assumes that the interacting pairs are homogenous if a 2:1 model for fitting the data results in a better fit, it indicates that the clones require further sub-cloning due to inherent heterogeneity. The data curve fits provide the dissociation constant as a ratio of the on and off-rate constants

Protocol for off-rate estimation by Biosensor: This method is used to estimate the dissociation rate constant of test clones when the concentration of antibodies is not known or if the test clones require further subcloning. A capture molecule, such as Protein G or anti-mouse IgG-monoclonal or anti-human IgG-monoclonal is coated on the biosensor tip. Test clones are captured on the capture molecule coated surface. To these test clones, antigens in solution are made to associate and dissociate for time periods ranging from 60 to 600 seconds for association phase and 60 to 1800 seconds for dissociation phase. The result data (or ‘sensograms’) are then fit using either a 1:1 Langmuir model or 2:1 heterogeneous model. The former assumes that the interacting pairs are homogenous if a 2:1 model for fitting the data results in a better fit, it indicates that the clones require further sub-cloning due to inherent heterogeneity. The data is fit only for the off-rate constant and not the on-rate (or association) rate constant. This provides the estimates of off-rate constant, which can be used to rank-order the test clones.

Example 6: Selection of Engineered Polypeptides Using a CD25 Portion as the Reference Target

The sequence and three dimensional (3D) structure of CD25 was retrieved from the protein databank (PDB) (PDB ID NO: 2ERJ, chain Δ):

(SEQ ID NO: 845) ELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKSGSLYMLCTGSS SHSSWDNQCQCTSSATRSTTKQVTPQPEEQKERKTTEMQSPMQPVDQASL PGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMT HGKTRWTQPQLICTG

As shown in FIG. 6 , a putative therapeutic epitopes of CD25 were identified as reference targets for engineered polypeptide selection. Residues positions with respect to SEQ ID NO: 1) and epitope sequences are provided in Table 7.

TABLE 7 Epitope # Epitope ID Epitope Positions Epitope Sequence 1 _55-63_ 55-63 SWDNQCQCT (SEQ ID NO: 22) 2 _13-20_127-132_ 13-20:127-132 ATFKAMA (SEQ ID NO: 23) . . . MVYYQC (SEQ ID NO: 24) 3  _6-17_  5-17 DDPPEIPHATFKA (SEQ ID NO: 25) 4  _5-11_156-163_  5-11:156-163 DDPPEIP (SEQ ID NO: 26) . . . RWTQPQLI (SEQ ID NO: 27) 5 _77-89_ 77-89 QPEEQKERKTTEM (SEQ ID NO: 28) 6 _147-157_ 147-157 VCKMTHGKTRW (SEQ ID NO: 29) 7 _11-14_ 11-14 IPHA (SEQ ID NO: 30) 8 _44-56_ 44-56 YMLCTGSSSHSSW (SEQ ID NO: 31)

Atomic distance and amino acid descriptor topology were determined. The atomic distance and amino acid descriptor topology of the reference target were obtained using dynamic simulations, and a covariance matrix of atomic fluctuations was generated for the epitope in the reference target. Next, different engineered polypeptide candidates were generated using computational protein design (e.g., Rosetta), dynamics simulations performed on the candidates, and the atomic distance and amino acid descriptor topologies determined. A covariance matrix of atomic fluctuations was generated for the reference target epitope, and for the residues in the candidates corresponding to the residues in the epitope of the reference target.

Principal component analysis was performed to compute the eigenvectors and eigenvalues for each covariance matrix—one covariance matrix for each reference target and one covariance for each of the candidates—and only those eigenvectors with the largest eigenvalues are retained. Eigenvectors describe the most, second-most, third-most, N-most dominant motion observed in a set of simulated molecular structures. If a candidate moves like the reference epitope, its eigenvectors will be similar to the eigenvectors of the reference target (epitope). The similarity of eigenvectors corresponds to their components (a 3D vector centered on each CA atom) being aligned—pointing in the same direction. This similarity between candidates and reference target eigenvectors was computed using the inner product of two eigenvectors. The inner product value was 0 if two eigenvectors are 90 degrees to each other or 1 if the two eigenvectors point precisely in the same direction.

Since the ordering of eigenvectors is based on their eigenvalues, and eigenvalues may not necessarily be the same between two different molecules due to the stochastic nature by which molecular dynamics simulations sample the underlying energy landscape of those different molecules, the inner product between multiple, differentially ranked eigenvectors was needed (e.g., eigenvector 1 of the candidate by eigenvector 2, 3, 4, etc. of the reference target). In addition, without wishing to be bound by any theory, molecular motions are complex and may involve more than one (or more than a few) dominant/principal modes of motion.

To solve these two challenges, the inner product between all pairs of eigenvectors in the candidates and the reference target were computed. This resulted in a matrix of inner products the dimensions of which were determined by the number of eigenvectors analyzed—for 10 eigenvectors, the matrix of inner products is 10 by 10. This matrix of inner products was distilled into a single value by computing the root mean-square value of the inner products. This is the root mean square inner product (RMSIP).

Principal component analysis (PCA) reduces the 3 L×3 L dimensional coordinate covariance matrices (L being number of atoms) into sets of eigenvectors, Φ (reference target) and Ψ (MEM), and eigenvalues, Λ. The set Φ contains N eigenvectors pi for the reference target and the set Ψ contains N eigenvectors ψ_(j) for the MEM, where eigenvectors are ordered in their respective sets by their associated eigenvalues. The eigenvector with the largest eigenvalue accounts for the largest fraction of total coordinate covariation. The inner product of each φ_(i) and ψ_(j) eigenvector is computed to compare the similarity of motion between the reference target and the MEM. The root mean square of all inner product combinations of φ_(i) and ψ_(j) eigenvectors renders the total similarity of motion of the engineered polypeptide candidate (MEM) to the reference target (RMSIP).

As shown in FIG. 7 , in each engineered polypeptide, epitope residues (gold) and position in the in 3D space by addition of scaffold residues (grey) selected by this computational design procedure. Residues positions with respect to PDB ID NO: 2ERJ, chain Δ, and epitope sequences are provided in Table 8 and Table 9. Crosslink positions refer to the expected occurrence of intracellular disulfide bond formation in each MEM sequence.

TABLE 8 N-Terminal MEM Sequence C-Terminal Crosslink MEM ID Linker (N→C) Linker Positions Epitope # 57_63 — CDCQAQWTPGMR GSGSGK- C1-C23, 1 APGYDPYCLNC Biotin (SEQ ID C3-C20 (SEQ ID NO: 1) NO: 846) 13_131 — MVYCQPDCTAKC GSGSGK- C12-C16, 2 MHGCDRDTMKEC Biotin (SEQ ID C8-C25, CDRLK (SEQ ID NO: 846) C4-C24 NO: 2) 6_130 — DDCPEVPHATFKG GSGSGK- C3-C26 3 PGQKWEGPGGGD Biotin (SEQ ID CSK (SEQ ID NO: 3) NO: 846) 6_163 — DDCIEVPGPAECA GSGSGK- C3-C17, 4 ERACRAQEERQRQ Biotin (SEQ ID C12-C29 PQCI NO: 846) (SEQ ID NO: 4) 77_89 — AEEEKIKIEQKERK GSGSGK- none 5 TTIKLAKEAK (SEQ Biotin (SEQ ID ID NO: 5) NO: 846) 147_156 — CHLQIMTHGKIIYV GSGSGK- C1-C23 6 PC (SEQ ID NO: 6) Biotin (SEQ ID NO: 846) 11_14 — DDGDRCAKEHEIP GSGSGK- C6-C20 7 HATGEECQKRDKS Biotin (SEQ ID (SEQ ID NO: 7) NO: 846) 44_56 — CKQLVIYFTGNSS GSGSGK- C1-C24 8 HSSVFYIYYDC Biotin (SEQ ID (SEQ ID NO: 8) NO: 846) 6_130_J1 Biotin- GSGDEDCKKFQSD — C7-C28 3 PEG2 DNWENYTSTRHLT FCDEKRS (SEQ ID NO: 9) 44_56_J1 Biotin- GSGNEEIEKKIKDC — C14-C29 8 PEG2 TGNSSHSSWEEAL ECALKK (SEQ ID NO: 10) 44_56_J2 Biotin- GSGDERIERLIKEC — C14-C29 8 PEG2 TGNSSHSSWEEAL ECALRR (SEQ ID NO: 11) 147_157_J1 Biotin- GSGSHPCAYWRW — C7-C30 6 PEG2 VIKMTHGKTRWV LELVFCYRD (SEQ ID NO: 12) 147_157_J2 Biotin- GSGKCEEEAKKIA — C5-C33 6 PEG2 SKMTHGKTREEEA EEYLKKC (SEQ ID NO: 13) 33_63_J1 Biotin- GSGDDESEKRTTE — C19-C29 1 PEG2 RDTRKCTKAKAN DNQCQPTE (SEQ ID NO: 14) 33_63_J2 Biotin- GSGSSEWDKWVE — C19-C29 1 PEG2 EWYKKMCTEAKK NDNQCQPTK (SEQ ID NO: 15) 33_63_J3 Biotin- GSGQCRVWVFRN — C5-C22 1 PEG2 GDKILYIYEDCDN DNQHQQTL (SEQ ID NO: 16) *Biotin-PEG2 = Biotin-Poly-ethyleneglycol(2)

TABLE 9 Epitope CD25 Interface Residues (bold and underline:  X ) MEM ID # MEM Scaffold Residues (plain text: X) 57_63 1 C D C Q A QWT PGMRAPGYDPYCLNC (SEQ ID NO: 1) 13_131 2 MVY C Q PDC T A K C M HGCDRDTMKECCDRLK (SEQ ID NO: 2) 6_130 3 DD C PE V PHATFK GPGQKWEGPGGGDCSK (SEQ ID NO: 3) 6_163 4 DD CI E V P GPAECAERACRAQEE R QR QPQ C I (SEQ ID NO: 4) 77_89 5 AE EE KI K IE QKERKTT IKLAKEAK (SEQ ID NO: 5) 147_156 6 CHLQI MTHGK IIYVPC (SEQ ID NO: 6) 11_14 7 DDGDRCAKEH EIPHAT GEECQKRDKS (SEQ ID NO: 7) 44_56 8 CKQLVIYF TGNSS HSSVFYIYYDC (SEQ ID NO: 8) 6_130_J1 3 GSGDEDCKKFQSD D NW E NYTSTR H L TF CDEKRS (SEQ ID NO: 9) 44_56_J1 8 GSGNEEIEKKIKDC TGNSSHSSW EEALECALKK (SEQ ID NO: 10) 44_56_J2 8 GSGDERIERLIKEC TGNSSHSSW EEALECALRR (SEQ ID NO: 11) 147_157_J1 6 GSGSHPCAYWRWVI KMTHGKTRW VLELVFCYRD (SEQ ID NO: 12) 147_157_J2 6 GSGKCEEEAKKIAS KMTHGKTR EEEAEEYLKKC (SEQ ID NO: 13) 33_63_J1 1 GSGDDESEKRTTERDTRKCTKAKAN DNQCQ P T E (SEQ ID NO: 14) 33_63_J2 1 GSGSSEWDKWVEEWYKKMCTEAKKN DNQCQ P T K (SEQ ID NO: 15) 33_63_J3 1 GSGQCRVWVFRNGDKILYIYEDCDN DNQ H Q Q T L (SEQ ID NO: 16)

Example 7: Selection of Antibodies Using MEM Programmed In Vitro Selection

Thirty-two different panning strategies (S1-S32) were devised, each comprising three rounds, of positive selection (Table 10). Each program used at least one engineered polypeptide as a selection molecule. A conventional selection was also included using conventional methods (CD25 as the positive target). Bovine serum albumin (BSA) was used a negative target selecting against non-specific binding.

The panning protocol began with a human naïve scFv library, and panning was performed in solution, with the selection molecules bound to biotin (but still in solution). For each round, the starting pool was combined with the negative selection molecule (BSA) first in solution, and then a streptavidin-coated substrate (e.g., magnetic beads) was applied to the mixture to bind the negative selection molecules. Thus, any phage in the pool that was bound to the negative selection molecule was also bound to the streptavidin-coated support. The remaining solution was removed, and this flow through was then taken on to the positive selection step. The flow through was combined with positive selection molecule (antigen 1), allowed to bind, and then a streptavidin-coated solid substrate applied to the mixture. In this step, the bound phage were retained while the remaining unbound phage were removed. Then the bound phage were eluted. E. coli were transfected with the eluted phage using a 30 minute cultivation, the transfected cells were split for next-generation sequencing and DNA isolation for analysis, and then the phage amplified for use in the subsequent panning round. For each panning program, in each round negative selection was performed first, and positive selection second.

TABLE 10 Round 1 Round 2 Round 3 Strategy Antigen Antigen Antigen S1 57_63 CD25 57_63 S2 57_63 CD25 CD25 S3 13_131 CD25 13_131 S4 13_131 CD25 CD25 S5 6_130 CD25 6_130 S6 6_130 CD25 CD25 S7 6_163 CD25 6_163 S8 6_163 CD25 CD25 S9 77_89 CD25 77_89 S10 77_89 CD25 CD25 S11 147_156 CD25 147_156 S12 147_156 CD25 CD25 S13 11_14 CD25 11_14 S14 11_14 CD25 CD25 S15 44_56 CD25 44_56 S16 44_56 CD25 CD25 S17 6_130_J1 CD25 6_130_J1 S18 6_130_J1 CD25 CD25 S19 44_56_J1 CD25 44_56_J1 S20 44_56_J1 CD25 CD25 S21 44_56_J2 CD25 44_56_J2 S22 44_56_J2 CD25 CD25 S23 147_157_J1 CD25 147_157_J1 S24 147_157_J1 CD25 CD25 S25 147_157_J2 CD25 147_157_J2 S26 147_157_J2 CD25 CD25 S27 33_63_J1 CD25 33_63_J1 S28 33_63_J1 CD25 CD25 S29 33_63_J2 CD25 33_63_J2 S30 33_63_J2 CD25 CD25 S31 33_63_J3 CD25 33_63_J3 S32 33_63_J3 CD25 CD25 S33 CD25 CD25 CD25

Primary ELISA Screen and Hit Selection

384 clones for each strategy were selected for ELISA response analysis to full-length CD25 after three rounds of panning (FIG. 9 ). Data are shown with the sorted strategies ordered by epitope (FIG. 6 ). At least one strategy for each epitope yielded clones capable of binding to CD25. It was observed that different strategies using the same engineered polypeptides enrich distinct high-affinity clonal subsets (FIG. 10 , black bars). As shown in Table 11, most iVEM-programmed selection strategies produced anti-CD25 hits more productively than conventional full-length panning.

TABLE 11 Strategy CD25 Epitope Anti-Hu CD25% Hit Rate S16 8 65.0 S2 1 59.0 S12 6 51.0 S6 4 46.0 S10 5 30.0 S33 Full-length CD25 19.0 S4 3 17.0 S14 7 16.0

Of the hits 1475 were selected for further characterization because they met one of two criteria in ELISA: 1)>10:1 signal to noise (s/n) in full-length CD25 ELISA; or 2)>3:1 s/n in MEM ELISA and >5:1 s/n in CD25 ELISA.

Confirmatory Testing by Biolayer Interferometry

The affinity of the different scFv antibodies were evaluated on a ForteBio® Octet RED384™ biolayer interferometry instrument, using a single-cycle kinetics assay design. His-tagged scFv's were immobilized on anti-his biosensor (Fortebio® HIS1K). Full-length CD25 analyte was washed over the sensor tip and the binding of the molecules in the analyte to the scFv's recorded. Each assay was run in duplicate. Controls were also run, using just a buffer (to control for sensor drift) and a separate control of purified polyclonal IgG isotype antibodies from human serum (to control for non-specific IgG binding).

As shown in FIG. 11 , biolayer interferometry of 1475 anti-CD25 scFv's identified by phage display panning. Shows that 1433 hits (97%) are confirm to bind CD25. The observed K_(D) range of the hits was 10-200 nM, with a median K_(D) of 28.5 nM. As shown in FIG. 11 , most screening strategies generated scFv with high affinity for CD25. Only scFv's having k_(off) less than 10⁻³/s are shown. Approximate K_(D) values are given on the y-axis. As shown in FIG. 12 , most of the panning strategies resulted in at least one hit that has k_(off) of less than 10⁻³/s.

Confirmatory Testing by Flow Cytometry

The CD25 specificity the different scFv antibodies were evaluated on flow cytometer using cells that express CD25 [CD25(+)] or do not express CD25 [CD25(−)]. As shown in FIG. 13 , of 1248 scFv hits analyzed in this assay, 1160 (93%) bind specifically to CD25(+) cells.

Sequence Analysis of Hits

Next generation sequencing was performed on each round of panned phage. As shown in FIG. 15 , MEM-steered panning focuses CDR diversity of antibody libraries in a strategy-dependent manner. Each round of selection decreased repertoire diversity (FIG. 16 ) and focused CDR length to preferred lengths for each MEM (FIG. 17 ).

Individual scFv's were sequenced using Sanger sequencing methods. Complete protein sequences for each scFv are provided in Table 5. Immunoglobulin gene usage and complementarity determining regions are provided in Table 12 and Table 2, respectively.

TABLE 12 VJ Clone ID VH Germline DH Germline JH Germline VL Germline Germline YU389-A01 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU389-A02 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ3*01 YU389-A03 IGHV4-31*03 IGHD3-3*01 IGHJ5*02 IGLV1-51*01 IGLJ1*01 YU389-A05 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU389-A07 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU389-B11 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ2*02 YU389-D07 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ2*02 YU390-A11 IGHV3-30*18 IGHD6-19*01 IGHJ3*02 IGLV3-21*02 IGLJ3*01 YU390-A12 IGHV1-46*01 IGHD3-10*01 IGHJ4*02 IGLV3-1*01 IGLJ1*01 YU390-B12 IGHV3-30*18 IGHD6-19*01 IGHJ3*02 IGLV3-21*02 IGLJ3*01 YU390-C03 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU390-C11 IGHV1-18*01 IGHD2-15*01 IGHJ6*01 IGKV3-15*01 IGKJ4*01 YU390-D01 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU390-D03 IGHV1-69*01 IGHD3-22*01 IGHJ6*01 IGKV1-5*03 IGKJ2*01 YU390-D05 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU390-D11 IGHV1-18*01 IGHD2-15*01 IGHJ6*01 IGKV3-15*01 IGKJ4*01 YU390-G03 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU390-H11 IGHV1-18*01 IGHD2-15*01 IGHJ6*01 IGKV3-15*01 IGKJ4*01 YU392-A05 IGHV1-46*01 IGHD1-26*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01 YU392-A07 IGHV1-69-2*01 IGHD5-5*01 IGHJ4*02 IGLV1-44*01 IGLJ3*01 YU392-A09 IGHV1-69-2*01 IGHD2-15*01 IGHJ6*01 IGLV1-47*01 IGLJ3*01 YU392-B11 IGHV1-69-2*01 IGHD3-22*01 IGHJ4*02 IGLV1-47*02 IGLJ3*01 YU393-A01 IGHV4-30-2*01 IGHD3-10*01 IGHJ6*01 IGKV1-39*01 IGKJ4*01 YU393-A02 IGHV1-69*14 IGHD3-10*01 IGHJ4*02 IGKV1-5*01 IGKJ1*01 YU393-A03 IGHV4-4*02 IGHD3-10*01 IGHJ5*02 IGKV3-15*01 IGKJ1*01 YU393-A04 IGHV1-18*01 IGHD1-1*01 IGHJ1*01 IGKV1-5*03 IGKJ1*01 YU393-A08 IGHV3-30*18 IGHD3-16*02 IGHJ4*02 IGLV3-21*02 IGLJ3*01 YU393-A09 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU393-A11 IGHV5-51*01 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU393-B02 IGHV1-69*14 IGHD2-2*01 IGHJ6*01 IGKV1-39*01 IGKJ2*01 YU393-B03 IGHV1-69*14 IGHD2-8*01 IGHJ6*01 IGKV1-12*01 IGKJ4*01 YU393-B04 IGHV1-69*01 IGHD2-2*01 IGHJ6*01 IGKV1-39*01 IGKJ2*01 YU393-B05 IGHV3-30*18 IGHD6-19*01 IGHJ4*02 IGKV3-20*01 IGKJ3*01 YU393-B06 IGHV3-30-3*01 IGHD3-3*01 IGHJ6*01 IGKV1-33*01 IGKJ4*01 YU393-B07 IGHV3-7*01 IGHD3-10*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01 YU393-B08 IGHV1-18*01 IGHD3-22*01 IGHJ5*02 IGLV2-14*01 IGLJ1*01 YU393-C02 IGHV3-30-3*01 IGHD4-17*01 IGHJ4*02 IGKV1-33*01 IGKJ2*01 YU393-C03 IGHV1-18*01 IGHD3-10*02 IGHJ4*02 IGKV1-NL1*01 IGKJ4*01 YU393-C05 IGHV1-69*12 IGHD3-10*01 IGHJ6*01 IGKV1-39*01 IGKJ4*01 YU393-C07 IGHV3-30-3*01 IGHD5-12*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01 YU393-C08 IGHV1-18*04 IGHD2-8*01 IGHJ4*02 IGLV1-51*01 IGLJ1*01 YU393-D03 IGHV7-4-1*02 IGHD2-21*01 IGHJ6*01 IGKV3-15*01 IGKJ1*01 YU393-D04 IGHV1-18*04 IGHD1-26*01 IGHJ4*02 IGKV1-12*01 IGKJ4*01 YU393-D05 IGHV3-15*01 IGHD3-10*01 IGHJ4*02 IGKV1-39*01 IGKJ2*01 YU393-D07 IGHV3-48*03 IGHD2-15*01 IGHJ4*02 IGLV2-14*01 IGLJ1*01 YU393-E04 IGHV3-7*01 IGHD3-10*01 IGHJ5*02 IGKV3-20*01 IGKJ4*01 YU393-E05 IGHV1-69*06 IGHD2-8*01 IGHJ6*01 IGKV1-9*01 IGKJ3*01 YU393-E07 IGHV3-48*02 IGHD5-12*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01 YU393-F03 IGHV5-51*03 IGHD6-19*01 IGHJ4*02 IGKV1-17*01 IGKJ2*01 YU393-F04 IGHV1-18*04 IGHD3-10*01 IGHJ6*01 IGKV1-39*01 IGKJ4*01 YU393-F06 IGHV5-51*01 IGHD3-16*01 IGHJ4*02 IGKV1-5*03 IGKJ3*01 YU393-F07 IGHV5-51*03 IGHD6-19*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01 YU393-G01 IGHV5-51*01 IGHD2-8*02 IGHJ4*02 IGKV3-20*01 IGKJ2*01 YU393-G03 IGHV1-69*06 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ4*01 YU393-G04 IGHV1-18*01 IGHD3-3*01 IGHJ6*01 IGKV1-12*01 IGKJ1*01 YU393-G07 IGHV3-7*01 IGHD2-8*02 IGHJ6*01 IGLV6-57*02 IGLJ3*01 YU393-G08 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU393-G11 IGHV5-51*01 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU393-G12 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU393-H03 IGHV4-4*02 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU393-H07 IGHV3-30-3*01 IGHD5-12*01 IGHJ4*02 IGLV3-21*03 IGLJ3*01 YU393-H09 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-A01 IGHV3-7*01 IGHD4-17*01 IGHJ4*02 IGLV1-51*01 IGLJ3*02 YU394-A02 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-A07 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-A09 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU394-C01 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-E02 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-H01 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-H03 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-H04 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-H05 IGHV5-51*03 IGHD1-7*01 IGHJ5*02 IGLV3-21*02 IGLJ3*02 YU394-H07 IGHV1-69*13 IGHJ6*01 IGKV1-39*01 IGKJ4*01 YU395-A02 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU395-B12 IGHV1-18*01 IGHD3-16*02 IGHJ6*01 IGLV3-19*01 IGLJ3*01 YU395-C06 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ2*02 YU395-C08 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU395-D05 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ2*02 YU396-B12 IGHV5-51*01 IGHD2-21*01 IGHJ4*02 IGLV3-1*01 IGLJ3*01 YU396-C03 IGHV3-30*18 IGHD3-9*01 IGHJ4*02 IGLV8-61*01 IGLJ3*02 YU396-C12 IGHV5-51*01 IGHD2-21*01 IGHJ4*02 IGLV1-47*01 IGLJ3*02 YU396-G10 IGHV1-69*12 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU396-H12 IGHV3-30*18 IGHD3-9*01 IGHJ6*01 IGLV2-14*01 IGLJ3*01 YU397-A01 IGHV5-51*03 IGHD6-19*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU397-A02 IGHV1-18*01 IGHD3-3*01 IGHJ6*01 IGKV1-33*01 IGKJ4*02 YU397-A03 IGHV3-48*03 IGHD2-15*01 IGHJ4*02 IGLV2-14*01 IGLJ3*02 YU397-B01 IGHV5-51*03 IGHD3-10*01 IGHJ6*01 IGKV1-39*01 IGKJ1*01 YU397-B02 IGHV1-69*14 IGHD2-2*01 IGHJ4*02 IGKV1-33*01 IGKJ4*01 YU397-D01 IGHV4-4*02 IGHD2-15*01 IGHJ4*02 IGKV1-9*01 IGKJ4*01 YU398-A11 IGHV3-30*18 IGHD3-9*01 IGHJ6*01 IGLV1-44*01 IGLJ1*01 YU398-E10 IGHV3-21*01 IGHD6-6*01 IGHJ6*01 IGLV3-21*02 IGLJ3*01 YU400-A05 IGHV3-30*18 IGHD3-10*01 IGHJ6*01 IGLV3-21*02 IGLJ3*02 YU400-A12 IGHV4-4*02 IGHD3-10*01 IGHJ6*01 IGKV1-39*01 IGKJ4*01 YU400-B07 IGHV3-30*18 IGHD3-10*01 IGHJ6*01 IGLV3-21*03 IGLJ3*02 YU400-D09 IGHV1-69*01 IGHD3-3*01 IGHJ6*01 IGLV1-51*01 IGLJ3*01 YU400-F07 IGHV3-30*18 IGHD3-10*01 IGHJ6*01 IGLV3-21*02 IGLJ3*02 YU400-H08 IGHV3-30*18 IGHD3-10*01 IGHJ6*01 IGLV3-21*02 IGLJ3*02 YU401-A11 IGHV3-30*18 IGHD3-16*01 IGHJ4*02 IGLV1-44*01 IGLJ3*01 YU401-B01 IGHV1-69*01 IGHD2-8*01 IGHJ6*01 IGKV1-39*01 IGKJ2*02 YU401-D11 IGHV3-30*18 IGHD3-16*01 IGHJ4*02 IGLV1-44*01 IGLJ3*01 YU401-E11 IGHV3-30*01 IGHD6-6*01 IGHJ4*02 IGKV2D-29*01 IGKJ4*01 YU401-F11 IGHV3-30*01 IGHD6-6*01 IGHJ4*02 IGKV2D-29*01 IGKJ4*01 YU401-G07 IGHV3-30*18 IGHD3-10*01 IGHJ6*01 IGLV3-21*02 IGLJ3*02 YU402-A02 IGHV4-39*07 IGHD6-13*01 IGHJ4*02 IGKV1-12*01 IGKJ3*01 YU402-A11 IGHV4-4*02 IGHD2-8*01 IGHJ3*02 IGLV6-57*02 IGLJ3*01 YU402-D10 IGHV3-30*18 IGHD6-6*01 IGHJ4*02 IGLV2-14*01 IGLJ3*02 YU403-G05 IGHV4-4*02 IGHD2-8*01 IGHJ3*02 IGLV6-57*02 IGLJ3*01

Analysis of the CDRs and germline usages suggest that the 1475 scFv's sequenced represent at least 126 distinct clones. The set includes 40 different VH+JH frameworks choices, and 35 VL+JL framework choices. Unique CDR sequences include:

CDR-H1 GGTFSSYA , GGSISSGGYY (SEQ ID NO: 283), GFTFSSYG (SEQ ID NO: 275), GYTFTSYY (SEQ ID NO: 313), GYTFTSYG (SEQ ID NO: 312), GYTFTDYY (SEQ ID NO: 306), GGSISSGGYS (SEQ ID NO: 282), GGSISSSNW (SEQ ID NO: 284), GYSFTSYW , GFTFSNYG (SEQ ID NO: 271), GFTFSSSA (SEQ ID NO: 272), GFTFSSYW (SEQ ID NO: 277), GFIFSRHA (SEQ ID NO: 264), GYTFNNYG (SEQ ID NO: 302), GFTFSSYA (SEQ ID NO: 273), GYTFTTYA (SEQ ID NO: 314), GFTFNNAW (SEQ ID NO: 267), GFTFSSYE (SEQ ID NO: 274), GYSFTTYW (SEQ ID NO: 300), GYSFNTYW (SEQ ID NO: 297), GFTFRRYW (SEQ ID NO: 268), GYSFSTYW (SEQ ID NO: 298), GFAFSSYG (SEQ ID NO: 262), GYKFANYW (SEQ ID NO: 296), GYTFKNFG (SEQ ID NO: 301), GFTFSSYS (SEQ ID NO: 276), GDSISSSSYY (SEQ ID NO: 261), and GGSISRSNW (SEQ ID NO: 281) CDR-H2 IIPIFGTA (SEQ ID NO: 326), IIPIFGTA (SEQ ID NO: 326), IYYSGST (SEQ ID NO: 384), ISYDGSNK (SEQ ID NO: 362), INPSGGST (SEQ ID NO: 339), ISAYNGNT , IMPIFDTA (SEQ ID NO: 332), VDPEDGET (SEQ ID NO: 693), IYHSGST (SEQ ID NO: 365), IYPGDSDT (SEQ ID NO: 377), ISHDGHVK (SEQ ID NO: 349), IKQDGSEK (SEQ ID NO: 328), ISVYNGDI (SEQ ID NO: 359), INTNTGDP (SEQ ID NO: 344), IKSKTDGGTT (SEQ ID NO: 330), ISSSGSTI (SEQ ID NO: 351), ISSRGSTI (SEQ ID NO: 350), IYPSDSDT (SEQ ID NO: 383), ISGRKGNT (SEQ ID NO: 347), ISSSSSYI (SEQ ID NO: 352), INHSGST (SEQ ID NO: 333), IYHTGST (SEQ ID NO: 366), and ISYDGNNK (SEQ ID NO: 360) CDR-H3 AREMYYYYGMDV (SEQ ID NO: 103), AREMYYYYGMDV (SEQ ID NO: 103), ARGNLWSGYYF (SEQ ID NO: 111), AKELLEGAFDI (SEQ ID NO: 64), ARDRVTMVRGALAY (SEQ ID NO: 97), ARERSYYGMDV (SEQ ID NO: 105), ASWSERIGYQYGLDV (SEQ ID NO: 145), ARDILGLDY (SEQ ID NO: 81), ATEDTAMGGIDY (SEQ ID NO: 146), ATEGRYGMDV (SEQ ID NO: 147), AVEGGRAPGTYYYDSSGLAY (SEQ ID NO: 153), ARAGYYYGMDV (SEQ ID NO: 71), ARDLGTMVRGVIEPYYFDY (SEQ ID NO: 85), ARGVRGTGFDP (SEQ ID NO: 118), ARDRNGYFQH (SEQ ID NO: 94), AKDLLGELSFFDY (SEQ ID NO: 61), ARLENNWDYGGWFDP , ARDRSYYGMDV (SEQ ID NO: 96), ARDKGYYGMDV (SEQ ID NO: 83), AKEISPRSSVGWPLDY (SEQ ID NO: 63), ARDFWSGYNELGGMDV (SEQ ID NO: 76), ARTWFGEFFDY (SEQ ID NO: 134), ARVIGGWFDP (SEQ ID NO: 136), ARGRLAYGDTEGFDY (SEQ ID NO: 112), ARDILRGESSILDH (SEQ ID NO: 82), ARDRYYYGMDV (SEQ ID NO: 98), ARDLLGSGYDIIDY (SEQ ID NO: 86), ARVWGKNGDFDY (SEQ ID NO: 142), ARDRFHYGMDV (SEQ ID NO: 90), ARDRGDY (SEQ ID NO: 92), TTEGVELLSFGGAPFDY (SEQ ID NO: 683), ARRRGGGFDY (SEQ ID NO: 132), AREKGSWFDP (SEQ ID NO: 102), ARDRGDRVGGLVFDY (SEQ ID NO: 91), ARQVAGGLDY (SEQ ID NO: 131), ARDRGYYGMDV (SEQ ID NO: 93), FRFGEGFDY (SEQ ID NO: 259), ARDGGYYFDD (SEQ ID NO: 79), ARDFRMDV (SEQ ID NO: 75), ARDAYAYGLDV (SEQ ID NO: 73), ARDLMNYGMDV (SEQ ID NO: 87), AREYDYGDYVFDY (SEQ ID NO: 107), ARLENNWNYGGWFDP (SEQ ID NO: 128), ARDYYYYGMDV (SEQ ID NO: 101), ARDIGYYYGMDV (SEQ ID NO: 80), ARVGDGYSLDY (SEQ ID NO: 135), AKAITSIEPY (SEQ ID NO: 60), AKGQGDGMDV (SEQ ID NO: 66), ARLGWGMDV (SEQ ID NO: 129), ARVWGDTTLGYGMDV (SEQ ID NO: 141), AIPWDAELGNYGMDV (SEQ ID NO: 59), ARGRWSGLGDY (SEQ ID NO: 113), ARARGGRYFDY (SEQ ID NO: 72), ARDQLAARRGYYYGMDV (SEQ ID NO: 89), AKGDVNYGMDV (SEQ ID NO: 65), ARDFYYGSGSYPNGYYYGMDV (SEQ ID NO: 77), ARDFNPFSITIFEMDV (SEQ ID NO: 74), ANLAMGQYFDY (SEQ ID NO: 70), ARDLGEAKSSSPHEPDY (SEQ ID NO: 84), ARDQEMYYFDY (SEQ ID NO: 88), ARGKGSYAFDI (SEQ ID NO: 110), and AKGYSSSPGDY (SEQ ID NO: 67) CDR-L1 QSISSY (SEQ ID NO: 567), QSISSY (SEQ ID NO: 567), SSNIGNNF (SEQ ID NO: 650), QSISNY (SEQ ID NO: 563), NIETKS (SEQ ID NO: 455), KLGDKY (SEQ ID NO: 404), QSVSNY (SEQ ID NO: 574), QTISQW (SEQ ID NO: 582), SSNIGSNY (SEQ ID NO: 655), NFNIGNNL (SEQ ID NO: 453), RNIWSY (SEQ ID NO: 634), QSISSW (SEQ ID NO: 566), QSVSSR (SEQ ID NO: 576), QTISGL (SEQ ID NO: 581), DIESEM (SEQ ID NO: 163), NIGSKS (SEQ ID NO: 456), QSIGNY (SEQ ID NO: 558), QGISSW (SEQ ID NO: 489), QSVSSTY (SEQ ID NO: 577), QDISNY (SEQ ID NO: 485), NIESES (SEQ ID NO: 454), SSDVGAYNY (SEQ ID NO: 647), QDINNY (SEQ ID NO: 482), QGISNS (SEQ ID NO: 488), SSNIGNNY (SEQ ID NO: 651), EGIRTS (SEQ ID NO: 218), QGTSSW (SEQ ID NO: 491), SSDVGGYNY (SEQ ID NO: 649), QSVSNNY (SEQ ID NO: 573), QGINSY (SEQ ID NO: 487), QAVRID (SEQ ID NO: 472), QSISRY (SEQ ID NO: 564), QSIGYW (SEQ ID NO: 559), SSNVGSNY (SEQ ID NO: 656), QSIKNY (SEQ ID NO: 561), QDIKRR (SEQ ID NO: 480), SGSIASSY (SEQ ID NO: 640), NSNVGNNY (SEQ ID NO: 465), SLRSYY (SEQ ID NO: 643), KLGERF (SEQ ID NO: 405), SGSVSTSYY (SEQ ID NO: 641), SSNIGRNY (SEQ ID NO: 652), EDIRMY (SEQ ID NO: 215), QGISTY (SEQ ID NO: 490), SSNVGSRT (SEQ ID NO: 657), NIGTKS (SEQ ID NO: 459), NIGSKT (SEQ ID NO: 457), QSINSY (SEQ ID NO: 562), SSNIGSNT (SEQ ID NO: 654), QSIITY (SEQ ID NO: 560), QSLLHSDGKTY (SEQ ID NO: 570), and GGNIARNY (SEQ ID NO: 279) CDR-L2 AAS (SEQ ID NO: 49), AAS (SEQ ID NO: 49), DST (SEQ ID NO: 191), DDD (SEQ ID NO: 158), KDN (SEQ ID NO: 386), GAS (SEQ ID NO: 260), KAS (SEQ ID NO: 385), RNN (SEQ ID NO: 635), SNN (SEQ ID NO: 644), AND, DAF (SEQ ID NO: 156), DDS (SEQ ID NO: 159), AAT (SEQ ID NO: 50), AVS (SEQ ID NO: 154), DAS (SEQ ID NO: 157), GVS (SEQ ID NO: 295), DNN (SEQ ID NO: 190), DVS (SEQ ID NO: 201), RAS (SEQ ID NO: 619), GTS (SEQ ID NO: 291), EDN (SEQ ID NO: 216), DND (SEQ ID NO: 188), GKN (SEQ ID NO: 287), QYI (SEQ ID NO: 616), NTD (SEQ ID NO: 467), RNH (SEQ ID NO: 633), EGS (SEQ ID NO: 219), DGR (SEQ ID NO: 162), TAS (SEQ ID NO: 667), DDT (SEQ ID NO: 160), EVS (SEQ ID NO: 237), and EDD (SEQ ID NO: 214) CDR-L3 QQSYSTPPT (SEQ ID NO: 534), QQSYSTPPT (SEQ ID NO: 534), GSWDTNLSGYV (SEQ ID NO: 289), QVWDSSSGHREV (SEQ ID NO: 613), QAWDSSTYV (SEQ ID NO: 473), QQYNHWPPL (SEQ ID NO: 544), QQYSGDSMYT (SEQ ID NO: 553), AAWDDSLSGVV (SEQ ID NO: 56), AAWDDSLNGVV (SEQ ID NO: 53), ATWDDSLSGVV (SEQ ID NO: 151), QQSHSTPIT (SEQ ID NO: 526), QQYNSYSRT (SEQ ID NO: 551), QQYTNWPQT (SEQ ID NO: 554), LQYDRYSGA (SEQ ID NO: 426), QVWHTTNDHVL (SEQ ID NO: 615), QVWDSSSDHWV (SEQ ID NO: 611), QQSKQIPYT (SEQ ID NO: 528), QQSYSLPLT (SEQ ID NO: 531), QQFDISGGLI (SEQ ID NO: 518), QQYDNLPLT (SEQ ID NO: 542), QVWDSSSDHTVA (SEQ ID NO: 609), SSYTTTDTFV (SEQ ID NO: 665), QQYDNLPYT (SEQ ID NO: 543), QQYYSTPPH (SEQ ID NO: 556), QQSYSTPLT (SEQ ID NO: 532), QVWDSSSDHVV (SEQ ID NO: 610), GTWDSSLSAYV (SEQ ID NO: 294), QQTHTWPWT (SEQ ID NO: 538), QQANSFPLT (SEQ ID NO: 514), QQSYSTPYT (SEQ ID NO: 536), SSYTSSSTYV (SEQ ID NO: 664), QRYGSSPR (SEQ ID NO: 557), QQVHSFPFT (SEQ ID NO: 541), LQHNTFPYT (SEQ ID NO: 423), QQSHSTPLT (SEQ ID NO: 527), QQYNSYPFT (SEQ ID NO: 548), QQYNSSPLMYT (SEQ ID NO: 547), QQTYSTPLT (SEQ ID NO: 540), QQANTFPQT (SEQ ID NO: 516), QSYDGSSVV (SEQ ID NO: 579), GSWEARESVFV (SEQ ID NO: 290), QQTYNDPPT (SEQ ID NO: 539), NSRDSSGNHVV (SEQ ID NO: 466), QTWDGSIVV (SEQ ID NO: 583), VLYMGSGIWV (SEQ ID NO: 694), ATWDDALSGWV (SEQ ID NO: 149), SSYTSSSTLVV (SEQ ID NO: 660), QQSYSTPWT (SEQ ID NO: 535), SSYTSSSTWV (SEQ ID NO: 663), LQDYNYPPA (SEQ ID NO: 422), QQYYDDPQ (SEQ ID NO: 555), QQLNGYPTT (SEQ ID NO: 525), AAWDDSLIGHV (SEQ ID NO: 51), QVWDTSGDLHWA (SEQ ID NO: 614), QQSYTTPLT (SEQ ID NO: 537), QVWDSSSDLLWV (SEQ ID NO: 612), GTWDSSLSALV (SEQ ID NO: 292), AAWDDSLNGPV (SEQ ID NO: 52), MQTKQLPLT (SEQ ID NO: 443), QQANSFPPT (SEQ ID NO: 515), QSYDGNNHMV (SEQ ID NO: 578), and SSYTSSSTLWV (SEQ ID NO: 661)

Sequence analysis applied to scFv's directed to individual target epitopes identifies common CDR usage patterns within each set of antibody:

For CD25 epitope 1 (55-63), CDRs used include:

CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKGDVNYGMDV (SEQ ID NIGSKS DDT QVWDSSSDLLWV (SEQ ID (SEQ ID NO: 65) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 456) ID NO: 612) 160) NIGSKT DGR QVWDTSGDLHWA (SEQ ID (SEQ (SEQ ID NO: NO: 457) ID NO: 614) 162) ISYDGNNK AKGYSSSPGDY (SEQ ID SSDVGAYNY DVS SSYTSSSTLWV (SEQ ID NO: 67) (SEQ ID (SEQ (SEQ ID NO: NO: 360) NO: 647) ID NO: 661) 201) GGTFSSYA IIPIFGTA ARDFNPFSITIFEMDV (SEQ SSNIGNNY DNN GTWDSSLSALV (SEQ ID (SEQ ID ID NO: 74) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 651) ID NO: 292) 190) GGSISSSNW IYHSGST ARDFYYGSGSYPNGYYYGMDV QSINSY TAS QQSYTTPLT (SEQ ID (SEQ ID (SEQ ID NO: 77) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 562) ID NO: 537) 667) GYSFNTYW IYPSDSDT ARDGGYYFDD (SEQ ID QSVSSTY GTS QQYNSSPLMYT (SEQ ID (SEQ ID NO: 79) (SEQ ID (SEQ (SEQ ID NO: NO: 297) NO: 383) NO: 577) ID NO: 547) 291) GGTFSSYA IIPIFGTA ARDYYYYGMDV (SEQ ID QSISRY GAS QQTYNDPPT (SEQ ID (SEQ ID NO: 101) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 564) ID NO: 539) 260) AREMYYYYGMDV (SEQ ID QSISSY AAS QQSYSTPPT NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 567) ID NO: 534) 49) QSISNY (SEQ ID NO: 563) QSIITY (SEQ ID NO: 560) QSISSY (SEQ ID NO: 567) GGSISRSNW IYHTGST ARGKGSYAFDI (SEQ ID GGNIARNY EDD QSYDGNNHMV (SEQ ID (SEQ ID NO: 110) (SEQ ID (SEQ (SEQ ID NO: NO: 281) NO: 366) NO: 279) ID NO: 578) 214)

For CD25 epitope 2 (13-20:127-132), CDRs used include:

CDR-HI CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK ANLAMGQYFDY (SEQ ID SSNIGSNT SNN  AAWDDSLNGPV (SEQ ID (SEQ ID NO: 70) (SEQ ID NO: (SEQ ID (SEQ ID NO: NO: 275) NO: 362) 654) NO: 644) 52) GFTFSSYA ARDLGEAKSSSPHEPDY QSLLHSDGKTY EVS MQTKQLPLT (SEQ ID (SEQ ID NO: 84) (SEQ ID NO: (SEQ ID (SEQ ID NO: NO: 273) 570) NO: 237) 443) GDSISSSSYY INHSGST ARDQEMYYFDY (SEQ ID QGISSW (SEQ AAS QQANSFPPT (SEQ ID (SEQ ID NO: 88) ID NO: 489) (SEQ ID (SEQ ID NO: NO: 261) NO: 333) NO: 49) 515) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ QSISSY (SEQ AAS QQSYSTPPT (SEQ ID (SEQ ID ID NO: 103) ID NO: 567) (SEQ ID (SEQ ID NO: NO: 286) NO: 326) NO: 49) 534)

For CD25 epitope 3 (5-17), CDRs used include:

CDR-HI CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKAITSIEPY (SEQ ID SGSVSTSYY NTD VLYMGSGIWV (SEQ ID (SEQ ID NO: 60) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 641) ID NO: 694) 467) GFTFSSYG ISYDGSNK AKELLEGAFDI (SEQ ID NIETKS DDD QVWDSSSGHREV (SEQ ID (SEQ ID NO: 64) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 455) ID NO: 613) 158) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID NO: 534) QSISNY 49) (SEQ ID NO: 563)

For CD25 epitope 4 (5-11:156-163), CDRs used include:

CDR-HI CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ ID QSISNY AAS QQSYSTPPT (SEQ ID (SEQ ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 563) ID NO: 534) 49) GYTFTSYG ISAYNGNT ARERSYYGMDV (SEQ ID QSVSNY GAS QQYNHWPPL (SEQ ID (SEQ ID NO: 105) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 574) ID NO: 544) 260)

For CD25 epitope 5 (77-89), CDRs used include:

CDR-HI CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKELLEGAFDI (SEQ ID NIETKS DDD QVWDSSSGHREV (SEQ ID (SEQ ID NO: 64) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 455) ID NO: 613) 158) GYTFTSYY INPSGGST ARDRVTMVRGALAY (SEQ KLGDKY KDN QAWDSSTYV (SEQ ID (SEQ ID ID NO: 97) (SEQ ID (SEQ (SEQ ID NO: NO: 313) NO: 339) NO: 404) ID NO: 473) 386)

For CD25 epitope 6 (147-157), CDRs used include:

CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKGQGDGMDV (SEQ ID SSNVGSRT SNN AAWDDSLIGHV (SEQ ID (SEQ ID NO: 66) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 657) ID NO: 51) 644) GGSISSGGYS IYHSGST ARAGYYYGMDV (SEQ ID RNIWSY GAS QQSHSTPIT (SEQ ID (SEQ ID NO: 71) (SEQ ID (SEQ (SEQ ID NO: NO: 282) NO: 365) NO: 634) ID NO: 526) 260) GYTFTSYG ISAYNGNT ARDIGYYYGMDV (SEQ ID SLRSYY GKN NSRDSSGNHVV (SEQ ID (SEQ ID NO: 80) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 643) ID NO: 466) 287) GYTFTSYY INPSGGST ARDILGLDY (SEQ ID SSNIGSNY RNN AAWDDSLSGVV (SEQ ID (SEQ ID NO: 81) (SEQ ID (SEQ (SEQ ID NO: NO: 313) NO: 339) NO: 655) ID NO: 56) 635) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ ID QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID NO: 534) 49) QSISNY (SEQ ID NO: 563) GFTFSSYW IKQDGSEK AREYDYGDYVFDY (SEQ NSNVGNNY DND GSWEARESVFV (SEQ ID (SEQ ID ID NO: 107) (SEQ ID (SEQ (SEQ ID NO: NO: 277) NO: 328) NO: 465) ID NO: 290) 188) GYSFTSYW IYPGDSDT ARLENNWDYGGWFDP (SEQ NIGSKS DDS QVWDSSSDHWV (SEQ ID (SEQ ID ID NO: 127) (SEQ ID (SEQ (SEQ ID NO: NO: 299) NO: 377) NO: 456) ID NO: 611) 159) IYPGDSDT (SEQ ID NO: 377) GYTFTDYY VDPEDGET ATEDTAMGGIDY (SEQ ID SSNIGSNY SNN AAWDDSLNGVV (SEQ ID (SEQ ID NO: 146) (SEQ ID (SEQ (SEQ ID NO: NO: 306) NO: 693) NO: 655) ID NO: 53) 644) ATEGRYGMDV (SEQ ID NFNIGNNL AND ATWDDSLSGVV NO: 147) (SEQ ID (SEQ (SEQ ID NO: NO: 453) ID NO: 151) 69) AVEGGRAPGTYYYDSSGLAY SSNIGSNY SNN (SEQ ID NO: 153) (SEQ ID (SEQ NO: 655) ID NO: 644)

For CD25 epitope 7 (11-14), CDRs used include:

CDR-HI CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID (SEQ ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID NO: 534) 49)

For CD25 epitope 8 (44-56), CDRs used include:

CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GYSFTSYW IYPGDSDT AIPWDAELGNYGMDV (SEQ QSISSY AAS LQDYNYPPA (SEQ ID (SEQ ID ID NO: 59) (SEQ ID (SEQ ID (SEQ ID NO: NO: 299) NO: 377) NO: 567) NO: 49) 422) GFAFSSYG ISYDGSNK AKGQGDGMDV (SEQ ID SSDVGGYNY GVS SSYTSSSTLVV (SEQ ID (SEQ ID NO: 66) (SEQ ID (SEQ ID (SEQ ID NO: NO: 262) NO: 362) NO: 649) NO: 295) 660) GGSISSSNW IYHSGST ARARGGRYFDY (SEQ ID QGISTY AAS QQLNGYPTT (SEQ ID (SEQ ID NO: 72) (SEQ ID (SEQ ID (SEQ ID NO: NO: 284) NO: 365) NO: 490) NO: 49) 525) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ ID QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID NO: 103) (SEQ ID (SEQ ID (SEQ ID NO: NO: 286) NO: 326) NO: 567) NO: 49) 534) QSISNY (SEQ ID NO: 563) ARGRWSGLGDY (SEQ ID EDIRMY EGS QQYYDDPQ NO: 113) (SEQ ID SEQ ID (SEQ ID NO: NO: 215) NO: 219) 555) GYKFANYW IYPGDSDT ARLGWGMDV (SEQ ID QSISSY AAS QQSYSTPWT (SEQ ID (SEQ ID NO: 129) (SEQ ID (SEQ (SEQ ID NO: NO: 296) NO: 377) NO: 567) ID 535) NO: 49) GFTFSSYE ISSSGSTI ARRRGGGFDY (SEQ ID SSDVGGYNY DVS SSYTSSSTWV (SEQ ID (SEQ ID NO: 132) (SEQ ID (SEQ (SEQ ID NO: NO: 274) NO: 351) NO: 649) ID 663) NO: 201) GYSFSTYW IYPGDSDT ARVGDGYSLDY (SEQ ID SSNIGRNY RNH ATWDDALSGWV (SEQ ID (SEQ ID NO: 135) (SEQ ID (SEQ (SEQ ID NO: NO: 298) NO: 377) NO: 652) ID 149) NO: 633) KLGERF QYI QTWDGSIVV (SEQ ID (SEQ (SEQ ID NO: NO: 405) ID 583) NO: 616) GYTFKNFG ISGRKGNT ARVWGDTTLGYGMDV (SEQ QDISNY DAS QQYDNLPLT (SEQ ID (SEQ ID ID NO: 141) (SEQ ID (SEQ (SEQ ID NO: NO: 301) NO: 347) NO: 485) ID 542) NO: 157) GFTFSSYG ISYDGSNK AKDLLGELSFFDY (SEQ DIESEM DDS QVWHTTNDHVL (SEQ ID (SEQ ID ID NO: 61) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 163) ID 615) NO: 159) GFTFSNYG ISHDGHVK AKEISPRSSVGWPLDY QSVSSTY GAS QQFDISGGLI (SEQ ID (SEQ ID (SEQ ID NO: 63) (SEQ ID (SEQ (SEQ ID NO: NO: 271) NO: 349) NO: 577) ID 518) NO: 260) GFTFRRYW IKQDGSEK ARDAYAYGLDV (SEQ ID SGSIASSY EDN QSYDGSSVV (SEQ ID (SEQ ID NO: 73) (SEQ ID (SEQ (SEQ ID NO: NO: 268) NO: 328) NO: 640) ID 579) NO: 216) GYTFTSYG ISAYNGNT ARDFRMDV (SEQ ID NO: QDIKRR DAS QQANTFPQT (SEQ ID (SEQ ID 75) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 480) ID 516) NO: 157) GFTFSSSA ISYDGSNK ARDFWSGYNELGGMDV QDISNY QQYDNLPLT (SEQ ID (SEQ ID (SEQ ID NO: 76) (SEQ ID (SEQ ID NO: NO: 272) NO: 362) NO: 485) 542) GYTFNNYG ISVYNGDI ARDILRGESSILDH (SEQ QGISNS AAS QQYYSTPPH (SEQ ID (SEQ ID ID NO: 82) (SEQ ID (SEQ ID (SEQ ID NO: NO: 302) NO: 359) NO: 488) NO: 49) 556) GGTFSSYA IIPIFGTA ARDKGYYGMDV (SEQ ID QSIKNY QQTYSTPLT (SEQ ID (SEQ ID NO: 83) (SEQ ID (SEQ ID NO: NO: 286) NO: 326) NO: 561) 540) QGINSY QQVHSFPFT (SEQ ID (SEQ ID NO: NO: 487) 541) QGISSW AVS QQSYSLPLT (SEQ ID (SEQ ID (SEQ ID NO: NO: 489) NO: 154) 531) ARDLGTMVRGVIEPYYFDY QSISSW DAF QQYNSYSRT (SEQ ID NO: 85) (SEQ ID (SEQ ID (SEQ ID NO: NO: 566) NO: 156) 551) GFTFSSYA ISYDGSNK ARDLLGSGYDIIDY (SEQ NIGSKS DDS QVWDSSSDHVV (SEQ ID (SEQ ID ID NO: 86) (SEQ ID (SEQ (SEQ ID NO: NO: 273) NO: 362) NO: 456) ID 610) NO: 159) GGSISSSNW IYHSGST ARDLMNYGMDV (SEQ ID QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID NO: 87) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 567) ID 534) NO: 49) GFTFSSYS ISSSSSYI ARDQLAARRGYYYGMDV NIGTKS DDS QVWDSSSDHVV (SEQ ID (SEQ ID (SEQ ID NO: 89) (SEQ ID (SEQ (SEQ ID NO: NO: 276) NO: 352) NO: 459) ID 610) NO: 159) GYTFTTYA INTNIGDP ARDRFHYGMDV (SEQ ID EGIRTS GAS QQTHTWPWT (SEQ ID (SEQ ID NO: 90) (SEQ ID (SEQ (SEQ ID NO: NO: 314) NO: 344) NO: 218) ID 538) NO: 260) GFTFSSYG ISSRGSTI ARDRGDRVGGLVFDY (SEQ NIGSKS DDS QVWDSSSDHVV (SEQ ID (SEQ ID ID NO: 91) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 350) NO: 456) ID 610) NO: 159) GYTFTSYG ISAYNGNT ARDRGDY (SEQ ID NO: QGTSSW AAS QQANSFPLT (SEQ ID (SEQ ID 92) (SEQ ID (SEQ ID (SEQ ID NO: NO: 312) NO: 346) NO: 491) NO: 49) 514) ARDRGYYGMDV (SEQ ID QSISRY QQSHSTPLT NO: 93) (SEQ ID (SEQ ID NO: NO: 564) 527) ARDRNGYFQH (SEQ ID QTISGL GAS LQYDRYSGA NO: 94) (SEQ ID (SEQ ID (SEQ ID NO: NO: 581) NO: 260) 426) GGTFSSYA IIPIFGTA ARDRSYYGMDV (SEQ ID QSIGNY AAT QQSKQIPYT (SEQ ID (SEQ ID NO: 96) (SEQ ID (SEQ ID (SEQ ID NO: NO: 286) NO: 326) NO: 558) NO: 50) 528) ARDRYYYGMDV (SEQ ID QSISSY AAS QQSYSTPLT NO: 98) (SEQ ID (SEQ (SEQ ID NO: NO: 567) ID 532) NO: 49) GFTFSSYW IKQDGSEK AREKGSWFDP (SEQ ID QSVSNNY GAS QRYGSSPR (SEQ ID (SEQ ID NO: 102) (SEQ ID (SEQ (SEQ ID NO: NO: 277) NO: 328) NO: 573) ID 557) NO: 260) GFIFSRHA ISYDGSNK ARGRLAYGDTEGFDY (SEQ QDINNY DAS QQYDNLPYT (SEQ ID (SEQ ID ID NO: 112) (SEQ ID (SEQ (SEQ ID NO: NO: 264) NO: 362) NO: 482) ID 543) NO: 157) GGSISSSNW IYHSGST ARGVRGTGFDP (SEQ ID QSVSSR GAS QQYTNWPQT (SEQ ID (SEQ ID NO: 118) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 576) ID 554) NO: 260) GYSFTTYW IYPGDSDT ARQVAGGLDY (SEQ ID SSNVGSNY RNN AAWDDSLSGVV (SEQ ID (SEQ ID NO: 131) (SEQ ID (SEQ (SEQ ID NO: NO: 300) NO: 377) NO: 656) ID 56) NO: 635) QAVRID GAS LQHNTFPYT (SEQ ID (SEQ (SEQ ID NO: NO: 472) ID 423) NO: 260) GFTFSSYE ISSSGSTI ARRRGGGFDY (SEQ ID SSDVGGYNY DVS SSYTSSSTYV (SEQ ID (SEQ ID NO: 132) (SEQ ID (SEQ (SEQ ID NO: NO: 274) NO: 351) NO: 649) ID 664) NO: 201) GFTFSSYW IKQDGSEK ARTWFGEFFDY (SEQ ID NIESES DDS QVWDSSSDHTVA (SEQ ID (SEQ ID NO: 134) (SEQ ID (SEQ (SEQ ID NO: NO: 277) NO: 328) NO: 454) ID 609) NO: 159) GYTFTSYG ISAYNGNT ARVIGGWFDP (SEQ ID SSDVGAYNY GVS SSYTTTDTFV (SEQ ID (SEQ ID NO: 136) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 647) ID 665) NO: 295) ARVWGKNGDFDY (SEQ ID SSNIGNNY DNN GTWDSSLSAYV NO: 142) (SEQ ID (SEQ (SEQ ID NO: NO: 651) ID 294) NO: 190) GYSFTSYW IYPGDSDT FRFGEGFDY (SEQ ID QSIGYW RAS QQYNSYPFT (SEQ ID (SEQ ID NO: 259) (SEQ ID (SEQ (SEQ ID NO: NO: 299) NO: 377) NO: 559) ID 548) NO: 619) GFTFNNAW IKSKIDGGIT TTEGVELLSFGGAPFDY QSISSY AAS QQSYSTPYT (SEQ ID (SEQ ID (SEQ ID NO: 683) (SEQ ID (SEQ (SEQ ID NO: NO: 267) NO: 330) NO: 567) ID 536) NO: 49)

Example 8: Confirmation of Epitope Specificity by Competitive Binding

126 anti-CD25 clones were subjected to epitope resolution with a four-target competitive binding assay, as depicted in FIG. 18 . The binding sites for IL-2, daclizumab, and basioliximab shown in the figure are based on X-ray crystallographic structure determination. The binding site for 7G7B6 is based on peptide mapping.

Cross-competition assays were performed in the classical sandwich format, involves immobilizing the first antibody onto the biosensor, followed by incubation with the antigen, and then the second sandwiching antibody. His-tagged scFv were expressed and purified in situ on the biosensor using His-tag capture from supernatant. Biosensor His-tag capture was normalized across scFv clones by monitoring the tip loading response to a consistent level across all scFv measurements. The scFv's were each individually captured to an anti-His biosensor (Fortebio HIS1K). A baseline measurement was taken in running buffer. Then CD25 was captured to the antibodies. Finally each of various competitive analytes were added, including IL-2, 7G7B6, Basiliximab, or Daclizumab. The competitive analyte can bind the captured CD25 only if competitive analyte's binding epitope does not overlap that of immobilized scFv.

As shown in FIG. 19 , the full-length CD25 panning clones are dominated by IL-2 interface epitope. Most clones are blocked by IL-2, daclizumab, and basioliximab, but not 7G7B6.

As shown in FIG. 20 , the 147-157 epitope MEM-steered clones primarily bind at the intended epitope. Most clones are blocked by daclizumab but not by IL-2, basioliximab, or 7G7B6.

As shown in FIG. 21 , the 6-17 epitope MEM-steered clones primarily bind at the intended epitope. Most clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab.

As shown in FIG. 22 , the 13-20:127-132 epitope MEM-steered clones primarily bind at the intended epitope. Most clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab.

As shown in FIG. 23 , the 44-56 epitope MEM-steered clones primarily bind at the intended epitope. The clones divided into two profiles. In profile 1, clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab. In profile 2, clones are blocked by IL-2, daclizumab, and basioliximab, but not 7G7B6. These blocking profiles indicate binding to the intended epitope from different approach angles.

As shown in FIG. 24 , the 55-63 epitope MEM-steered clones primarily bind at the intended epitope. The clones divided into three profiles. In profile 1, clones are blocked by 7G7B6 but not by IL-2, daclizumab, or basioliximab. In profile 2, clones are blocked by IL-2, daclizumab, and basioliximab, but not 7G7B6. These blocking profiles indicate binding to the intended epitope from different approach angles. In profile 3, clones are blocked by IL-2 and 7G7B6, but not daclizumab or basioliximab. These blocking profiles indicate binding to the intended epitope from different approach angles.

Example 9: Mapping of Functional Epitopes by Alanine Mutagenesis

Alanine mutations were designed to confirm or reject that MEM-steered clones bin the intended epitopes (FIG. 25 ). Alanine mutagenesis was selected as an orthogonal method for binning antibodies because it operates on the functional epitope, rather than the structural epitope defined by competition assays. Various pairs of surface-accessible residues were selected for mutagenesis. Computational modeling is used to confirm that the alanine mutations selected for use in these assays do not impact global or local stability. For example, FIG. 26 shows results for modeling of alanine mutations within the 145-157 epitope. For each mutant and wild-type: RMSD from 3 independent 100 ns MD simulations in explicit solvent for each of 8 different starting apo-CD25 configurations using the crystal structure as the reference. As shown in FIGS. 27-29 , alanine mutant versions of CD25 have the binding responses to basiliximab, daclizumab, and 7G7B6, respectively.

As intended, binding scFv hits from in vitro selection with the 147-157 epitope-targeted engineered polypeptides are consistent with specificity for the intended portion of CD25.

Each of 117 scFv's from the screening campaign were tested against four alanine mutations pairs (FIG. 31 ). Functional epitope diversity is observed. MEM-steered hits have distinct in-epitope alanine substitution position sensitivity.

Example 10: Confirmatory Testing of Antibodies in Immunoglobulin G (IgG1) Format

Thirty antibodies were selected for additional testing as full-length immunoglobulins. The heavy and light chain sequences were cloned into human immunoglobulin G (IgG1) format and expressed and purified. Binding to CD25 was assessed by Octet® as shown in Table 13.

TABLE 13 Human IgG1 Clone Selection/Epitope Details and Biophysical Measurements Biosensor Measured CD25 Selection Selection Selection Sample_ID Affinity Epitope R1_Antigen R2_Antigen R3_Antigen YU390-B12 1.366E−08 _77-89_ 77_89 CD25 77_89 YU397-F01 7.053E−08 _44-56_ 44_56 CD25 CD25 YU397-D01 3.857E−09 _44-56_ 44_56 CD25 CD25 YU398-A11 1.209E−08 _147-157_ 147_156 CD25 CD25 YU404-H01 5.179E−08 _55-63_ 57_63 CD25 CD25 YU400-B07 5.775E−08 _55-63_ 57_63 CD25 57_63 YU400-D09 5.455E−08 _55-63_ 57_63 CD25 57_63 YU401-B01 7.038E−08 _55-63_ 57_63 CD25 CD25 YU401-G07 1.535E−08 _55-63_ 57_63 CD25 57_63 YU404-C02 1.262E−08 _55-63_ 57_63 CD25 CD25 YU403-G07 2.956E−08 _55-63_ 57_63 CD25 CD25 YU403-G05 3.193E−08 _55-63_ 57_63 CD25 CD25 YU391-B12 4.581E−08 _77-89_ 77_89 CD25 CD25 YU400-A03 1.022E−08 _147-157_ 147_156 CD25 CD25 YU400-D02 1.011E−08 _147-157_ 147_156 CD25 CD25 YU392-A09 1.237E−08 _147-157_ 147_156 CD25 147_156 YU392-B11 6.558E−08 _147-157_ 147_156 CD25 147_156 YU392-B12 4.04E−08 _147-157_ 147_156 CD25 CD25 YU392-E05 1.612E−08 _147-157_ 147_156 CD25 147_156 YU392-E06 8.301E−09 _147-157_ 147_156 CD25 147_156 YU392-G08 8.259E−09 _147-157_ 147_156 CD25 147_156 YU389-A03 9.546E−09 _6-17_ 6_130 CD25 CD25 YU392-G09 2.019E−08 _147-157_ 147_156 CD25 147_156 YU392-G12 2.571E−08 _147-157_ 147_156 CD25 CD25 YU392-H02 1.055E−08 _77-89_ 77_89 CD25 CD25 YU392-H04 9.098E−09 _147-157_ 147_156 CD25 147_156 YU402-F01 6.303E−09 _13-20_127-132_ 13_131 CD25 CD25 YU389-B11 1.418E−07 _6-17_ 6_130 CD25 CD25 YU394-D08 4.432E−08 _11-14_ 11_14 CD25 11_14 YU390-A11 1.327E−08 _6-17_ 6_130 CD25 CD25

Example 11: Panning Biased Library of Mouse Antibody Sequences

A phage-display library was generated from the immunoglobulin genes of a mouse immunized with full-length CD25. This library, biased towards CD25-binding antibodies, was panned against the indicated engineered polypeptides, yielding the complementarity determining region sequences indicated in Table 14 Å and Table 14B.

TABLE 14A H CDR1 H CDR2 H FR4 ID Epitope H FR1 AA AA H FR2 AA AA H FR3 AA H CDR3 AA AA M1 33_63 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TV (SEQ ID NO: 236) (SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID ID NO: ID NO: 318) NO: 684) 702) 265) M2 33_63 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TV (SEQ ID NO: 236) (SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID ID NO: ID NO: 318) NO: 684) 702) 265) M3 44_56 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TV (SEQ ID NO: 236) SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID ID NO: ID NO: 318) NO: 684) 702) 265) M4 44_56 EVHLQQFGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTPV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLAPEDTAVYYC (SEQ ID AGFAY TVSS ID NO: 228) (SEQ ID NO: 324) ID NO: NO: 238) (SEQ ID (SEQ ID ID NO: 318) NO: 684) NO: 265) 705) M5 147_156 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TV (SEQ ID NO: 477) (SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID ID NO: ID NO: 318) NO: 684) 702) 265) M6 44_56 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTPV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TVSS ID NO: 477) (SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID (SEQ ID ID NO: 318) NO: 684) NO: 265) 705) M7 6_130 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TVSS ID NO: 477) (SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID (SEQ ID ID NO: 318) NO: 684) NO: 265) 704) M8 6_163 EVLLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE EYAPKFQGKATMTADTSSNTAHLQ TVFWYGNNY WGQGTLV SAKLSCTAS (SEQ YY EWIGW (SEQ T (SEQ LSSLTSEDTAVYYC (SEQ ID AGFAY TV (SEQ ID NO: 233) (SEQ ID NO: 324) ID NO: NO: 239) (SEQ ID ID NO: ID NO: 318) NO: 684) 702) 265) M9 147_157 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTPV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSS ID NO: 236) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 705) M10 147_157 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 477) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M11 147_157 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 236) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M12 33_63 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 236) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M13 33_63 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 236) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M14 33_63 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTPV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSS ID NO: 236) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 705) M15 33_63 EVRLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSS ID NO: 236) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 704) M16 33_63 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 477) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M17 33_63 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 477) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M18 44_56 QAYLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGQGTLV SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSA ID NO: 477) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 703) M19 44_56 EVHLQQSGAELVRSGA GFNIKD IHWVKQRPEQGL IDPDNGE KFQGKATMTADTSSNTAHLQLSSL TVFWYGNNY WGAGTSL SVKLSCTAS (SEQ YY EWIGW (SEQ TEYAP TSEDTAVYYC (SEQ ID NO: AGFAY TVSS ID NO: 231) (SEQ ID NO: 324) (SEQ ID 403) (SEQ ID (SEQ ID ID NO: NO: NO: 684) NO: 265) 319) 699) M20 33_63 QVQLQQPGAELVRPGA GYSFTS MNWVKQRPGQGL IHPSDSE KFKDKATLIVDKSSSTAYMQLSSP ARSRGIPFA WGQGTLV SVKLSCKAS (SEQ YW EWIGI (SEQ TRLNQ TSEDSAVYYC (SEQ ID NO: Y (SEQ ID TVSA ID NO: 589) (SEQ ID NO: 442) (SEQ ID 390) NO: 133) (SEQ ID ID NO: NO: NO: 299) 322) 703) M21 33_63 QVQLQQPGADLMKPGA GYTFSN IEWIKQRPGHGL ILPGSGF NFKGKATFTADISSNITYMQLSSL ARGGTSVVH WGQGTSL SVKISCKAS (SEQ YW EWVGE (SEQ TNYNE TSEDSAVYYC (SEQ ID NO: FDY (SEQ TVSS ID NO: 587) (SEQ ID NO: 321) (SEQ ID 452) ID NO: (SEQ ID ID NO: NO: 109) NO: 304) 331) 708) M22 44_56 EVRLQQSGADLMKPGA GYTFSN IEWIKQRPGHGL ILPGSGF NFKGKATFTADISSNITYMQLSSL ARGGTSVVH WGQGTTV SVKISCKAS (SEQ YW EWVGE (SEQ TNYNE TSEDSAVYYC (SEQ ID NO: FDY (SEQ TVSS ID NO: 235) (SEQ ID NO: 321) (SEQ ID 452) ID NO: (SEQ ID ID NO: NO: 109) NO: 304) 331) 713) M23 44_56 EVRLQQSGADLMKPGA GYTFSN IEWIKQRPGHGL ILPGSGF NFKGKATFTADISSNITYMQLSSL SRGGTSFVH WGQGTTL SVKISCKAS (SEQ YW EWIGE (SEQ TNYNE SSEDSAVYYC (SEQ ID NO: FDY (SEQ TVSS ID NO: 235) (SEQ ID NO: 320) (SEQ ID 451) ID NO: (SEQ ID ID NO: NO: 646) NO: 304) 331) 709) M24 6_130 QIQLQQPGAELAKPGA GYTFTR MRWVKQRPGQDL INPGSDY DYNEKEKDKAILTADKSSSTAYMQ ARXGYFDY WGRGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 446) ID NO: NO: 213) NO: 143) (SEQ ID ID NO: 334) NO: 311) 716) M25 33_63 QVQLQQSGAELAKPGA GYTFNR IHWIRQRPGQSL INPNSDY EYNQMFEDRATLTADTSSSTAYIQ ARGTIIDY WGQGTTL SVKMSCKAS (SEQ FW EWIGY (SEQ I (SEQ LSSLTSEDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 323) ID NO: NO: 245) NO: 114) (SEQ ID ID NO: 335) NO: 303) 709) M26 6_163 QVQLQQSGAELAKPGA GYTFNR IHWIRQRPGQSL INPNSDY EYNQMFEDRATLTADTSSSTAYIQ ARGTIIDY WGQGTTL SVKMSCKAS (SEQ FW EWIGY (SEQ I (SEQ LSSLTSEDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 323) ID NO: NO: 245) NO: 114) (SEQ ID ID NO: 335) NO: 303) 709) M27 33_63 QVQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M28 33_63 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M29 33_63 QIQLQQPGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 713) M30 33_63 QIQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVS S ID NO: 503) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 708) M31 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M32 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M33 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M34 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M35 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M36 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M37 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) NO: 242) NO: 124) (SEQ ID ID NO: ID NO: NO: 311) 337) 709) M38 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M39 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M40 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M41 44_56 QVQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M42 44_56 QVQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M43 44_56 QIQLQQPGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 713) M44 44_56 QIQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M45 44_56 QIQLQQPGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 713) M46 44_56 QVQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLASDDSAVYYC (SEQ ID (SEQ ID TV (SEQ ID NO: 593) (SEQ ID NO: 325) ID NO: NO: 241) NO: 124) ID NO: ID NO: 337) 711) 311) M47 57_63 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M48 6_130 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M49 6_130 QVQLQQPGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M50 6_130 QVQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLASDDSAVYYC (SEQ ID (SEQ ID TV (SEQ ID NO: 593) (SEQ ID NO: 325) ID NO: NO: 241) NO: 124) ID NO: ID NO: 337) 711) 311) M51 6_163 QVQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFKDKATLTADKSSSTAYMQ ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 432) ID NO: NO: 242) NO: 124) (SEQ ID ID NO: 337) NO: 311) 709) M52 6_163 QIQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY EYNQKFEDRATLTADKSSSTAYMQ ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 432) ID NO: NO: 240) NO: 124) (SEQ ID ID NO: 337) NO: 311) 713) M53 57_63 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY EYNQKFKDKATLTANKSSSTAYMQ ARHXYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ T (SEQ LSSLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) ID NO: NO: 243) NO: 125) (SEQ ID ID NO: 337) NO: 311) 709) M54 33_63 QVQLQQSGAELAKPGA GYTFTK MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL AIHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 432) (SEQ ID 389) NO: 57) (SEQ ID ID NO: NO: NO: 308) 338) 709) M55 147_157 QVQMKQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 604) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 708) M56 147_157 QVQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 432) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M57 147_157 QVQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 713) M58 33_63 QIQLKESGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 499) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M59 33_63 QVQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 432) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M60 33_63 QIQLQQPGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 432) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 713) M61 33_63 QIQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M62 33_63 QVQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ ASDDSAVYYC (SEQ ID NO: (SEQ ID TVSA ID NO: 593) (SEQ ID NO: 325) (SEQ ID 388) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 712) M63 33_63 QIQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 708) M64 33_63 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M65 33_63 QIQLQQSGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 708) M66 33_63 QIQLQQPGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFEDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 432) (SEQ ID 387) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M67 33_63 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M68 33_63 QIQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTV SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 500) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 713) M69 33_63 QIQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 432) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 708) M70 33_63 QIQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 432) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 708) M71 33_63 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M72 33_63 QIQLQQSGAELAKPGA GYTFTR MHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTSL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 503) (SEQ ID NO: 432) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 708) M73 44_56 QVQLQQPGAELAKPGA GYTFTR IHWVKQRPGQDL INPRTDY KFKDKATLTADKSSSTAYMQLSSL ARHGYFDY WGQGTTL SVKMSCKAS (SEQ YW EWIGY (SEQ TEYNQ TSDDSAVYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 588) (SEQ ID NO: 325) (SEQ ID 389) NO: 124) (SEQ ID ID NO: NO: NO: 311) 338) 709) M74 44_56 EVHLQQSGAELAKPGA GYTFTR MHWVKQRPGQGL INPSTDY EYNQMFEDRATLTADKSSSTAYIQ ARGTIIDY WGQGTTL SVKMSCKAS (SEQ FW EWIGY (SEQ I (SEQ LTSLTSEDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 229) (SEQ ID NO: 433) ID NO: NO: 244) NO: 114) (SEQ ID ID NO: 340) NO: 310) 709) M75 6_163 QVQLQQSGAELAKPGA GYTFNR MHWVKQRPGQGL INPSTGY EHNQKFKDKATLTADKSSSTAYMQ ARGTVVDY WGQGTTL SVKMSCKAS (SEQ FW EWIGY (SEQ I (SEQ LSSLTSEDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 593) (SEQ ID NO: 433) ID NO: NO: 220) NO: 115) (SEQ ID ID NO: 341) NO: 303) 709) M76 147_157 QVQLVETGGGLVQPGG GFTFSG MSWVRQTPGKTL INSDGSA SIKDRFTIFRDNDKSTLYLQMSNV MRYDGYYWY WGAGTTV SRGLSCEGS (SEQ FW EWIGD (SEQ INYAP RSEDTATYFC (SEQ ID NO: FDV (SEQ TVSS ID NO: 603) (SEQ ID NO: 448) (SEQ ID 642) ID NO: (SEQ ID ID NO: NO: 447) NO: 269) 342) 700) M77 44_56 QVQLQQSGAGLVRPGV GYTFTD MHWVRQTHAKSL INTYSGD IYNQKFKGKATMTVDKSSNTAYRE ARGVSFDY WGQGTTV SLKISCKGS (SEQ YA KWIGV (SEQ A (SEQ LAKLTSEDSAIYYC (SEQ ID (SEQ ID TVYS ID NO: 602) (SEQ ID NO: 440) ID NO: NO: 370) NO: 119) (SEQ ID ID NO: 345) NO: 305) 714) M78 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL INTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 345) NO: 305) 708) M79 57_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL INTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 345) NO: 305) 713) M80 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRPSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVPFDY WAQSTIL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 435) ID NO: NO: 371) NO: 117) (SEQ ID ID NO: 353) NO: 305) 697) M81 147_156 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDI WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 371) NO: 120) (SEQ ID ID NO: 353) NO: 305) 708) M82 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M83 33_63 QVQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 591) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) V NO: 305) 713) M84 33_63 QIQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDNSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 502) (SEQ ID NO: 436) ID NO: NO: 373) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M85 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M86 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVNKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 375) NO: 122) (SEQ ID ID NO: 353) NO: 305) 708) M87 33_63 QVQLIQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 584) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M88 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYDQKFQGKATMTVDKSSSTAYLG ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 364) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M89 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M90 33_63 QVQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 591) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M91 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKDKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 367) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M92 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 708) M93 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 708) M94 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 374) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M95 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 708) M96 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 708) M97 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 374) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M98 147_156 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDHSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 372) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M99 147_156 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 708) M100 147_156 QVQLQQSGAELMRPGV GYTFTD MHWVRQSHAKSL ISTYSGD LYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 594) (SEQ ID NO: 436) ID NO: NO: 431) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M101 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSP ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 439) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M102 57_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M103 57_63 QVQMQQSGAELVRPGV GYTFTD MQWVRQSHAKSL ISTYSGD IYNQKFKSKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 606) (SEQ ID NO: 445) ID NO: NO: 376) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M104 6_130 QVQLQQSGAGLVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 602) (SEQ ID NO: 436) ID NO: NO: 374) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M105 6_130 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TV (SEQ ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) ID NO: ID NO: 353) 706) 305) M106 6_130 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 374) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M107 6_130 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) ID NO: NO: 374) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M108 6_163 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M109 77_89 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M110 77_89 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 371) NO: 122) (SEQ ID ID NO: 353) NO: 305) 713) M111 77_89 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 374) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M112 77_89 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD LYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) ID NO: NO: 431) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M113 77_89 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD LYNQKFKGKATMTVDKSSSTAYLE ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) ID NO: NO: 431) NO: 122) (SEQ ID ID NO: 353) NO: 305) 709) M114 57_63 QIQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSITAYLE ARXVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIVV (SEQ A (SEQ LARLTSDDSAVYYC (SEQ ID (SEQ ID TVSS ID NO: 502) (SEQ ID NO: 437) ID NO: NO: 368) NO: 144) (SEQ ID ID NO: 353) NO: 305) 713) M115 44_56 QVQMQQSGAELVRPGV GYTFTD MQWVRQSHAKSL ISTYSGD IYNQKFKSKATMTVDKSSSTAYLE ATGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 606) (SEQ ID NO: 445) ID NO: NO: 376) NO: 148) (SEQ ID ID NO: 353) NO: 305) 713) M116 57_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD IYNQKFKGKATMTVDKSSNTAYLE ATGVTFDY WGQGTIL SLKISCKGS (SEQ YA EWIGV (SEQ A (SEQ LARLTSDDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) ID NO: NO: 369) NO: 148) (SEQ ID ID NO: 353) NO: 305) 701) M117 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M118 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD (SEQ ID NO: 398) ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M119 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M120 147_157 EVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 234) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M121 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M122 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M123 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKDKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 391) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M124 147_157 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSA ID NO: 506) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 707) M125 147_157 QVQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 591) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M126 147_157 QVQLQQPGAELVRPGV GYTFTD MQWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 591) (SEQ ID NO: 445) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M127 147_157 QVQLQQPGAELVRPGV GYTFTD MQWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 591) (SEQ ID NO: 445) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M128 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M129 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M130 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA KWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 438) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M131 33_63 QVQMKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 605) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M132 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M133 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M134 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M135 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSP ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 439) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M136 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M137 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M138 33_63 QVQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIG (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 591) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M139 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M140 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M141 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M142 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M143 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M144 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M145 33_63 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M146 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M147 33_63 QVQLKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 585) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M148 33_63 QVQMKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 605) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M149 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M150 33_63 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M151 33_63 QAYLQQSGAELVRPGV GYTFTD VQWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 695) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M152 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M153 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M154 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M155 44_56 QVQLKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 585) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M156 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M157 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M158 44_56 QVQMKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 605) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M159 44_56 QVQMKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 605) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M160 44_56 QVQMKQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 605) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M161 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M162 44_56 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSA ID NO: 506) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 707) M163 44_56 QIQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 502) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M164 44_56 QIQLQQPGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 502) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M165 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M166 44_56 QVQMQQSGAELVRPGV GYTFTD MQWVRQSHAKSL ISTYSGD KFKSKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 606) (SEQ ID NO: 445) (SEQ ID 402) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M167 44_56 QVQMQQSGAELVRPGV GYTFTD MQWVRQSHAKSL ISTYSGD KFKSKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 606) (SEQ ID NO: 445) (SEQ ID 402) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M168 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 709) M169 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M170 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M171 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 713) M172 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ AIYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 354) 708) M173 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 713) M174 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTV SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 713) M175 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 709) M176 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 708) M177 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTSL SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 598) (SEQ ID NO: 436) (SEQ ID 399) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 708) M178 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 709) M179 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYLELARL ARGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 475) (SEQ ID NO: 436) (SEQ ID 398) NO: 122) (SEQ ID ID NO: NO: NO: 305) 355) 709) M180 44_56 QIQLQQSGAELVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSXTAYLELARL AXGVTFDY WGQGTTL SLKISCKGS (SEQ YA EWIGV (SEQ ALYNQ TSDDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 506) (SEQ ID NO: 436) (SEQ ID 401) NO: 155) (SEQ ID ID NO: NO: NO: 305) 355) 709) M181 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 709) M182 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 713) M183 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 713) M184 33_63 QAYLQQSGAEMVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 478) (SEQ ID NO: 436) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 709) M185 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 709) M186 6_130 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 708) M187 6_130 QIQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 507) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 709) M188 6_163 QVQLQQPGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 592) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 713) M189 6_163 EVHLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 230) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 713) M190 77_89 QIQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 507) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 708) M191 77_89 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) ID NO: NO: 666) NO: 121) (SEQ ID ID NO: 356) NO: 305) 713) M192 57_63 QIQLQQSGAEMVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD SYNQKFKGKATMTVDKSSSTAYME ATXVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ V (SEQ LARLTSEDSAIYYC (SEQ ID (SEQ ID TVSS ID NO: 509) (SEQ ID NO: 436) ID NO: NO: 666) NO: 152) (SEQ ID ID NO: 356) NO: 305) 709) M193 147_157 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VNYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 357) 708) M194 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VNYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 357) 708) M195 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VNYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 357) 708) M196 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VNYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 357) 708) M197 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VNYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 357) 708) M198 147_157 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKDKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 392) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M199 147_157 QIQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 507) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M200 33_63 QVQLQQPGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 592) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M201 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 708) M202 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M203 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TXSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 710) M204 33_63 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M205 33_63 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M206 33_63 QVQMQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 607) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M207 33_63 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M208 33_63 QIQLQQSGAELVRPGV GYTFTD MQWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSNTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 507) (SEQ ID NO: 444) (SEQ ID 397) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M209 33_63 QIQLQQSGAEMVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 509) (SEQ ID NO: 436) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M210 33_63 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M211 33_63 QVQLQQSGAEMVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 601) (SEQ ID NO: 436) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M212 33_63 QAYLQQSGAEMVRPGV GYTFTD MHWVRQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 478) (SEQ ID NO: 436) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M213 44_56 EVLLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 232) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M214 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M215 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M216 44_56 QAYLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 476) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 709) M217 44_56 QVQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTFDS WGQGTTV SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 599) (SEQ ID NO: 434) (SEQ ID 400) NO: 121) (SEQ ID ID NO: NO: NO: 305) 358) 713) M218 33_63 QIQLQQSGAELVRPGV GYTFTD MHWVKQSHAKSL ISTYSGD KFKGKATMTVDKSSSTAYMELARL ARGVTSDS WGQGTSL SVKISCKGS (SEQ YA EWIGV (SEQ VSYNQ TSEDSAIYYC (SEQ ID NO: (SEQ ID TVSS ID NO: 507) (SEQ ID NO: 434) (SEQ ID 400) NO: 123) (SEQ ID ID NO: NO: NO: 305) 358) 708) M219 6_163 QVQLQQSGAEMVRPGT GYTFTK LGWVKQRPGHGL IYPGGDY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 600) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 378) NO: 308) 713) M220 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY NYNEKFKGKATLTADTSSSTAYMQ ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 140) (SEQ ID ID NO: 378) NO: 309) 709) M221 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY NYNEKFKGKATLTADTSSSTAYMQ ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 140) (SEQ ID ID NO: 378) NO: 309) 709) M222 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY NYNEKFKGKATLTADTSSSTAYMQ ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 140) (SEQ ID ID NO: 378) NO: 309) 709) M223 44_56 QIQLQQSGAEMVRPGT GYTFTK LGWVKQRPGHGL IYPGGDY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 508) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 308) 379) 708) M224 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY KFKGKATLTADTSSSTAYMQLSSL ARVTPSS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAAYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 394) NO: 140) (SEQ ID ID NO: NO: NO: 309) 379) 713) M225 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY KFKGKAILTADISSSTAYMQLSSL ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 140) (SEQ ID ID NO: NO: NO: 309) 379) 709) M226 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY KFKGKAILTADISSSTAYMQLSSL ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 140) (SEQ ID ID NO: NO: NO: 309) 379) 709) M227 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY KFKGKAILTADISSSTAYMQLSSL ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 140) (SEQ ID ID NO: NO: NO: 309) 379) 709) M228 44_56 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGDY KFKGKAILTADISSSTAYMQLSSL ARVTPSS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 140) (SEQ ID ID NO: NO: NO: 309) 379) 709) M229 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ A (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 380) NO: 309) 713) M230 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTIL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 701) M231 147_157 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M232 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCRAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 505) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M233 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M234 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFQGKATLTADTSSSTAYMQ ARVTPAS WGQGTPV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 470) NO: 139) (SEQ ID ID NO: 381) NO: 309) 705) M235 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M236 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M237 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M238 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M239 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKATLTADTSSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M240 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M241 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M242 44_56 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M243 44_56 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M244 6_130 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKERGKAILTADTSSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) ID NO: NO: 471) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M245 6_130 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M246 6_163 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M247 6_163 QVQLQQPGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 590) (SEQ ID NO: 416) NO: 469) NO: 139) (SEQ ID ID NO: ID NO: NO: 309) 381) 708) M248 6_163 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M249 6_163 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M250 6_163 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M251 77_89 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M252 77_89 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M253 77_89 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M254 77_89 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M255 77_89 QIQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 414) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 713) M256 77_89 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M257 77_89 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M258 77_89 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSNTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) ID NO: NO: 468) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M259 77_89 QAYLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 474) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 708) M260 77_89 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY NYNEKFKGKAILTADISSSTAYMQ ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ T (SEQ LSSLTSEDSAVYFC (SEQ ID (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) ID NO: NO: 469) NO: 139) (SEQ ID ID NO: 381) NO: 309) 709) M261 33_63 QAYLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKAILTADISSSTAYMQLSSL ARITPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 474) (SEQ ID NO: 416) (SEQ ID 395) NO: 126) (SEQ ID ID NO: NO: NO: 309) 382) 708) M262 33_63 QIQLQQPGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKAILTADISSSTAYMQLNSL ARVSPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 501) (SEQ ID NO: 416) (SEQ ID 393) NO: 138) (SEQ ID ID NO: NO: NO: 309) 382) 709) M263 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS(SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M264 147_157 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M265 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M266 147_157 QVQLQPGAELVRPGTS GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV VKISCKAS (SEQ ID YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS NO: 586) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M267 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY EFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 217) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M268 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M269 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M270 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M271 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M272 147_157 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M273 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTXL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 715) M274 147_157 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M275 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M276 33_63 QVQLQQPGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 590) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M277 33_63 QVQLQQSGAELVRPGI GYTFTN LGWVKQRPGHGL IYPGGGY EFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 595) (SEQ ID NO: 416) (SEQ ID 217) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M278 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQGPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 415) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M279 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M280 33_63 QVQLQQPGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 590) (SEQ ID NO: 414) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M281 33_63 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M282 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M283 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQGPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 415) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M284 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M285 33_63 QVQLQQPGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 590) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M286 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M287 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M288 33_63 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M289 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY EFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 217) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M290 33_63 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M291 33_63 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M292 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M293 33_63 QVQLQQSGAELVRPGT GYTFTN LGWIKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 414) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M294 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M295 33_63 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY EFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 217) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M296 44_56 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M297 44_56 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M298 44_56 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTSL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 708) M299 44_56 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTV SVKISCRAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 597) (SEQ ID NO: 416) (SEQ ID 395) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 713) M300 44_56 QVQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY EFKGKATLTADTSSSTAYMQLSSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 596) (SEQ ID NO: 416) (SEQ ID 217) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709) M301 44_56 QIQLQQSGAELVRPGT GYTFTN LGWVKQRPGHGL IYPGGGY KFKGKATLTADTSSSTAYMQLXSL ARVTPAS WGQGTTL SVKISCKAS (SEQ YW EWIGD (SEQ TNYNE TSEDSAVYFC (SEQ ID NO: (SEQ ID TVSS ID NO: 504) (SEQ ID NO: 416) (SEQ ID 396) NO: 139) (SEQ ID ID NO: NO: NO: 309) 382) 709)

TABLE 14B Epi- L CDR1 L CDR2 L CDR3 L FR4 ID tope L FR1 AA AA L FR2 AA AA L FR3 AA AA AA M1 33_63 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQP KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: T (SEQ LEIK NO: 202) (SEQ ID ID NO: 408) NO: 461) 406) ID NO: (SEQ NO: 569) 257) ID NO: 249) M2 33_63 DVVVTQTPLSLPVSLGDQ QSLVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEMK NO: 212) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 571) 250) M3 44_56 DVVVTQTPLSLPVSLGDQ QSLVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFILKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEMK NO: 212) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 571) 250) M4 44_56 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 202) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M5 147_156 DVVMTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 209) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ ID NO: 406) 255) NO:  569) 249) M6 44_56 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVGAEDLGVYYC (SEQ ID NO: PT (SEQ LEMK NO: 202) (SEQ ID ID NO: 409) NO: 462) ID NO: (SEQ NO: 406) 255) ID NO: 569) 250) M7 6_130 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 202) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M8 6_163 DVVMTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 209) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M9 147_157 DVVMTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEMK NO: 209) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 250) M10 147_157 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M11 147_157 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKQDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 419) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M12 33_63 DVVVTQTPLSLPVSLGDQ QSLVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEMK  NO: 212) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 571) (406) 255) ID NO: 250) M13 33_63 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQP KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP GGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: TF (SEQ LEIK NO: 202) (SEQ ID ID NO: 408) NO: 461) ID NO: (SEQ NO: 406) 258) ID NO: 569) 278) M14 33_63 DVVMTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEMK NO: 209) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 250) M15 33_63 DVVMTQTPLSLPVNLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGIYYC (SEQ ID NO: PT (SEQ LEIK NO: 208) (SEQ ID ID NO: 409) NO: 460) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M16 33_63 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 202) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M17 33_63 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 202) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M18 44_56 DVVMTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 209) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M19 44_56 DVVVTQTPLSLPVSLGDQ QSIVHSN LEWYLQKPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: RT (SEQ LEIK NO: 212) (SEQ ID ID NO: 409) NO: 461) ID NO: (SEQ NO: 406) 256) ID NO: 569) 249) M20 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: LT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 549) ID NO: 249) M21 33_63 DIQMTQSPKFLDVSAGDR QSVNND VVWYQQKPGQS YAS NRYTGVPDRFTGSGYGTDFTFTIS QQAYWSP FGGGTK VTITCKAS (SEQ ID (SEQ ID PKLLIY (SEQ (SEQ ID TVQAEDLAVYFC (SEQ ID NO: YT (SEQ LEMK NO: 169) NO: ID NO: 696) NO: 464) ID NO: (SEQ 572) 717) 517) ID NO: 250) M22 44_56 EIVMTQSPPTLSLSPGER QDVNTA VAWYQQKPGQA WAS TRHIGVPSRFSGSGSGTDFTLTIS QQHYSSP FGGGTK VTLSCKAS (SEQ ID (SEQ ID PRLLIY (SEQ (SEQ ID SLQPEDFATYYC (SEQ ID NO: WT (SEQ VEIK NO: 221) NO: ID NO: 687) NO: 681) ID NO: (SEQ 486) 698) 524) ID NO: 252) M23 44_56 EIVMTQSPPTLSLSPGER QDVNTA VAWYQQKQGQA WAS TRHIGVPSRFSGSGSGTDFTLTIS QQHYSSP FGGGTK VTLSCKAS (SEQ ID (SEQ ID PRLLIY (SEQ (SEQ ID SLQPEDFATYYC (SEQ ID NO: WT (SEQ VEIK NO: 221) NO: ID NO: 690) NO: 681) ID NO: (SEQ 486) 698) 524) ID NO: 252) M24 6_130 DVVMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGEGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 211) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 248) M25 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGAGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: LT (SEQ LEMK NO: 176) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 519) ID NO: 247) M26 6_163 DIQMTQTTSSLSASLGDR QYISNY LNWYQQRPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEMK NO: 176) NO: ID NO: 420) NO: 626) ID NO: (SEQ 617) 727) 520) ID NO: 250) M27 33_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 173) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M28 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M29 33_63 DVVMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 211) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M30 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 177) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M31 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M32 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M33 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M34 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M35 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M36 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M37 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFIGSGSGIDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M38 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M39 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M40 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M41 44_56 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 530) ID NO: 249) M42 44_56 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 530) ID NO: 249) M43 44_56 DVVMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VKLLIY (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 211) NO:  ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M44 44_56 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 186) NO:  ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M45 44_56 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 211) NO:  ID NO: 418) NO: 624) ID NO: (SEQ 520) 485) 317) 520) ID NO: 249) M46 44_56 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO:  ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M47 57_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNSLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO:  ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M48 6_130 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNSLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO:  ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M49 6_130 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNSLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 177) NO:  ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M50 6_130 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M51 6_163 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 530) ID NO: 249) M52 6_163 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M53 57_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M54 33_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 530) ID NO: 249) M55 147_157 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M56 147_157 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 530) ID NO: 249) M57 147_157 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 173) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M58 33_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M59 33_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQSNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 530) ID NO: 249) M60 33_63 DVVMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 211) NO: ID NO: 418) NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M61 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ  (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M62 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ  (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M63 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ  (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M64 33_63 DIQMTQTTSSLSASLGDR QYISNY LNWYQQRQDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ  (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEMK NO: 176) NO: ID NO: 421) NO: 626) ID NO: (SEQ 617) 727) 520) ID NO: 250) M65 33_63 DIVMTQTTSSLSASLGDR QDISNY LNWYQQKQDGT HTS RLHSGVPSRFSGSEPGTDYSLTIS QQGNTLP FGGGTK (SEQ ID VKLLIY (SEQ (SEQ NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK VTITCGAS (SEQ ID  NO: ID NO: 419) ID NO: 623) ID NO: (SEQ NO: 187) 485) 317) 520) ID NO: 249) M66 33_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKQDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 174) NO: ID NO: 419) ID NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M67 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) ID NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M68 33_63 DIVMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 186) NO: ID NO: 418) ID NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M69 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 177) NO: ID NO: 418) ID NO: 624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M70 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS  RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK  NO: 177) NO: ID NO: 418) NO:  624) ID NO: (SEQ 485) 317)  520) ID NO: 249) M71 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS  RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO:  627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M72 33_63 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKQDGT HTS  RLHSGVPSRFSGSESGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 177) NO: ID NO: 419) NO:  624) ID NO: (SEQ 485) 317) 520) ID NO: 249) M73 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M74 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 249) M75 6_163 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGADYSLTIS QQGNTLP FGAGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 625) ID NO: (SEQ 485) 727) 520) ID NO: 246) M76 147_157 DIQMTQSQKFMSTSVGDR QNVSTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ  (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 513) 637) 550) ID NO: 250) M77 44_56 DIQMTQSPASLSASVGET ENIHSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 222) 450) 496) ID NO: 250) M78 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M79 57_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M80 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M81 147_156 DVQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 196) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M82 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 224) 450) 496) ID NO: 249) M83 33_63 DIVLTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 179) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M84 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M85 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M86 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M87 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M88 33_63 DVVMTQSPASLSASVGES ENSYNY LEWYQQKQGKS NAK TLAEGVPSRFSGSGFGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 203) NO: ID NO: 413) NO: 669) ID NO: (SEQ 225) 450) 496) ID NO: 249) M89 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEMK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 250) M90 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M91 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M92 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 196) NO: ID NO: 413) NO: 671) ID NO: (SEQ 224) 450) 496) ID NO: 249) M93 33_63 DVQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 196) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M94 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QQHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 196) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 523) ID NO: 249) M95 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M96 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M97 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M98 147_156 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M99 147_156 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M100 147_156 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M101 44_56 DIQMTQSPASLSASVGES ENIYSY LEWSQQKQGKS NAK TLPEGVPSRFSGSGSGTQFSLKIS QHHYGIP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 407) NO: 676) ID NO: (SEQ 224) 450) 494) ID NO: 249) M102 57_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M103 57_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTRFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 674) ID NO: (SEQ 224) 450) 493) ID NO: 249) M104 6_130 DIQMTQSPASLSASVGET ENIHSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 22) 450) 496) ID NO: 250) M105 6_130 DIQMTQTPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTQ VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 175) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 254) M106 6_130 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLTEGVPSRFSGSGSGTQFSLKIN QQHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 677) ID NO: (SEQ 224) 450) 523) ID NO: 249) M107 6_130 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: WT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 522) ID NO: 249) M108 6_163 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M109 77_89 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M110 77_89 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M111 77_89 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M112 77_89 DVQMTQSPSSMYASLGER QDINSY LSWFQQKPGKS RAN RLVDGAPSRFSGSGSGQDYSLTIS LQYDEFP FGGGTK VTITCKAS (SEQ ID (SEQ ID PKTLIY (SEQ (SEQ ID SLEYEDMGIYYC (SEQ ID NO: YT (SEQ LEIK NO: 199) NO: ID NO: 427) NO: 628) ID NO: (SEQ 484) 618) 425) ID NO: 249) M113 77_89 DVQMTQSPSSMYASLGER QDINRY LSWFQQKPGKS RAN RLVDGVPSRFSGSGSGQNYSLTIS LQYDEFP FGGGTK VTFTCKAS (SEQ ID (SEQ ID PKTLIY (SEQ (SEQ ID SLEYEDMGIYYC (SEQ ID NO: YT (SEQ LEIK NO: 198) NO: ID NO: 427) NO: 632) ID NO: (SEQ 483) 618) 425) ID NO: 249) M114 57_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M115 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTRFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 674) ID NO: (SEQ 224) 450) 493) ID NO: 249) M116 57_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M117 147_157 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M118 147_157 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M119 147_157 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M120 147_157 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M121 147_157 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M122 147_157 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M123 147_157 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M124 147_157 DIQMTQTPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTQ VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 175) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 254) M125 147_157 DVVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 679) ID NO: (SEQ 224) 450) 493) ID NO: 251) M126 147_157 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 250) M127 147_157 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEMK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 250) M128 147_157 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QQHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 523) ID NO: 249) M129 147_157 DIVMTQTTSSLSASLGDR QDISNY LNWYQQKQDGT HTS RLHSGVPSRFSGSEPGTDYSLTIS QQGNTLP FGGGTK VTITCGAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 187) NO: ID NO: 419) NO: 623) ID NO: (SEQ 485) 317) 520) ID NO: 249) M130 147_157 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKQDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 419) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M131 33_63 DIVMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 181) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M132 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M133 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M134 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M135 33_63 DIQMTQSPASLSASVGES ENIYSY LEWSQQKQGKS NAK TLPEGVPSRFSGSGSGTQFSLKIS QHHYGIP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 407) NO: 676) ID NO: (SEQ 224) 450) 494) ID NO: 249) M136 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M137 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M138 33_63 DIVLTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 179) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M139 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M140 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 496) ID NO: 249) M141 33_63 DVVMTQTPSSLSASLGER QDINSY LSWFQQKPGKS RAN RLVDGVPSRFSGSGSGQDYSLTIS LQYDEFP FGGGTK VTITCKAS (SEQ ID (SEQ ID PKTLIY (SEQ (SEQ ID SLEYEDMGIYYC (SEQ ID NO: YT (SEQ LEIK NO: 210) NO: ID NO: 427) NO: 630) ID NO: (SEQ 484) 618) 425) ID NO: 249) M142 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M143 33_63 DVVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M144 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M145 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M146 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M147 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKKGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M148 33_63 DTTVTQSPSSMYASLGER QDINNF LSWFQQKPGKS RAN RLVDGVPSRFSGSGSGQDYSLTIS LQYDEFP FGGGTK VTITCKAS (SEQ ID (SEQ ID PQTLIY (SEQ (SEQ ID SLEYEDLGIYYC (SEQ ID NO: WT (SEQ LEIK NO: 192) NO: ID NO: 428) NO: 629) ID NO: (SEQ 481) 618) 424) ID NO: 249) M149 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QQHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 523) ID NO: 249) M150 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M151 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 26) 450) 496) ID NO: 249) M152 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M153 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M154 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M155 44_56 DIQMTQSPASLSASVGES ENIYSY LEWYQQKKGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 411) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M156 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M157 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M158 44_56 DIVMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 181) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M159 44_56 DIVMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 181) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M160 44_56 DIVMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 181) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M161 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M162 44_56 DIQMTQTPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTQ VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 175) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 254) M163 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M164 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M165 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M166 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTRFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 674) ID NO: (SEQ 224) 450) 493) ID NO: 249) M167 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTRFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 674) ID NO: (SEQ 224) 450) 493) ID NO: 249) M168 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M169 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M170 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M171 44_56 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKQDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 419) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M172 44_56 EIVMTQSPPTLSLSPGER QDVNTA VAWYQQKQGQA WAS TRHTGVPSRFSGSGSGTDFTLTIS QQHYSSP FGGGTK VTLSCKAS (SEQ ID (SEQ ID PRLLIY (SEQ (SEQ ID SLQPEDFATYYC (SEQ ID NO: WT (SEQ VEIK NO: 221) NO: ID NO: 690) NO: 681) ID NO: (SEQ 486) 698) 524) ID NO: 252) M173 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M174 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M175 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M176 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M177 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 224) 450) 496) ID NO: 249) M178 44_56 DVQMNQSPSSMYASLGER QDINNF LSWFQQKPGKS RAN RLVDGVPSRFSGSGSGQHYSLTIS LQYDEFP FGGGTK VTITCKAS (SEQ ID (SEQ ID PQTLIY (SEQ (SEQ ID GLEYEDLGIYYC (SEQ ID NO: WT (SEQ LEIK NO: 194) NO: ID NO: 428) NO: 631) ID NO: (SEQ 481) 618) 424) ID NO: 249) M179 44_56 DVQMNQSPSSMYASLGER QDINNF LSWFQQKQGKS RAN RLVDGVPSRFSGSGSGQHYSLTIS LQYDEFP FGGGTK VTITCKAS (SEQ ID (SEQ ID PQTLIY (SEQ (SEQ ID GLEYEDLGIYYC (SEQ ID NO: WT (SEQ LEIK NO: 194) NO: ID NO: 429) NO: 631) ID NO: (SEQ 481) 618) 424) ID NO: 249) M180 44_56 DVQMTQSPPSLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 197) NO: ID NO: 413) NO: 671) ID NO: (SEQ 224) 450) 496) ID NO: 249) M181 33_63 DIVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYSTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQSEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 182) NO: ID NO: 413) NO: 672) ID NO: (SEQ 224) 450) 498) ID NO: 249) M182 33_63 DIVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 182) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M183 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEMK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 250) M184 33_63 DIQMTQSTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHSGVPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEMK NO: 173) NO: ID NO: 418) NO: 626) ID NO: (SEQ 485) 727) 520) ID NO: 250) M185 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M186 6_130 DVVMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 203) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M187 6_130 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT YTS RLHIGIPSRFSGSGSGTDYSLTIS QQGNTLP FGGGTK VTITCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: ST (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 622) ID NO: (SEQ 485) 727) 521) ID NO: 249) M188 6_163 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 496) ID NO: 249) M189 6_163 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M190 77_89 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRTS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 166) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 250) M191 77_89 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 496) ID NO: 249) M192 57_63 DIVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 182) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 250) M193 147_157 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M194 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M195 44_56 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M196 44_56 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M197 44_56 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M198 147_157 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEMK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 250) M199 147_157 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M200 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M201 33_63 DIQMTQTPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 175) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M202 33_63 DIGMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 164) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M203 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLRIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 673) ID NO: (SEQ 224) 450) 495) ID NO: 249) M204 33_63 DIVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 182) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M205 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M206 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M207 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEMK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 250) M208 33_63 DVVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 204) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M209 33_63 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M210 33_63 DVVMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 203) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M211 33_63 DIQMTQTPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 175) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M212 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M213 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M214 44_56 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M215 44_56 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M216 44_56 DIQMTQSPASLSASVGES ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGSP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 165) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 495) ID NO: 249) M217 44_56 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VTITCRAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M218 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M219 6_163 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKIGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS HQYNNYP FGGGTK VTITCRAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID SVKSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 686) NO: 723) ID NO: (SEQ 512) 637) 316) ID NO: 249) M220 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS HQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 316) ID NO: 249) M221 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS HQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 316) ID NO: 249) M222 33_63 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 206) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M223 44_56 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M224 147_157 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 180) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M225 147_157 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 206) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M226 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS HQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 316) ID NO: 249) M227 33_63 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 206) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M228 44_56 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS HQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 316) ID NO: 249) M229 33_63 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M230 147_157 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQC SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 688) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M231 147_157 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M232 33_63 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M233 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M234 33_63 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGRGSGTDFTLTIS QQYNTYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLADYFC (SEQ ID NO: YT (SEQ LEIK NO: 180) NO: ID NO: 689) NO: 724) ID NO: (SEQ 512) 637) 552) ID NO: 249) M235 33_63 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M236 33_63 DIQMTQSQKFMSASVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 170) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M237 33_63 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 206) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M238 33_63 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M239 33_63 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M240 33_63 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M241 33_63 HIQMTHSPPPLSASVGET ENIYNY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTLTCRAS (SEQ ID (SEQ ID PHLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 315) NO: ID NO: 412) NO: 671) ID NO: (SEQ 223) 450) 496) ID NO: 249) M242 44_56 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M243 44_56 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M244 6_130 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQRPGQS SAS YRYTGVPDRFTGSGSGTDFTLTIS HQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 180) NO: ID NO: 692) NO: 725) ID NO: (SEQ 512) 637) 316) ID NO: 250) M245 6_130 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRITGRGSGTDFTLTIS QQYNTYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 180) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M246 6_163 DIVITQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 178) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M247 6_163 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M248 6_163 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M249 6_163 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNTYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLVEYFC (SEQ ID NO: YT (SEQ LEMK NO: 180) NO: ID NO: 689) NO: 721) ID NO: (SEQ 512) 637) 552) ID NO: 250) M250 6_163 DVQMNQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNTYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 195) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 552) ID NO: 249) M251 77_89 DIVMTQSQKFMSTSVGDR QNVGIN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 719) ID NO: (SEQ 511) 637) 546) ID NO: 249) M252 77_89 DIVMTQSQKFMSTSVGDR QNVGIN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNNYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 511) 637) 546) ID NO: 249) M253 77_89 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M254 77_89 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M255 77_89 DIVMTQTQKFMSTSVGGR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 185) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M256 77_89 DIVMTQSQKFMSTSVGDR QNVGIN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 719) ID NO: (SEQ 511) 637) 550) ID NO: 249) M257 77_89 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M258 77_89 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M259 77_89 DIVITQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 178) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M260 77_89 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M261 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M262 33_63 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 206) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M263 147_157 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 180) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M264 147_157 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFIGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M265 147_157 RHCESQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: LT (SEQ LEIK NO: 621) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 549) ID NO: 249) M266 147_157 DIQMTQSQKFMSTSAGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172171 NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M267 147_157 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: LT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 549) ID NO: 249) M268 147_157 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRITGRGSGTDFTLTIS QQYNTYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLADYFC (SEQ ID NO: YT (SEQ LEIK NO: 180) NO: ID NO: 689) NO: 724) ID NO: (SEQ 512) 637) 552) ID NO: 249) M269 147_157 DIQMTQTTSSLSASLGDR QDISNY LNWYQQKPDGT HTS RLQSGVPSRFTGSGSGTDYSLTIS QQSNSLP FGGGTK VTISCRAS (SEQ ID (SEQ ID VKLLIY (SEQ (SEQ ID NLEQEDIATYFC (SEQ ID NO: PT (SEQ LEIK NO: 176) NO: ID NO: 418) NO: 627) ID NO: (SEQ 485) 317) 529) ID NO: 249) M270 147_157 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEMK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 250) M271 147_157 DVVMTQTPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 207) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M272 147_157 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M273 147_157 DIVMTQSPPTLSLSPGER RDVNTA VAWYQQKQGQA WAS TRHTGVPSRFGGGGSGTDFTLTIS QHHYSSP FGGGTK VTLSCGAS (SEQ ID (SEQ ID PRLLIY (SEQ (SEQ ID RLQPENFATYYC (SEQ ID NO: WT (SEQ LEMK NO: 183) NO: ID NO: 690) NO: 680) ID NO: (SEQ 620) 698) 497) ID NO: 250) M274 147_157 DIVMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 182) NO: ID NO: 413) NO: 670) ID NO: (SEQ 224) 450) 493) ID NO: 249) M275 33_63 DIVMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 182) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M276 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M277 33_63 DIQMTQSPASLSASVGET ENIYSY LEWYQQKQGKS NAK TLVEGVPSRFSGSGSGTQFSLKIN QHHYDTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 678) ID NO: (SEQ 224) 450) 493) ID NO: 249) M278 33_63 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSGDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 689) NO: 722) ID NO: (SEQ 512) 637) 550) ID NO: 249) M279 33_63 MLVMTQTPLSLPVSLGDQ QSLVHSN LHWYLQKPGQS KVS NRFSGVPDRFSVSGSGTDFTLKIS SQSTHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYFC (SEQ ID NO: PT (SEQ LEIK NO: 441) (SEQ ID ID NO: 417) NO: 463) ID NO: (SEQ NO: 571) 406) 645) ID NO: 249) M280 33_63 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 206) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M281 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M282 33_63 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M283 33_63 DIVMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSGDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 691) NO: 722) ID NO: (SEQ 512) 637) 550) ID NO: 249) M284 33_63 DIQMTQSPASLSASVGET ENSYSY LEWYQQKQGKS NAK TLAEGVPSRFSGSGSGTQFSLKIN QHHYGTP FGGGTK VTITCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: YT (SEQ LEIK NO: 168) NO: ID NO: 413) NO: 671) ID NO: (SEQ 226) 450) 496) ID NO: 249) M285 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M286 33_63 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQEPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M287 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M288 33_63 DIVLTQSQKFMSTSVGDR QNVGTN VAWYQQEPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAKYFC (SEQ ID NO: YT (SEQ LEIK NO: 180) NO: ID NO: 685) NO: 720) ID NO: (SEQ 512) 637) 550) ID NO: 249) M289 33_63 DIQMTQSPASLSASVGES DNIYSY LEWYQQKQGKS NAK TLAXGVPSRFXGSGSGTQFSLKIN QHHYGTP FGGGTK VTLTCQAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGSYYC (SEQ ID NO: YT (SEQ XEMK NO: 167) NO: ID NO: 413) NO: 675) ID NO: (SEQ 189) 450) 496) ID NO: 253) M290 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M291 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M292 33_63 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 193) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M293 33_63 DIQMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 172) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M294 33_63 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 691) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M295 33_63 DVVMTQSPPSLSASVGET GNVHNF LTWYQQKQGKS NAE TLADGVPSRFSGSGSRSQYSLMIN QHFWNTP FGGGTK VTISCRAS (SEQ ID (SEQ ID PQLLVY (SEQ (SEQ ID SLQPEDFGTYYC (SEQ ID NO: PT (SEQ LEIK NO: 205) NO: ID NO: 430) NO: 668) ID NO: (SEQ 288) 449) 492) ID NO: 249) M296 44_56 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M297 44_56 DVQMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 200) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 249) M298 44_56 DVVMTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 206) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M299 44_56 DTTVTQSQKFMSTSVGDR QNVGTN VAWYQQKPGQS SAS YRYSGVPDRFTGSGSGTDFALTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEMK NO: 193) NO: ID NO: 689) NO: 719) ID NO: (SEQ 512) 637) 550) ID NO: 250) M300 44_56 DVVLTQTPLSLPVSLGDQ QSIVHSN LEWYLQRPGQS KVS NRFSGVPDRFSGSGSGTDFTLKIS FQGSHVP FGGGTK ASISCRSS (SEQ ID GNTY PKLLIY (SEQ (SEQ ID RVEAEDLGVYYC (SEQ ID NO: PT (SEQ LEIK NO: 202) (SEQ ID ID NO: 410) NO: 461) ID NO: (SEQ NO: 406) 255) ID NO: 569) 249) M301 44_56 DIVMTQSQKFMSTSVGDR QNVGIN VAWYQQKQGQS SAS YRYSGVPDRFTGSGSGTDFTLTIS QQYNSYP FGGGTK VSVTCKAS (SEQ ID (SEQ ID PKALIY (SEQ (SEQ ID NVQSEDLAEYFC (SEQ ID NO: YT (SEQ LEIK NO: 184) NO: ID NO: 691) NO: 719) ID NO: (SEQ 511) 637) 550) ID NO: 249)

Sequence analysis suggests that these antibodies derive from clonal lineages that may be grouped as indicated in Table 15 Å and Table 15B.

TABLE 15A # Baits CDRH1 CDRH2 CDRH3 1 147_156 GFNIKDYY IDPDNGET (SEQ TVFWYGNNYAGFAY 147_157_J2 (SEQ ID NO: ID NO: 318) (SEQ ID NO: 684) 33_63_J1 265) 33_63_J2 33_63_J3 44_56 44_56_J1 44_56_J2 6_130 6_163 2 147_156 GYTFTDYA ISTYSGDA SEQ ID ARGVTFDI (SEQ ID NO: 147 157J2 (SEQ ID NO: NO: 353) 120) 33_63_J1 305) INPRTDYTEYNQ ARGVTFDY (SEQ ID NO: 33_63_J2 GYTFTRYW (SEQ ID NO: 338) 122) 33_63_J3 (SEQ ID NO: ISTYSGDAIYNQ ARHGYFDY (SEQ ID NO: 44_56 311) (SEQ ID NO: 354) 124) 44_56_J1 GYSFTSYW ISTYSGDVNYNQ ARGVTFDS (SEQ ID NO: 44_56_J2 (SEQ ID NO: (SEQ ID NO: 357) 121) 57_63 299) ISTYSGDVSYNQ ARSRGIPFAY (SEQ ID NO: 6_130 GYTFSNYW (SEQ ID NO: 358) 133) 6_163 (SEQ ID NO: IHPSDSETRLNQ ARGGTSVVHFDY (SEQ ID 77_89 304) (SEQ ID NO: 322) NO: 109) GYTFTKYW ILPGSGFTNYNE AIHGYFDY (SEQ ID NO: (SEQ ID NO: (SEQ ID NO: 331) 57) 308) ISTYSGDALYNQ ARGVTSDS (SEQ ID NO: GYTFNRFW (SEQ ID NO: 355) 123) (SEQ ID NO: INPRTDYT (SEQ ID ARGTIIDY (SEQ ID NO: 303) NO: 337) 114) GYTFTRFW ISTYSGDV (SEQ ID ARGVSFDY (SEQ ID NO: (SEQ ID NO: NO: 356) 119) 310) INPNSDYI (SEQ ID ARGVPFDY (SEQ ID NO: NO: 335) 117) INTYSGDA (SEQ ATGVTFDY (SEQ ID NO: ID NO: 345) 148) INPSTDYI (SEQ ID SRGGTSFVHFDY (SEQ ID NO: 340) NO: 646) INPGSDYT (SEQ ID AXGVTFDY (SEQ ID NO: NO: 334) 155) INPSTGYI (SEQ ID ARHXYFDY (SEQ ID NO: NO: 341) 125) ARXVTFDY (SEQ ID NO: 144) ATXVTFDS (SEQ ID NO: 152) ARXGYFDY (SEQ ID NO: 143) ARGTVVDY (SEQ ID NO: 115) 3 6_163 GYTFTKYW IYPGGDYT (SEQ ARVTPAS (SEQ ID NO: 33_63_J3 (SEQ ID NO: ID NO: 378) 139) 44_56_J2 308) IYPGGDYTNYNE ARVTPSS (SEQ ID NO: 147_157_J2 GYTFTNYW (SEQ ID NO: 379) 140) 33_63_J1 (SEQ ID NO: IYPGGGYA (SEQ ARITPAS (SEQ ID NO: 33_63_J2 309) ID NO: 380) 126) 147_157_J1 IYPGGGYT (SEQ ARVSPAS (SEQ ID NO: 44_56_J1 ID NO: 381) 138) 6_130 IYPGGGYTNYNE (SEQ ID NO: 382)

TABLE 15B # Baits CDRL1 CDRL2 CDRL3 1 147_156 QSIVHSNGNTY KVS (SEQ ID NO: FQGSHVPPT (SEQ ID 147_157_J2 (SEQ ID NO: 406) NO: 255) 33_63_J1 569) NAK (SEQ ID NO: FQGSHVPT (SEQ ID 33_63_J2 ENIYSY (SEQ 450) NO: 257) 33_63_J3 ID NO: 224) HTS (SEQ ID NO: QHHYGSPYT (SEQ 44_56 QDISNY (SEQ 317) ID NO: 495) 44_56_J1 ID NO: 485) QQSNSLPPT (SEQ ID 44_56_J2 NO: 529) 6_130 6_163 2 147_156 ENIYSY (SEQ NAK (SEQ ID NO: QHHYDTPYT (SEQ 147_157_J2 ID NO: 224) 450) ID NO: 493) 33_63_J1 QDISNY (SEQ YTS (SEQ ID NO: QHHYGSPYT (SEQ 33_63_J2 ID NO: 485) 727) ID NO: 495) 33_63_J3 ENSYSY (SEQ HTS (SEQ ID NO: QQGNTLPPT (SEQ 44_56 ID NO: 226) 317) ID NO: 520) 44_56_J1 QNVGTN (SEQ SAS (SEQ ID NO: QQSNTLPPT (SEQ ID 44_56_J2 ID NO: 512) 637) NO: 530) 57_63 QSVNND (SEQ YAS (SEQ ID NO: QHHYGTPYT (SEQ 6_130 ID NO: 572) 717) ID NO: 496) 6_163 QYISNY (SEQ RAN (SEQ ID NO: QQHYGTPYT (SEQ 77_89 ID NO: 617) 618) ID NO: 523) QDINSY (SEQ WAS (SEQ ID NO: QQSNSLPPT (SEQ ID ID NO: 484) 698) NO: 529) QDINNF (SEQ QQYNSYPLT (SEQ ID NO: 481) ID NO: 549) ENSYNY (SEQ QQAYWSPYT (SEQ ID NO: 225) ID NO: 517) ENIHSY (SEQ QHHYGIPYT (SEQ ID NO: 222) ID NO: 494) QDVNTA (SEQ LQYDEFPYT (SEQ ID NO: 486) ID NO: 425) QDINRY (SEQ LQYDEFPWT (SEQ ID NO: 483) ID NO: 424) QHHYSTPYT (SEQ ID NO: 498) QQGNTLPLT (SEQ ID NO: 519) QQHYSSPWT (SEQ ID NO: 524) QQYNSYPYT (SEQ ID NO: 550) QQGNTLPWT (SEQ ID NO: 522) QQGNTLPST (SEQ ID NO: 521) 3 6_163 QNVGTN (SEQ SAS (SEQ ID NO: HQYNNYPYT (SEQ 33_63_J3 ID NO: 512) 637) ID NO: 316) 44_56_J2 ENIYNY (SEQ NAK (SEQ ID NO: QQYNSYPYT (SEQ 147_157_J2 ID NO: 223) 450) ID NO: 550) 33_63_J1 ENIYSY (SEQ HTS (SEQ ID NO: QQYNTYPYT (SEQ 33_63_J2 ID NO: 224) 317) ID NO: 552) 147_157_J1 QNVGIN (SEQ WAS (SEQ ID NO: QHHYGTPYT (SEQ 44_56_J1 ID NO: 511) 698) ID NO: 496) 6_130 QDISNY (SEQ KVS (SEQ ID NO: QHHYDTPYT (SEQ 77_89 ID NO: 485) 406) ID NO: 493) ENSYSY (SEQ NAE (SEQ ID NO: QQYNNYPYT (SEQ ID NO: 226) 449) ID NO: 546) RDVNTA (SEQ QQYNSYPLT (SEQ ID NO: 620) ID NO: 549) QSLVHSNGNTY QQSNSLPPT (SEQ ID (SEQ ID NO: NO: 529) 571) QHHYSSPWT (SEQ DNIYSY (SEQ ID NO: 497) ID NO: 189) SQSTHVPPT (SEQ ID GNVHNF (SEQ NO: 645) ID NO: 288) QHFWNTPPT (SEQ QSIVHSNGNTY ID NO: 492) (SEQ ID NO: FQGSHVPPT (SEQ ID 569) NO: 255) 

1. An engineered polypeptide, wherein the engineered polypeptide shares at least 4600 structural and/or dynamic identity to a CD25 reference target, wherein the CD25 reference target is a portion of a CD25 selected from: Reference Target No. CD25 Residues Sequence 1 55-63 SWDNQCQCT (SEQ ID NO: 22) 2 13-20:127-132 ATFKAMA (SEQ ID NO: 23):MVYYQC (SEQ ID NO: 24) 3  5-17 DDPPEIPHATFKA (SEQ ID NO: 25) 4 5-11:156-163 DDPPEIP (SEQ ID NO: 26):RWTQPQLI (SEQ ID NO: 27) 5 77-89 QPEEQKERKTTEM (SEQ ID NO: 28) 6 147-157 VCKMTHGKTRW (SEQ ID NO: 29) 7 11-14 IPHA (SEQ ID NO: 30) 8 44-56 YMLCTGSSSHSSW (SEQ ID NO: 31)


2. (canceled)
 3. (canceled)
 4. The engineered polypeptide of claim 1, wherein the engineered polypeptide shares at least 8000 sequence identity to an amino-acid sequence selected from: (SEQ ID NO: 1) C D C Q A QWT PGMRAPGYDPYCLNC (SEQ ID NO: 2) MVY C Q PDC T A K C M HGCDRDTMKECCDRLK (SEQ ID NO: 3) DD C PE V PHATFK GPGQKWEGPGGGDCSK (SEQ ID NO: 4) DD CI E V P GPAECAERACRAQEE R QR QPQ C I (SEQ ID NO: 5) AE EE KI K IE QKERKTT IKLAKEAK (SEQ ID NO: 6) CHLQI MTHGK IIYVPC (SEQ ID NO: 7) DDGDRCAKEH EIPHAT GEECQKRDKS (SEQ ID NO: 8) CKQLVIYF TGNSS HSSVFYIYYDC (SEQ ID NO: 9) GSGDEDCKKFQSD D NW E NYTSTR H L TF CDEKRS (SEQ ID NO: 10) GSGNEEIEKKIKDC TGNSSHSSW EEALECALKK (SEQ ID NO: 11) GSGDERIERLIKEC TGNSSHSSW EEALECALRR (SEQ ID NO: 12) GSGSHPCAYWRWVI KMTHGKTRW VLELVFCYRD (SEQ ID NO: 13) GSGKCEEEAKKIAS KMTHGKTR EEEAEEYLKKC (SEQ ID NO: 14) GSGDDESEKRTTERDTRKCTKAKAN DNQCQ P T E (SEQ ID NO: 15) GSGSSEWDKWVEEWYKKMCTEAKKN DNQCQ P T K (SEQ ID NO: 16) GSGQCRVWVFRNGDKILYIYEDCDN DNQ H Q Q T L


5. An engineered polypeptide designed to mimic a selected CD25 epitope, wherein the engineered polypeptide shares at least 800% sequence identity to an amino-acid sequence selected from: (SEQ ID NO: 1) C D C Q A QWT PGMRAPGYDPYCLNC (SEQ ID NO: 2) MVY C Q PDC T A K C M HGCDRDTMKECCDRLK (SEQ ID NO: 3) DD C PE V PHATFK GPGQKWEGPGGGDCSK (SEQ ID NO: 4) DD CI E V P GPAECAERACRAQEE R QR QPQ C I (SEQ ID NO: 5) AE EE KI K IE QKERKTT IKLAKEAK (SEQ ID NO: 6) CHLQI MTHGK IIYVPC (SEQ ID NO: 7) DDGDRCAKEH EIPHAT GEECQKRDKS (SEQ ID NO: 8) CKQLVIYF TGNSS HSSVFYIYYDC (SEQ ID NO: 9) GSGDEDCKKFQSD D NW E NYTSTR H L TF CDEKRS (SEQ ID NO: 10) GSGNEEIEKKIKDC TGNSSHSSW EEALECALKK (SEQ ID NO: 11) GSGDERIERLIKEC TGNSSHSSW EEALECALRR (SEQ ID NO: 12) GSGSHPCAYWRWVI KMTHGKTRW VLELVFCYRD (SEQ ID NO: 13) GSGKCEEEAKKIAS KMTHGKT REEEAEEYLKKC (SEQ ID NO: 14) GSGDDESEKRTTERDTRKCTKAKAN DNQCQ P T E (SEQ ID NO: 15) GSGSSEWDKWVEEWYKKMCTEAKKN DNQCQ P T K (SEQ ID NO: 16) GSGQCRVWVFRNGDKILYIYEDCDN DNQ H Q Q T L


6. The engineered polypeptide of claim 5, wherein the engineered polypeptide shares at least 46% structural and/or dynamic identity to a CD25 reference target, wherein the CD25 reference target is a portion of CD25 selected from: Reference Target No. CD25 Residues Sequence 1 55-63 SWDNQCQCT (SEQ ID NO: 22) 2 13-20:127-132 ATFKAMA (SEQ ID NO: 23) . . . MVYYQC (SEQ ID NO: 24) 3  5-17 DDPPEIPHATFKA (SEQ ID NO: 25) 4 5-11:156-163 DDPPEIP (SEQ ID NO: 26) . . . RWTQPQLI (SEQ ID NO: 27) 5 77-89 QPEEQKERKTTEM (SEQ ID NO: 28) 6 147-157 VCKMTHGKTRW (SEQ ID NO: 29) 7 11-14 IPHA (SEQ ID NO: 30) 8 44-56 YMLCTGSSSHSSW (SEQ ID NO: 31)


7. (canceled)
 8. The engineered polypeptide of claim 1, wherein the structural and/or dynamic identity to the CD25 reference target is determined using the structure of CD25 deposited at PDB ID NO: 2ERJ, chain Δ.
 9. The engineered polypeptide of claim 1, wherein the engineered polypeptide comprises an N-terminal modification or a C-terminal modification, optionally an N-terminal Biotin-PEG₂- or a C-terminal -GSGSGK-Biotin (SEQ ID NO: 846).
 10. The engineered polypeptide of claim 1, wherein between 10% to 98% of the amino acids of the engineered polypeptide meet one or more CD25 reference target-derived constraints, wherein optionally the amino acids of the polypeptide that meet the one or more reference target-derived constraints are the underlined residues in claim
 5. 11. The engineered polypeptide of claim 10, wherein the amino acids that meet the one or more CD25 reference target-derived constraints have less than 8.0 Å backbone root-mean-square deviation (RSMD) structural homology with the CD25 reference target,
 12. The engineered polypeptide of claim 10, wherein the amino acids that meet the one or more CD25 reference target-derived constraints have a van der Waals surface area overlap with the reference of between 30 Å² to 3000 Å².
 13. The engineered polypeptide of claim 1, wherein the CD25 reference target-derived constraints are independently selected from the group consisting of: atomic distances; atomic fluctuations; atomic energies; chemical descriptors; solvent exposures; amino acid sequence similarity; bioinformatic descriptors; non-covalent bonding propensity; phi angles; psi angles; van der Waals radii; secondary structure propensity; amino acid adjacency; and amino acid contact.
 14. (canceled)
 15. A CD25-specific antibody, comprising an antigen-binding domain that specifically binds a CD25 epitope selected from: 1 55-63 SWDNQCQCT (SEQ ID NO: 22) 2 13-20:127-132 ATFKAMA (SEQ ID NO: 23). . . MVYYQC (SEQ ID NO: 24) 3  5-17 DDPPEIPHATFKA (SEQ ID NO: 25) 4 5-11:156-163 DDPPEIP (SEQ ID NO: 26). . .  RWTQPQLI (SEQ ID NO: 27) 5 77-89 QPEEQKERKTTEM (SEQ ID NO: 28) 6 147-157 VCKMTHGKTRW (SEQ ID NO: 29) 7 11-14 IPHA (SEQ ID NO: 30) 8 44-56 YMLCTGSSSHSSW (SEQ ID NO: 31)


16. The antibody of claim 15, wherein the CD25 epitope is 55-63, and wherein the antibody comprises six complementarity determining regions (CDRs) each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKGDVNYGMDV (SEQ ID NIGSKS DDT QVWDSSSDLLWV (SEQ ID (SEQ ID NO: 65) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 456) ID NO: 612) 160) NIGSKT DGR QVWDTSGDLHWA (SEQ ID (SEQ (SEQ ID NO: NO: 457) ID NO: 614) 162) ISYDGNNK AKGYSSSPGDY (SEQ ID SSDVGAYNY DVS SSYTSSSTLWV (SEQ ID NO: 67) (SEQ ID (SEQ (SEQ ID NO: NO: 360) NO: 647) ID NO: 661) 201) GGTFSSYA IIPIFGTA ARDFNPFSITIFEMDV (SEQ SSNIGNNY DNN GTWDSSLSALV (SEQ ID (SEQ ID ID NO: 74) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 651) ID NO: 292) 190) GGSISSSNW IYHSGST ARDFYYGSGSYPNGYYYGMDV QSINSY TAS QQSYTTPLT (SEQ ID (SEQ ID (SEQ ID NO: 77) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 562) ID NO: 537) 667) GYSFNTYW IYPSDSDT ARDGGYYFDD (SEQ ID QSVSSTY GTS QQYNSSPLMYT (SEQ ID (SEQ ID NO: 79) (SEQ ID (SEQ ID (SEQ ID NO: NO: 297) NO: 383) NO: 577) NO: 291) 547) GGTFSSYA IIPIFGTA ARDYYYYGMDV (SEQ ID QSISRY GAS QQTYNDPPT (SEQ ID (SEQ ID NO: 101) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 564) ID NO: 539) 260) AREMYYYYGMDV (SEQ ID QSISSY AAS QQSYSTPPT NO: 103) (SEQ ID (SEQ ID (SEQ ID NO: NO: 567) NO: 49) 534) QSISNY (SEQ ID NO: 563) QSIITY (SEQ ID NO: 560) QSISSY (SEQ ID NO: 567) GGSISRSNW IYHTGST ARGKGSYAFDI (SEQ ID GGNIARNY EDD QSYDGNNHMV (SEQ ID (SEQ ID NO: 110) (SEQ ID (SEQ (SEQ ID NO: NO: 281) NO: 366) NO: 279) ID NO: 578) 214)


17. The antibody of claim 15, wherein the CD25 epitope is 13-20:127-132, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK ANLAMGQYFDY (SEQ ID SSNIGSNT SNN AAWDDSLNGPV (SEQ ID (SEQ ID NO: 70) (SEQ ID NO: (SEQ (SEQ ID NO: NO: 275) NO: 362) 654) ID 52) NO: 644) GFTFSSYA ARDLGEAKSSSPHEPDY QSLLHSDGKTY EVS MQTKQLPLT (SEQ ID (SEQ ID NO: 84) (SEQ ID NO: (SEQ (SEQ ID NO: NO: 273) 570) ID 443) NO: 237) GDSISSSSYY INHSGST ARDQEMYYFDY (SEQ ID QGISSW (SEQ AAS QQANSFPPT (SEQ ID (SEQ ID NO: 88) ID NO: 489) (SEQ (SEQ ID NO: NO: 261) NO: 333) ID 515) NO: 49) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ QSISSY (SEQ AAS QQSYSTPPT (SEQ ID (SEQ ID ID NO: 103) ID NO: 567) (SEQ (SEQ ID NO: NO: 286) NO: 326) ID 534) NO: 49)


18. The antibody of claim 15, wherein the CD25 epitope is 5-17, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKAITSIEPY (SEQ ID SGSVSTSYY NTD VLYMGSGIWV (SEQ ID (SEQ ID NO: 60) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 641) ID NO: 694) 467) GFTFSSYG ISYDGSNK AKELLEGAFDI (SEQ NIETKS DDD QVWDSSSGHREV (SEQ ID (SEQ ID ID NO: 64) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 455) ID NO: 613) 158) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID NO: 534) 49) QSISNY (SEQ ID NO: 563)


19. The antibody of claim 15, wherein the CD25 epitope is 5-11:156-163, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ QSISNY AAS QQSYSTPPT (SEQ ID (SEQ ID ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 563) ID NO: 534) 49) GYTFTSYG ISAYNGNT ARERSYYGMDV (SEQ ID QSVSNY GAS QQYNHWPPL (SEQ ID (SEQ ID NO: 105) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 574) ID NO: 544) 260)


20. The antibody of claim 15, wherein the CD25 epitope is 77-89, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKELLEGAFDI (SEQ NIETKS DDD QVWDSSSGHREV (SEQ ID (SEQ ID ID NO: 64) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 455) ID NO: 613) 158) GYTFTSYY INPSGGST ARDRVTMVRGALAY KLGDKY KDN QAWDSSTYV (SEQ ID (SEQ ID (SEQ ID NO: 97) (SEQ ID (SEQ (SEQ ID NO: NO: 313) NO: 339) NO: 404) ID NO: 473) 386)


21. The antibody of claim 15, wherein the CD25 epitope is 147-157, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GFTFSSYG ISYDGSNK AKGQGDGMDV (SEQ ID SSNVGSRT SNN AAWDDSLIGHV (SEQ ID (SEQ ID NO: 66) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 657) ID NO: 51) 644) GGSISSGGYS IYHSGST ARAGYYYGMDV (SEQ ID RNIWSY GAS QQSHSTPIT (SEQ ID (SEQ ID NO: 71) (SEQ ID (SEQ (SEQ ID NO: NO: 282) NO: 365) NO: 634) ID NO: 526) 260) GYTFTSYG ISAYNGNT ARDIGYYYGMDV (SEQ SLRSYY GKN NSRDSSGNHVV (SEQ ID (SEQ ID ID NO: 80) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 643) ID NO: 466) 287) GYTFTSYY INPSGGST ARDILGLDY (SEQ ID SSNIGSNY RNN AAWDDSLSGVV (SEQ ID (SEQ ID NO: 81) (SEQ ID (SEQ (SEQ ID NO: NO: 313) NO: 339) NO: 655) ID NO: 56) 635) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID NO: 534) 49) QSISNY (SEQ ID NO: 563) GFTFSSYW IKQDGSEK AREYDYGDYVFDY (SEQ NSNVGNNY DND GSWEARESVFV (SEQ ID (SEQ ID ID NO: 107) (SEQ ID (SEQ (SEQ ID NO: NO: 277) NO: 328) NO: 465) ID NO: 290) 188) GYSFTSYW IYPGDSDT ARLENNWDYGGWFDP NIGSKS DDS QVWDSSSDHWV (SEQ ID (SEQ ID (SEQ ID NO: 127) (SEQ ID (SEQ (SEQ ID NO: NO: 299) NO: 377) NO: 456) ID NO: 611) 159) IYPGDSDT (SEQ ID NO: 377) GYTFTDYY VDPEDGET ATEDTAMGGIDY (SEQ SSNIGSNY SNN AAWDDSLNGVV (SEQ ID (SEQ ID ID NO: 146) (SEQ ID (SEQ (SEQ ID NO: NO: 306) NO: 693) NO: 655) ID NO: 53) 644) ATEGRYGMDV (SEQ ID NFNIGNNL AND ATWDDSLSGVV NO: 147) (SEQ ID (SEQ (SEQ ID NO: NO: 453) ID NO: 151) 69) AVEGGRAPGTYYYDSSGLAY  SSNIGSNY SNN (SEQ ID NO: 153) (SEQ ID (SEQ NO: 655) ID NO: 644)


22. The antibody of claim 15, wherein the CD25 epitope is 11-14, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GGTFSSYA IIPIFGTA AREMYYYYGMDV QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID (SEQ ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID NO: 534) 49)


23. The antibody of claim 15, wherein the CD25 epitope is 44-56, and wherein the antibody comprises six CDRs each independently selected from: CDR-H1 CDR-H2 CDR-H3 CDR-L1 CDR-L2 CDR-L3 GYSFTSYW IYPGDSDT AIPWDAELGNYGMDV (SEQ QSISSY AAS LQDYNYPPA (SEQ ID (SEQ ID ID NO: 59) (SEQ ID (SEQ (SEQ ID NO: NO: 299) NO: 377) NO: 567) ID 422) NO: 49) GFAFSSYG ISYDGSNK AKGQGDGMDV (SEQ ID SSDVGGYNY GVS SSYTSSSTLVV (SEQ ID (SEQ ID NO: 66) (SEQ ID (SEQ (SEQ ID NO: NO: 262) NO: 362) NO: 649) ID 660) NO: 295) GGSISSSNW IYHSGST ARARGGRYFDY (SEQ ID QGISTY AAS QQLNGYPTT (SEQ ID (SEQ ID NO: 72) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 490) ID 525) NO: 49) GGTFSSYA IIPIFGTA AREMYYYYGMDV (SEQ ID QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID NO: 103) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 567) ID 534) NO: 49) QSISNY (SEQ ID NO: 563) ARGRWSGLGDY (SEQ ID EDIRMY EGS QQYYDDPQ NO: 113) (SEQ ID (SEQ (SEQ ID NO: NO: 215) ID 555) NO: 219) GYKFANYW IYPGDSDT ARLGWGMDV (SEQ ID QSISSY AAS QQSYSTPWT (SEQ ID (SEQ ID NO: 129) (SEQ ID (SEQ (SEQ ID NO: NO: 296) NO: 377) NO: 567) ID 535) NO: 49) GFTFSSYE ISSSGSTI ARRRGGGFDY (SEQ ID SSDVGGYNY DVS SSYTSSSTWV (SEQ ID (SEQ ID NO: 132) (SEQ ID (SEQ (SEQ ID NO: NO: 274) NO: 351) NO: 649) ID 663) NO: 201) GYSFSTYW IYPGDSDT ARVGDGYSLDY (SEQ ID SSNIGRNY RNH ATWDDALSGWV (SEQ ID (SEQ ID NO: 135) (SEQ ID (SEQ (SEQ ID NO: NO: 298) NO: 377) NO: 652) ID 149) NO: 633) KLGERF QYI QTWDGSIVV (SEQ ID (SEQ (SEQ ID NO: NO: 405) ID 583) NO: 616) GYTFKNFG ISGRKGNT ARVWGDTTLGYGMDV (SEQ QDISNY DAS QQYDNLPLT (SEQ ID (SEQ ID ID NO: 141) (SEQ ID (SEQ (SEQ ID NO: NO: 301) NO: 347) NO: 485) ID 542) NO: 157) GFTFSSYG ISYDGSNK AKDLLGELSFFDY (SEQ DIESEM DDS QVWHTTNDHVL (SEQ ID (SEQ ID ID NO: 61) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 362) NO: 163) ID 615) NO: 159) GFTFSNYG ISHDGHVK AKEISPRSSVGWPLDY QSVSSTY GAS QQFDISGGLI (SEQ ID (SEQ ID (SEQ ID NO: 63) (SEQ ID (SEQ (SEQ ID NO: NO: 271) NO: 349) NO: 577) ID 518) NO: 260) GFTFRRYW IKQDGSEK ARDAYAYGLDV (SEQ ID SGSIASSY EDN QSYDGSSVV (SEQ ID (SEQ ID NO: 73) (SEQ ID (SEQ (SEQ ID NO: NO: 268) NO: 328) NO: 640) ID 579) NO: 216) GYTFTSYG ISAYNGNT ARDFRMDV (SEQ ID NO: QDIKRR DAS QQANTFPQT (SEQ ID (SEQ ID 75) (SEQ ID (SEQ ID (SEQ ID NO: NO: 312) NO: 346) NO: 480) NO: 157) 516) GFTFSSSA ISYDGSNK ARDFWSGYNELGGMDV QDISNY QQYDNLPLT (SEQ ID (SEQ ID (SEQ ID NO: 76) (SEQ ID (SEQ ID NO: NO: 272) NO: 362) NO: 485) 542) GYTFNNYG ISVYNGDI ARDILRGESSILDH (SEQ QGISNS AAS QQYYSTPPH (SEQ ID (SEQ ID ID NO: 82) (SEQ ID (SEQ ID (SEQ ID NO: NO: 302) NO: 359) NO: 488) NO: 49) 556) GGTFSSYA IIPIFGTA ARDKGYYGMDV (SEQ ID QSIKNY QQTYSTPLT (SEQ ID (SEQ ID NO: 83) (SEQ ID (SEQ ID NO: NO: 286) NO: 326) NO: 561) 540) QGINSY QQVHSFPFT (SEQ ID (SEQ ID NO: NO: 487) 541) QGISSW AVS QQSYSLPLT (SEQ ID (SEQ (SEQ ID NO: NO: 489) ID 531) NO: 154) ARDLGTMVRGVIEPYYFDY QSISSW DAF QQYNSYSRT (SEQ ID NO: 85) (SEQ ID (SEQ ID (SEQ ID NO: NO: 566) NO: 156)  551) GFTFSSYA ISYDGSNK ARDLLGSGYDIIDY (SEQ NIGSKS DDS QVWDSSSDHVV (SEQ ID (SEQ ID ID NO: 86) (SEQ ID (SEQ (SEQ ID NO: NO: 273) NO: 362) NO: 456) ID 610) NO: 159) GGSISSSNW IYHSGST ARDLMNYGMDV (SEQ ID QSISSY AAS QQSYSTPPT (SEQ ID (SEQ ID NO: 87) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 567) ID 534) NO: 49) GFTFSSYS ISSSSSYI ARDQLAARRGYYYGMDV NIGTKS DDS QVWDSSSDHVV (SEQ ID (SEQ ID (SEQ ID NO: 89) (SEQ ID (SEQ (SEQ ID NO: NO: 276) NO: 352) NO: 459) ID 610) NO: 159) GYTFTTYA INTNIGDP ARDRFHYGMDV (SEQ ID EGIRTS GAS QQTHTWPWT (SEQ ID (SEQ ID NO: 90) (SEQ ID (SEQ (SEQ ID NO: NO: 314) NO: 344) NO: 218) ID 538) NO: 260) GFTFSSYG ISSRGSTI ARDRGDRVGGLVFDY (SEQ NIGSKS DDS QVWDSSSDHVV (SEQ ID (SEQ ID ID NO: 91) (SEQ ID (SEQ (SEQ ID NO: NO: 275) NO: 350) NO: 456) ID 610) NO: 159) GYTFTSYG ISAYNGNT ARDRGDY (SEQ ID NO: QGTSSW AAS QQANSFPLT (SEQ ID (SEQ ID 92) (SEQ ID (SEQ ID (SEQ ID NO: NO: 312) NO: 346) NO: 491) NO: 49) 514) ARDRGYYGMDV (SEQ ID QSISRY QQSHSTPLT NO: 93) (SEQ ID (SEQ ID NO: NO: 564) 527) ARDRNGYFQH (SEQ ID QTISGL GAS LQYDRYSGA NO: 94) (SEQ ID (SEQ (SEQ ID NO: NO: 581) ID 426) NO: 260) GGTFSSYA IIPIFGTA ARDRSYYGMDV (SEQ ID QSIGNY AAT QQSKQIPYT (SEQ ID (SEQ ID NO: 96) (SEQ ID (SEQ (SEQ ID NO: NO: 286) NO: 326) NO: 558) ID 528) NO: 50) ARDRYYYGMDV (SEQ ID QSISSY AAS QQSYSTPLT NO: 98) (SEQ ID (SEQ (SEQ ID NO: NO: 567) ID 532) NO: 49) GFTFSSYW IKQDGSEK AREKGSWFDP (SEQ ID QSVSNNY GAS QRYGSSPR (SEQ ID (SEQ ID NO: 102) (SEQ ID (SEQ (SEQ ID NO: NO: 277) NO: 328) NO: 573) ID 557) NO: 260) GFIFSRHA ISYDGSNK ARGRLAYGDTEGFDY (SEQ QDINNY DAS QQYDNLPYT (SEQ ID (SEQ ID ID NO: 112) (SEQ ID (SEQ (SEQ ID NO: NO: 264) NO: 362) NO: 482) ID 543) NO: 157) GGSISSSNW IYHSGST ARGVRGTGFDP (SEQ ID QSVSSR GAS QQYTNWPQT (SEQ ID (SEQ ID NO: 118) (SEQ ID (SEQ (SEQ ID NO: NO: 284) NO: 365) NO: 576) ID 554) NO: 260) GYSFTTYW IYPGDSDT ARQVAGGLDY (SEQ ID SSNVGSNY RNN AAWDDSLSGVV (SEQ ID (SEQ ID NO: 131) (SEQ ID (SEQ (SEQ ID NO: NO: 300) NO: 377) NO: 656) ID 56) NO: 635) QAVRID GAS LQHNTFPYT (SEQ ID (SEQ (SEQ ID NO: NO: 472) ID 423) NO: 260) GFTFSSYE ISSSGSTI ARRRGGGFDY (SEQ ID SSDVGGYNY DVS SSYTSSSTYV (SEQ ID (SEQ ID NO: 132) (SEQ ID (SEQ (SEQ ID NO: NO: 274) NO: 351) NO: 649) ID 664) NO: 201) GFTFSSYW IKQDGSEK ARTWFGEFFDY (SEQ ID NIESES DDS QVWDSSSDHTVA (SEQ ID (SEQ ID NO: 134) (SEQ ID (SEQ (SEQ ID NO: NO: 277) NO: 328) NO: 454) ID 609) NO: 159) GYTFTSYG ISAYNGNT ARVIGGWFDP (SEQ ID SSDVGAYNY GVS SSYTTTDTFV (SEQ ID (SEQ ID NO: 136) (SEQ ID (SEQ (SEQ ID NO: NO: 312) NO: 346) NO: 647) ID 665) NO: 295) ARVWGKNGDFDY (SEQ ID SSNIGNNY DNN GTWDSSLSAYV NO: 142) (SEQ ID (SEQ (SEQ ID NO: NO: 651) ID 294) NO: 190) GYSFTSYW IYPGDSDT FRFGEGFDY (SEQ ID QSIGYW RAS QQYNSYPFT (SEQ ID (SEQ ID NO: 259) (SEQ ID (SEQ (SEQ ID NO: NO: 299) NO: 377) NO: 559) ID 548) NO: 619) GFTFNNAW IKSKIDGGIT TTEGVELLSFGGAPFDY QSISSY AAS QQSYSTPYT (SEQ ID (SEQ ID (SEQ ID NO: 683) (SEQ ID (SEQ (SEQ ID NO: NO: 267) NO: 330) NO: 567) ID 536) NO: 49)

24-37. (canceled)
 38. A pharmaceutical composition comprising the antibody of claim 15, and optionally a pharmaceutically acceptable excipient.
 39. A method of treating a subject in need of treatment comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim
 38. 40-78. (canceled) 